{"PMC2536793": [["What Should A Model Model? ::: THE CHALLENGE OF MODELING HUMAN LUNG INJURYIdeally, animal models of ALI should reproduce the mechanisms and consequences of ALI in humans, including the physiological and pathological changes that occur (Table 1).", [["ALI", "DISEASE", 100, 103], ["ALI", "DISEASE", 156, 159], ["humans", "ORGANISM", 163, 169], ["humans", "SPECIES", 163, 169], ["humans", "SPECIES", 163, 169], ["ALI", "PROBLEM", 100, 103], ["ALI", "PROBLEM", 156, 159], ["the physiological and pathological changes", "PROBLEM", 181, 223], ["LUNG", "ANATOMY", 63, 67]]], ["Because the responses of the lungs to injury change with time, the evolution of the injury and repair should also be reproduced in the model, even if specific studies focus on a narrow time frame.", [["lungs", "ANATOMY", 29, 34], ["lungs", "ORGAN", 29, 34], ["injury change", "PROBLEM", 38, 51], ["the injury", "PROBLEM", 80, 90], ["repair", "TREATMENT", 95, 101], ["specific studies", "TEST", 150, 166], ["lungs", "ANATOMY", 29, 34], ["injury", "OBSERVATION", 38, 44], ["injury", "OBSERVATION", 84, 90], ["repair", "OBSERVATION", 95, 101]]], ["In humans, the intrapulmonary inflammatory response begins before the onset of clinically defined ALI and is most intense in the first 3 days after the onset of ALI/ARDS (78, 158).", [["intrapulmonary", "ANATOMY", 15, 29], ["ALI", "DISEASE", 98, 101], ["ALI", "DISEASE", 161, 164], ["ARDS", "DISEASE", 165, 169], ["humans", "ORGANISM", 3, 9], ["intrapulmonary", "MULTI-TISSUE_STRUCTURE", 15, 29], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["the intrapulmonary inflammatory response", "PROBLEM", 11, 51], ["ALI", "PROBLEM", 161, 164], ["ARDS", "PROBLEM", 165, 169], ["intrapulmonary", "ANATOMY", 15, 29], ["inflammatory", "OBSERVATION", 30, 42], ["ALI", "OBSERVATION", 98, 101], ["most intense", "OBSERVATION_MODIFIER", 109, 121], ["ALI", "OBSERVATION", 161, 164], ["ARDS", "OBSERVATION", 165, 169]]], ["The acute inflammatory phase is followed by a chronic fibroproliferative phase in patients who remain intubated and mechanically ventilated.", [["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["The acute inflammatory phase", "PROBLEM", 0, 28], ["a chronic fibroproliferative phase", "PROBLEM", 44, 78], ["intubated", "TREATMENT", 102, 111], ["mechanically ventilated", "TREATMENT", 116, 139], ["acute", "OBSERVATION_MODIFIER", 4, 9], ["inflammatory phase", "OBSERVATION", 10, 28], ["chronic", "OBSERVATION_MODIFIER", 46, 53], ["fibroproliferative", "OBSERVATION_MODIFIER", 54, 72], ["mechanically ventilated", "OBSERVATION", 116, 139]]], ["In patients who survive, pulmonary function tests often show restriction, consistent with the parenchymal fibrosis seen in lung biopsies or autopsy specimens (137, 173).What Should A Model Model? ::: THE CHALLENGE OF MODELING HUMAN LUNG INJURYThe acute physiological changes at the onset of ALI/ARDS in humans include severe hypoxemia that is usually responsive to positive end-expiratory pressure (PEEP) and a fall in total thoracic compliance caused by reduced lung compliance.", [["pulmonary", "ANATOMY", 25, 34], ["parenchymal", "ANATOMY", 94, 105], ["lung biopsies", "ANATOMY", 123, 136], ["specimens", "ANATOMY", 148, 157], ["thoracic", "ANATOMY", 425, 433], ["lung", "ANATOMY", 463, 467], ["fibrosis", "DISEASE", 106, 114], ["ALI", "DISEASE", 291, 294], ["ARDS", "DISEASE", 295, 299], ["hypoxemia", "DISEASE", 325, 334], ["patients", "ORGANISM", 3, 11], ["pulmonary", "ORGAN", 25, 34], ["parenchymal", "TISSUE", 94, 105], ["lung biopsies", "CANCER", 123, 136], ["autopsy specimens", "CANCER", 140, 157], ["humans", "ORGANISM", 303, 309], ["thoracic", "ORGANISM_SUBDIVISION", 425, 433], ["lung", "ORGAN", 463, 467], ["patients", "SPECIES", 3, 11], ["humans", "SPECIES", 303, 309], ["humans", "SPECIES", 303, 309], ["pulmonary function tests", "TEST", 25, 49], ["the parenchymal fibrosis", "PROBLEM", 90, 114], ["lung biopsies", "TEST", 123, 136], ["autopsy specimens", "TEST", 140, 157], ["MODELING HUMAN LUNG INJURY", "PROBLEM", 217, 243], ["The acute physiological changes", "PROBLEM", 243, 274], ["ALI", "PROBLEM", 291, 294], ["ARDS", "PROBLEM", 295, 299], ["severe hypoxemia", "PROBLEM", 318, 334], ["positive end-expiratory pressure", "TREATMENT", 365, 397], ["PEEP", "TREATMENT", 399, 403], ["a fall", "PROBLEM", 409, 415], ["total thoracic compliance", "TREATMENT", 419, 444], ["reduced lung compliance", "PROBLEM", 455, 478], ["pulmonary", "ANATOMY", 25, 34], ["consistent with", "UNCERTAINTY", 74, 89], ["parenchymal", "ANATOMY_MODIFIER", 94, 105], ["fibrosis", "OBSERVATION", 106, 114], ["lung", "ANATOMY", 123, 127], ["biopsies", "OBSERVATION", 128, 136], ["LUNG", "ANATOMY", 232, 236], ["INJURY", "OBSERVATION", 237, 243], ["acute", "OBSERVATION_MODIFIER", 247, 252], ["physiological", "OBSERVATION", 253, 266], ["ALI", "OBSERVATION", 291, 294], ["ARDS", "OBSERVATION", 295, 299], ["severe", "OBSERVATION_MODIFIER", 318, 324], ["hypoxemia", "OBSERVATION", 325, 334], ["thoracic", "ANATOMY", 425, 433], ["reduced", "OBSERVATION_MODIFIER", 455, 462], ["lung", "ANATOMY", 463, 467], ["compliance", "OBSERVATION", 468, 478]]], ["A marked increase in extravascular lung water is caused by an increase in endothelial and epithelial permeability, associated with an impairment in the ability of the alveolar epithelium to actively clear alveolar fluid (37, 134, 193, 234).", [["extravascular lung", "ANATOMY", 21, 39], ["endothelial", "ANATOMY", 74, 85], ["epithelial", "ANATOMY", 90, 100], ["alveolar epithelium", "ANATOMY", 167, 186], ["alveolar fluid", "ANATOMY", 205, 219], ["lung", "ORGAN", 35, 39], ["endothelial", "TISSUE", 74, 85], ["epithelial", "TISSUE", 90, 100], ["alveolar epithelium", "TISSUE", 167, 186], ["alveolar fluid", "TISSUE", 205, 219], ["A marked increase in extravascular lung water", "PROBLEM", 0, 45], ["an increase in endothelial and epithelial permeability", "PROBLEM", 59, 113], ["an impairment", "PROBLEM", 131, 144], ["marked", "OBSERVATION_MODIFIER", 2, 8], ["increase", "OBSERVATION_MODIFIER", 9, 17], ["extravascular", "ANATOMY_MODIFIER", 21, 34], ["lung", "ANATOMY", 35, 39], ["water", "OBSERVATION", 40, 45], ["increase", "OBSERVATION_MODIFIER", 62, 70], ["endothelial", "OBSERVATION_MODIFIER", 74, 85], ["epithelial permeability", "OBSERVATION", 90, 113], ["impairment", "OBSERVATION", 134, 144], ["alveolar", "ANATOMY_MODIFIER", 167, 175], ["epithelium", "ANATOMY_MODIFIER", 176, 186], ["actively", "OBSERVATION_MODIFIER", 190, 198], ["clear", "OBSERVATION_MODIFIER", 199, 204], ["alveolar fluid", "OBSERVATION", 205, 219]]], ["These changes cause severe ventilation/perfusion mismatching and an increase in shunt fraction.", [["severe ventilation/perfusion mismatching", "PROBLEM", 20, 60], ["an increase in shunt fraction", "PROBLEM", 65, 94], ["severe", "OBSERVATION_MODIFIER", 20, 26], ["ventilation", "OBSERVATION", 27, 38], ["perfusion mismatching", "OBSERVATION", 39, 60], ["increase", "OBSERVATION_MODIFIER", 68, 76], ["shunt fraction", "OBSERVATION", 80, 94]]], ["Studies that have sampled lung alveolar fluids either by bronchoalveolar lavage (BAL) or by direct aspiration of edema fluid using deep airway suction have shown that the hallmark is an acute neutrophilic inflammatory response with fibrin-rich proteinaceous exudates containing an array of pro- and anti-inflammatory cytokines (reviewed in Ref.", [["lung alveolar fluids", "ANATOMY", 26, 46], ["bronchoalveolar lavage", "ANATOMY", 57, 79], ["BAL", "ANATOMY", 81, 84], ["edema fluid", "ANATOMY", 113, 124], ["airway", "ANATOMY", 136, 142], ["edema", "DISEASE", 113, 118], ["lung alveolar", "MULTI-TISSUE_STRUCTURE", 26, 39], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 57, 79], ["BAL", "MULTI-TISSUE_STRUCTURE", 81, 84], ["airway", "ORGANISM_SUBDIVISION", 136, 142], ["fibrin", "GENE_OR_GENE_PRODUCT", 232, 238], ["fibrin", "PROTEIN", 232, 238], ["pro- and anti-inflammatory cytokines", "PROTEIN", 290, 326], ["Studies", "TEST", 0, 7], ["sampled lung alveolar fluids", "PROBLEM", 18, 46], ["bronchoalveolar lavage", "TEST", 57, 79], ["edema fluid", "PROBLEM", 113, 124], ["deep airway suction", "TREATMENT", 131, 150], ["an acute neutrophilic inflammatory response", "PROBLEM", 183, 226], ["fibrin", "PROBLEM", 232, 238], ["proteinaceous exudates", "PROBLEM", 244, 266], ["pro- and anti-inflammatory cytokines", "TREATMENT", 290, 326], ["lung", "ANATOMY", 26, 30], ["alveolar fluids", "OBSERVATION", 31, 46], ["bronchoalveolar lavage", "OBSERVATION", 57, 79], ["edema", "OBSERVATION", 113, 118], ["deep", "ANATOMY_MODIFIER", 131, 135], ["airway", "ANATOMY", 136, 142], ["acute", "OBSERVATION_MODIFIER", 186, 191], ["neutrophilic", "OBSERVATION_MODIFIER", 192, 204], ["inflammatory response", "OBSERVATION", 205, 226], ["fibrin", "OBSERVATION_MODIFIER", 232, 238], ["rich", "OBSERVATION_MODIFIER", 239, 243], ["proteinaceous", "OBSERVATION_MODIFIER", 244, 257], ["exudates", "OBSERVATION", 258, 266], ["anti-inflammatory cytokines", "OBSERVATION", 299, 326]]], ["ALI/ARDS also occurs in neutropenic patients, when alveolar structures are damaged by ionizing radiation or chemotherapeutic agents (156).", [["alveolar structures", "ANATOMY", 51, 70], ["ALI", "DISEASE", 0, 3], ["ARDS", "DISEASE", 4, 8], ["neutropenic", "DISEASE", 24, 35], ["patients", "ORGANISM", 36, 44], ["alveolar structures", "MULTI-TISSUE_STRUCTURE", 51, 70], ["patients", "SPECIES", 36, 44], ["ALI", "PROBLEM", 0, 3], ["ARDS", "PROBLEM", 4, 8], ["alveolar structures", "PROBLEM", 51, 70], ["ionizing radiation", "TREATMENT", 86, 104], ["chemotherapeutic agents", "TREATMENT", 108, 131], ["ARDS", "OBSERVATION", 4, 8], ["neutropenic", "OBSERVATION_MODIFIER", 24, 35], ["alveolar", "ANATOMY", 51, 59]]], ["Markers of the fibrotic response such as procollagen peptide III are evident as soon as the lung injury begins (29, 130) and are greatest in patients who die (29, 130).", [["lung", "ANATOMY", 92, 96], ["lung injury", "DISEASE", 92, 103], ["procollagen peptide III", "GENE_OR_GENE_PRODUCT", 41, 64], ["lung", "ORGAN", 92, 96], ["patients", "ORGANISM", 141, 149], ["procollagen peptide III", "PROTEIN", 41, 64], ["patients", "SPECIES", 141, 149], ["the fibrotic response", "PROBLEM", 11, 32], ["procollagen peptide III", "PROBLEM", 41, 64], ["the lung injury", "PROBLEM", 88, 103], ["fibrotic", "OBSERVATION", 15, 23], ["lung", "ANATOMY", 92, 96], ["injury", "OBSERVATION", 97, 103], ["greatest", "OBSERVATION_MODIFIER", 129, 137]]], ["Surfactant abnormalities were suspected when ALI/ARDS was first described, and abnormalities of surfactant composition and function have been described in a number of studies (80, 81, 164).What Should A Model Model? ::: THE CHALLENGE OF MODELING HUMAN LUNG INJURYDetailed studies of lung pathology in patients at the onset and during the course of ALI/ARDS are limited, and information is derived from the study of the lungs of patients who died or underwent late open lung biopsy (6, 10).", [["lung", "ANATOMY", 283, 287], ["lungs", "ANATOMY", 419, 424], ["lung", "ANATOMY", 469, 473], ["ALI", "DISEASE", 45, 48], ["ARDS", "DISEASE", 49, 53], ["lung pathology", "DISEASE", 283, 297], ["ALI", "DISEASE", 348, 351], ["ARDS", "DISEASE", 352, 356], ["surfactant", "SIMPLE_CHEMICAL", 96, 106], ["lung", "ORGAN", 283, 287], ["patients", "ORGANISM", 301, 309], ["lungs", "ORGAN", 419, 424], ["patients", "ORGANISM", 428, 436], ["lung biopsy", "MULTI-TISSUE_STRUCTURE", 469, 480], ["patients", "SPECIES", 301, 309], ["patients", "SPECIES", 428, 436], ["Surfactant abnormalities", "PROBLEM", 0, 24], ["ALI", "PROBLEM", 45, 48], ["ARDS", "PROBLEM", 49, 53], ["abnormalities of surfactant composition", "PROBLEM", 79, 118], ["MODELING HUMAN LUNG INJURYDetailed studies", "TEST", 237, 279], ["lung pathology", "PROBLEM", 283, 297], ["ALI", "PROBLEM", 348, 351], ["ARDS", "PROBLEM", 352, 356], ["the study", "TEST", 402, 411], ["late open lung biopsy", "TEST", 459, 480], ["ARDS", "OBSERVATION", 49, 53], ["surfactant composition", "OBSERVATION", 96, 118], ["LUNG", "ANATOMY", 252, 256], ["lung", "ANATOMY", 283, 287], ["pathology", "OBSERVATION", 288, 297], ["ALI", "OBSERVATION", 348, 351], ["ARDS", "OBSERVATION", 352, 356], ["lungs", "ANATOMY", 419, 424], ["lung", "ANATOMY", 469, 473], ["biopsy", "OBSERVATION", 474, 480]]], ["These studies confirm the severe epithelial and endothelial injury and the late fibroproliferative response (Fig. 1).", [["epithelial", "ANATOMY", 33, 43], ["endothelial", "ANATOMY", 48, 59], ["epithelial", "TISSUE", 33, 43], ["endothelial", "TISSUE", 48, 59], ["These studies", "TEST", 0, 13], ["the severe epithelial and endothelial injury", "PROBLEM", 22, 66], ["the late fibroproliferative response", "PROBLEM", 71, 107], ["severe", "OBSERVATION_MODIFIER", 26, 32], ["epithelial", "ANATOMY_MODIFIER", 33, 43], ["endothelial", "ANATOMY", 48, 59], ["injury", "OBSERVATION", 60, 66], ["late", "OBSERVATION_MODIFIER", 75, 79], ["fibroproliferative", "OBSERVATION_MODIFIER", 80, 98], ["response", "OBSERVATION_MODIFIER", 99, 107]]], ["The injury to the epithelium tends to be more pronounced than the endothelial injury (10), but endothelial injury and microvascular thrombi are detectable, supporting angiographic findings in humans with ALI/ARDS (218).", [["epithelium", "ANATOMY", 18, 28], ["endothelial", "ANATOMY", 66, 77], ["endothelial", "ANATOMY", 95, 106], ["microvascular thrombi", "ANATOMY", 118, 139], ["thrombi", "DISEASE", 132, 139], ["ALI", "DISEASE", 204, 207], ["ARDS", "DISEASE", 208, 212], ["epithelium", "TISSUE", 18, 28], ["endothelial", "TISSUE", 66, 77], ["endothelial", "TISSUE", 95, 106], ["microvascular thrombi", "PATHOLOGICAL_FORMATION", 118, 139], ["humans", "ORGANISM", 192, 198], ["humans", "SPECIES", 192, 198], ["humans", "SPECIES", 192, 198], ["The injury to the epithelium", "PROBLEM", 0, 28], ["the endothelial injury", "PROBLEM", 62, 84], ["endothelial injury", "PROBLEM", 95, 113], ["microvascular thrombi", "PROBLEM", 118, 139], ["ALI", "PROBLEM", 204, 207], ["ARDS", "PROBLEM", 208, 212], ["injury", "OBSERVATION", 4, 10], ["epithelium", "ANATOMY", 18, 28], ["more pronounced", "OBSERVATION_MODIFIER", 41, 56], ["endothelial", "ANATOMY", 66, 77], ["injury", "OBSERVATION", 78, 84], ["endothelial", "ANATOMY", 95, 106], ["injury", "OBSERVATION", 107, 113], ["microvascular", "ANATOMY", 118, 131], ["thrombi", "OBSERVATION", 132, 139], ["ALI", "OBSERVATION", 204, 207], ["ARDS", "OBSERVATION", 208, 212]]], ["The hallmark of the late fibroproliferative response is injury of the alveolar basement membrane, with fibroblast proliferation and increases in types I and III collagen in the alveolar walls and the alveolar spaces (173).What Should A Model Model? ::: THE CHALLENGE OF MODELING HUMAN LUNG INJURYTo simulate human ALI/ARDS, animal models should reproduce the acute injury to the epithelial and endothelial barriers in the lungs and the acute inflammatory response in the air spaces.", [["alveolar basement membrane", "ANATOMY", 70, 96], ["fibroblast", "ANATOMY", 103, 113], ["alveolar walls", "ANATOMY", 177, 191], ["alveolar spaces", "ANATOMY", 200, 215], ["epithelial", "ANATOMY", 379, 389], ["endothelial", "ANATOMY", 394, 405], ["lungs", "ANATOMY", 422, 427], ["ALI", "DISEASE", 314, 317], ["ARDS", "DISEASE", 318, 322], ["alveolar basement membrane", "CELLULAR_COMPONENT", 70, 96], ["fibroblast", "CELL", 103, 113], ["types I and III collagen", "GENE_OR_GENE_PRODUCT", 145, 169], ["alveolar walls", "MULTI-TISSUE_STRUCTURE", 177, 191], ["alveolar", "MULTI-TISSUE_STRUCTURE", 200, 208], ["human", "ORGANISM", 308, 313], ["epithelial", "TISSUE", 379, 389], ["endothelial", "CELL", 394, 405], ["lungs", "ORGAN", 422, 427], ["I and III collagen", "PROTEIN", 151, 169], ["human", "SPECIES", 308, 313], ["human", "SPECIES", 308, 313], ["injury of the alveolar basement membrane", "PROBLEM", 56, 96], ["fibroblast proliferation", "PROBLEM", 103, 127], ["human ALI", "PROBLEM", 308, 317], ["ARDS", "PROBLEM", 318, 322], ["animal models", "TREATMENT", 324, 337], ["the acute injury", "PROBLEM", 355, 371], ["the epithelial and endothelial barriers in the lungs", "PROBLEM", 375, 427], ["the acute inflammatory response in the air spaces", "PROBLEM", 432, 481], ["hallmark", "OBSERVATION_MODIFIER", 4, 12], ["late", "OBSERVATION_MODIFIER", 20, 24], ["fibroproliferative", "OBSERVATION_MODIFIER", 25, 43], ["response", "OBSERVATION", 44, 52], ["injury", "OBSERVATION", 56, 62], ["alveolar", "ANATOMY_MODIFIER", 70, 78], ["basement", "ANATOMY_MODIFIER", 79, 87], ["membrane", "ANATOMY_MODIFIER", 88, 96], ["fibroblast proliferation", "OBSERVATION", 103, 127], ["increases", "OBSERVATION_MODIFIER", 132, 141], ["III collagen", "OBSERVATION_MODIFIER", 157, 169], ["alveolar", "ANATOMY_MODIFIER", 177, 185], ["walls", "ANATOMY_MODIFIER", 186, 191], ["alveolar", "ANATOMY_MODIFIER", 200, 208], ["LUNG", "ANATOMY", 285, 289], ["ARDS", "OBSERVATION", 318, 322], ["acute", "OBSERVATION_MODIFIER", 359, 364], ["injury", "OBSERVATION", 365, 371], ["epithelial", "ANATOMY_MODIFIER", 379, 389], ["endothelial", "ANATOMY", 394, 405], ["lungs", "ANATOMY", 422, 427], ["acute", "OBSERVATION_MODIFIER", 436, 441], ["inflammatory", "OBSERVATION", 442, 454], ["air spaces", "OBSERVATION", 471, 481]]], ["Ideally, the injury should evolve over time if the animals are supported for prolonged periods.", [["animals", "ORGANISM", 51, 58], ["the injury", "PROBLEM", 9, 19], ["injury", "OBSERVATION", 13, 19]]], ["One of the most difficult aspects of modeling human ALI in humans is that the lungs of humans can be affected by the mechanisms involved in the primary illness (e.g., sepsis) and/or they can be affected by therapeutic modalities used for supportive care (e.g., mechanical ventilation) (224).", [["lungs", "ANATOMY", 78, 83], ["ALI", "DISEASE", 52, 55], ["primary illness", "DISEASE", 144, 159], ["sepsis", "DISEASE", 167, 173], ["human", "ORGANISM", 46, 51], ["humans", "ORGANISM", 59, 65], ["lungs", "ORGAN", 78, 83], ["humans", "ORGANISM", 87, 93], ["human", "SPECIES", 46, 51], ["humans", "SPECIES", 59, 65], ["humans", "SPECIES", 87, 93], ["human", "SPECIES", 46, 51], ["humans", "SPECIES", 59, 65], ["humans", "SPECIES", 87, 93], ["sepsis", "PROBLEM", 167, 173], ["supportive care", "TREATMENT", 238, 253], ["mechanical ventilation", "TREATMENT", 261, 283], ["most difficult", "OBSERVATION_MODIFIER", 11, 25], ["ALI", "OBSERVATION", 52, 55], ["lungs", "ANATOMY", 78, 83], ["sepsis", "OBSERVATION", 167, 173]]], ["This increases the complexity of the ideal animal model of lung injury, as it requires the incorporation of specific treatment modalities into experimental protocols, adding additional variables to the experimental design.What Should A Model Model? ::: THE CHALLENGE OF MODELING HUMAN LUNG INJURYNo single animal model reproduces all of the characteristics of ALI/ARDS in humans, and most of the existing animal models are relevant for only limited aspects of human ALI/ARDS.", [["lung", "ANATOMY", 59, 63], ["lung injury", "DISEASE", 59, 70], ["ALI", "DISEASE", 360, 363], ["ARDS", "DISEASE", 364, 368], ["ALI", "DISEASE", 466, 469], ["ARDS", "DISEASE", 470, 474], ["lung", "ORGAN", 59, 63], ["humans", "ORGANISM", 372, 378], ["human", "ORGANISM", 460, 465], ["humans", "SPECIES", 372, 378], ["human", "SPECIES", 460, 465], ["humans", "SPECIES", 372, 378], ["human", "SPECIES", 460, 465], ["lung injury", "PROBLEM", 59, 70], ["specific treatment modalities", "TREATMENT", 108, 137], ["experimental protocols", "TREATMENT", 143, 165], ["ALI", "PROBLEM", 360, 363], ["ARDS in humans", "PROBLEM", 364, 378], ["human ALI", "PROBLEM", 460, 469], ["ARDS", "PROBLEM", 470, 474], ["complexity", "OBSERVATION_MODIFIER", 19, 29], ["lung", "ANATOMY", 59, 63], ["injury", "OBSERVATION", 64, 70], ["LUNG", "ANATOMY", 285, 289], ["INJURYNo", "OBSERVATION", 290, 298], ["ALI", "OBSERVATION", 360, 363], ["ARDS", "OBSERVATION", 364, 368], ["ALI", "OBSERVATION", 466, 469], ["ARDS", "OBSERVATION", 470, 474]]], ["Nevertheless, if the characteristics of an animal model are well understood, and the results are interpreted within the limits of the specific model, animal studies can provide focused tests of key elements of the lung injury response in humans.Species differences in Toll-like receptors. ::: Species Differences in the Innate Immune Response ::: UNIQUE CHARACTERISTICS OF ANIMAL SPECIES IN MODELING HUMAN LUNG INJURYEarly investigators studying the physiological consequences of endotoxin recognized that differences existed between animal species in the development of ALI (123).", [["lung", "ANATOMY", 214, 218], ["lung injury", "DISEASE", 214, 225], ["endotoxin", "CHEMICAL", 480, 489], ["ALI", "DISEASE", 571, 574], ["lung", "ORGAN", 214, 218], ["humans", "ORGANISM", 238, 244], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 268, 287], ["Toll-like receptors", "PROTEIN", 268, 287], ["endotoxin", "PROTEIN", 480, 489], ["humans", "SPECIES", 238, 244], ["humans", "SPECIES", 238, 244], ["animal studies", "TEST", 150, 164], ["focused tests", "TEST", 177, 190], ["the lung injury", "PROBLEM", 210, 225], ["Species differences", "PROBLEM", 245, 264], ["endotoxin", "TREATMENT", 480, 489], ["animal species", "PROBLEM", 534, 548], ["ALI", "PROBLEM", 571, 574], ["lung", "ANATOMY", 214, 218], ["injury", "OBSERVATION", 219, 225], ["ANIMAL SPECIES", "OBSERVATION", 373, 387], ["LUNG", "ANATOMY", 406, 410], ["ALI", "ANATOMY", 571, 574]]], ["Because humans and mice diverged as separate species millions of years ago, they have adapted to pathogens that are specific to their unique environmental niches, so it is not surprising that differences exist in the innate immune response of humans and mice to microbes and microbial products.", [["humans", "ORGANISM", 8, 14], ["mice", "ORGANISM", 19, 23], ["humans", "ORGANISM", 243, 249], ["mice", "ORGANISM", 254, 258], ["humans", "SPECIES", 8, 14], ["mice", "SPECIES", 19, 23], ["humans", "SPECIES", 243, 249], ["mice", "SPECIES", 254, 258], ["humans", "SPECIES", 8, 14], ["mice", "SPECIES", 19, 23], ["humans", "SPECIES", 243, 249], ["mice", "SPECIES", 254, 258], ["pathogens", "PROBLEM", 97, 106], ["microbial products", "TREATMENT", 275, 293]]], ["Leukocytes and some mesenchymal cells of humans and lower animals recognize microbial products via a group of specialized pattern recognition receptors called Toll-like receptors.", [["Leukocytes", "ANATOMY", 0, 10], ["mesenchymal cells", "ANATOMY", 20, 37], ["Leukocytes", "CELL", 0, 10], ["mesenchymal cells", "CELL", 20, 37], ["humans", "ORGANISM", 41, 47], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 159, 178], ["Leukocytes", "CELL_TYPE", 0, 10], ["mesenchymal cells", "CELL_TYPE", 20, 37], ["pattern recognition receptors", "PROTEIN", 122, 151], ["Toll-like receptors", "PROTEIN", 159, 178], ["humans", "SPECIES", 41, 47], ["humans", "SPECIES", 41, 47], ["Leukocytes", "TEST", 0, 10], ["some mesenchymal cells of humans", "PROBLEM", 15, 47], ["some", "OBSERVATION_MODIFIER", 15, 19], ["mesenchymal cells", "OBSERVATION", 20, 37], ["lower", "ANATOMY_MODIFIER", 52, 57], ["microbial products", "OBSERVATION", 76, 94]]], ["The work of Hajjar and colleagues (83) suggested evolutionary divergence in these receptors by showing that Toll-like receptor 4 (TLR4) from humans and mice recognize different lipopolysaccharide structures.", [["lipopolysaccharide", "CHEMICAL", 177, 195], ["Toll-like receptor 4", "GENE_OR_GENE_PRODUCT", 108, 128], ["TLR4", "GENE_OR_GENE_PRODUCT", 130, 134], ["humans", "ORGANISM", 141, 147], ["mice", "ORGANISM", 152, 156], ["Toll-like receptor 4", "PROTEIN", 108, 128], ["TLR4", "PROTEIN", 130, 134], ["humans", "SPECIES", 141, 147], ["mice", "SPECIES", 152, 156], ["humans", "SPECIES", 141, 147], ["mice", "SPECIES", 152, 156]]], ["Other examples include species differences in TLR2 (133, 146), TRL3 (89), TLR7, TLR8 (248), and TLR9 (100) (reviewed in Ref.", [["TLR2", "GENE_OR_GENE_PRODUCT", 46, 50], ["TRL3", "GENE_OR_GENE_PRODUCT", 63, 67], ["TLR7", "GENE_OR_GENE_PRODUCT", 74, 78], ["TLR8", "GENE_OR_GENE_PRODUCT", 80, 84], ["TLR9", "GENE_OR_GENE_PRODUCT", 96, 100], ["TLR2", "PROTEIN", 46, 50], ["TRL3", "PROTEIN", 63, 67], ["TLR7", "PROTEIN", 74, 78], ["TLR8", "PROTEIN", 80, 84], ["TLR9", "PROTEIN", 96, 100], ["species differences", "PROBLEM", 23, 42], ["TLR2", "TEST", 46, 50], ["TRL3", "TEST", 63, 67], ["TLR7", "TEST", 74, 78], ["TLR8", "TEST", 80, 84], ["TLR9", "TEST", 96, 100], ["TLR7", "ANATOMY", 74, 78]]], ["Species differences in innate immune responses need to be taken into account in selecting animal models of ALI for specific experimental protocols.Species differences in the mononuclear phagocyte system. ::: Species Differences in the Innate Immune Response ::: UNIQUE CHARACTERISTICS OF ANIMAL SPECIES IN MODELING HUMAN LUNG INJURYThe mononuclear phagocyte system (MPS) is composed of macrophages and macrophage precursors such as blood monocytes.", [["mononuclear phagocyte", "ANATOMY", 174, 195], ["macrophages", "ANATOMY", 386, 397], ["macrophage precursors", "ANATOMY", 402, 423], ["blood monocytes", "ANATOMY", 432, 447], ["ALI", "DISEASE", 107, 110], ["mononuclear phagocyte", "CELL", 174, 195], ["mononuclear phagocyte", "CELL", 336, 357], ["macrophages", "CELL", 386, 397], ["macrophage", "CELL", 402, 412], ["blood monocytes", "CELL", 432, 447], ["mononuclear phagocyte", "CELL_TYPE", 174, 195], ["macrophages", "CELL_TYPE", 386, 397], ["macrophage precursors", "CELL_TYPE", 402, 423], ["blood monocytes", "CELL_TYPE", 432, 447], ["Species differences", "PROBLEM", 0, 19], ["specific experimental protocols", "TREATMENT", 115, 146], ["Species differences in the mononuclear phagocyte system", "PROBLEM", 147, 202], ["macrophages", "PROBLEM", 386, 397], ["macrophage precursors", "PROBLEM", 402, 423], ["blood monocytes", "TEST", 432, 447], ["mononuclear phagocyte system", "OBSERVATION", 174, 202], ["ANIMAL SPECIES", "OBSERVATION", 288, 302], ["LUNG", "ANATOMY", 321, 325], ["INJURYThe mononuclear phagocyte", "OBSERVATION", 326, 357], ["macrophages", "OBSERVATION", 386, 397], ["macrophage precursors", "OBSERVATION", 402, 423]]], ["Intravascular macrophages directly face the circulation where they can bind to and ingest microorganisms, endotoxin, and particles circulating in blood.", [["Intravascular macrophages", "ANATOMY", 0, 25], ["blood", "ANATOMY", 146, 151], ["endotoxin", "CHEMICAL", 106, 115], ["Intravascular macrophages", "CELL", 0, 25], ["endotoxin", "SIMPLE_CHEMICAL", 106, 115], ["blood", "ORGANISM_SUBSTANCE", 146, 151], ["Intravascular macrophages", "CELL_TYPE", 0, 25], ["endotoxin", "PROTEIN", 106, 115], ["Intravascular macrophages", "PROBLEM", 0, 25], ["endotoxin", "TEST", 106, 115], ["macrophages", "OBSERVATION", 14, 25], ["circulation", "ANATOMY", 44, 55]]], ["The distribution of intravascular macrophages varies across species.", [["intravascular macrophages", "ANATOMY", 20, 45], ["intravascular macrophages", "CELL", 20, 45], ["intravascular macrophages", "CELL_TYPE", 20, 45], ["intravascular macrophages", "PROBLEM", 20, 45], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["intravascular macrophages", "OBSERVATION", 20, 45], ["species", "OBSERVATION_MODIFIER", 60, 67]]], ["In many species, intravascular macrophages are restricted to the spleen and liver, e.g., splenic macrophages and Kupffer cells.", [["intravascular macrophages", "ANATOMY", 17, 42], ["spleen", "ANATOMY", 65, 71], ["liver", "ANATOMY", 76, 81], ["splenic macrophages", "ANATOMY", 89, 108], ["Kupffer cells", "ANATOMY", 113, 126], ["intravascular macrophages", "CELL", 17, 42], ["spleen", "ORGAN", 65, 71], ["liver", "ORGAN", 76, 81], ["splenic macrophages", "CELL", 89, 108], ["Kupffer cells", "CELL", 113, 126], ["intravascular macrophages", "CELL_TYPE", 17, 42], ["splenic macrophages", "CELL_TYPE", 89, 108], ["Kupffer cells", "CELL_TYPE", 113, 126], ["intravascular macrophages", "PROBLEM", 17, 42], ["many", "OBSERVATION_MODIFIER", 3, 7], ["species", "OBSERVATION", 8, 15], ["intravascular macrophages", "OBSERVATION", 17, 42], ["spleen", "ANATOMY", 65, 71], ["liver", "ANATOMY", 76, 81], ["splenic", "ANATOMY", 89, 96], ["macrophages", "ANATOMY_MODIFIER", 97, 108], ["Kupffer cells", "OBSERVATION", 113, 126]]], ["But in some species, the lungs contain pulmonary intravascular macrophages (PIM), a resident population of mature macrophages that adhere to endothelial cells in pulmonary capillaries.Species differences in the mononuclear phagocyte system. ::: Species Differences in the Innate Immune Response ::: UNIQUE CHARACTERISTICS OF ANIMAL SPECIES IN MODELING HUMAN LUNG INJURYThe PIM are found in the lungs of many species including sheep, cattle, pigs, cats, goats, horses, and cetaceans.", [["lungs", "ANATOMY", 25, 30], ["pulmonary intravascular macrophages", "ANATOMY", 39, 74], ["PIM", "ANATOMY", 76, 79], ["macrophages", "ANATOMY", 114, 125], ["endothelial cells", "ANATOMY", 141, 158], ["pulmonary capillaries", "ANATOMY", 162, 183], ["mononuclear phagocyte", "ANATOMY", 211, 232], ["lungs", "ANATOMY", 394, 399], ["lungs", "ORGAN", 25, 30], ["pulmonary intravascular macrophages", "CELL", 39, 74], ["macrophages", "CELL", 114, 125], ["endothelial cells", "CELL", 141, 158], ["pulmonary capillaries", "TISSUE", 162, 183], ["mononuclear phagocyte", "CELL", 211, 232], ["PIM", "GENE_OR_GENE_PRODUCT", 373, 376], ["lungs", "ORGAN", 394, 399], ["sheep", "ORGANISM", 426, 431], ["cattle", "ORGANISM", 433, 439], ["pigs", "ORGANISM", 441, 445], ["cats", "ORGANISM", 447, 451], ["goats", "ORGANISM", 453, 458], ["pulmonary intravascular macrophages", "CELL_TYPE", 39, 74], ["PIM", "CELL_TYPE", 76, 79], ["mature macrophages", "CELL_TYPE", 107, 125], ["endothelial cells", "CELL_TYPE", 141, 158], ["mononuclear phagocyte", "CELL_TYPE", 211, 232], ["sheep", "SPECIES", 426, 431], ["cattle", "SPECIES", 433, 439], ["pigs", "SPECIES", 441, 445], ["cats", "SPECIES", 447, 451], ["goats", "SPECIES", 453, 458], ["sheep", "SPECIES", 426, 431], ["cattle", "SPECIES", 433, 439], ["pigs", "SPECIES", 441, 445], ["goats", "SPECIES", 453, 458], ["pulmonary intravascular macrophages", "PROBLEM", 39, 74], ["mature macrophages", "PROBLEM", 107, 125], ["Species differences in the mononuclear phagocyte system", "PROBLEM", 184, 239], ["MODELING HUMAN LUNG INJURY", "PROBLEM", 343, 369], ["species", "OBSERVATION", 12, 19], ["lungs", "ANATOMY", 25, 30], ["pulmonary", "ANATOMY", 39, 48], ["intravascular macrophages", "OBSERVATION", 49, 74], ["mature", "OBSERVATION_MODIFIER", 107, 113], ["macrophages", "OBSERVATION", 114, 125], ["endothelial cells", "OBSERVATION", 141, 158], ["pulmonary capillaries", "ANATOMY", 162, 183], ["mononuclear phagocyte system", "OBSERVATION", 211, 239], ["ANIMAL SPECIES", "OBSERVATION", 325, 339], ["LUNG", "ANATOMY", 358, 362], ["INJURY", "OBSERVATION", 363, 369], ["lungs", "ANATOMY", 394, 399], ["many", "OBSERVATION_MODIFIER", 403, 407], ["species", "OBSERVATION", 408, 415]]], ["In species that have PIM, particulate matter and LPS in blood are localized to the lungs.", [["blood", "ANATOMY", 56, 61], ["lungs", "ANATOMY", 83, 88], ["LPS", "CHEMICAL", 49, 52], ["PIM", "SIMPLE_CHEMICAL", 21, 24], ["LPS", "SIMPLE_CHEMICAL", 49, 52], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["lungs", "ORGAN", 83, 88], ["PIM", "PROBLEM", 21, 24], ["LPS in blood", "TEST", 49, 61], ["particulate matter", "OBSERVATION_MODIFIER", 26, 44], ["LPS", "OBSERVATION_MODIFIER", 49, 52], ["lungs", "ANATOMY", 83, 88]]], ["In contrast, species that lack PIM such as the dog, rat, mouse, rabbit, and non-human primates, localize particulate matter in blood to the liver and spleen (24).", [["particulate matter", "ANATOMY", 105, 123], ["blood", "ANATOMY", 127, 132], ["liver", "ANATOMY", 140, 145], ["spleen", "ANATOMY", 150, 156], ["dog", "ORGANISM", 47, 50], ["rat", "ORGANISM", 52, 55], ["mouse", "ORGANISM", 57, 62], ["rabbit", "ORGANISM", 64, 70], ["non-human primates", "ORGANISM", 76, 94], ["blood", "ORGANISM_SUBSTANCE", 127, 132], ["liver", "ORGAN", 140, 145], ["spleen", "ORGAN", 150, 156], ["dog", "SPECIES", 47, 50], ["rat", "SPECIES", 52, 55], ["mouse", "SPECIES", 57, 62], ["rabbit", "SPECIES", 64, 70], ["non-human", "SPECIES", 76, 85], ["rat", "SPECIES", 52, 55], ["mouse", "SPECIES", 57, 62], ["rabbit", "SPECIES", 64, 70], ["particulate matter", "OBSERVATION", 105, 123], ["liver", "ANATOMY", 140, 145], ["spleen", "ANATOMY", 150, 156]]], ["Most evidence suggests that PIM are not part of the MPS in normal humans (236).", [["MPS", "DISEASE", 52, 55], ["PIM", "SIMPLE_CHEMICAL", 28, 31], ["humans", "ORGANISM", 66, 72], ["humans", "SPECIES", 66, 72], ["humans", "SPECIES", 66, 72], ["PIM", "PROBLEM", 28, 31], ["PIM", "OBSERVATION", 28, 31], ["normal", "OBSERVATION", 59, 65]]], ["The role of PIMs in the development of lung injury was investigated in studies through depletion of these macrophages in sheep, which decreased endotoxin-induced lung injury (206).", [["lung", "ANATOMY", 39, 43], ["macrophages", "ANATOMY", 106, 117], ["lung", "ANATOMY", 162, 166], ["lung injury", "DISEASE", 39, 50], ["endotoxin", "CHEMICAL", 144, 153], ["lung injury", "DISEASE", 162, 173], ["PIMs", "GENE_OR_GENE_PRODUCT", 12, 16], ["lung", "ORGAN", 39, 43], ["macrophages", "CELL", 106, 117], ["sheep", "ORGANISM", 121, 126], ["endotoxin", "SIMPLE_CHEMICAL", 144, 153], ["lung", "ORGAN", 162, 166], ["PIMs", "PROTEIN", 12, 16], ["macrophages", "CELL_TYPE", 106, 117], ["sheep", "SPECIES", 121, 126], ["sheep", "SPECIES", 121, 126], ["lung injury", "PROBLEM", 39, 50], ["these macrophages in sheep", "PROBLEM", 100, 126], ["lung injury", "PROBLEM", 162, 173], ["PIMs", "OBSERVATION", 12, 16], ["lung", "ANATOMY", 39, 43], ["injury", "OBSERVATION", 44, 50], ["macrophages", "OBSERVATION", 106, 117], ["decreased", "OBSERVATION_MODIFIER", 134, 143], ["endotoxin", "OBSERVATION_MODIFIER", 144, 153], ["lung", "ANATOMY", 162, 166], ["injury", "OBSERVATION", 167, 173]]], ["Therefore, the presence of PIM increases the susceptibility of a species to lung injury (Table 2), which should be taken into account when developing animal models of human lung injury (236).Species differences in nitric oxide. ::: Species Differences in the Innate Immune Response ::: UNIQUE CHARACTERISTICS OF ANIMAL SPECIES IN MODELING HUMAN LUNG INJURYClinical studies and animal models suggest that nitric oxide (NO) is involved in the pathogenesis of lung injury (202, 232), and important species-dependent differences in NO pathways have been described.", [["lung", "ANATOMY", 76, 80], ["lung", "ANATOMY", 173, 177], ["lung", "ANATOMY", 457, 461], ["lung injury", "DISEASE", 76, 87], ["lung injury", "DISEASE", 173, 184], ["nitric oxide", "CHEMICAL", 214, 226], ["nitric oxide", "CHEMICAL", 404, 416], ["NO", "CHEMICAL", 418, 420], ["lung injury", "DISEASE", 457, 468], ["NO", "CHEMICAL", 528, 530], ["nitric oxide", "CHEMICAL", 214, 226], ["nitric oxide", "CHEMICAL", 404, 416], ["NO", "CHEMICAL", 418, 420], ["NO", "CHEMICAL", 528, 530], ["PIM", "SIMPLE_CHEMICAL", 27, 30], ["lung", "ORGAN", 76, 80], ["human", "ORGANISM", 167, 172], ["lung", "ORGAN", 173, 177], ["nitric oxide", "SIMPLE_CHEMICAL", 214, 226], ["nitric oxide", "SIMPLE_CHEMICAL", 404, 416], ["NO", "SIMPLE_CHEMICAL", 418, 420], ["lung", "ORGAN", 457, 461], ["NO", "GENE_OR_GENE_PRODUCT", 528, 530], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 167, 172], ["PIM", "PROBLEM", 27, 30], ["a species to lung injury", "PROBLEM", 63, 87], ["human lung injury", "PROBLEM", 167, 184], ["nitric oxide", "TREATMENT", 214, 226], ["INJURYClinical studies", "TEST", 350, 372], ["nitric oxide", "TREATMENT", 404, 416], ["lung injury", "PROBLEM", 457, 468], ["PIM increases", "OBSERVATION", 27, 40], ["lung", "ANATOMY", 76, 80], ["injury", "OBSERVATION", 81, 87], ["lung", "ANATOMY", 173, 177], ["injury", "OBSERVATION", 178, 184], ["nitric oxide", "OBSERVATION", 214, 226], ["ANIMAL SPECIES", "OBSERVATION", 312, 326], ["LUNG", "ANATOMY", 345, 349], ["nitric oxide", "OBSERVATION", 404, 416], ["lung", "ANATOMY", 457, 461], ["injury", "OBSERVATION", 462, 468], ["dependent", "OBSERVATION_MODIFIER", 503, 512]]], ["For example, the production of NO during the TLR-mediated antimicrobial response to Mycobacterium tuberculosis varies among species.", [["NO", "CHEMICAL", 31, 33], ["Mycobacterium tuberculosis", "DISEASE", 84, 110], ["NO", "CHEMICAL", 31, 33], ["NO", "GENE_OR_GENE_PRODUCT", 31, 33], ["TLR", "GENE_OR_GENE_PRODUCT", 45, 48], ["Mycobacterium tuberculosis", "ORGANISM", 84, 110], ["TLR", "PROTEIN", 45, 48], ["Mycobacterium tuberculosis", "SPECIES", 84, 110], ["Mycobacterium tuberculosis", "SPECIES", 84, 110], ["Mycobacterium tuberculosis varies among species", "PROBLEM", 84, 131], ["Mycobacterium tuberculosis", "OBSERVATION", 84, 110]]], ["In humans, macrophages kill M. tuberculosis through a vitamin D-dependent response (127).", [["macrophages", "ANATOMY", 11, 22], ["tuberculosis", "DISEASE", 31, 43], ["vitamin D", "CHEMICAL", 54, 63], ["vitamin D", "CHEMICAL", 54, 63], ["humans", "ORGANISM", 3, 9], ["macrophages", "CELL", 11, 22], ["M. tuberculosis", "ORGANISM", 28, 43], ["vitamin D", "SIMPLE_CHEMICAL", 54, 63], ["macrophages", "CELL_TYPE", 11, 22], ["humans", "SPECIES", 3, 9], ["M. tuberculosis", "SPECIES", 28, 43], ["humans", "SPECIES", 3, 9], ["M. tuberculosis", "SPECIES", 28, 43], ["tuberculosis", "PROBLEM", 31, 43], ["a vitamin D-dependent response", "TREATMENT", 52, 82], ["macrophages", "ANATOMY", 11, 22]]], ["In contrast, mice, nocturnal animals with minimal exposure to sunlight, have developed a TLR-mediated pathway in macrophages, which kills M. tuberculosis through NO-dependent mechanisms (216).", [["macrophages", "ANATOMY", 113, 124], ["tuberculosis", "DISEASE", 141, 153], ["NO", "CHEMICAL", 162, 164], ["NO", "CHEMICAL", 162, 164], ["mice", "ORGANISM", 13, 17], ["TLR", "GENE_OR_GENE_PRODUCT", 89, 92], ["macrophages", "CELL", 113, 124], ["M. tuberculosis", "ORGANISM", 138, 153], ["NO", "SIMPLE_CHEMICAL", 162, 164], ["TLR", "PROTEIN", 89, 92], ["macrophages", "CELL_TYPE", 113, 124], ["mice", "SPECIES", 13, 17], ["M. tuberculosis", "SPECIES", 138, 153], ["mice", "SPECIES", 13, 17], ["M. tuberculosis", "SPECIES", 138, 153], ["macrophages", "PROBLEM", 113, 124], ["macrophages", "ANATOMY", 113, 124], ["tuberculosis", "OBSERVATION", 141, 153]]], ["Additional studies show that human and rodent macrophages differ significantly in their ability to produce NO.", [["macrophages", "ANATOMY", 46, 57], ["NO", "CHEMICAL", 107, 109], ["NO", "CHEMICAL", 107, 109], ["human", "ORGANISM", 29, 34], ["macrophages", "CELL", 46, 57], ["NO", "SIMPLE_CHEMICAL", 107, 109], ["human and rodent macrophages", "CELL_TYPE", 29, 57], ["human", "SPECIES", 29, 34], ["rodent", "SPECIES", 39, 45], ["human", "SPECIES", 29, 34], ["Additional studies", "TEST", 0, 18], ["human and rodent macrophages", "PROBLEM", 29, 57], ["macrophages", "OBSERVATION", 46, 57]]], ["Rodent macrophages produce large amounts of NO, whereas normal nonactivated human macrophages make very little NO (187, 188).", [["macrophages", "ANATOMY", 7, 18], ["macrophages", "ANATOMY", 82, 93], ["NO", "CHEMICAL", 44, 46], ["NO", "CHEMICAL", 111, 113], ["NO", "CHEMICAL", 44, 46], ["NO (187, 188", "CHEMICAL", 111, 123], ["Rodent", "ORGANISM", 0, 6], ["macrophages", "CELL", 7, 18], ["NO", "GENE_OR_GENE_PRODUCT", 44, 46], ["human", "ORGANISM", 76, 81], ["macrophages", "CELL", 82, 93], ["NO", "SIMPLE_CHEMICAL", 111, 113], ["Rodent macrophages", "CELL_TYPE", 0, 18], ["nonactivated human macrophages", "CELL_TYPE", 63, 93], ["human", "SPECIES", 76, 81], ["Rodent", "SPECIES", 0, 6], ["human", "SPECIES", 76, 81], ["macrophages", "OBSERVATION", 7, 18], ["large", "OBSERVATION_MODIFIER", 27, 32], ["amounts", "OBSERVATION_MODIFIER", 33, 40], ["NO", "UNCERTAINTY", 44, 46]]], ["Macrophages of cattle produce NO, whereas macrophages of hamsters, monkeys, goats, and pigs are more like human macrophages and generate very little NO (48, 104, 106, 188).", [["Macrophages", "ANATOMY", 0, 11], ["macrophages", "ANATOMY", 42, 53], ["macrophages", "ANATOMY", 112, 123], ["NO", "CHEMICAL", 30, 32], ["NO", "CHEMICAL", 149, 151], ["NO", "CHEMICAL", 30, 32], ["NO", "CHEMICAL", 149, 151], ["Macrophages", "CELL", 0, 11], ["cattle", "ORGANISM", 15, 21], ["NO", "GENE_OR_GENE_PRODUCT", 30, 32], ["macrophages", "CELL", 42, 53], ["hamsters", "ORGANISM", 57, 65], ["monkeys", "ORGANISM", 67, 74], ["goats", "ORGANISM", 76, 81], ["pigs", "ORGANISM", 87, 91], ["human", "ORGANISM", 106, 111], ["macrophages", "CELL", 112, 123], ["NO", "SIMPLE_CHEMICAL", 149, 151], ["Macrophages", "CELL_TYPE", 0, 11], ["macrophages", "CELL_TYPE", 42, 53], ["human macrophages", "CELL_TYPE", 106, 123], ["cattle", "SPECIES", 15, 21], ["hamsters", "SPECIES", 57, 65], ["monkeys", "SPECIES", 67, 74], ["goats", "SPECIES", 76, 81], ["pigs", "SPECIES", 87, 91], ["human", "SPECIES", 106, 111], ["cattle", "SPECIES", 15, 21], ["hamsters", "SPECIES", 57, 65], ["goats", "SPECIES", 76, 81], ["pigs", "SPECIES", 87, 91], ["human", "SPECIES", 106, 111]]], ["Variability in the production of NO by macrophages of different species must be taken into consideration when extrapolating results from animal studies to humans (Table 2).Species differences in chemokines and chemokine receptors. ::: Species Differences in the Innate Immune Response ::: UNIQUE CHARACTERISTICS OF ANIMAL SPECIES IN MODELING HUMAN LUNG INJURYCXCL8/interleukin-8 is a potent neutrophil chemotactic factor that has been implicated in the pathogenesis of ALI (15, 139).", [["macrophages", "ANATOMY", 39, 50], ["NO", "CHEMICAL", 33, 35], ["ALI", "DISEASE", 469, 472], ["NO", "CHEMICAL", 33, 35], ["NO", "GENE_OR_GENE_PRODUCT", 33, 35], ["macrophages", "CELL", 39, 50], ["humans", "ORGANISM", 155, 161], ["interleukin-8", "GENE_OR_GENE_PRODUCT", 365, 378], ["neutrophil", "CELL", 391, 401], ["macrophages", "CELL_TYPE", 39, 50], ["chemokines", "PROTEIN", 195, 205], ["chemokine receptors", "PROTEIN", 210, 229], ["interleukin-8", "PROTEIN", 365, 378], ["neutrophil chemotactic factor", "PROTEIN", 391, 420], ["humans", "SPECIES", 155, 161], ["humans", "SPECIES", 155, 161], ["different species", "PROBLEM", 54, 71], ["animal studies", "TEST", 137, 151], ["Species differences", "PROBLEM", 172, 191], ["chemokine receptors", "TREATMENT", 210, 229], ["MODELING HUMAN LUNG INJURYCXCL8", "TEST", 333, 364], ["interleukin", "TEST", 365, 376], ["a potent neutrophil chemotactic factor", "PROBLEM", 382, 420], ["ALI", "PROBLEM", 469, 472], ["ANIMAL SPECIES", "OBSERVATION", 315, 329], ["LUNG", "ANATOMY", 348, 352], ["potent", "OBSERVATION_MODIFIER", 384, 390], ["neutrophil chemotactic factor", "OBSERVATION", 391, 420], ["ALI", "ANATOMY", 469, 472]]], ["CXCL8 and related CXC-chemokines are produced by all species in response to bacterial products.", [["CXCL8", "GENE_OR_GENE_PRODUCT", 0, 5], ["CXC", "GENE_OR_GENE_PRODUCT", 18, 21], ["CXCL8", "PROTEIN", 0, 5], ["CXC", "PROTEIN", 18, 21], ["chemokines", "PROTEIN", 22, 32], ["CXCL8", "TEST", 0, 5], ["CXC", "TEST", 18, 21], ["chemokines", "PROBLEM", 22, 32], ["all species", "PROBLEM", 49, 60], ["bacterial products", "TREATMENT", 76, 94], ["CXC", "OBSERVATION_MODIFIER", 18, 21], ["bacterial products", "OBSERVATION", 76, 94]]], ["Mice and rats lack the gene for CXCL8 but produce two related CXC chemokines, KC and macrophage inflammatory protein-2 (MIP-2).", [["Mice", "ORGANISM", 0, 4], ["rats", "ORGANISM", 9, 13], ["CXCL8", "GENE_OR_GENE_PRODUCT", 32, 37], ["CXC", "GENE_OR_GENE_PRODUCT", 62, 65], ["KC", "GENE_OR_GENE_PRODUCT", 78, 80], ["macrophage inflammatory protein-2", "GENE_OR_GENE_PRODUCT", 85, 118], ["MIP-2", "GENE_OR_GENE_PRODUCT", 120, 125], ["CXCL8", "PROTEIN", 32, 37], ["CXC chemokines", "PROTEIN", 62, 76], ["KC", "PROTEIN", 78, 80], ["macrophage inflammatory protein-2 (MIP-2", "PROTEIN", 85, 125], ["Mice", "SPECIES", 0, 4], ["rats", "SPECIES", 9, 13], ["CXCL8", "TEST", 32, 37], ["CXC chemokines", "TEST", 62, 76], ["KC", "TEST", 78, 80], ["macrophage inflammatory protein", "TEST", 85, 116], ["MIP", "TEST", 120, 123]]], ["KC and MIP-2 share more sequence identity with human CXCL1-3/GRO\u03b1, \u03b2, and \u03b3 than they do with CXCL8 (253) but are considered the functional homologs of human CXCL8 because of their critical role in the recruitment of neutrophils into lungs (219).", [["neutrophils", "ANATOMY", 217, 228], ["lungs", "ANATOMY", 234, 239], ["KC", "GENE_OR_GENE_PRODUCT", 0, 2], ["MIP-2", "GENE_OR_GENE_PRODUCT", 7, 12], ["human", "ORGANISM", 47, 52], ["CXCL1-3", "GENE_OR_GENE_PRODUCT", 53, 60], ["GRO\u03b1", "GENE_OR_GENE_PRODUCT", 61, 65], ["\u03b2", "GENE_OR_GENE_PRODUCT", 67, 68], ["\u03b3", "GENE_OR_GENE_PRODUCT", 74, 75], ["CXCL8 (253)", "GENE_OR_GENE_PRODUCT", 94, 105], ["human", "ORGANISM", 152, 157], ["CXCL8", "GENE_OR_GENE_PRODUCT", 158, 163], ["neutrophils", "CELL", 217, 228], ["lungs", "ORGAN", 234, 239], ["KC", "PROTEIN", 0, 2], ["MIP", "PROTEIN", 7, 10], ["CXCL1", "PROTEIN", 53, 58], ["GRO\u03b1", "PROTEIN", 61, 65], ["\u03b2", "PROTEIN", 67, 68], ["\u03b3", "DNA", 74, 75], ["CXCL8", "PROTEIN", 94, 99], ["human CXCL8", "PROTEIN", 152, 163], ["neutrophils", "CELL_TYPE", 217, 228], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 152, 157], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 152, 157], ["KC", "TEST", 0, 2], ["MIP", "TEST", 7, 10], ["human CXCL1", "TEST", 47, 58], ["GRO\u03b1", "TEST", 61, 65], ["CXCL8", "TEST", 94, 99], ["human CXCL8", "TEST", 152, 163], ["lungs", "ANATOMY", 234, 239]]], ["Recent work by Fan and colleagues (58) demonstrated that mice express two CXC-receptors, CXCR1 and CXCR2, similar to humans, and that human CXCL8 and mouse GCP-2/CXCL6 bind murine CXCR1.", [["mice", "ORGANISM", 57, 61], ["CXC", "GENE_OR_GENE_PRODUCT", 74, 77], ["CXCR1", "GENE_OR_GENE_PRODUCT", 89, 94], ["CXCR2", "GENE_OR_GENE_PRODUCT", 99, 104], ["humans", "ORGANISM", 117, 123], ["human", "ORGANISM", 134, 139], ["CXCL8", "GENE_OR_GENE_PRODUCT", 140, 145], ["mouse", "ORGANISM", 150, 155], ["GCP-2", "GENE_OR_GENE_PRODUCT", 156, 161], ["CXCL6", "GENE_OR_GENE_PRODUCT", 162, 167], ["murine", "ORGANISM", 173, 179], ["CXCR1", "GENE_OR_GENE_PRODUCT", 180, 185], ["CXC", "PROTEIN", 74, 77], ["CXCR1", "PROTEIN", 89, 94], ["CXCR2", "PROTEIN", 99, 104], ["human CXCL8", "PROTEIN", 134, 145], ["mouse GCP-2", "PROTEIN", 150, 161], ["CXCL6", "PROTEIN", 162, 167], ["murine CXCR1", "PROTEIN", 173, 185], ["mice", "SPECIES", 57, 61], ["humans", "SPECIES", 117, 123], ["human", "SPECIES", 134, 139], ["mouse", "SPECIES", 150, 155], ["murine", "SPECIES", 173, 179], ["mice", "SPECIES", 57, 61], ["humans", "SPECIES", 117, 123], ["human", "SPECIES", 134, 139], ["mouse", "SPECIES", 150, 155], ["two CXC", "TEST", 70, 77], ["CXCR1", "TEST", 89, 94], ["CXCR2", "TEST", 99, 104], ["human CXCL8", "TEST", 134, 145], ["mouse GCP", "TEST", 150, 159], ["CXCR1", "TEST", 180, 185]]], ["In contrast, murine MIP-2 and KC activate neutrophils by binding to murine CXCR2 and do not bind to murine CXCR1.", [["neutrophils", "ANATOMY", 42, 53], ["murine", "ORGANISM", 13, 19], ["MIP-2", "GENE_OR_GENE_PRODUCT", 20, 25], ["KC", "GENE_OR_GENE_PRODUCT", 30, 32], ["neutrophils", "CELL", 42, 53], ["murine", "ORGANISM", 68, 74], ["CXCR2", "GENE_OR_GENE_PRODUCT", 75, 80], ["murine", "ORGANISM", 100, 106], ["CXCR1", "GENE_OR_GENE_PRODUCT", 107, 112], ["MIP", "PROTEIN", 20, 23], ["KC", "PROTEIN", 30, 32], ["neutrophils", "CELL_TYPE", 42, 53], ["murine CXCR2", "PROTEIN", 68, 80], ["murine CXCR1", "PROTEIN", 100, 112], ["murine", "SPECIES", 13, 19], ["murine", "SPECIES", 68, 74], ["murine", "SPECIES", 100, 106], ["murine MIP", "TEST", 13, 23], ["murine CXCR2", "TEST", 68, 80]]], ["Additional work is needed to determine the role of murine GCP-2/CXCL6 in the development of ALI in mice.Animal size. ::: Special Considerations ::: UNIQUE CHARACTERISTICS OF ANIMAL SPECIES IN MODELING HUMAN LUNG INJURYAnimal size is an important consideration in selecting animal models of ALI.", [["ALI", "DISEASE", 92, 95], ["ALI", "DISEASE", 290, 293], ["murine", "ORGANISM", 51, 57], ["GCP-2", "GENE_OR_GENE_PRODUCT", 58, 63], ["CXCL6", "GENE_OR_GENE_PRODUCT", 64, 69], ["mice", "ORGANISM", 99, 103], ["murine GCP-2", "PROTEIN", 51, 63], ["CXCL6", "PROTEIN", 64, 69], ["murine", "SPECIES", 51, 57], ["mice", "SPECIES", 99, 103], ["mice", "SPECIES", 99, 103], ["murine GCP", "TEST", 51, 61], ["CXCL6", "TREATMENT", 64, 69], ["ANIMAL SPECIES IN MODELING HUMAN LUNG INJURYAnimal size", "PROBLEM", 174, 229], ["ALI", "PROBLEM", 290, 293], ["ALI", "OBSERVATION", 92, 95], ["size", "OBSERVATION_MODIFIER", 111, 115], ["ANIMAL SPECIES", "OBSERVATION", 174, 188], ["HUMAN", "ANATOMY_MODIFIER", 201, 206], ["LUNG", "ANATOMY", 207, 211], ["INJURYAnimal", "OBSERVATION_MODIFIER", 212, 224], ["size", "OBSERVATION_MODIFIER", 225, 229], ["important consideration", "UNCERTAINTY", 236, 259], ["ALI", "OBSERVATION", 290, 293]]], ["This is especially true when physiological parameters such as arterial oxygen tension and mean arterial pressure are monitored (135).", [["arterial", "ANATOMY", 62, 70], ["arterial", "ANATOMY", 95, 103], ["oxygen", "CHEMICAL", 71, 77], ["oxygen", "CHEMICAL", 71, 77], ["arterial", "MULTI-TISSUE_STRUCTURE", 62, 70], ["oxygen", "SIMPLE_CHEMICAL", 71, 77], ["arterial", "MULTI-TISSUE_STRUCTURE", 95, 103], ["physiological parameters", "TEST", 29, 53], ["arterial oxygen tension", "TEST", 62, 85], ["mean arterial pressure", "TEST", 90, 112], ["arterial", "ANATOMY", 62, 70], ["oxygen tension", "OBSERVATION", 71, 85]]], ["Until recently, body size has prohibited the measurement of physiological parameters in mice.", [["body", "ANATOMY", 16, 20], ["body", "ORGANISM_SUBDIVISION", 16, 20], ["mice", "ORGANISM", 88, 92], ["mice", "SPECIES", 88, 92], ["mice", "SPECIES", 88, 92], ["size", "OBSERVATION_MODIFIER", 21, 25]]], ["With the development of small implantable radiotelemetry transmitters, the measurement of systemic blood pressure, heart rate, and temperature is now possible in unrestrained mice, although it remains difficult and expensive (27).", [["blood", "ANATOMY", 99, 104], ["heart", "ANATOMY", 115, 120], ["blood", "ORGANISM_SUBSTANCE", 99, 104], ["heart", "ORGAN", 115, 120], ["mice", "ORGANISM", 175, 179], ["mice", "SPECIES", 175, 179], ["mice", "SPECIES", 175, 179], ["small implantable radiotelemetry transmitters", "TREATMENT", 24, 69], ["systemic blood pressure", "TEST", 90, 113], ["heart rate", "TEST", 115, 125], ["small", "OBSERVATION_MODIFIER", 24, 29], ["implantable radiotelemetry", "OBSERVATION", 30, 56], ["heart", "ANATOMY", 115, 120]]], ["Size is also an important consideration for the collection of blood.", [["blood", "ANATOMY", 62, 67], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["the collection of blood", "PROBLEM", 44, 67], ["important consideration for", "UNCERTAINTY", 16, 43], ["collection", "OBSERVATION", 48, 58], ["blood", "OBSERVATION", 62, 67]]], ["It is easier to obtain sufficient quantities of blood or to obtain multiple blood samples in larger species such as the rabbit or nonhuman primates.", [["blood", "ANATOMY", 48, 53], ["blood samples", "ANATOMY", 76, 89], ["blood", "ORGANISM_SUBSTANCE", 48, 53], ["blood samples", "ORGANISM_SUBSTANCE", 76, 89], ["rabbit", "ORGANISM", 120, 126], ["nonhuman primates", "ORGANISM", 130, 147], ["rabbit", "SPECIES", 120, 126], ["rabbit", "SPECIES", 120, 126], ["multiple blood samples", "TEST", 67, 89], ["larger species", "PROBLEM", 93, 107]]], ["The ability to obtain multiple blood samples is important when the study design requires monitoring of physiological parameters, such as blood gases, plasma cytokines, and leukocyte counts over time.", [["blood samples", "ANATOMY", 31, 44], ["blood", "ANATOMY", 137, 142], ["plasma", "ANATOMY", 150, 156], ["leukocyte", "ANATOMY", 172, 181], ["blood samples", "ORGANISM_SUBSTANCE", 31, 44], ["blood", "ORGANISM_SUBSTANCE", 137, 142], ["plasma", "ORGANISM_SUBSTANCE", 150, 156], ["leukocyte", "CELL", 172, 181], ["plasma cytokines", "PROTEIN", 150, 166], ["multiple blood samples", "TEST", 22, 44], ["the study", "TEST", 63, 72], ["monitoring of physiological parameters", "TEST", 89, 127], ["blood gases", "TEST", 137, 148], ["plasma cytokines", "TEST", 150, 166], ["leukocyte counts", "TEST", 172, 188], ["leukocyte", "ANATOMY", 172, 181]]], ["Conversely, cost constraints, the amount of reagent required, and availability can limit the use of larger species.Species-specific reagents. ::: Special Considerations ::: UNIQUE CHARACTERISTICS OF ANIMAL SPECIES IN MODELING HUMAN LUNG INJURYInvestigators are often faced with a lack of species-specific reagents to measure inflammatory mediators, receptors, or other proteins, which are involved in the pathogenesis of ALI.", [["ALI", "DISEASE", 421, 424], ["inflammatory mediators", "PROTEIN", 325, 347], ["larger species", "PROBLEM", 100, 114], ["ANIMAL SPECIES IN MODELING HUMAN LUNG INJURYInvestigators", "PROBLEM", 199, 256], ["a lack of species", "PROBLEM", 278, 295], ["inflammatory mediators", "PROBLEM", 325, 347], ["other proteins", "PROBLEM", 363, 377], ["ALI", "PROBLEM", 421, 424], ["ANIMAL SPECIES", "OBSERVATION", 199, 213], ["LUNG", "ANATOMY", 232, 236], ["ALI", "OBSERVATION", 421, 424]]], ["To circumvent this problem, cross-species reagents have been used.", [["this problem", "PROBLEM", 14, 26], ["cross-species reagents", "TREATMENT", 28, 50]]], ["In several studies in which comparisons were made between species-specific and cross-species ELISAs, species-specific ELISAs produced more sensitive and specific results (107, 108).", [["several studies", "TEST", 3, 18], ["cross-species ELISAs", "TEST", 79, 99], ["specific ELISAs", "TEST", 109, 124]]], ["While this does not exclude their use, cross-species ELISA may underestimate the amount of a specific protein in a biological sample.The Mouse as a Tool to Study the Biology of ALI ::: UNIQUE CHARACTERISTICS OF ANIMAL SPECIES IN MODELING HUMAN LUNG INJURYMouse models of human disease are widely used because of the availability of specific reagents and the development of genetically modified mice that can be used to evaluate the physiological function of specific genes.", [["ALI", "DISEASE", 177, 180], ["human disease", "DISEASE", 271, 284], ["Mouse", "ORGANISM", 137, 142], ["human", "ORGANISM", 271, 276], ["mice", "ORGANISM", 394, 398], ["Mouse", "SPECIES", 137, 142], ["human", "SPECIES", 271, 276], ["mice", "SPECIES", 394, 398], ["human", "SPECIES", 271, 276], ["mice", "SPECIES", 394, 398], ["cross-species ELISA", "TEST", 39, 58], ["ANIMAL SPECIES", "PROBLEM", 211, 225], ["human disease", "PROBLEM", 271, 284], ["specific reagents", "TREATMENT", 332, 349], ["genetically modified mice", "TREATMENT", 373, 398], ["ANIMAL SPECIES", "OBSERVATION", 211, 225], ["LUNG", "ANATOMY", 244, 248], ["INJURYMouse", "OBSERVATION", 249, 260], ["human disease", "OBSERVATION", 271, 284]]], ["Genetically modified mice have been used extensively in the study of inflammatory processes in the lungs.", [["lungs", "ANATOMY", 99, 104], ["mice", "ORGANISM", 21, 25], ["lungs", "ORGAN", 99, 104], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 21, 25], ["the study", "TEST", 56, 65], ["inflammatory processes in the lungs", "PROBLEM", 69, 104], ["inflammatory", "OBSERVATION", 69, 81], ["lungs", "ANATOMY", 99, 104]]], ["A number of excellent reviews of the production of genetically modified mice are available (56, 97, 203) (reviewed in Refs.", [["mice", "ORGANISM", 72, 76], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 72, 76], ["excellent", "OBSERVATION_MODIFIER", 12, 21]]], ["An important consideration when using genetically modified mice is the selection of appropriate controls to eliminate genetic and environmental background effects (200).", [["mice", "ORGANISM", 59, 63], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 59, 63]]], ["The best controls are congenic mice, which are essentially isogenic with an inbred strain of mice except for the gene of interest.", [["mice", "ORGANISM", 31, 35], ["mice", "ORGANISM", 93, 97], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 93, 97], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 93, 97], ["an inbred strain of mice", "PROBLEM", 73, 97], ["congenic mice", "OBSERVATION", 22, 35], ["essentially", "OBSERVATION_MODIFIER", 47, 58], ["isogenic", "OBSERVATION_MODIFIER", 59, 67]]], ["Another option is to use the offspring of heterozygous breeding pairs, so that age- and sex-matched littermates can be used to minimize environmental and genetic variability.", [["littermates", "ORGANISM", 100, 111], ["heterozygous breeding pairs", "PROBLEM", 42, 69]]], ["From a practical standpoint it is often difficult to use congenic mice or the offspring of heterozygous breeding pairs because of the number of animals involved.", [["mice", "ORGANISM", 66, 70], ["mice", "SPECIES", 66, 70], ["mice", "SPECIES", 66, 70], ["congenic mice", "TREATMENT", 57, 70], ["heterozygous breeding pairs", "PROBLEM", 91, 118]]], ["However, it is important to understand how to select appropriate controls for experiments using transgenic mice so that robust conclusions can be drawn about the function of specific genes.The Mouse as a Tool to Study the Biology of ALI ::: UNIQUE CHARACTERISTICS OF ANIMAL SPECIES IN MODELING HUMAN LUNG INJURYALI has many etiologies, suggesting that numerous genetic, environmental, and developmental factors are involved in the progression of this clinical syndrome.", [["ALI", "DISEASE", 233, 236], ["mice", "ORGANISM", 107, 111], ["Mouse", "ORGANISM", 193, 198], ["mice", "SPECIES", 107, 111], ["Mouse", "SPECIES", 193, 198], ["mice", "SPECIES", 107, 111], ["transgenic mice", "TREATMENT", 96, 111], ["ANIMAL SPECIES", "PROBLEM", 267, 281], ["developmental factors", "PROBLEM", 389, 410], ["this clinical syndrome", "PROBLEM", 446, 468], ["ANIMAL SPECIES", "OBSERVATION", 267, 281], ["HUMAN", "ANATOMY_MODIFIER", 294, 299], ["LUNG", "ANATOMY", 300, 304], ["INJURYALI", "ANATOMY_MODIFIER", 305, 314], ["numerous", "OBSERVATION_MODIFIER", 352, 360], ["genetic", "OBSERVATION", 361, 368]]], ["In recent years, genomic, proteomic, statistical, and computational resources have been applied to developing animal models that can be used to investigate complex genetic traits.", [["computational resources", "TREATMENT", 54, 77]]], ["Specific examples include association mapping in classic inbred mouse strains (32, 160).", [["mouse", "ORGANISM", 64, 69], ["mouse", "SPECIES", 64, 69], ["mouse", "SPECIES", 64, 69], ["classic inbred mouse strains", "PROBLEM", 49, 77]]], ["By taking full advantage of the genetic power of mice, investigators will be able to better understand complex disease processes such as ALI.", [["ALI", "DISEASE", 137, 140], ["mice", "ORGANISM", 49, 53], ["mice", "SPECIES", 49, 53], ["mice", "SPECIES", 49, 53], ["complex disease processes", "PROBLEM", 103, 128], ["ALI", "PROBLEM", 137, 140], ["ALI", "OBSERVATION", 137, 140]]], ["However, it is also important to remember that mice and humans have evolved under different evolutionary pressures, so caution is needed when extrapolating findings in mouse models to human disease.Oleic acid. ::: Models That Target Primarily the Capillary Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSBasis for the model: oleic acid (cis-9-octadecenoic acid) is the most common free fatty acid in mammals, representing 60% of the free fatty acid pool (61).", [["human disease", "DISEASE", 184, 197], ["Oleic acid", "CHEMICAL", 198, 208], ["oleic acid", "CHEMICAL", 336, 346], ["cis-9-octadecenoic acid", "CHEMICAL", 348, 371], ["fatty acid", "CHEMICAL", 397, 407], ["fatty acid", "CHEMICAL", 449, 459], ["Oleic acid", "CHEMICAL", 198, 208], ["oleic acid", "CHEMICAL", 336, 346], ["cis-9-octadecenoic acid", "CHEMICAL", 348, 371], ["fatty acid", "CHEMICAL", 397, 407], ["fatty acid", "CHEMICAL", 449, 459], ["mice", "ORGANISM", 47, 51], ["humans", "ORGANISM", 56, 62], ["mouse", "ORGANISM", 168, 173], ["human", "ORGANISM", 184, 189], ["Oleic acid", "SIMPLE_CHEMICAL", 198, 208], ["Capillary Endothelium", "TISSUE", 247, 268], ["oleic acid", "SIMPLE_CHEMICAL", 336, 346], ["cis-9-octadecenoic acid", "SIMPLE_CHEMICAL", 348, 371], ["free fatty acid", "SIMPLE_CHEMICAL", 392, 407], ["free fatty acid", "SIMPLE_CHEMICAL", 444, 459], ["mice", "SPECIES", 47, 51], ["humans", "SPECIES", 56, 62], ["mouse", "SPECIES", 168, 173], ["human", "SPECIES", 184, 189], ["mice", "SPECIES", 47, 51], ["humans", "SPECIES", 56, 62], ["mouse", "SPECIES", 168, 173], ["human", "SPECIES", 184, 189], ["human disease", "PROBLEM", 184, 197], ["LUNG INJURY", "PROBLEM", 290, 301], ["oleic acid", "TEST", 336, 346], ["cis", "TEST", 348, 351], ["octadecenoic acid", "TEST", 354, 371], ["the free fatty acid pool", "TEST", 440, 464], ["pressures", "OBSERVATION_MODIFIER", 105, 114], ["acid", "OBSERVATION_MODIFIER", 204, 208], ["Capillary Endothelium", "OBSERVATION", 247, 268], ["LUNG", "ANATOMY", 290, 294], ["INJURY", "OBSERVATION", 295, 301], ["fatty acid", "OBSERVATION", 397, 407]]], ["Oleic acid also represents \u223c50% of the total fatty acids present in pulmonary emboli in patients with long bone trauma (198).", [["pulmonary emboli", "ANATOMY", 68, 84], ["bone", "ANATOMY", 107, 111], ["Oleic acid", "CHEMICAL", 0, 10], ["fatty acids", "CHEMICAL", 45, 56], ["pulmonary emboli", "DISEASE", 68, 84], ["bone trauma", "DISEASE", 107, 118], ["Oleic acid", "CHEMICAL", 0, 10], ["fatty acids", "CHEMICAL", 45, 56], ["Oleic acid", "SIMPLE_CHEMICAL", 0, 10], ["fatty acids", "SIMPLE_CHEMICAL", 45, 56], ["pulmonary emboli", "MULTI-TISSUE_STRUCTURE", 68, 84], ["patients", "ORGANISM", 88, 96], ["bone", "TISSUE", 107, 111], ["patients", "SPECIES", 88, 96], ["Oleic acid", "TEST", 0, 10], ["the total fatty acids", "TEST", 35, 56], ["pulmonary emboli", "PROBLEM", 68, 84], ["long bone trauma", "PROBLEM", 102, 118], ["acid", "OBSERVATION_MODIFIER", 6, 10], ["fatty acids", "OBSERVATION", 45, 56], ["pulmonary", "ANATOMY", 68, 77], ["emboli", "OBSERVATION", 78, 84], ["long", "OBSERVATION_MODIFIER", 102, 106], ["bone", "ANATOMY", 107, 111], ["trauma", "OBSERVATION", 112, 118]]], ["The oleic acid model was developed as an attempt to reproduce ALI due to lipid embolism (191).Oleic acid. ::: Models That Target Primarily the Capillary Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSMechanism: oleic acid is directly toxic to endothelial cells at concentrations of 5 \u00d7 10\u22124 M in vitro (17).", [["endothelial cells", "ANATOMY", 254, 271], ["oleic acid", "CHEMICAL", 4, 14], ["ALI", "DISEASE", 62, 65], ["lipid embolism", "DISEASE", 73, 87], ["Oleic acid", "CHEMICAL", 94, 104], ["oleic acid", "CHEMICAL", 222, 232], ["oleic acid", "CHEMICAL", 4, 14], ["Oleic acid", "CHEMICAL", 94, 104], ["oleic acid", "CHEMICAL", 222, 232], ["oleic acid", "SIMPLE_CHEMICAL", 4, 14], ["Oleic acid", "SIMPLE_CHEMICAL", 94, 104], ["Capillary Endothelium", "TISSUE", 143, 164], ["oleic acid", "SIMPLE_CHEMICAL", 222, 232], ["endothelial cells", "CELL", 254, 271], ["endothelial cells", "CELL_TYPE", 254, 271], ["The oleic acid model", "TEST", 0, 20], ["ALI", "PROBLEM", 62, 65], ["lipid embolism", "PROBLEM", 73, 87], ["LUNG INJURY", "PROBLEM", 186, 197], ["oleic acid", "PROBLEM", 222, 232], ["oleic", "OBSERVATION_MODIFIER", 4, 9], ["acid model", "OBSERVATION", 10, 20], ["lipid embolism", "OBSERVATION", 73, 87], ["acid", "OBSERVATION_MODIFIER", 100, 104], ["Capillary Endothelium", "OBSERVATION", 143, 164], ["LUNG", "ANATOMY", 186, 190], ["INJURY", "OBSERVATION", 191, 197], ["oleic acid", "OBSERVATION", 222, 232]]], ["Within 1 min of intravenous oleic acid administration (0.04 ml/kg in dogs), electron microscopy reveals severe vacuolation of endothelial cells, and passage of an intravascular marker, Evans blue dye, into the subendothelial space (144).", [["intravenous", "ANATOMY", 16, 27], ["endothelial cells", "ANATOMY", 126, 143], ["intravascular", "ANATOMY", 163, 176], ["subendothelial space", "ANATOMY", 210, 230], ["oleic acid", "CHEMICAL", 28, 38], ["oleic acid", "CHEMICAL", 28, 38], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 16, 27], ["oleic acid", "SIMPLE_CHEMICAL", 28, 38], ["endothelial cells", "CELL", 126, 143], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 163, 176], ["Evans blue dye", "SIMPLE_CHEMICAL", 185, 199], ["subendothelial space", "CELLULAR_COMPONENT", 210, 230], ["endothelial cells", "CELL_TYPE", 126, 143], ["intravenous oleic acid administration", "TREATMENT", 16, 53], ["electron microscopy", "TEST", 76, 95], ["severe vacuolation of endothelial cells", "PROBLEM", 104, 143], ["an intravascular marker", "TEST", 160, 183], ["Evans blue dye", "TREATMENT", 185, 199], ["severe", "OBSERVATION_MODIFIER", 104, 110], ["vacuolation", "OBSERVATION", 111, 122], ["endothelial cells", "OBSERVATION", 126, 143], ["intravascular marker", "OBSERVATION", 163, 183], ["subendothelial space", "ANATOMY", 210, 230]]], ["The damage to the endothelium appears to be due to necrosis, rather than apoptosis (96).", [["endothelium", "ANATOMY", 18, 29], ["necrosis", "DISEASE", 51, 59], ["endothelium", "TISSUE", 18, 29], ["The damage to the endothelium", "PROBLEM", 0, 29], ["necrosis", "PROBLEM", 51, 59], ["apoptosis", "TEST", 73, 82], ["damage", "OBSERVATION", 4, 10], ["endothelium", "ANATOMY", 18, 29], ["appears to be due to", "UNCERTAINTY", 30, 50], ["necrosis", "OBSERVATION", 51, 59]]], ["Endothelial injury is followed by epithelial injury, with swelling and necrosis of type I cells, but no evidence of apoptosis (96).", [["Endothelial", "ANATOMY", 0, 11], ["epithelial", "ANATOMY", 34, 44], ["type I cells", "ANATOMY", 83, 95], ["Endothelial injury", "DISEASE", 0, 18], ["swelling", "DISEASE", 58, 66], ["necrosis", "DISEASE", 71, 79], ["Endothelial", "TISSUE", 0, 11], ["epithelial", "TISSUE", 34, 44], ["type I cells", "CELL", 83, 95], ["type I cells", "CELL_TYPE", 83, 95], ["Endothelial injury", "PROBLEM", 0, 18], ["epithelial injury", "PROBLEM", 34, 51], ["swelling", "PROBLEM", 58, 66], ["necrosis of type I cells", "PROBLEM", 71, 95], ["apoptosis", "PROBLEM", 116, 125], ["injury", "OBSERVATION", 12, 18], ["epithelial", "OBSERVATION_MODIFIER", 34, 44], ["injury", "OBSERVATION", 45, 51], ["swelling", "OBSERVATION", 58, 66], ["necrosis", "OBSERVATION", 71, 79], ["type I cells", "OBSERVATION_MODIFIER", 83, 95], ["no evidence of", "UNCERTAINTY", 101, 115], ["apoptosis", "OBSERVATION", 116, 125]]], ["Within 30 min, oleic acid becomes detectable in the air spaces.", [["oleic acid", "CHEMICAL", 15, 25], ["oleic acid", "CHEMICAL", 15, 25], ["oleic acid", "SIMPLE_CHEMICAL", 15, 25], ["oleic acid", "TEST", 15, 25], ["air spaces", "OBSERVATION", 52, 62]]], ["Oleic acid is not detected intracellularly and remains in the extracellular space and the air spaces (17).", [["extracellular space", "ANATOMY", 62, 81], ["Oleic acid", "CHEMICAL", 0, 10], ["Oleic acid", "CHEMICAL", 0, 10], ["Oleic acid", "SIMPLE_CHEMICAL", 0, 10], ["extracellular space", "CELLULAR_COMPONENT", 62, 81], ["Oleic acid", "TEST", 0, 10], ["acid", "OBSERVATION_MODIFIER", 6, 10], ["not detected", "UNCERTAINTY", 14, 26], ["intracellularly", "OBSERVATION_MODIFIER", 27, 42], ["extracellular", "ANATOMY_MODIFIER", 62, 75], ["space", "ANATOMY_MODIFIER", 76, 81], ["air spaces", "OBSERVATION", 90, 100]]], ["The actual mechanism whereby oleic acid induces cell death is not clear, but direct membrane damage is likely to be an important event.Oleic acid. ::: Models That Target Primarily the Capillary Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSTechnical issues: oleic acid is insoluble in water and must be dissolved in ethanol or emulsified in blood before administration.", [["cell", "ANATOMY", 48, 52], ["membrane", "ANATOMY", 84, 92], ["blood", "ANATOMY", 353, 358], ["oleic acid", "CHEMICAL", 29, 39], ["death", "DISEASE", 53, 58], ["Oleic acid", "CHEMICAL", 135, 145], ["oleic acid", "CHEMICAL", 270, 280], ["ethanol", "CHEMICAL", 328, 335], ["oleic acid", "CHEMICAL", 29, 39], ["Oleic acid", "CHEMICAL", 135, 145], ["oleic acid", "CHEMICAL", 270, 280], ["ethanol", "CHEMICAL", 328, 335], ["oleic acid", "SIMPLE_CHEMICAL", 29, 39], ["cell", "CELL", 48, 52], ["membrane", "CELLULAR_COMPONENT", 84, 92], ["Oleic acid", "SIMPLE_CHEMICAL", 135, 145], ["Capillary Endothelium", "TISSUE", 184, 205], ["oleic acid", "SIMPLE_CHEMICAL", 270, 280], ["water", "SIMPLE_CHEMICAL", 297, 302], ["ethanol", "SIMPLE_CHEMICAL", 328, 335], ["blood", "ORGANISM_SUBSTANCE", 353, 358], ["oleic acid induces cell death", "PROBLEM", 29, 58], ["direct membrane damage", "PROBLEM", 77, 99], ["LUNG INJURY", "PROBLEM", 227, 238], ["oleic acid", "PROBLEM", 270, 280], ["oleic acid", "OBSERVATION", 29, 39], ["cell death", "OBSERVATION", 48, 58], ["likely to be", "UNCERTAINTY", 103, 115], ["acid", "OBSERVATION_MODIFIER", 141, 145], ["Capillary Endothelium", "OBSERVATION", 184, 205], ["LUNG", "ANATOMY", 227, 231], ["INJURY", "OBSERVATION", 232, 238]]], ["It can be administered via a peripheral vein, a central vein, or directly into the right atrium or the pulmonary artery.", [["peripheral vein", "ANATOMY", 29, 44], ["central vein", "ANATOMY", 48, 60], ["right atrium", "ANATOMY", 83, 95], ["pulmonary artery", "ANATOMY", 103, 119], ["peripheral vein", "MULTI-TISSUE_STRUCTURE", 29, 44], ["central vein", "MULTI-TISSUE_STRUCTURE", 48, 60], ["atrium", "MULTI-TISSUE_STRUCTURE", 89, 95], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 103, 119], ["a peripheral vein", "TREATMENT", 27, 44], ["a central vein", "TREATMENT", 46, 60], ["peripheral vein", "ANATOMY", 29, 44], ["central vein", "ANATOMY", 48, 60], ["right atrium", "ANATOMY", 83, 95], ["pulmonary artery", "ANATOMY", 103, 119]]], ["Because of the need for intravenous administration, oleic acid has been used more extensively in rats and larger animals than in mice.", [["intravenous", "ANATOMY", 24, 35], ["oleic acid", "CHEMICAL", 52, 62], ["oleic acid", "CHEMICAL", 52, 62], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 24, 35], ["oleic acid", "SIMPLE_CHEMICAL", 52, 62], ["rats", "ORGANISM", 97, 101], ["mice", "ORGANISM", 129, 133], ["rats", "SPECIES", 97, 101], ["mice", "SPECIES", 129, 133], ["mice", "SPECIES", 129, 133], ["intravenous administration", "TREATMENT", 24, 50], ["oleic acid", "TREATMENT", 52, 62], ["larger", "OBSERVATION_MODIFIER", 106, 112], ["animals", "OBSERVATION_MODIFIER", 113, 120]]], ["Regardless of the route of intravenous administration (peripheral vs. central), the effects of oleic acid are evident almost immediately (247).", [["intravenous", "ANATOMY", 27, 38], ["oleic acid", "CHEMICAL", 95, 105], ["oleic acid", "CHEMICAL", 95, 105], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 27, 38], ["oleic acid", "SIMPLE_CHEMICAL", 95, 105], ["intravenous administration (peripheral vs. central)", "TREATMENT", 27, 78], ["oleic acid", "PROBLEM", 95, 105], ["oleic acid", "OBSERVATION", 95, 105]]], ["Single doses of oleic acid lead to ALI that is greatest at 12 h and decreases towards 24 h, whereas repeated doses result in pulmonary fibrosis (44).Oleic acid. ::: Models That Target Primarily the Capillary Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSCharacteristics of the lung injury: oleic-acid lung injury is characterized by an early phase of necrosis and microvascular thrombosis, followed by a repair stage with proliferation of type 2 cells and fibrotic foci in subpleural areas (44).", [["pulmonary", "ANATOMY", 125, 134], ["lung", "ANATOMY", 289, 293], ["lung", "ANATOMY", 313, 317], ["microvascular", "ANATOMY", 376, 389], ["type 2 cells", "ANATOMY", 451, 463], ["fibrotic foci", "ANATOMY", 468, 481], ["subpleural areas", "ANATOMY", 485, 501], ["oleic acid", "CHEMICAL", 16, 26], ["ALI", "DISEASE", 35, 38], ["fibrosis", "DISEASE", 135, 143], ["Oleic acid", "CHEMICAL", 149, 159], ["lung injury", "DISEASE", 289, 300], ["oleic-acid", "CHEMICAL", 302, 312], ["lung injury", "DISEASE", 313, 324], ["necrosis", "DISEASE", 363, 371], ["thrombosis", "DISEASE", 390, 400], ["oleic acid", "CHEMICAL", 16, 26], ["Oleic acid", "CHEMICAL", 149, 159], ["oleic-acid", "CHEMICAL", 302, 312], ["oleic acid", "SIMPLE_CHEMICAL", 16, 26], ["pulmonary", "ORGAN", 125, 134], ["Oleic acid", "SIMPLE_CHEMICAL", 149, 159], ["Capillary Endothelium", "TISSUE", 198, 219], ["lung", "ORGAN", 289, 293], ["oleic-acid", "SIMPLE_CHEMICAL", 302, 312], ["lung", "ORGAN", 313, 317], ["microvascular", "TISSUE", 376, 389], ["type 2 cells", "CELL", 451, 463], ["fibrotic foci", "CELL", 468, 481], ["subpleural areas", "MULTI-TISSUE_STRUCTURE", 485, 501], ["type 2 cells", "CELL_TYPE", 451, 463], ["oleic acid lead", "TREATMENT", 16, 31], ["ALI", "PROBLEM", 35, 38], ["pulmonary fibrosis", "PROBLEM", 125, 143], ["LUNG INJURY", "PROBLEM", 241, 252], ["the lung injury", "PROBLEM", 285, 300], ["oleic-acid lung injury", "PROBLEM", 302, 324], ["necrosis", "PROBLEM", 363, 371], ["microvascular thrombosis", "PROBLEM", 376, 400], ["a repair stage", "TREATMENT", 414, 428], ["type 2 cells", "PROBLEM", 451, 463], ["fibrotic foci in subpleural areas", "PROBLEM", 468, 501], ["greatest", "OBSERVATION_MODIFIER", 47, 55], ["pulmonary", "ANATOMY", 125, 134], ["fibrosis", "OBSERVATION", 135, 143], ["acid", "OBSERVATION_MODIFIER", 155, 159], ["Capillary Endothelium", "OBSERVATION", 198, 219], ["LUNG", "ANATOMY", 241, 245], ["INJURY", "OBSERVATION", 246, 252], ["MODEL SYSTEMSCharacteristics", "OBSERVATION", 253, 281], ["lung", "ANATOMY", 289, 293], ["injury", "OBSERVATION", 294, 300], ["oleic", "OBSERVATION_MODIFIER", 302, 307], ["acid", "ANATOMY_MODIFIER", 308, 312], ["lung", "ANATOMY", 313, 317], ["injury", "OBSERVATION", 318, 324], ["early", "OBSERVATION_MODIFIER", 348, 353], ["phase", "OBSERVATION_MODIFIER", 354, 359], ["necrosis", "OBSERVATION", 363, 371], ["microvascular", "OBSERVATION_MODIFIER", 376, 389], ["thrombosis", "OBSERVATION", 390, 400], ["proliferation", "OBSERVATION_MODIFIER", 434, 447], ["type 2", "OBSERVATION_MODIFIER", 451, 457], ["cells", "OBSERVATION", 458, 463], ["fibrotic", "OBSERVATION_MODIFIER", 468, 476], ["foci", "OBSERVATION", 477, 481], ["subpleural", "ANATOMY_MODIFIER", 485, 495]]], ["Microscopically, the injury is multifocal and heterogeneous, with some areas showing only minimal changes; other areas show interstitial edema and varying degrees of air space edema, and some areas show extensive hemorrhagic infiltration with fibrin deposition (74, 221) (Fig. 2).", [["interstitial edema", "ANATOMY", 124, 142], ["air space edema", "ANATOMY", 166, 181], ["interstitial edema", "DISEASE", 124, 142], ["air space edema", "DISEASE", 166, 181], ["hemorrhagic", "DISEASE", 213, 224], ["interstitial edema", "PATHOLOGICAL_FORMATION", 124, 142], ["edema", "PATHOLOGICAL_FORMATION", 176, 181], ["fibrin", "GENE_OR_GENE_PRODUCT", 243, 249], ["the injury", "PROBLEM", 17, 27], ["minimal changes", "PROBLEM", 90, 105], ["interstitial edema", "PROBLEM", 124, 142], ["air space edema", "PROBLEM", 166, 181], ["extensive hemorrhagic infiltration", "PROBLEM", 203, 237], ["fibrin deposition", "PROBLEM", 243, 260], ["injury", "OBSERVATION", 21, 27], ["multifocal", "OBSERVATION_MODIFIER", 31, 41], ["heterogeneous", "OBSERVATION_MODIFIER", 46, 59], ["minimal", "OBSERVATION_MODIFIER", 90, 97], ["changes", "OBSERVATION", 98, 105], ["interstitial", "ANATOMY_MODIFIER", 124, 136], ["edema", "OBSERVATION", 137, 142], ["varying", "OBSERVATION_MODIFIER", 147, 154], ["degrees", "OBSERVATION_MODIFIER", 155, 162], ["air space edema", "OBSERVATION", 166, 181], ["extensive", "OBSERVATION_MODIFIER", 203, 212], ["hemorrhagic", "OBSERVATION_MODIFIER", 213, 224], ["infiltration", "OBSERVATION", 225, 237], ["fibrin deposition", "OBSERVATION", 243, 260]]], ["There is neutrophilic infiltration, but the injury is not dependent on PMN, suggesting that a direct effect of oleic acid on the endothelium is the critical event (105).", [["neutrophilic", "ANATOMY", 9, 21], ["PMN", "ANATOMY", 71, 74], ["endothelium", "ANATOMY", 129, 140], ["oleic acid", "CHEMICAL", 111, 121], ["oleic acid", "CHEMICAL", 111, 121], ["PMN", "CELL", 71, 74], ["oleic acid", "SIMPLE_CHEMICAL", 111, 121], ["endothelium", "TISSUE", 129, 140], ["PMN", "CELL_TYPE", 71, 74], ["neutrophilic infiltration", "PROBLEM", 9, 34], ["the injury", "PROBLEM", 40, 50], ["PMN", "TEST", 71, 74], ["oleic acid", "TREATMENT", 111, 121], ["neutrophilic", "OBSERVATION_MODIFIER", 9, 21], ["infiltration", "OBSERVATION", 22, 34], ["injury", "OBSERVATION", 44, 50]]], ["Electron microscopic examination reveals necrosis and detachment of alveolar epithelial cells, necrosis of endothelial cells, and exposure of the basement membrane on both the epithelial and the endothelial sides (221).", [["alveolar epithelial cells", "ANATOMY", 68, 93], ["endothelial cells", "ANATOMY", 107, 124], ["basement membrane", "ANATOMY", 146, 163], ["epithelial", "ANATOMY", 176, 186], ["endothelial sides", "ANATOMY", 195, 212], ["necrosis", "DISEASE", 41, 49], ["necrosis", "DISEASE", 95, 103], ["alveolar epithelial cells", "CELL", 68, 93], ["endothelial cells", "CELL", 107, 124], ["basement membrane", "CELLULAR_COMPONENT", 146, 163], ["epithelial", "TISSUE", 176, 186], ["endothelial sides", "TISSUE", 195, 212], ["alveolar epithelial cells", "CELL_TYPE", 68, 93], ["endothelial cells", "CELL_TYPE", 107, 124], ["Electron microscopic examination", "TEST", 0, 32], ["necrosis", "PROBLEM", 41, 49], ["detachment", "PROBLEM", 54, 64], ["alveolar epithelial cells", "PROBLEM", 68, 93], ["necrosis of endothelial cells", "PROBLEM", 95, 124], ["necrosis", "OBSERVATION", 41, 49], ["detachment", "OBSERVATION_MODIFIER", 54, 64], ["alveolar", "ANATOMY_MODIFIER", 68, 76], ["epithelial cells", "OBSERVATION", 77, 93], ["necrosis", "OBSERVATION", 95, 103], ["endothelial cells", "OBSERVATION", 107, 124], ["basement", "ANATOMY_MODIFIER", 146, 154], ["membrane", "ANATOMY_MODIFIER", 155, 163], ["both", "ANATOMY_MODIFIER", 167, 171], ["epithelial", "ANATOMY_MODIFIER", 176, 186], ["endothelial", "ANATOMY", 195, 206], ["sides", "ANATOMY_MODIFIER", 207, 212]]], ["On macroscopic examination, the lungs show patchy areas of hemorrhage and edema, which become confluent in dependent areas.", [["lungs", "ANATOMY", 32, 37], ["edema", "ANATOMY", 74, 79], ["hemorrhage", "DISEASE", 59, 69], ["edema", "DISEASE", 74, 79], ["lungs", "ORGAN", 32, 37], ["edema", "PATHOLOGICAL_FORMATION", 74, 79], ["macroscopic examination", "TEST", 3, 26], ["hemorrhage", "PROBLEM", 59, 69], ["edema", "PROBLEM", 74, 79], ["lungs", "ANATOMY", 32, 37], ["patchy", "OBSERVATION_MODIFIER", 43, 49], ["hemorrhage", "OBSERVATION", 59, 69], ["edema", "OBSERVATION", 74, 79], ["confluent", "OBSERVATION_MODIFIER", 94, 103], ["dependent", "OBSERVATION_MODIFIER", 107, 116], ["areas", "OBSERVATION_MODIFIER", 117, 122]]], ["Nondependent areas are usually spared (44, 46).Oleic acid. ::: Models That Target Primarily the Capillary Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSThe histological changes of oleic acid lung injury are associated with marked functional changes.", [["lung", "ANATOMY", 203, 207], ["Oleic acid", "CHEMICAL", 47, 57], ["oleic acid", "CHEMICAL", 192, 202], ["lung injury", "DISEASE", 203, 214], ["Oleic acid", "CHEMICAL", 47, 57], ["oleic acid", "CHEMICAL", 192, 202], ["Oleic acid", "SIMPLE_CHEMICAL", 47, 57], ["Capillary Endothelium", "TISSUE", 96, 117], ["oleic acid", "SIMPLE_CHEMICAL", 192, 202], ["lung", "ORGAN", 203, 207], ["LUNG INJURY", "PROBLEM", 139, 150], ["oleic acid lung injury", "PROBLEM", 192, 214], ["marked functional changes", "PROBLEM", 235, 260], ["areas", "OBSERVATION_MODIFIER", 13, 18], ["acid", "OBSERVATION_MODIFIER", 53, 57], ["Capillary Endothelium", "OBSERVATION", 96, 117], ["LUNG", "ANATOMY", 139, 143], ["INJURY", "OBSERVATION", 144, 150], ["oleic acid", "OBSERVATION", 192, 202], ["lung", "ANATOMY", 203, 207], ["injury", "OBSERVATION", 208, 214], ["marked", "OBSERVATION_MODIFIER", 235, 241], ["functional", "OBSERVATION", 242, 252]]], ["Pulmonary microvascular permeability is markedly increased, with elevation of extravascular lung water and leakage of protein-rich fluid into the interstitium and the air spaces (46, 247).", [["Pulmonary microvascular", "ANATOMY", 0, 23], ["extravascular lung", "ANATOMY", 78, 96], ["interstitium", "ANATOMY", 146, 158], ["Pulmonary microvascular", "TISSUE", 0, 23], ["lung", "ORGAN", 92, 96], ["interstitium", "MULTI-TISSUE_STRUCTURE", 146, 158], ["Pulmonary microvascular permeability", "TEST", 0, 36], ["elevation of extravascular lung water", "PROBLEM", 65, 102], ["leakage of protein", "PROBLEM", 107, 125], ["microvascular", "ANATOMY", 10, 23], ["permeability", "OBSERVATION", 24, 36], ["markedly", "OBSERVATION_MODIFIER", 40, 48], ["increased", "OBSERVATION_MODIFIER", 49, 58], ["elevation", "OBSERVATION_MODIFIER", 65, 74], ["extravascular", "ANATOMY_MODIFIER", 78, 91], ["lung", "ANATOMY", 92, 96], ["water", "OBSERVATION_MODIFIER", 97, 102], ["leakage", "OBSERVATION_MODIFIER", 107, 114], ["rich", "OBSERVATION_MODIFIER", 126, 130], ["fluid", "OBSERVATION", 131, 136], ["interstitium", "ANATOMY_MODIFIER", 146, 158], ["air spaces", "OBSERVATION", 167, 177]]], ["These changes in alveolar permeability are proportional to the dose of oleic acid, develop within 1 h of administration, and are rapidly reversible, with the alveolar fluid clearance normalizing within 8 h (54).", [["alveolar", "ANATOMY", 17, 25], ["alveolar fluid", "ANATOMY", 158, 172], ["oleic acid", "CHEMICAL", 71, 81], ["oleic acid", "CHEMICAL", 71, 81], ["alveolar", "TISSUE", 17, 25], ["oleic acid", "SIMPLE_CHEMICAL", 71, 81], ["alveolar fluid", "TISSUE", 158, 172], ["These changes in alveolar permeability", "PROBLEM", 0, 38], ["oleic acid", "TREATMENT", 71, 81], ["the alveolar fluid clearance", "TEST", 154, 182], ["alveolar permeability", "OBSERVATION", 17, 38], ["rapidly", "OBSERVATION_MODIFIER", 129, 136], ["reversible", "OBSERVATION_MODIFIER", 137, 147], ["alveolar", "ANATOMY_MODIFIER", 158, 166], ["fluid clearance", "OBSERVATION", 167, 182]]], ["There are also severe alterations in gas exchange, with respiratory acidosis, hypoxemia, and increased alveolar-arterial oxygen difference within 90 min of intravenous administration (40, 46, 170, 221).", [["respiratory", "ANATOMY", 56, 67], ["alveolar", "ANATOMY", 103, 111], ["arterial", "ANATOMY", 112, 120], ["intravenous", "ANATOMY", 156, 167], ["respiratory acidosis", "DISEASE", 56, 76], ["hypoxemia", "DISEASE", 78, 87], ["oxygen", "CHEMICAL", 121, 127], ["oxygen", "CHEMICAL", 121, 127], ["alveolar-arterial", "MULTI-TISSUE_STRUCTURE", 103, 120], ["oxygen", "SIMPLE_CHEMICAL", 121, 127], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 156, 167], ["severe alterations in gas exchange", "PROBLEM", 15, 49], ["respiratory acidosis", "PROBLEM", 56, 76], ["hypoxemia", "PROBLEM", 78, 87], ["increased alveolar-arterial oxygen difference", "PROBLEM", 93, 138], ["intravenous administration", "TREATMENT", 156, 182], ["severe", "OBSERVATION_MODIFIER", 15, 21], ["alterations", "OBSERVATION", 22, 33], ["gas exchange", "OBSERVATION", 37, 49], ["respiratory acidosis", "OBSERVATION", 56, 76], ["hypoxemia", "OBSERVATION", 78, 87], ["increased", "OBSERVATION_MODIFIER", 93, 102], ["alveolar", "ANATOMY_MODIFIER", 103, 111], ["arterial", "ANATOMY", 112, 120], ["oxygen difference", "OBSERVATION", 121, 138]]], ["The gas exchange alterations result from severe ventilation/perfusion (V/Q) mismatching, increased intrapulmonary shunt, and increased dead space ventilation (170).", [["intrapulmonary", "ANATOMY", 99, 113], ["intrapulmonary", "MULTI-TISSUE_STRUCTURE", 99, 113], ["The gas exchange alterations", "PROBLEM", 0, 28], ["severe ventilation/perfusion (V/Q) mismatching", "PROBLEM", 41, 87], ["increased intrapulmonary shunt", "PROBLEM", 89, 119], ["increased dead space ventilation", "PROBLEM", 125, 157], ["gas", "OBSERVATION", 4, 7], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["ventilation", "OBSERVATION", 48, 59], ["increased", "OBSERVATION_MODIFIER", 89, 98], ["intrapulmonary shunt", "OBSERVATION", 99, 119], ["increased", "OBSERVATION_MODIFIER", 125, 134], ["dead space ventilation", "OBSERVATION", 135, 157]]], ["The static lung compliance and functional residual capacity (FRC) fall rapidly, and mean airway pressure rises (40, 125).", [["lung", "ANATOMY", 11, 15], ["airway", "ANATOMY", 89, 95], ["lung", "ORGAN", 11, 15], ["airway", "MULTI-TISSUE_STRUCTURE", 89, 95], ["The static lung compliance", "TEST", 0, 26], ["functional residual capacity", "PROBLEM", 31, 59], ["mean airway pressure", "TEST", 84, 104], ["lung", "ANATOMY", 11, 15], ["compliance", "OBSERVATION", 16, 26], ["residual capacity", "OBSERVATION", 42, 59], ["airway", "ANATOMY", 89, 95], ["pressure", "OBSERVATION_MODIFIER", 96, 104], ["rises", "OBSERVATION_MODIFIER", 105, 110]]], ["Systemically, the cellular damage induced by oleic acid becomes evident rapidly, and increases in circulating angiotensin converting enzyme (ACE) can be detected within 2.5 min after intravenous administration of 0.1 ml/kg to dogs (151).", [["cellular", "ANATOMY", 18, 26], ["intravenous", "ANATOMY", 183, 194], ["oleic acid", "CHEMICAL", 45, 55], ["angiotensin", "CHEMICAL", 110, 121], ["oleic acid", "CHEMICAL", 45, 55], ["cellular", "CELL", 18, 26], ["oleic acid", "SIMPLE_CHEMICAL", 45, 55], ["angiotensin converting enzyme", "GENE_OR_GENE_PRODUCT", 110, 139], ["ACE", "GENE_OR_GENE_PRODUCT", 141, 144], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 183, 194], ["dogs", "ORGANISM", 226, 230], ["angiotensin converting enzyme", "PROTEIN", 110, 139], ["ACE", "PROTEIN", 141, 144], ["dogs", "SPECIES", 226, 230], ["the cellular damage", "PROBLEM", 14, 33], ["oleic acid", "PROBLEM", 45, 55], ["circulating angiotensin converting enzyme", "TREATMENT", 98, 139], ["cellular damage", "OBSERVATION", 18, 33], ["oleic acid", "OBSERVATION", 45, 55], ["increases", "OBSERVATION_MODIFIER", 85, 94], ["circulating angiotensin", "OBSERVATION", 98, 121]]], ["The hemodynamic responses are dose dependent and are characterized by myocardial depression, early systemic hypotension, and pulmonary hypertension (40, 46, 125, 190, 231).Oleic acid. ::: Models That Target Primarily the Capillary Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSCombination with other models: the intravenous administration of small doses of endotoxin markedly worsens gas exchange in the canine oleic acid model, primarily by increasing the distribution of blood flow towards injured areas (192).Oleic acid. ::: Models That Target Primarily the Capillary Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSAdvantages and disadvantages: the oleic acid model produces the basic characteristics of ALI, early and rapidly reversible patchy inflammatory lung injury with permeability changes and impairment in gas exchange and lung mechanics.", [["myocardial", "ANATOMY", 70, 80], ["pulmonary", "ANATOMY", 125, 134], ["intravenous", "ANATOMY", 324, 335], ["blood", "ANATOMY", 485, 490], ["lung", "ANATOMY", 784, 788], ["lung", "ANATOMY", 857, 861], ["myocardial depression", "DISEASE", 70, 91], ["hypotension", "DISEASE", 108, 119], ["pulmonary hypertension", "DISEASE", 125, 147], ["Oleic acid", "CHEMICAL", 172, 182], ["endotoxin", "CHEMICAL", 369, 378], ["oleic acid", "CHEMICAL", 423, 433], ["Oleic acid", "CHEMICAL", 524, 534], ["oleic acid", "CHEMICAL", 675, 685], ["ALI", "DISEASE", 730, 733], ["lung injury", "DISEASE", 784, 795], ["Oleic acid", "CHEMICAL", 172, 182], ["oleic acid", "CHEMICAL", 423, 433], ["Oleic acid", "CHEMICAL", 524, 534], ["oleic acid", "CHEMICAL", 675, 685], ["myocardial", "MULTI-TISSUE_STRUCTURE", 70, 80], ["pulmonary", "ORGAN", 125, 134], ["Oleic acid", "SIMPLE_CHEMICAL", 172, 182], ["Capillary Endothelium", "TISSUE", 221, 242], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 324, 335], ["endotoxin", "SIMPLE_CHEMICAL", 369, 378], ["canine", "ORGANISM", 416, 422], ["oleic acid", "SIMPLE_CHEMICAL", 423, 433], ["blood", "ORGANISM_SUBSTANCE", 485, 490], ["Oleic acid", "SIMPLE_CHEMICAL", 524, 534], ["Capillary Endothelium", "TISSUE", 573, 594], ["oleic acid", "SIMPLE_CHEMICAL", 675, 685], ["lung", "ORGAN", 784, 788], ["lung", "ORGAN", 857, 861], ["canine", "SPECIES", 416, 422], ["myocardial depression", "PROBLEM", 70, 91], ["early systemic hypotension", "PROBLEM", 93, 119], ["pulmonary hypertension", "PROBLEM", 125, 147], ["LUNG INJURY", "PROBLEM", 264, 275], ["the intravenous administration", "TREATMENT", 320, 350], ["small doses of endotoxin", "TREATMENT", 354, 378], ["gas exchange", "PROBLEM", 396, 408], ["the canine oleic acid model", "TEST", 412, 439], ["LUNG INJURY", "PROBLEM", 616, 627], ["the oleic acid model", "TREATMENT", 671, 691], ["ALI", "PROBLEM", 730, 733], ["rapidly reversible patchy inflammatory lung injury", "PROBLEM", 745, 795], ["permeability changes", "PROBLEM", 801, 821], ["impairment in gas exchange", "PROBLEM", 826, 852], ["lung mechanics", "TEST", 857, 871], ["myocardial", "ANATOMY", 70, 80], ["depression", "OBSERVATION", 81, 91], ["early", "OBSERVATION_MODIFIER", 93, 98], ["systemic", "OBSERVATION_MODIFIER", 99, 107], ["hypotension", "OBSERVATION", 108, 119], ["pulmonary", "ANATOMY", 125, 134], ["hypertension", "OBSERVATION", 135, 147], ["acid", "OBSERVATION_MODIFIER", 178, 182], ["Capillary Endothelium", "OBSERVATION", 221, 242], ["LUNG", "ANATOMY", 264, 268], ["INJURY", "OBSERVATION", 269, 275], ["gas exchange", "OBSERVATION", 396, 408], ["oleic acid model", "OBSERVATION", 423, 439], ["increasing", "OBSERVATION_MODIFIER", 454, 464], ["distribution", "OBSERVATION_MODIFIER", 469, 481], ["blood flow", "OBSERVATION", 485, 495], ["acid", "OBSERVATION_MODIFIER", 530, 534], ["Capillary Endothelium", "OBSERVATION", 573, 594], ["LUNG", "ANATOMY", 616, 620], ["INJURY", "OBSERVATION", 621, 627], ["ALI", "OBSERVATION", 730, 733], ["reversible", "OBSERVATION_MODIFIER", 753, 763], ["patchy", "OBSERVATION_MODIFIER", 764, 770], ["inflammatory", "OBSERVATION_MODIFIER", 771, 783], ["lung", "ANATOMY", 784, 788], ["injury", "OBSERVATION", 789, 795], ["permeability changes", "OBSERVATION", 801, 821], ["impairment", "OBSERVATION_MODIFIER", 826, 836], ["gas exchange", "OBSERVATION", 840, 852], ["lung", "ANATOMY", 857, 861], ["mechanics", "OBSERVATION", 862, 871]]], ["A major advantage of this model is its reproducibility; the administration of the same dose of oleic acid by the same route to different animals is followed by a reasonably reproducible pulmonary injury.", [["pulmonary", "ANATOMY", 186, 195], ["oleic acid", "CHEMICAL", 95, 105], ["pulmonary injury", "DISEASE", 186, 202], ["oleic acid", "CHEMICAL", 95, 105], ["oleic acid", "SIMPLE_CHEMICAL", 95, 105], ["pulmonary", "ORGAN", 186, 195], ["oleic acid", "TREATMENT", 95, 105], ["a reasonably reproducible pulmonary injury", "PROBLEM", 160, 202], ["reproducible", "OBSERVATION_MODIFIER", 173, 185], ["pulmonary", "ANATOMY", 186, 195], ["injury", "OBSERVATION", 196, 202]]], ["Oleic acid instillation provides an excellent model to study ventilatory strategies, lung mechanics, and V/Q distribution during lung injury in large and small animals.", [["lung", "ANATOMY", 85, 89], ["lung", "ANATOMY", 129, 133], ["Oleic acid", "CHEMICAL", 0, 10], ["lung injury", "DISEASE", 129, 140], ["Oleic acid", "CHEMICAL", 0, 10], ["Oleic acid", "SIMPLE_CHEMICAL", 0, 10], ["lung", "ORGAN", 85, 89], ["lung", "ORGAN", 129, 133], ["Oleic acid instillation", "TREATMENT", 0, 23], ["ventilatory strategies", "TREATMENT", 61, 83], ["lung mechanics", "TEST", 85, 99], ["V/Q distribution", "TEST", 105, 121], ["lung injury in large and small animals", "PROBLEM", 129, 167], ["lung", "ANATOMY", 85, 89], ["mechanics", "OBSERVATION", 90, 99], ["lung", "ANATOMY", 129, 133], ["injury", "OBSERVATION", 134, 140], ["large", "OBSERVATION_MODIFIER", 144, 149], ["small", "OBSERVATION_MODIFIER", 154, 159]]], ["One disadvantage is the requirement for intravenous administration, which requires expertise in small animals like mice.", [["intravenous", "ANATOMY", 40, 51], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 40, 51], ["mice", "ORGANISM", 115, 119], ["mice", "SPECIES", 115, 119], ["mice", "SPECIES", 115, 119], ["intravenous administration", "TREATMENT", 40, 66], ["small", "OBSERVATION_MODIFIER", 96, 101]]], ["One question is the extent to which this type of injury actually occurs in humans, because few cases of ARDS are associated with long bone trauma or lipid injury (95), and there is no evidence that the pathophysiology of the injury caused by oleic acid (direct toxicity to endothelial cells) is similar to that underlying ARDS associated with sepsis and aspiration.", [["bone", "ANATOMY", 134, 138], ["endothelial cells", "ANATOMY", 273, 290], ["ARDS", "DISEASE", 104, 108], ["bone trauma", "DISEASE", 134, 145], ["lipid injury", "DISEASE", 149, 161], ["oleic acid", "CHEMICAL", 242, 252], ["toxicity", "DISEASE", 261, 269], ["ARDS", "DISEASE", 322, 326], ["sepsis", "DISEASE", 343, 349], ["oleic acid", "CHEMICAL", 242, 252], ["humans", "ORGANISM", 75, 81], ["bone", "TISSUE", 134, 138], ["oleic acid", "SIMPLE_CHEMICAL", 242, 252], ["endothelial cells", "CELL", 273, 290], ["endothelial cells", "CELL_TYPE", 273, 290], ["humans", "SPECIES", 75, 81], ["humans", "SPECIES", 75, 81], ["injury", "PROBLEM", 49, 55], ["ARDS", "PROBLEM", 104, 108], ["long bone trauma", "PROBLEM", 129, 145], ["lipid injury", "PROBLEM", 149, 161], ["the injury", "PROBLEM", 221, 231], ["oleic acid (direct toxicity to endothelial cells", "PROBLEM", 242, 290], ["underlying ARDS", "PROBLEM", 311, 326], ["sepsis", "PROBLEM", 343, 349], ["aspiration", "PROBLEM", 354, 364], ["injury", "OBSERVATION", 49, 55], ["ARDS", "OBSERVATION", 104, 108], ["associated with", "UNCERTAINTY", 113, 128], ["long", "OBSERVATION_MODIFIER", 129, 133], ["bone", "ANATOMY", 134, 138], ["trauma", "OBSERVATION", 139, 145], ["lipid", "OBSERVATION_MODIFIER", 149, 154], ["injury", "OBSERVATION", 155, 161], ["no evidence", "UNCERTAINTY", 181, 192], ["injury", "OBSERVATION", 225, 231], ["ARDS", "OBSERVATION", 322, 326], ["sepsis", "OBSERVATION", 343, 349], ["aspiration", "OBSERVATION", 354, 364]]], ["Therefore, the oleic acid model is probably not as appropriate for studying the pathophysiology of ALI due to sepsis, or therapeutic strategies aimed at modifying host inflammatory responses to reduce the severity of lung injury.Endotoxin. ::: Models That Target Primarily the Capillary Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSBasis for the model: LPS is a glycolipid present in the outer membrane of gram-negative bacteria that is composed of a polar lipid head group (lipid A) and a chain of repeating disaccharides (171).", [["lung", "ANATOMY", 217, 221], ["outer membrane", "ANATOMY", 401, 415], ["oleic acid", "CHEMICAL", 15, 25], ["ALI", "DISEASE", 99, 102], ["sepsis", "DISEASE", 110, 116], ["lung injury", "DISEASE", 217, 228], ["Endotoxin", "CHEMICAL", 229, 238], ["LPS", "CHEMICAL", 366, 369], ["oleic acid", "CHEMICAL", 15, 25], ["disaccharides", "CHEMICAL", 522, 535], ["oleic acid", "SIMPLE_CHEMICAL", 15, 25], ["lung", "ORGAN", 217, 221], ["LPS", "SIMPLE_CHEMICAL", 366, 369], ["outer membrane", "CELLULAR_COMPONENT", 401, 415], ["lipid A", "SIMPLE_CHEMICAL", 488, 495], ["the oleic acid model", "TEST", 11, 31], ["ALI", "PROBLEM", 99, 102], ["sepsis", "PROBLEM", 110, 116], ["therapeutic strategies", "TREATMENT", 121, 143], ["host inflammatory responses", "TREATMENT", 163, 190], ["lung injury", "PROBLEM", 217, 228], ["LUNG INJURY", "PROBLEM", 320, 331], ["a glycolipid", "TEST", 373, 385], ["gram-negative bacteria", "PROBLEM", 419, 441], ["repeating disaccharides", "TEST", 512, 535], ["probably not", "UNCERTAINTY", 35, 47], ["sepsis", "OBSERVATION", 110, 116], ["lung", "ANATOMY", 217, 221], ["injury", "OBSERVATION", 222, 228], ["Capillary Endothelium", "OBSERVATION", 277, 298], ["LUNG", "ANATOMY", 320, 324], ["INJURY", "OBSERVATION", 325, 331], ["negative bacteria", "OBSERVATION", 424, 441]]], ["Most of the biological effects of LPS are reproduced by lipid A (189), although the presence or absence of the repeating oligosaccharide O antigen influences the magnitude of the response (112).", [["LPS", "CHEMICAL", 34, 37], ["lipid A", "CHEMICAL", 56, 63], ["LPS", "SIMPLE_CHEMICAL", 34, 37], ["lipid A", "SIMPLE_CHEMICAL", 56, 63], ["oligosaccharide O antigen", "GENE_OR_GENE_PRODUCT", 121, 146], ["oligosaccharide O antigen", "PROTEIN", 121, 146], ["LPS", "TREATMENT", 34, 37], ["the repeating oligosaccharide O antigen", "TEST", 107, 146]]], ["In serum, LPS binds to a specific LPS binding protein (LBP) (131, 217), forming an LPS:LBP complex that activates the CD14/TLR4 receptor structure on monocytes, macrophages, and other cells, triggering the production of inflammatory mediators (211, 244, 249) (Fig. 3, C and D).", [["serum", "ANATOMY", 3, 8], ["monocytes", "ANATOMY", 150, 159], ["macrophages", "ANATOMY", 161, 172], ["cells", "ANATOMY", 184, 189], ["LPS", "CHEMICAL", 10, 13], ["LPS", "CHEMICAL", 34, 37], ["LPS", "CHEMICAL", 83, 86], ["serum", "ORGANISM_SUBSTANCE", 3, 8], ["LPS", "SIMPLE_CHEMICAL", 10, 13], ["LPS binding protein", "GENE_OR_GENE_PRODUCT", 34, 53], ["LBP", "GENE_OR_GENE_PRODUCT", 55, 58], ["LPS", "SIMPLE_CHEMICAL", 83, 86], ["LBP", "GENE_OR_GENE_PRODUCT", 87, 90], ["CD14", "GENE_OR_GENE_PRODUCT", 118, 122], ["TLR4", "GENE_OR_GENE_PRODUCT", 123, 127], ["monocytes", "CELL", 150, 159], ["macrophages", "CELL", 161, 172], ["cells", "CELL", 184, 189], ["LPS binding protein", "PROTEIN", 34, 53], ["LBP", "PROTEIN", 55, 58], ["LBP complex", "PROTEIN", 87, 98], ["CD14", "PROTEIN", 118, 122], ["TLR4 receptor structure", "PROTEIN", 123, 146], ["monocytes", "CELL_TYPE", 150, 159], ["macrophages", "CELL_TYPE", 161, 172], ["inflammatory mediators", "PROTEIN", 220, 242], ["LPS binds", "TEST", 10, 19], ["a specific LPS binding protein", "TEST", 23, 53], ["LBP", "TEST", 55, 58], ["an LPS", "TEST", 80, 86], ["LBP complex", "PROBLEM", 87, 98], ["the CD14", "TEST", 114, 122], ["monocytes", "TEST", 150, 159], ["macrophages", "TEST", 161, 172], ["other cells", "PROBLEM", 178, 189], ["inflammatory mediators", "PROBLEM", 220, 242], ["Fig.", "TEST", 260, 264], ["LPS", "ANATOMY", 83, 86], ["LBP", "OBSERVATION", 87, 90], ["monocytes", "ANATOMY", 150, 159], ["macrophages", "ANATOMY", 161, 172], ["inflammatory", "OBSERVATION_MODIFIER", 220, 232]]], ["LPS is an important mediator of sepsis in response to gram-negative bacteria, and systemic administration of LPS was one of the earliest approaches used to model the consequences of bacterial sepsis.Endotoxin. ::: Models That Target Primarily the Capillary Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSMechanism: following intravenous administration of LPS, the capillary endothelium is the initial site of injury.", [["intravenous", "ANATOMY", 336, 347], ["capillary endothelium", "ANATOMY", 375, 396], ["site", "ANATOMY", 412, 416], ["LPS", "CHEMICAL", 0, 3], ["sepsis", "DISEASE", 32, 38], ["LPS", "CHEMICAL", 109, 112], ["sepsis", "DISEASE", 192, 198], ["Endotoxin", "CHEMICAL", 199, 208], ["LPS", "CHEMICAL", 366, 369], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["LPS", "SIMPLE_CHEMICAL", 109, 112], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 336, 347], ["LPS", "SIMPLE_CHEMICAL", 366, 369], ["capillary endothelium", "TISSUE", 375, 396], ["LPS", "TEST", 0, 3], ["sepsis", "PROBLEM", 32, 38], ["gram", "TEST", 54, 58], ["negative bacteria", "PROBLEM", 59, 76], ["systemic administration of LPS", "TREATMENT", 82, 112], ["bacterial sepsis", "PROBLEM", 182, 198], ["LPS", "TREATMENT", 366, 369], ["the capillary endothelium", "TREATMENT", 371, 396], ["injury", "PROBLEM", 420, 426], ["sepsis", "OBSERVATION", 32, 38], ["negative bacteria", "OBSERVATION", 59, 76], ["bacterial sepsis", "OBSERVATION", 182, 198], ["Capillary Endothelium", "OBSERVATION", 247, 268], ["LUNG", "ANATOMY", 290, 294], ["INJURY", "OBSERVATION", 295, 301], ["capillary endothelium", "ANATOMY", 375, 396], ["injury", "OBSERVATION", 420, 426]]], ["The cellular injury induced by LPS appears to be related to apoptosis, in contrast to the oleic acid model, in which the injury is due to a direct toxic effect resulting in necrosis.", [["cellular", "ANATOMY", 4, 12], ["cellular injury", "DISEASE", 4, 19], ["LPS", "CHEMICAL", 31, 34], ["oleic acid", "CHEMICAL", 90, 100], ["necrosis", "DISEASE", 173, 181], ["oleic acid", "CHEMICAL", 90, 100], ["cellular", "CELL", 4, 12], ["LPS", "SIMPLE_CHEMICAL", 31, 34], ["oleic acid", "SIMPLE_CHEMICAL", 90, 100], ["The cellular injury", "PROBLEM", 0, 19], ["LPS", "PROBLEM", 31, 34], ["apoptosis", "PROBLEM", 60, 69], ["the oleic acid model", "TEST", 86, 106], ["the injury", "PROBLEM", 117, 127], ["a direct toxic effect", "PROBLEM", 138, 159], ["necrosis", "PROBLEM", 173, 181], ["cellular", "OBSERVATION_MODIFIER", 4, 12], ["injury", "OBSERVATION", 13, 19], ["appears to be related to", "UNCERTAINTY", 35, 59], ["apoptosis", "OBSERVATION", 60, 69], ["injury", "OBSERVATION", 121, 127], ["toxic", "OBSERVATION_MODIFIER", 147, 152], ["necrosis", "OBSERVATION", 173, 181]]], ["Apoptosis of endothelial cells develops rapidly following administration of LPS and precedes other tissue damage (72, 230).", [["endothelial cells", "ANATOMY", 13, 30], ["tissue", "ANATOMY", 99, 105], ["LPS", "CHEMICAL", 76, 79], ["endothelial cells", "CELL", 13, 30], ["LPS", "SIMPLE_CHEMICAL", 76, 79], ["tissue", "TISSUE", 99, 105], ["endothelial cells", "CELL_TYPE", 13, 30], ["Apoptosis of endothelial cells", "PROBLEM", 0, 30], ["LPS", "TREATMENT", 76, 79], ["other tissue damage", "PROBLEM", 93, 112], ["endothelial cells", "OBSERVATION", 13, 30]]], ["Systemic treatment with the broad-spectrum caspase inhibitor Z-VAD.fmk blocks apoptosis and improves survival in mice treated with intravenous LPS (111).Endotoxin. ::: Models That Target Primarily the Capillary Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSThe hemodynamic response to intravenous LPS is characterized by an initial phase of leukopenia, decreased cardiac output, and a fall in arterial pressure.", [["intravenous", "ANATOMY", 131, 142], ["intravenous", "ANATOMY", 297, 308], ["cardiac", "ANATOMY", 375, 382], ["arterial", "ANATOMY", 405, 413], ["Z-VAD", "CHEMICAL", 61, 66], ["LPS", "CHEMICAL", 143, 146], ["Endotoxin", "CHEMICAL", 153, 162], ["LPS", "CHEMICAL", 309, 312], ["leukopenia", "DISEASE", 353, 363], ["decreased cardiac output", "DISEASE", 365, 389], ["Z-VAD", "CHEMICAL", 61, 66], ["caspase", "GENE_OR_GENE_PRODUCT", 43, 50], ["Z-VAD", "SIMPLE_CHEMICAL", 61, 66], ["fmk", "GENE_OR_GENE_PRODUCT", 67, 70], ["mice", "ORGANISM", 113, 117], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 131, 142], ["LPS", "SIMPLE_CHEMICAL", 143, 146], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 297, 308], ["LPS", "SIMPLE_CHEMICAL", 309, 312], ["cardiac", "ORGAN", 375, 382], ["arterial", "MULTI-TISSUE_STRUCTURE", 405, 413], ["fmk", "PROTEIN", 67, 70], ["mice", "SPECIES", 113, 117], ["mice", "SPECIES", 113, 117], ["Systemic treatment", "TREATMENT", 0, 18], ["the broad-spectrum caspase inhibitor Z-VAD", "TREATMENT", 24, 66], ["fmk blocks apoptosis", "PROBLEM", 67, 87], ["intravenous LPS", "TREATMENT", 131, 146], ["LUNG INJURY", "PROBLEM", 244, 255], ["intravenous LPS", "TREATMENT", 297, 312], ["leukopenia", "PROBLEM", 353, 363], ["decreased cardiac output", "PROBLEM", 365, 389], ["a fall in arterial pressure", "PROBLEM", 395, 422], ["apoptosis", "OBSERVATION_MODIFIER", 78, 87], ["Capillary Endothelium", "OBSERVATION", 201, 222], ["LUNG", "ANATOMY", 244, 248], ["INJURY", "OBSERVATION", 249, 255], ["leukopenia", "OBSERVATION", 353, 363], ["decreased", "OBSERVATION_MODIFIER", 365, 374], ["cardiac", "ANATOMY", 375, 382], ["output", "OBSERVATION_MODIFIER", 383, 389], ["arterial", "ANATOMY", 405, 413], ["pressure", "OBSERVATION_MODIFIER", 414, 422]]], ["There is an increase in pulmonary arterial pressure, which is due mainly to an increase in the resistance of postcapillary veins (123).", [["pulmonary arterial", "ANATOMY", 24, 42], ["postcapillary veins", "ANATOMY", 109, 128], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 24, 42], ["postcapillary veins", "MULTI-TISSUE_STRUCTURE", 109, 128], ["an increase in pulmonary arterial pressure", "PROBLEM", 9, 51], ["increase", "OBSERVATION_MODIFIER", 12, 20], ["pulmonary arterial", "ANATOMY", 24, 42], ["pressure", "OBSERVATION_MODIFIER", 43, 51], ["increase", "OBSERVATION_MODIFIER", 79, 87], ["resistance", "OBSERVATION", 95, 105], ["postcapillary veins", "ANATOMY", 109, 128]]], ["This initial phase is followed by slow improvement in leukocyte counts and the hemodynamic profile, over 4\u20136 h.", [["leukocyte", "ANATOMY", 54, 63], ["leukocyte", "CELL", 54, 63], ["leukocyte counts", "TEST", 54, 70], ["the hemodynamic profile", "TEST", 75, 98], ["leukocyte counts", "OBSERVATION", 54, 70]]], ["Changes in the lungs become evident within 2\u20134 h and include hypoxemia with an increase in the alveolar-arterial oxygen difference (A-a O2 difference).", [["lungs", "ANATOMY", 15, 20], ["alveolar", "ANATOMY", 95, 103], ["arterial", "ANATOMY", 104, 112], ["hypoxemia", "DISEASE", 61, 70], ["oxygen", "CHEMICAL", 113, 119], ["oxygen", "CHEMICAL", 113, 119], ["O2", "CHEMICAL", 136, 138], ["lungs", "ORGAN", 15, 20], ["alveolar", "TISSUE", 95, 103], ["arterial", "MULTI-TISSUE_STRUCTURE", 104, 112], ["oxygen", "SIMPLE_CHEMICAL", 113, 119], ["Changes in the lungs", "PROBLEM", 0, 20], ["hypoxemia", "PROBLEM", 61, 70], ["the alveolar-arterial oxygen difference", "PROBLEM", 91, 130], ["a O2 difference", "PROBLEM", 134, 149], ["lungs", "ANATOMY", 15, 20], ["hypoxemia", "OBSERVATION", 61, 70], ["increase", "OBSERVATION_MODIFIER", 79, 87], ["alveolar", "ANATOMY_MODIFIER", 95, 103], ["arterial", "ANATOMY", 104, 112], ["oxygen difference", "OBSERVATION", 113, 130]]], ["In the lungs, the administration of LPS, either by intravenous or intra-alveolar routes, is followed by changes in PMN deformability and the entrapment of PMN in the pulmonary capillaries (176).", [["lungs", "ANATOMY", 7, 12], ["intravenous", "ANATOMY", 51, 62], ["intra-alveolar", "ANATOMY", 66, 80], ["PMN", "ANATOMY", 115, 118], ["PMN", "ANATOMY", 155, 158], ["pulmonary capillaries", "ANATOMY", 166, 187], ["LPS", "CHEMICAL", 36, 39], ["lungs", "ORGAN", 7, 12], ["LPS", "SIMPLE_CHEMICAL", 36, 39], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 51, 62], ["intra-alveolar", "IMMATERIAL_ANATOMICAL_ENTITY", 66, 80], ["PMN", "CELL", 115, 118], ["PMN", "CELL", 155, 158], ["pulmonary capillaries", "TISSUE", 166, 187], ["PMN", "CELL_TYPE", 115, 118], ["PMN", "CELL_TYPE", 155, 158], ["LPS", "TREATMENT", 36, 39], ["PMN deformability", "TEST", 115, 132], ["the entrapment of PMN", "PROBLEM", 137, 158], ["lungs", "ANATOMY", 7, 12], ["PMN deformability", "OBSERVATION", 115, 132], ["entrapment", "OBSERVATION_MODIFIER", 141, 151], ["PMN", "OBSERVATION_MODIFIER", 155, 158], ["pulmonary capillaries", "ANATOMY", 166, 187]]], ["However, only small numbers of PMN migrate into the air spaces.", [["PMN", "ANATOMY", 31, 34], ["PMN", "CELL", 31, 34], ["PMN", "CELL_TYPE", 31, 34], ["small", "OBSERVATION_MODIFIER", 14, 19], ["numbers", "OBSERVATION_MODIFIER", 20, 27], ["PMN migrate", "OBSERVATION", 31, 42], ["air spaces", "OBSERVATION", 52, 62]]], ["PMN entrapment occurs before epithelial permeability changes or disruption of the alveolar/epithelial barrier (9, 239, 241).", [["PMN", "ANATOMY", 0, 3], ["epithelial", "ANATOMY", 29, 39], ["alveolar", "ANATOMY", 82, 90], ["epithelial", "ANATOMY", 91, 101], ["PMN", "CELL", 0, 3], ["epithelial", "TISSUE", 29, 39], ["alveolar", "TISSUE", 82, 90], ["epithelial barrier", "TISSUE", 91, 109], ["PMN entrapment", "PROBLEM", 0, 14], ["epithelial permeability changes", "PROBLEM", 29, 60], ["the alveolar/epithelial barrier", "TEST", 78, 109], ["entrapment", "OBSERVATION", 4, 14], ["epithelial permeability", "OBSERVATION", 29, 52], ["disruption", "OBSERVATION_MODIFIER", 64, 74], ["alveolar", "ANATOMY_MODIFIER", 82, 90], ["epithelial", "ANATOMY_MODIFIER", 91, 101]]], ["In contrast, intratracheal LPS is followed by large increases in PMN in the air spaces.Endotoxin. ::: Models That Target Primarily the Capillary Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSLPS has been administered to humans via the intravenous and the intratracheal routes.", [["PMN", "ANATOMY", 65, 68], ["intravenous", "ANATOMY", 247, 258], ["LPS", "CHEMICAL", 27, 30], ["Endotoxin", "CHEMICAL", 87, 96], ["SYSTEMSLPS", "CHEMICAL", 196, 206], ["LPS", "SIMPLE_CHEMICAL", 27, 30], ["PMN", "CELL", 65, 68], ["humans", "ORGANISM", 232, 238], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 247, 258], ["PMN", "CELL_TYPE", 65, 68], ["humans", "SPECIES", 232, 238], ["humans", "SPECIES", 232, 238], ["intratracheal LPS", "TEST", 13, 30], ["large increases in PMN in the air spaces", "PROBLEM", 46, 86], ["LUNG INJURY", "PROBLEM", 178, 189], ["the intravenous", "TREATMENT", 243, 258], ["the intratracheal routes", "TREATMENT", 263, 287], ["intratracheal LPS", "ANATOMY", 13, 30], ["large", "OBSERVATION_MODIFIER", 46, 51], ["increases", "OBSERVATION_MODIFIER", 52, 61], ["PMN", "OBSERVATION_MODIFIER", 65, 68], ["air spaces", "OBSERVATION", 76, 86], ["Capillary Endothelium", "OBSERVATION", 135, 156], ["LUNG", "ANATOMY", 178, 182], ["INJURY", "OBSERVATION", 183, 189], ["intratracheal", "ANATOMY", 267, 280]]], ["Intravenous doses ranging from 2 to 4 ng/kg are associated with evidence of systemic inflammation and priming of alveolar macrophages (92, 169, 205).", [["Intravenous", "ANATOMY", 0, 11], ["alveolar macrophages", "ANATOMY", 113, 133], ["inflammation", "DISEASE", 85, 97], ["Intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 11], ["alveolar macrophages", "CELL", 113, 133], ["alveolar macrophages", "CELL_TYPE", 113, 133], ["Intravenous doses", "TREATMENT", 0, 17], ["systemic inflammation", "PROBLEM", 76, 97], ["alveolar macrophages", "PROBLEM", 113, 133], ["with evidence of", "UNCERTAINTY", 59, 75], ["systemic", "OBSERVATION_MODIFIER", 76, 84], ["inflammation", "OBSERVATION", 85, 97], ["alveolar macrophages", "OBSERVATION", 113, 133]]], ["The ability of intravenous LPS to cause septic shock was evident when a research technician self-administered 1 mg of Salmonella LPS intravenously, and within 3 h developed high-cardiac output shock requiring intravenous pressors, disseminated intravascular coagulation, abnormalities of hepatic and renal function, and noncardiogenic pulmonary edema (213).", [["intravenous", "ANATOMY", 15, 26], ["intravenously", "ANATOMY", 133, 146], ["cardiac", "ANATOMY", 178, 185], ["intravenous", "ANATOMY", 209, 220], ["intravascular", "ANATOMY", 244, 257], ["hepatic", "ANATOMY", 288, 295], ["renal", "ANATOMY", 300, 305], ["pulmonary", "ANATOMY", 335, 344], ["LPS", "CHEMICAL", 27, 30], ["septic shock", "DISEASE", 40, 52], ["LPS", "CHEMICAL", 129, 132], ["high-cardiac output shock", "DISEASE", 173, 198], ["intravascular coagulation", "DISEASE", 244, 269], ["abnormalities of hepatic and renal function", "DISEASE", 271, 314], ["noncardiogenic pulmonary edema", "DISEASE", 320, 350], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 15, 26], ["LPS", "SIMPLE_CHEMICAL", 27, 30], ["LPS", "SIMPLE_CHEMICAL", 129, 132], ["cardiac", "ORGAN", 178, 185], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 209, 220], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 244, 257], ["hepatic", "MULTI-TISSUE_STRUCTURE", 288, 295], ["renal", "ORGAN", 300, 305], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 335, 350], ["Salmonella", "SPECIES", 118, 128], ["intravenous LPS", "TREATMENT", 15, 30], ["septic shock", "PROBLEM", 40, 52], ["Salmonella LPS intravenously", "TREATMENT", 118, 146], ["high-cardiac output shock", "PROBLEM", 173, 198], ["intravenous pressors", "TREATMENT", 209, 229], ["disseminated intravascular coagulation", "PROBLEM", 231, 269], ["abnormalities of hepatic and renal function", "PROBLEM", 271, 314], ["noncardiogenic pulmonary edema", "PROBLEM", 320, 350], ["septic shock", "OBSERVATION", 40, 52], ["cardiac", "ANATOMY", 178, 185], ["output shock", "OBSERVATION", 186, 198], ["disseminated", "OBSERVATION_MODIFIER", 231, 243], ["intravascular coagulation", "OBSERVATION", 244, 269], ["hepatic", "ANATOMY", 288, 295], ["renal", "ANATOMY", 300, 305], ["noncardiogenic", "OBSERVATION_MODIFIER", 320, 334], ["pulmonary", "ANATOMY", 335, 344], ["edema", "OBSERVATION", 345, 350]]], ["The intratracheal instillation of LPS at doses ranging from 1 to 4 ng/kg is followed by an early phase characterized by increases in BAL fluid PMN, albumin, and proinflammatory cytokines (TNF-\u03b1, IL-1\u03b2, IL-6, G-CSF, IL-8, ENA-78, MCP-1, MIP-1\u03b1, and MIP-1\u03b2) and a later phase 24\u201348 h after instillation characterized by normalization of the BAL fluid cytokine concentrations and increases in the BAL fluid PMN, monocyte, macrophage, and lymphocyte counts (153) (Fig. 3, C and D).Endotoxin. ::: Models That Target Primarily the Capillary Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSTechnical issues: as discussed in unique characteristics of animal species in modeling human lung injury, species responses to LPS are highly variable and differ in animals with and without PIM.", [["intratracheal", "ANATOMY", 4, 17], ["BAL fluid", "ANATOMY", 133, 142], ["BAL fluid", "ANATOMY", 339, 348], ["BAL fluid PMN", "ANATOMY", 394, 407], ["monocyte", "ANATOMY", 409, 417], ["macrophage", "ANATOMY", 419, 429], ["lymphocyte", "ANATOMY", 435, 445], ["lung", "ANATOMY", 686, 690], ["LPS", "CHEMICAL", 34, 37], ["Endotoxin", "CHEMICAL", 477, 486], ["lung injury", "DISEASE", 686, 697], ["LPS", "CHEMICAL", 720, 723], ["PIM", "DISEASE", 783, 786], ["intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 4, 17], ["LPS", "SIMPLE_CHEMICAL", 34, 37], ["BAL fluid", "ORGANISM_SUBSTANCE", 133, 142], ["PMN", "CELL", 143, 146], ["albumin", "GENE_OR_GENE_PRODUCT", 148, 155], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 188, 193], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 195, 200], ["IL-6", "GENE_OR_GENE_PRODUCT", 202, 206], ["G-CSF", "GENE_OR_GENE_PRODUCT", 208, 213], ["IL-8", "GENE_OR_GENE_PRODUCT", 215, 219], ["ENA-78", "GENE_OR_GENE_PRODUCT", 221, 227], ["MCP-1", "GENE_OR_GENE_PRODUCT", 229, 234], ["MIP-1\u03b1", "GENE_OR_GENE_PRODUCT", 236, 242], ["MIP-1\u03b2", "GENE_OR_GENE_PRODUCT", 248, 254], ["BAL fluid", "CELL", 394, 403], ["PMN", "CELL", 404, 407], ["monocyte", "CELL", 409, 417], ["macrophage", "CELL", 419, 429], ["lymphocyte", "CELL", 435, 445], ["human", "ORGANISM", 680, 685], ["lung", "ORGAN", 686, 690], ["LPS", "SIMPLE_CHEMICAL", 720, 723], ["albumin", "PROTEIN", 148, 155], ["proinflammatory cytokines", "PROTEIN", 161, 186], ["TNF", "PROTEIN", 188, 191], ["CSF", "PROTEIN", 210, 213], ["ENA", "PROTEIN", 221, 224], ["MCP", "PROTEIN", 229, 232], ["MIP-1\u03b1", "PROTEIN", 236, 242], ["MIP-1\u03b2", "PROTEIN", 248, 254], ["cytokine", "PROTEIN", 349, 357], ["PMN", "CELL_TYPE", 404, 407], ["monocyte", "CELL_TYPE", 409, 417], ["macrophage", "CELL_TYPE", 419, 429], ["human", "SPECIES", 680, 685], ["human", "SPECIES", 680, 685], ["The intratracheal instillation of LPS", "TREATMENT", 0, 37], ["BAL fluid PMN", "TEST", 133, 146], ["albumin", "TEST", 148, 155], ["proinflammatory cytokines", "TEST", 161, 186], ["TNF", "TEST", 188, 191], ["\u03b1", "TEST", 192, 193], ["IL", "TEST", 195, 197], ["IL", "TEST", 202, 204], ["G", "TEST", 208, 209], ["CSF", "TEST", 210, 213], ["IL", "TEST", 215, 217], ["ENA", "TEST", 221, 224], ["MCP", "TEST", 229, 232], ["MIP", "TEST", 236, 239], ["MIP", "TEST", 248, 251], ["instillation", "TREATMENT", 288, 300], ["the BAL fluid cytokine concentrations", "TEST", 335, 372], ["the BAL fluid PMN", "TEST", 390, 407], ["monocyte", "TEST", 409, 417], ["macrophage", "TEST", 419, 429], ["lymphocyte counts", "TEST", 435, 452], ["Fig.", "TEST", 460, 464], ["LUNG INJURY", "PROBLEM", 568, 579], ["animal species", "PROBLEM", 653, 667], ["modeling human lung injury", "PROBLEM", 671, 697], ["LPS", "TEST", 720, 723], ["PIM", "PROBLEM", 783, 786], ["intratracheal", "ANATOMY", 4, 17], ["instillation", "OBSERVATION", 18, 30], ["increases", "OBSERVATION_MODIFIER", 120, 129], ["BAL", "OBSERVATION", 133, 136], ["fluid PMN", "OBSERVATION", 137, 146], ["BAL fluid", "OBSERVATION", 339, 348], ["cytokine concentrations", "OBSERVATION", 349, 372], ["increases", "OBSERVATION_MODIFIER", 377, 386], ["BAL", "ANATOMY", 394, 397], ["fluid PMN", "OBSERVATION", 398, 407], ["macrophage", "ANATOMY", 419, 429], ["Capillary Endothelium", "OBSERVATION", 525, 546], ["LUNG", "ANATOMY", 568, 572], ["INJURY", "OBSERVATION", 573, 579], ["lung", "ANATOMY", 686, 690], ["injury", "OBSERVATION", 691, 697]]], ["Following treatment with small amounts of LPS, pulmonary inflammation occurs in sheep, calves, pigs, and cats, but not in rodents or dogs (242).", [["pulmonary", "ANATOMY", 47, 56], ["calves", "ANATOMY", 87, 93], ["LPS", "CHEMICAL", 42, 45], ["pulmonary inflammation", "DISEASE", 47, 69], ["LPS", "SIMPLE_CHEMICAL", 42, 45], ["pulmonary", "ORGAN", 47, 56], ["sheep", "ORGANISM", 80, 85], ["calves", "ORGANISM", 87, 93], ["pigs", "ORGANISM", 95, 99], ["cats", "ORGANISM", 105, 109], ["dogs", "ORGANISM", 133, 137], ["sheep", "SPECIES", 80, 85], ["calves", "SPECIES", 87, 93], ["pigs", "SPECIES", 95, 99], ["cats", "SPECIES", 105, 109], ["dogs", "SPECIES", 133, 137], ["sheep", "SPECIES", 80, 85], ["pigs", "SPECIES", 95, 99], ["treatment", "TREATMENT", 10, 19], ["LPS", "TREATMENT", 42, 45], ["pulmonary inflammation", "PROBLEM", 47, 69], ["small", "OBSERVATION_MODIFIER", 25, 30], ["amounts", "OBSERVATION_MODIFIER", 31, 38], ["pulmonary", "ANATOMY", 47, 56], ["inflammation", "OBSERVATION", 57, 69]]], ["Animals with PIM develop manifestations of sepsis and lung injury with very small doses of LPS, e.g., in the \u03bcg/kg range.", [["lung", "ANATOMY", 54, 58], ["PIM", "DISEASE", 13, 16], ["sepsis", "DISEASE", 43, 49], ["lung injury", "DISEASE", 54, 65], ["LPS", "CHEMICAL", 91, 94], ["Animals", "ORGANISM", 0, 7], ["lung", "ORGAN", 54, 58], ["LPS", "SIMPLE_CHEMICAL", 91, 94], ["sepsis", "PROBLEM", 43, 49], ["lung injury", "PROBLEM", 54, 65], ["LPS", "TREATMENT", 91, 94], ["sepsis", "OBSERVATION", 43, 49], ["lung", "ANATOMY", 54, 58], ["injury", "OBSERVATION", 59, 65], ["very", "OBSERVATION_MODIFIER", 71, 75], ["small", "OBSERVATION_MODIFIER", 76, 81]]], ["In contrast, animals without PIM require much higher doses, in the range of mg/kg.", [["PIM", "PROBLEM", 29, 32]]], ["In addition to species susceptibility, there are also differences in LPS responses between different strains of the same species.", [["LPS", "CHEMICAL", 69, 72], ["LPS", "SIMPLE_CHEMICAL", 69, 72], ["species susceptibility", "PROBLEM", 15, 37], ["LPS responses", "TEST", 69, 82], ["different strains of the same species", "PROBLEM", 91, 128], ["species susceptibility", "OBSERVATION", 15, 37]]], ["For example, BALB/c mice are very sensitive to LPS, whereas C57BL/6 mice are more resistant.Endotoxin. ::: Models That Target Primarily the Capillary Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSIn addition to differences in the susceptibility of different species to LPS, the response of LPS depends on the type of LPS used.", [["LPS", "CHEMICAL", 47, 50], ["Endotoxin", "CHEMICAL", 92, 101], ["LPS", "CHEMICAL", 281, 284], ["LPS", "CHEMICAL", 302, 305], ["LPS", "CHEMICAL", 329, 332], ["BALB/c mice", "ORGANISM", 13, 24], ["LPS", "SIMPLE_CHEMICAL", 47, 50], ["C57BL/6 mice", "ORGANISM", 60, 72], ["LPS", "SIMPLE_CHEMICAL", 281, 284], ["LPS", "SIMPLE_CHEMICAL", 302, 305], ["LPS", "SIMPLE_CHEMICAL", 329, 332], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 68, 72], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 68, 72], ["BALB", "TEST", 13, 17], ["LPS", "TEST", 47, 50], ["LUNG INJURY", "PROBLEM", 183, 194], ["LPS", "TREATMENT", 281, 284], ["LPS", "PROBLEM", 302, 305], ["Capillary Endothelium", "OBSERVATION", 140, 161], ["LUNG", "ANATOMY", 183, 187], ["INJURY", "OBSERVATION", 188, 194]]], ["LPS from bacteria-forming smooth colonies have the O-chain, consisting of variable numbers of repeating disaccharides, and are less pyrogenic.", [["smooth colonies", "ANATOMY", 26, 41], ["LPS", "CHEMICAL", 0, 3], ["disaccharides", "CHEMICAL", 104, 117], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["smooth colonies", "CELL", 26, 41], ["disaccharides", "SIMPLE_CHEMICAL", 104, 117], ["O-chain", "PROTEIN", 51, 58], ["LPS from bacteria", "TEST", 0, 17], ["smooth colonies", "TEST", 26, 41], ["repeating disaccharides", "PROBLEM", 94, 117], ["bacteria", "OBSERVATION_MODIFIER", 9, 17], ["smooth colonies", "OBSERVATION", 26, 41], ["O-chain", "OBSERVATION_MODIFIER", 51, 58], ["variable", "OBSERVATION_MODIFIER", 74, 82], ["numbers", "OBSERVATION_MODIFIER", 83, 90], ["repeating disaccharides", "OBSERVATION_MODIFIER", 94, 117], ["less", "OBSERVATION_MODIFIER", 127, 131], ["pyrogenic", "OBSERVATION_MODIFIER", 132, 141]]], ["LPS produced by bacteria growing in rough colonies lacks the O-chain and tends to be more pyrogenic (121).", [["colonies", "ANATOMY", 42, 50], ["LPS", "CHEMICAL", 0, 3], ["O", "CHEMICAL", 61, 62], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["O-chain", "PROTEIN", 61, 68], ["LPS", "TEST", 0, 3], ["bacteria", "PROBLEM", 16, 24], ["rough colonies", "TEST", 36, 50], ["bacteria", "OBSERVATION_MODIFIER", 16, 24], ["growing", "OBSERVATION_MODIFIER", 25, 32], ["rough colonies", "OBSERVATION", 36, 50], ["O-chain", "OBSERVATION_MODIFIER", 61, 68], ["more", "OBSERVATION_MODIFIER", 85, 89], ["pyrogenic", "OBSERVATION", 90, 99]]], ["LPS preparations often contain contaminants, such as bacterial lipoproteins, which may influence the biological effects of LPS by interacting with TLRs other than TLR4, which is the primary LPS receptor (211).Endotoxin. ::: Models That Target Primarily the Capillary Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSAdvantages and disadvantages: the use of bacterial LPS has a number of advantages as a method to model the effects of gram-negative bacteria in animals and humans.", [["LPS", "CHEMICAL", 0, 3], ["LPS", "CHEMICAL", 123, 126], ["Endotoxin", "CHEMICAL", 209, 218], ["LPS", "CHEMICAL", 376, 379], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["LPS", "SIMPLE_CHEMICAL", 123, 126], ["TLRs", "GENE_OR_GENE_PRODUCT", 147, 151], ["TLR4", "GENE_OR_GENE_PRODUCT", 163, 167], ["LPS receptor", "GENE_OR_GENE_PRODUCT", 190, 202], ["LPS", "SIMPLE_CHEMICAL", 376, 379], ["humans", "ORGANISM", 481, 487], ["bacterial lipoproteins", "PROTEIN", 53, 75], ["TLRs", "PROTEIN", 147, 151], ["TLR4", "PROTEIN", 163, 167], ["humans", "SPECIES", 481, 487], ["humans", "SPECIES", 481, 487], ["LPS preparations", "TEST", 0, 16], ["bacterial lipoproteins", "PROBLEM", 53, 75], ["LPS", "TREATMENT", 123, 126], ["LUNG INJURY", "PROBLEM", 300, 311], ["bacterial LPS", "TREATMENT", 366, 379], ["gram-negative bacteria in animals", "PROBLEM", 443, 476], ["contaminants", "OBSERVATION", 31, 43], ["Capillary Endothelium", "OBSERVATION", 257, 278], ["LUNG", "ANATOMY", 300, 304], ["INJURY", "OBSERVATION", 305, 311], ["negative bacteria", "OBSERVATION", 448, 465]]], ["LPS is easy to administer, and the results tend to be reproducible within experiments.", [["LPS", "CHEMICAL", 0, 3], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["LPS", "TEST", 0, 3]]], ["LPS is a potent activator of the innate immune responses via TLR4 pathways and has little direct toxicity to cells in vitro.", [["cells", "ANATOMY", 109, 114], ["LPS", "CHEMICAL", 0, 3], ["toxicity", "DISEASE", 97, 105], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["TLR4", "GENE_OR_GENE_PRODUCT", 61, 65], ["cells", "CELL", 109, 114], ["TLR4", "PROTEIN", 61, 65], ["LPS", "TEST", 0, 3], ["TLR4 pathways", "TREATMENT", 61, 74], ["little direct toxicity", "PROBLEM", 83, 105]]], ["Thus, the use of LPS provides information about the effects of host inflammatory responses, which occur in bacterial infections.", [["LPS", "CHEMICAL", 17, 20], ["bacterial infections", "DISEASE", 107, 127], ["LPS", "SIMPLE_CHEMICAL", 17, 20], ["LPS", "TREATMENT", 17, 20], ["host inflammatory responses", "PROBLEM", 63, 90], ["bacterial infections", "PROBLEM", 107, 127], ["bacterial", "OBSERVATION_MODIFIER", 107, 116], ["infections", "OBSERVATION", 117, 127]]], ["LPS has some significant disadvantages, however.", [["LPS", "CHEMICAL", 0, 3], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["LPS", "TEST", 0, 3], ["some", "OBSERVATION_MODIFIER", 8, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["disadvantages", "OBSERVATION", 25, 38]]], ["LPS preparations vary in purity and can be contaminated with bacterial lipoproteins and other bacterial materials (211).", [["LPS", "CHEMICAL", 0, 3], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["bacterial lipoproteins", "PROTEIN", 61, 83], ["LPS preparations", "TEST", 0, 16], ["bacterial lipoproteins", "PROBLEM", 61, 83], ["other bacterial materials", "PROBLEM", 88, 113]]], ["In general, LPS treatment does not cause the severe endothelial and epithelial injury that occurs in humans with ARDS (239).", [["endothelial", "ANATOMY", 52, 63], ["epithelial", "ANATOMY", 68, 78], ["LPS", "CHEMICAL", 12, 15], ["ARDS", "DISEASE", 113, 117], ["LPS", "SIMPLE_CHEMICAL", 12, 15], ["endothelial", "CELL", 52, 63], ["epithelial", "TISSUE", 68, 78], ["humans", "ORGANISM", 101, 107], ["humans", "SPECIES", 101, 107], ["humans", "SPECIES", 101, 107], ["LPS treatment", "TREATMENT", 12, 25], ["the severe endothelial", "PROBLEM", 41, 63], ["epithelial injury", "PROBLEM", 68, 85], ["ARDS", "PROBLEM", 113, 117], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["endothelial", "ANATOMY", 52, 63], ["epithelial", "ANATOMY_MODIFIER", 68, 78], ["injury", "OBSERVATION", 79, 85], ["ARDS", "OBSERVATION", 113, 117]]], ["Bacteria produce exotoxins that are potent cellular toxins (122) and use effector systems such as the type III systems that cause direct cellular lysis (183).", [["cellular", "ANATOMY", 43, 51], ["cellular", "ANATOMY", 137, 145], ["cellular", "CELL", 43, 51], ["cellular", "CELL", 137, 145], ["Bacteria produce exotoxins", "PROBLEM", 0, 26], ["potent cellular toxins", "PROBLEM", 36, 58], ["effector systems", "TREATMENT", 73, 89], ["direct cellular lysis", "PROBLEM", 130, 151], ["exotoxins", "OBSERVATION", 17, 26], ["potent", "OBSERVATION_MODIFIER", 36, 42], ["cellular lysis", "OBSERVATION", 137, 151]]], ["Thus, LPS by itself provides an incomplete picture of the effects of live bacteria in the lungs.Acid aspiration. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSBasis for the model: the development of acute respiratory failure following aspiration of gastric contents was first described in 1946 by Mendelson (138), and aspiration of gastric contents is now recognized as an important risk factor for ARDS (50, 95, 163).", [["lungs", "ANATOMY", 90, 95], ["Alveolar Epithelium", "ANATOMY", 150, 169], ["respiratory", "ANATOMY", 262, 273], ["gastric", "ANATOMY", 306, 313], ["gastric", "ANATOMY", 389, 396], ["LPS", "CHEMICAL", 6, 9], ["respiratory failure", "DISEASE", 262, 281], ["ARDS", "DISEASE", 456, 460], ["LPS", "SIMPLE_CHEMICAL", 6, 9], ["lungs", "ORGAN", 90, 95], ["Acid", "SIMPLE_CHEMICAL", 96, 100], ["Alveolar Epithelium", "TISSUE", 150, 169], ["gastric", "ORGAN", 306, 313], ["gastric", "ORGAN", 389, 396], ["LPS", "TEST", 6, 9], ["live bacteria in the lungs", "PROBLEM", 69, 95], ["Acid aspiration", "PROBLEM", 96, 111], ["LUNG INJURY", "PROBLEM", 191, 202], ["acute respiratory failure", "PROBLEM", 256, 281], ["aspiration of gastric contents", "PROBLEM", 292, 322], ["aspiration of gastric contents", "PROBLEM", 375, 405], ["ARDS", "PROBLEM", 456, 460], ["lungs", "ANATOMY", 90, 95], ["aspiration", "OBSERVATION", 101, 111], ["Alveolar Epithelium", "OBSERVATION", 150, 169], ["LUNG", "ANATOMY", 191, 195], ["INJURY", "OBSERVATION", 196, 202], ["acute", "OBSERVATION_MODIFIER", 256, 261], ["respiratory failure", "OBSERVATION", 262, 281], ["aspiration", "OBSERVATION", 292, 302], ["gastric", "ANATOMY", 306, 313], ["contents", "OBSERVATION", 314, 322], ["aspiration", "OBSERVATION", 375, 385], ["gastric", "ANATOMY", 389, 396], ["contents", "OBSERVATION", 397, 405]]], ["One of the main characteristics of gastric contents is a low pH, so investigators have used hydrochloric acid (HCl) to simulate lung injury due to gastric acid aspiration in animals.", [["gastric", "ANATOMY", 35, 42], ["lung", "ANATOMY", 128, 132], ["gastric", "ANATOMY", 147, 154], ["hydrochloric acid", "CHEMICAL", 92, 109], ["HCl", "CHEMICAL", 111, 114], ["lung injury", "DISEASE", 128, 139], ["hydrochloric acid", "CHEMICAL", 92, 109], ["HCl", "CHEMICAL", 111, 114], ["gastric", "ORGAN", 35, 42], ["hydrochloric acid", "SIMPLE_CHEMICAL", 92, 109], ["HCl", "SIMPLE_CHEMICAL", 111, 114], ["lung", "ORGAN", 128, 132], ["gastric acid", "MULTI-TISSUE_STRUCTURE", 147, 159], ["gastric contents", "PROBLEM", 35, 51], ["a low pH", "PROBLEM", 55, 63], ["hydrochloric acid (HCl", "TREATMENT", 92, 114], ["lung injury", "PROBLEM", 128, 139], ["gastric acid aspiration", "PROBLEM", 147, 170], ["main", "OBSERVATION_MODIFIER", 11, 15], ["gastric", "ANATOMY", 35, 42], ["contents", "OBSERVATION", 43, 51], ["low pH", "OBSERVATION_MODIFIER", 57, 63], ["lung", "ANATOMY", 128, 132], ["injury", "OBSERVATION", 133, 139], ["gastric", "ANATOMY", 147, 154], ["acid", "OBSERVATION_MODIFIER", 155, 159], ["aspiration", "OBSERVATION", 160, 170]]], ["However, it is important to keep in mind that in addition to low pH, gastric contents contain several other products such as food particles, bacterial cell wall products, and cytokines such as IL-1\u03b2, and also have a very high osmolarity.", [["gastric", "ANATOMY", 69, 76], ["cell wall", "ANATOMY", 151, 160], ["gastric", "ORGAN", 69, 76], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 193, 198], ["bacterial cell wall products", "PROTEIN", 141, 169], ["cytokines", "PROTEIN", 175, 184], ["IL-1\u03b2", "PROTEIN", 193, 198], ["low pH", "PROBLEM", 61, 67], ["gastric contents", "PROBLEM", 69, 85], ["several other products", "TREATMENT", 94, 116], ["food particles", "TREATMENT", 125, 139], ["bacterial cell wall products", "TREATMENT", 141, 169], ["cytokines", "PROBLEM", 175, 184], ["a very high osmolarity", "PROBLEM", 214, 236], ["gastric", "ANATOMY", 69, 76], ["bacterial cell wall products", "OBSERVATION", 141, 169]]], ["All of these factors may contribute to the pathogenesis of aspiration-induced lung injury (118, 172).", [["lung", "ANATOMY", 78, 82], ["aspiration-induced lung injury", "DISEASE", 59, 89], ["lung", "ORGAN", 78, 82], ["aspiration", "PROBLEM", 59, 69], ["induced lung injury", "PROBLEM", 70, 89], ["may contribute to", "UNCERTAINTY", 21, 38], ["aspiration", "OBSERVATION", 59, 69], ["lung", "ANATOMY", 78, 82], ["injury", "OBSERVATION", 83, 89]]], ["An important consideration is that a very low pH is required to produce lung injury in animals, e.g., pH 1.5, lower than is typically measured in human gastric contents, but the low pH model remains widely used.Acid aspiration. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSMechanism: low pH acid aspiration is a neutrophil-dependent form of lung injury that is characterized by injury of the airway and alveolar epithelium, including type I alveolar epithelial cells, followed by a repair process that involves proliferation of alveolar type II cells (60, 117).", [["lung", "ANATOMY", 72, 76], ["gastric", "ANATOMY", 152, 159], ["Alveolar Epithelium", "ANATOMY", 265, 284], ["neutrophil", "ANATOMY", 370, 380], ["lung", "ANATOMY", 399, 403], ["airway", "ANATOMY", 450, 456], ["alveolar epithelium", "ANATOMY", 461, 480], ["alveolar epithelial cells", "ANATOMY", 499, 524], ["alveolar type II cells", "ANATOMY", 586, 608], ["lung injury", "DISEASE", 72, 83], ["lung injury", "DISEASE", 399, 410], ["lung", "ORGAN", 72, 76], ["human", "ORGANISM", 146, 151], ["gastric", "ORGAN", 152, 159], ["Acid", "SIMPLE_CHEMICAL", 211, 215], ["Alveolar Epithelium", "TISSUE", 265, 284], ["neutrophil", "CELL", 370, 380], ["lung", "ORGAN", 399, 403], ["airway", "MULTI-TISSUE_STRUCTURE", 450, 456], ["alveolar epithelium", "TISSUE", 461, 480], ["alveolar epithelial cells", "CELL", 499, 524], ["alveolar type II cells", "CELL", 586, 608], ["type I alveolar epithelial cells", "CELL_TYPE", 492, 524], ["alveolar type II cells", "CELL_TYPE", 586, 608], ["human", "SPECIES", 146, 151], ["human", "SPECIES", 146, 151], ["a very low pH", "PROBLEM", 35, 48], ["lung injury", "PROBLEM", 72, 83], ["pH", "TEST", 102, 104], ["the low pH model", "PROBLEM", 174, 190], ["Acid aspiration", "PROBLEM", 211, 226], ["LUNG INJURY", "PROBLEM", 306, 317], ["low pH acid aspiration", "PROBLEM", 342, 364], ["lung injury", "PROBLEM", 399, 410], ["injury of the airway", "PROBLEM", 436, 456], ["alveolar epithelium", "PROBLEM", 461, 480], ["type I alveolar epithelial cells", "PROBLEM", 492, 524], ["a repair process", "TREATMENT", 538, 554], ["proliferation of alveolar type II cells", "PROBLEM", 569, 608], ["lung", "ANATOMY", 72, 76], ["injury", "OBSERVATION", 77, 83], ["gastric", "ANATOMY", 152, 159], ["contents", "OBSERVATION", 160, 168], ["low pH", "OBSERVATION_MODIFIER", 178, 184], ["aspiration", "OBSERVATION", 216, 226], ["Alveolar Epithelium", "OBSERVATION", 265, 284], ["LUNG", "ANATOMY", 306, 310], ["INJURY", "OBSERVATION", 311, 317], ["low pH", "OBSERVATION_MODIFIER", 342, 348], ["lung", "ANATOMY", 399, 403], ["injury", "OBSERVATION", 404, 410], ["injury", "OBSERVATION", 436, 442], ["airway", "ANATOMY", 450, 456], ["alveolar epithelium", "ANATOMY", 461, 480], ["alveolar", "ANATOMY_MODIFIER", 499, 507], ["epithelial cells", "OBSERVATION", 508, 524], ["repair", "OBSERVATION", 540, 546], ["proliferation", "OBSERVATION_MODIFIER", 569, 582], ["alveolar type II cells", "OBSERVATION", 586, 608]]], ["The evidence supporting the alveolar epithelium as a key target site of acid aspiration includes studies showing that acid aspiration causes an impairment in the alveolar epithelial fluid transport function, resulting in changes in alveolar fluid clearance independently of pulmonary blood flow or vascular filtration (136, 141).", [["alveolar epithelium", "ANATOMY", 28, 47], ["alveolar epithelial", "ANATOMY", 162, 181], ["alveolar fluid", "ANATOMY", 232, 246], ["pulmonary", "ANATOMY", 274, 283], ["blood", "ANATOMY", 284, 289], ["vascular", "ANATOMY", 298, 306], ["alveolar epithelium", "TISSUE", 28, 47], ["alveolar epithelial", "TISSUE", 162, 181], ["fluid", "TISSUE", 182, 187], ["alveolar fluid", "MULTI-TISSUE_STRUCTURE", 232, 246], ["pulmonary blood", "MULTI-TISSUE_STRUCTURE", 274, 289], ["vascular", "MULTI-TISSUE_STRUCTURE", 298, 306], ["the alveolar epithelium", "PROBLEM", 24, 47], ["acid aspiration", "PROBLEM", 72, 87], ["studies", "TEST", 97, 104], ["acid aspiration", "PROBLEM", 118, 133], ["an impairment", "PROBLEM", 141, 154], ["the alveolar epithelial fluid transport function", "PROBLEM", 158, 206], ["changes in alveolar fluid clearance", "PROBLEM", 221, 256], ["pulmonary blood flow", "TEST", 274, 294], ["vascular filtration", "TEST", 298, 317], ["alveolar", "ANATOMY_MODIFIER", 28, 36], ["epithelium", "ANATOMY_MODIFIER", 37, 47], ["acid aspiration", "OBSERVATION", 72, 87], ["impairment", "OBSERVATION_MODIFIER", 144, 154], ["alveolar", "ANATOMY_MODIFIER", 162, 170], ["epithelial", "ANATOMY_MODIFIER", 171, 181], ["fluid transport function", "OBSERVATION", 182, 206], ["alveolar", "ANATOMY_MODIFIER", 232, 240], ["fluid clearance", "OBSERVATION", 241, 256], ["pulmonary blood", "ANATOMY", 274, 289], ["flow", "OBSERVATION_MODIFIER", 290, 294], ["vascular", "ANATOMY", 298, 306], ["filtration", "OBSERVATION", 307, 317]]], ["However, acid aspiration also results in injury to the capillary endothelium, by a mechanism that appears to require circulating neutrophils (60, 117).", [["capillary endothelium", "ANATOMY", 55, 76], ["neutrophils", "ANATOMY", 129, 140], ["capillary endothelium", "TISSUE", 55, 76], ["neutrophils", "CELL", 129, 140], ["circulating neutrophils", "CELL_TYPE", 117, 140], ["acid aspiration", "PROBLEM", 9, 24], ["injury to the capillary endothelium", "PROBLEM", 41, 76], ["circulating neutrophils", "TEST", 117, 140], ["injury", "OBSERVATION", 41, 47], ["capillary endothelium", "ANATOMY", 55, 76]]], ["Although the exact mechanism of cellular injury is unclear, it is unclear whether the acid itself causes direct injury because it is rapidly neutralized in biological fluids that are buffered by proteins and the bicarbonate system (7).Acid aspiration. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSTechnical issues: acid injury is produced by instilling HCl directly into the trachea or bronchi while an animal is mechanically ventilated.", [["cellular", "ANATOMY", 32, 40], ["Alveolar Epithelium", "ANATOMY", 289, 308], ["trachea", "ANATOMY", 433, 440], ["bronchi", "ANATOMY", 444, 451], ["cellular injury", "DISEASE", 32, 47], ["bicarbonate", "CHEMICAL", 212, 223], ["acid injury", "DISEASE", 373, 384], ["HCl", "CHEMICAL", 411, 414], ["bicarbonate", "CHEMICAL", 212, 223], ["HCl", "CHEMICAL", 411, 414], ["cellular", "CELL", 32, 40], ["bicarbonate", "SIMPLE_CHEMICAL", 212, 223], ["Acid", "SIMPLE_CHEMICAL", 235, 239], ["Alveolar Epithelium", "TISSUE", 289, 308], ["HCl", "SIMPLE_CHEMICAL", 411, 414], ["trachea", "MULTI-TISSUE_STRUCTURE", 433, 440], ["bronchi", "MULTI-TISSUE_STRUCTURE", 444, 451], ["cellular injury", "PROBLEM", 32, 47], ["the acid itself", "PROBLEM", 82, 97], ["direct injury", "PROBLEM", 105, 118], ["the bicarbonate system", "TEST", 208, 230], ["Acid aspiration", "PROBLEM", 235, 250], ["LUNG INJURY", "PROBLEM", 330, 341], ["acid injury", "PROBLEM", 373, 384], ["mechanically ventilated", "PROBLEM", 471, 494], ["cellular injury", "OBSERVATION", 32, 47], ["rapidly", "OBSERVATION_MODIFIER", 133, 140], ["neutralized", "OBSERVATION_MODIFIER", 141, 152], ["aspiration", "OBSERVATION", 240, 250], ["Alveolar Epithelium", "OBSERVATION", 289, 308], ["LUNG", "ANATOMY", 330, 334], ["INJURY", "OBSERVATION", 335, 341], ["acid injury", "OBSERVATION", 373, 384], ["trachea", "ANATOMY", 433, 440], ["bronchi", "ANATOMY", 444, 451], ["mechanically ventilated", "OBSERVATION", 471, 494]]], ["Although HCl is rapidly neutralized in the lungs, the concentration of HCl affects the severity of injury.", [["lungs", "ANATOMY", 43, 48], ["HCl", "CHEMICAL", 9, 12], ["HCl", "CHEMICAL", 71, 74], ["HCl", "CHEMICAL", 9, 12], ["HCl", "CHEMICAL", 71, 74], ["HCl", "SIMPLE_CHEMICAL", 9, 12], ["lungs", "ORGAN", 43, 48], ["HCl", "SIMPLE_CHEMICAL", 71, 74], ["HCl", "PROBLEM", 9, 12], ["injury", "PROBLEM", 99, 105], ["rapidly", "OBSERVATION_MODIFIER", 16, 23], ["neutralized", "OBSERVATION", 24, 35], ["lungs", "ANATOMY", 43, 48], ["injury", "OBSERVATION", 99, 105]]], ["Most studies use 0.1 N HCl, although higher concentrations (up to 0.5 N) have been used.", [["N HCl", "CHEMICAL", 21, 26], ["HCl", "CHEMICAL", 23, 26], ["0.1 N HCl", "SIMPLE_CHEMICAL", 17, 26], ["HCl", "TREATMENT", 23, 26], ["higher concentrations", "PROBLEM", 37, 58]]], ["Because this results in a pH that is generally lower than that of gastric juice [most ICU patients have gastric juice pH in the range of 3.0\u20134.0 (23)], an alternative method is to use 0.3% NaCl titrated with HCl to a pH of 1.2\u20131.5.", [["gastric juice", "ANATOMY", 66, 79], ["gastric juice", "ANATOMY", 104, 117], ["NaCl", "CHEMICAL", 189, 193], ["HCl", "CHEMICAL", 208, 211], ["NaCl", "CHEMICAL", 189, 193], ["HCl", "CHEMICAL", 208, 211], ["gastric juice", "ORGANISM_SUBSTANCE", 66, 79], ["patients", "ORGANISM", 90, 98], ["gastric juice", "MULTI-TISSUE_STRUCTURE", 104, 117], ["HCl", "SIMPLE_CHEMICAL", 208, 211], ["patients", "SPECIES", 90, 98], ["a pH", "TEST", 24, 28], ["gastric juice", "TREATMENT", 66, 79], ["gastric juice pH", "TEST", 104, 120], ["an alternative method", "TREATMENT", 152, 173], ["NaCl", "TREATMENT", 189, 193], ["HCl", "TREATMENT", 208, 211], ["a pH", "TEST", 215, 219], ["gastric", "ANATOMY", 66, 73], ["gastric", "ANATOMY", 104, 111], ["juice pH", "OBSERVATION", 112, 120]]], ["This results in a solution with pH and osmolarity approaching the gastric juice of some patients.Acid aspiration. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSCharacteristics of the injury: the lung injury is characterized histologically by an acute inflammatory response with patchy areas of neutrophilic inflammation, alveolar hemorrhage, intra-alveolar and interstitial edema, and impairment in the alveolar fluid clearance (Fig. 4) (136, 251).", [["gastric juice", "ANATOMY", 66, 79], ["Alveolar Epithelium", "ANATOMY", 151, 170], ["lung", "ANATOMY", 252, 256], ["neutrophilic", "ANATOMY", 351, 363], ["alveolar", "ANATOMY", 378, 386], ["intra-alveolar", "ANATOMY", 399, 413], ["interstitial edema", "ANATOMY", 418, 436], ["alveolar fluid", "ANATOMY", 460, 474], ["lung injury", "DISEASE", 252, 263], ["inflammation", "DISEASE", 364, 376], ["alveolar hemorrhage", "DISEASE", 378, 397], ["interstitial edema", "DISEASE", 418, 436], ["gastric juice", "ORGANISM_SUBSTANCE", 66, 79], ["patients", "ORGANISM", 88, 96], ["Acid", "SIMPLE_CHEMICAL", 97, 101], ["Alveolar Epithelium", "TISSUE", 151, 170], ["lung", "ORGAN", 252, 256], ["alveolar", "MULTI-TISSUE_STRUCTURE", 378, 386], ["intra-alveolar", "IMMATERIAL_ANATOMICAL_ENTITY", 399, 413], ["interstitial edema", "PATHOLOGICAL_FORMATION", 418, 436], ["alveolar fluid", "MULTI-TISSUE_STRUCTURE", 460, 474], ["patients", "SPECIES", 88, 96], ["a solution with pH", "TREATMENT", 16, 34], ["osmolarity", "TEST", 39, 49], ["Acid aspiration", "PROBLEM", 97, 112], ["LUNG INJURY", "PROBLEM", 192, 203], ["the injury", "PROBLEM", 236, 246], ["the lung injury", "PROBLEM", 248, 263], ["an acute inflammatory response", "PROBLEM", 299, 329], ["neutrophilic inflammation", "PROBLEM", 351, 376], ["alveolar hemorrhage", "PROBLEM", 378, 397], ["intra-alveolar", "PROBLEM", 399, 413], ["interstitial edema", "PROBLEM", 418, 436], ["the alveolar fluid clearance", "TEST", 456, 484], ["gastric", "ANATOMY", 66, 73], ["aspiration", "OBSERVATION", 102, 112], ["Alveolar", "ANATOMY_MODIFIER", 151, 159], ["Epithelium", "ANATOMY_MODIFIER", 160, 170], ["LUNG", "ANATOMY", 192, 196], ["INJURY", "OBSERVATION", 197, 203], ["MODEL SYSTEMSCharacteristics", "OBSERVATION", 204, 232], ["injury", "OBSERVATION", 240, 246], ["lung", "ANATOMY", 252, 256], ["injury", "OBSERVATION", 257, 263], ["acute", "OBSERVATION_MODIFIER", 302, 307], ["inflammatory", "OBSERVATION_MODIFIER", 308, 320], ["patchy", "OBSERVATION_MODIFIER", 335, 341], ["areas", "OBSERVATION_MODIFIER", 342, 347], ["neutrophilic inflammation", "OBSERVATION", 351, 376], ["alveolar", "ANATOMY_MODIFIER", 378, 386], ["hemorrhage", "OBSERVATION", 387, 397], ["intra-alveolar", "ANATOMY_MODIFIER", 399, 413], ["interstitial", "ANATOMY_MODIFIER", 418, 430], ["edema", "OBSERVATION", 431, 436], ["impairment", "OBSERVATION_MODIFIER", 442, 452], ["alveolar", "ANATOMY_MODIFIER", 460, 468], ["fluid clearance", "OBSERVATION", 469, 484]]], ["The acute inflammatory response is followed by a fibrotic response that is evident \u223c1 wk after instillation (250).", [["The acute inflammatory response", "PROBLEM", 0, 31], ["a fibrotic response", "PROBLEM", 47, 66], ["acute", "OBSERVATION_MODIFIER", 4, 9], ["inflammatory", "OBSERVATION", 10, 22], ["fibrotic", "OBSERVATION", 49, 57]]], ["The main physiological features are an immediate increase in airway resistance and peak pressures, a fall in lung compliance, and a decrease in the FRC.", [["airway", "ANATOMY", 61, 67], ["lung", "ANATOMY", 109, 113], ["airway", "MULTI-TISSUE_STRUCTURE", 61, 67], ["lung", "ORGAN", 109, 113], ["an immediate increase in airway resistance", "PROBLEM", 36, 78], ["peak pressures", "TEST", 83, 97], ["a fall in lung compliance", "PROBLEM", 99, 124], ["a decrease in the FRC", "PROBLEM", 130, 151], ["main", "OBSERVATION_MODIFIER", 4, 8], ["immediate", "OBSERVATION_MODIFIER", 39, 48], ["increase", "OBSERVATION_MODIFIER", 49, 57], ["airway resistance", "OBSERVATION", 61, 78], ["peak", "OBSERVATION_MODIFIER", 83, 87], ["pressures", "OBSERVATION_MODIFIER", 88, 97], ["lung", "ANATOMY", 109, 113], ["compliance", "OBSERVATION", 114, 124], ["decrease", "OBSERVATION_MODIFIER", 132, 140]]], ["The vascular response includes elevation of the pulmonary vascular resistance and pulmonary arterial pressure, with an increase in the shunt fraction and dead space.", [["vascular", "ANATOMY", 4, 12], ["pulmonary vascular", "ANATOMY", 48, 66], ["pulmonary arterial", "ANATOMY", 82, 100], ["vascular", "MULTI-TISSUE_STRUCTURE", 4, 12], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 48, 66], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 82, 100], ["elevation of the pulmonary vascular resistance", "PROBLEM", 31, 77], ["pulmonary arterial pressure", "TEST", 82, 109], ["an increase in the shunt fraction", "PROBLEM", 116, 149], ["dead space", "PROBLEM", 154, 164], ["vascular", "ANATOMY", 4, 12], ["elevation", "OBSERVATION", 31, 40], ["pulmonary vascular", "ANATOMY", 48, 66], ["resistance", "OBSERVATION", 67, 77], ["pulmonary arterial", "ANATOMY", 82, 100], ["pressure", "OBSERVATION_MODIFIER", 101, 109], ["increase", "OBSERVATION_MODIFIER", 119, 127], ["shunt fraction", "OBSERVATION", 135, 149], ["dead space", "OBSERVATION", 154, 164]]], ["The pulmonary capillary wedge pressure and heart rate remain unchanged, whereas the cardiac output and mean arterial pressure either decrease or remain unchanged (159).", [["pulmonary capillary", "ANATOMY", 4, 23], ["heart", "ANATOMY", 43, 48], ["cardiac", "ANATOMY", 84, 91], ["arterial", "ANATOMY", 108, 116], ["pulmonary capillary", "MULTI-TISSUE_STRUCTURE", 4, 23], ["heart", "ORGAN", 43, 48], ["cardiac", "ORGAN", 84, 91], ["arterial", "MULTI-TISSUE_STRUCTURE", 108, 116], ["The pulmonary capillary wedge pressure", "TEST", 0, 38], ["heart rate", "TEST", 43, 53], ["the cardiac output", "TEST", 80, 98], ["mean arterial pressure", "TEST", 103, 125], ["pulmonary", "ANATOMY", 4, 13], ["capillary", "ANATOMY_MODIFIER", 14, 23], ["wedge pressure", "OBSERVATION", 24, 38], ["heart", "ANATOMY", 43, 48], ["rate", "OBSERVATION_MODIFIER", 49, 53], ["unchanged", "OBSERVATION", 61, 70], ["mean arterial pressure", "OBSERVATION", 103, 125], ["decrease", "OBSERVATION_MODIFIER", 133, 141], ["unchanged", "OBSERVATION_MODIFIER", 152, 161]]], ["The main systemic consequences are leukopenia and thrombocytopenia.", [["leukopenia", "DISEASE", 35, 45], ["thrombocytopenia", "DISEASE", 50, 66], ["leukopenia", "PROBLEM", 35, 45], ["thrombocytopenia", "PROBLEM", 50, 66], ["main", "OBSERVATION_MODIFIER", 4, 8], ["systemic", "OBSERVATION_MODIFIER", 9, 17], ["leukopenia", "OBSERVATION", 35, 45], ["thrombocytopenia", "OBSERVATION", 50, 66]]], ["Interestingly, the endobronchial administration of 0.1 N HCl is followed by an increase in microvascular permeability in the ileum, which can be blocked with antibodies targeting neutrophil adhesion molecules (anti-CD18) (207), showing that acid aspiration in the lungs is linked to neutrophil-dependent injury to distant organs.Acid aspiration. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSAdvantages/disadvantages: the acid aspiration model is particularly useful for studying hemodynamic and physiological changes of ALI, ventilatory strategies, and mechanisms of neutrophil recruitment.", [["endobronchial", "ANATOMY", 19, 32], ["microvascular", "ANATOMY", 91, 104], ["ileum", "ANATOMY", 125, 130], ["lungs", "ANATOMY", 264, 269], ["neutrophil", "ANATOMY", 283, 293], ["organs", "ANATOMY", 322, 328], ["Alveolar Epithelium", "ANATOMY", 383, 402], ["neutrophil", "ANATOMY", 625, 635], ["0.1 N HCl", "CHEMICAL", 51, 60], ["ALI", "DISEASE", 578, 581], ["HCl", "CHEMICAL", 57, 60], ["0.1 N HCl", "SIMPLE_CHEMICAL", 51, 60], ["microvascular", "TISSUE", 91, 104], ["ileum", "ORGAN", 125, 130], ["neutrophil adhesion molecules", "GENE_OR_GENE_PRODUCT", 179, 208], ["anti-CD18", "GENE_OR_GENE_PRODUCT", 210, 219], ["lungs", "ORGAN", 264, 269], ["neutrophil", "CELL", 283, 293], ["organs", "ORGAN", 322, 328], ["Acid", "SIMPLE_CHEMICAL", 329, 333], ["Alveolar Epithelium", "TISSUE", 383, 402], ["neutrophil", "CELL", 625, 635], ["antibodies", "PROTEIN", 158, 168], ["neutrophil adhesion molecules", "PROTEIN", 179, 208], ["CD18", "PROTEIN", 215, 219], ["the endobronchial administration", "TREATMENT", 15, 47], ["an increase in microvascular permeability in the ileum", "PROBLEM", 76, 130], ["antibodies", "TEST", 158, 168], ["neutrophil adhesion molecules", "TEST", 179, 208], ["anti-CD18", "TEST", 210, 219], ["acid aspiration in the lungs", "PROBLEM", 241, 269], ["neutrophil-dependent injury to distant organs", "PROBLEM", 283, 328], ["Acid aspiration", "PROBLEM", 329, 344], ["LUNG INJURY", "PROBLEM", 424, 435], ["the acid aspiration model", "TEST", 475, 500], ["ALI", "PROBLEM", 578, 581], ["ventilatory strategies", "TREATMENT", 583, 605], ["neutrophil recruitment", "PROBLEM", 625, 647], ["endobronchial", "ANATOMY", 19, 32], ["increase", "OBSERVATION_MODIFIER", 79, 87], ["microvascular permeability", "OBSERVATION", 91, 117], ["ileum", "ANATOMY", 125, 130], ["acid", "OBSERVATION_MODIFIER", 241, 245], ["aspiration", "OBSERVATION", 246, 256], ["lungs", "ANATOMY", 264, 269], ["dependent", "OBSERVATION_MODIFIER", 294, 303], ["injury", "OBSERVATION", 304, 310], ["distant organs", "OBSERVATION", 314, 328], ["aspiration", "OBSERVATION", 334, 344], ["Alveolar Epithelium", "OBSERVATION", 383, 402], ["LUNG", "ANATOMY", 424, 428], ["INJURY", "OBSERVATION", 429, 435], ["ALI", "OBSERVATION", 578, 581], ["ventilatory strategies", "OBSERVATION", 583, 605], ["neutrophil recruitment", "OBSERVATION", 625, 647]]], ["Acid aspiration can also be used in conjunction with other techniques, such as mechanical ventilation, to further reproduce clinically relevant scenarios (60).", [["Acid", "SIMPLE_CHEMICAL", 0, 4], ["Acid aspiration", "PROBLEM", 0, 15], ["mechanical ventilation", "TREATMENT", 79, 101], ["aspiration", "OBSERVATION", 5, 15]]], ["A limitation of the acid aspiration method is that the difference between injurious and noninjurious acid concentrations is very narrow.", [["the acid aspiration method", "TREATMENT", 16, 42], ["the difference between injurious and noninjurious acid concentrations", "PROBLEM", 51, 120], ["narrow", "OBSERVATION_MODIFIER", 129, 135]]], ["Another limitation is that humans do not aspirate HCl, but instead aspirate complex gastric contents, which is a suspension of particulate matter, bacterial products, cytokines, and a pH that is usually higher than 1.5.", [["gastric", "ANATOMY", 84, 91], ["HCl", "CHEMICAL", 50, 53], ["HCl", "CHEMICAL", 50, 53], ["humans", "ORGANISM", 27, 33], ["HCl", "SIMPLE_CHEMICAL", 50, 53], ["gastric", "ORGAN", 84, 91], ["bacterial products", "PROTEIN", 147, 165], ["cytokines", "PROTEIN", 167, 176], ["humans", "SPECIES", 27, 33], ["humans", "SPECIES", 27, 33], ["HCl", "TREATMENT", 50, 53], ["aspirate complex gastric contents", "PROBLEM", 67, 100], ["a suspension of particulate matter", "TREATMENT", 111, 145], ["bacterial products", "TREATMENT", 147, 165], ["cytokines", "PROBLEM", 167, 176], ["a pH", "TEST", 182, 186], ["gastric", "ANATOMY", 84, 91], ["contents", "OBSERVATION", 92, 100], ["particulate matter", "OBSERVATION_MODIFIER", 127, 145], ["bacterial products", "OBSERVATION", 147, 165]]], ["Further studies are needed to determine whether these differences between gastric fluid and HCl result in a difference between this model and the injury seen in humans following the aspiration of gastric contents.Hyperoxia. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSBasis for the model: in most mammalian species, exposure to 100% O2 eventually results in respiratory distress and death (67).", [["gastric fluid", "ANATOMY", 74, 87], ["gastric", "ANATOMY", 196, 203], ["Alveolar Epithelium", "ANATOMY", 261, 280], ["respiratory", "ANATOMY", 417, 428], ["HCl", "CHEMICAL", 92, 95], ["Hyperoxia", "DISEASE", 213, 222], ["O2", "CHEMICAL", 392, 394], ["respiratory distress", "DISEASE", 417, 437], ["death", "DISEASE", 442, 447], ["HCl", "CHEMICAL", 92, 95], ["O2", "CHEMICAL", 392, 394], ["gastric fluid", "MULTI-TISSUE_STRUCTURE", 74, 87], ["HCl", "SIMPLE_CHEMICAL", 92, 95], ["humans", "ORGANISM", 161, 167], ["gastric", "ORGAN", 196, 203], ["Alveolar Epithelium", "TISSUE", 261, 280], ["O2", "SIMPLE_CHEMICAL", 392, 394], ["humans", "SPECIES", 161, 167], ["humans", "SPECIES", 161, 167], ["Further studies", "TEST", 0, 15], ["gastric fluid", "TEST", 74, 87], ["HCl", "TREATMENT", 92, 95], ["the injury", "PROBLEM", 142, 152], ["the aspiration of gastric contents", "PROBLEM", 178, 212], ["Hyperoxia", "PROBLEM", 213, 222], ["LUNG INJURY", "PROBLEM", 302, 313], ["100% O2", "TREATMENT", 387, 394], ["respiratory distress", "PROBLEM", 417, 437], ["death", "PROBLEM", 442, 447], ["gastric", "ANATOMY", 74, 81], ["fluid", "OBSERVATION", 82, 87], ["injury", "OBSERVATION", 146, 152], ["aspiration", "OBSERVATION", 182, 192], ["gastric", "ANATOMY", 196, 203], ["contents", "OBSERVATION", 204, 212], ["Alveolar Epithelium", "OBSERVATION", 261, 280], ["LUNG", "ANATOMY", 302, 306], ["INJURY", "OBSERVATION", 307, 313], ["respiratory distress", "OBSERVATION", 417, 437]]], ["However, the same findings have not been reproduced in humans with normal lungs, who develop only mild increases in alveolar capillary permeability after 24 h of exposure to 100% oxygen, and no clinical or pathological evidence of lung injury when the exposure is extended to several days (12, 42).", [["lungs", "ANATOMY", 74, 79], ["alveolar capillary", "ANATOMY", 116, 134], ["lung", "ANATOMY", 231, 235], ["oxygen", "CHEMICAL", 179, 185], ["lung injury", "DISEASE", 231, 242], ["oxygen", "CHEMICAL", 179, 185], ["humans", "ORGANISM", 55, 61], ["lungs", "ORGAN", 74, 79], ["alveolar capillary", "TISSUE", 116, 134], ["oxygen", "SIMPLE_CHEMICAL", 179, 185], ["lung", "ORGAN", 231, 235], ["humans", "SPECIES", 55, 61], ["humans", "SPECIES", 55, 61], ["mild increases in alveolar capillary permeability", "PROBLEM", 98, 147], ["100% oxygen", "TREATMENT", 174, 185], ["lung injury", "PROBLEM", 231, 242], ["normal", "OBSERVATION", 67, 73], ["lungs", "ANATOMY", 74, 79], ["mild", "OBSERVATION_MODIFIER", 98, 102], ["increases", "OBSERVATION_MODIFIER", 103, 112], ["alveolar", "ANATOMY_MODIFIER", 116, 124], ["capillary", "ANATOMY_MODIFIER", 125, 134], ["permeability", "OBSERVATION_MODIFIER", 135, 147], ["no", "UNCERTAINTY", 191, 193], ["evidence of", "UNCERTAINTY", 219, 230], ["lung", "ANATOMY", 231, 235], ["injury", "OBSERVATION", 236, 242]]], ["Many clinicians suspect that oxygen may exacerbate and even cause ALI in critically ill patients, although there still is no conclusive evidence that oxygen either produces or exacerbates ARDS in humans (42).", [["oxygen", "CHEMICAL", 29, 35], ["ALI", "DISEASE", 66, 69], ["critically ill", "DISEASE", 73, 87], ["oxygen", "CHEMICAL", 150, 156], ["ARDS", "DISEASE", 188, 192], ["oxygen", "CHEMICAL", 29, 35], ["oxygen", "CHEMICAL", 150, 156], ["oxygen", "SIMPLE_CHEMICAL", 29, 35], ["patients", "ORGANISM", 88, 96], ["oxygen", "SIMPLE_CHEMICAL", 150, 156], ["humans", "ORGANISM", 196, 202], ["patients", "SPECIES", 88, 96], ["humans", "SPECIES", 196, 202], ["humans", "SPECIES", 196, 202], ["oxygen", "TREATMENT", 29, 35], ["ALI", "PROBLEM", 66, 69], ["ARDS in humans", "PROBLEM", 188, 202], ["no conclusive evidence", "UNCERTAINTY", 122, 144]]], ["Hyperoxia has been used as a direct cause of injury in animal studies, and as a secondary injury in animals with another underlying injury process, such as cecal ligation and puncture (75).Hyperoxia. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSMechanism: although the molecular basis of oxygen toxicity is still unclear, it is generally agreed that oxygen damage is mediated by reactive oxygen species (free radicals) derived directly from molecular oxygen, or from interactions with other species, such as NO.Hyperoxia. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSOxygen radicals have an unpaired orbital electron and act chemically as either reductants (electron donors) or oxidants (electron acceptors) (181).", [["cecal", "ANATOMY", 156, 161], ["Alveolar Epithelium", "ANATOMY", 237, 256], ["Alveolar Epithelium", "ANATOMY", 617, 636], ["Hyperoxia", "CHEMICAL", 0, 9], ["Hyperoxia", "DISEASE", 189, 198], ["oxygen", "CHEMICAL", 346, 352], ["toxicity", "DISEASE", 353, 361], ["oxygen", "CHEMICAL", 408, 414], ["oxygen", "CHEMICAL", 446, 452], ["oxygen", "CHEMICAL", 509, 515], ["NO", "CHEMICAL", 566, 568], ["Hyperoxia", "DISEASE", 569, 578], ["oxygen", "CHEMICAL", 346, 352], ["oxygen", "CHEMICAL", 408, 414], ["oxygen", "CHEMICAL", 446, 452], ["oxygen", "CHEMICAL", 509, 515], ["NO", "CHEMICAL", 566, 568], ["SYSTEMSOxygen", "CHEMICAL", 676, 689], ["cecal", "ORGANISM_SUBDIVISION", 156, 161], ["Alveolar Epithelium", "TISSUE", 237, 256], ["oxygen", "SIMPLE_CHEMICAL", 346, 352], ["oxygen", "SIMPLE_CHEMICAL", 408, 414], ["reactive oxygen species", "SIMPLE_CHEMICAL", 437, 460], ["free radicals", "SIMPLE_CHEMICAL", 462, 475], ["oxygen", "SIMPLE_CHEMICAL", 509, 515], ["NO", "SIMPLE_CHEMICAL", 566, 568], ["Alveolar Epithelium", "TISSUE", 617, 636], ["reductants", "SIMPLE_CHEMICAL", 762, 772], ["oxidants", "SIMPLE_CHEMICAL", 794, 802], ["electron", "SIMPLE_CHEMICAL", 804, 812], ["Hyperoxia", "PROBLEM", 0, 9], ["injury", "PROBLEM", 45, 51], ["animal studies", "TEST", 55, 69], ["a secondary injury", "PROBLEM", 78, 96], ["another underlying injury process", "PROBLEM", 113, 146], ["cecal ligation", "TREATMENT", 156, 170], ["puncture", "TEST", 175, 183], ["Hyperoxia", "PROBLEM", 189, 198], ["LUNG INJURY", "PROBLEM", 278, 289], ["oxygen toxicity", "PROBLEM", 346, 361], ["oxygen damage", "PROBLEM", 408, 421], ["reactive oxygen species", "PROBLEM", 437, 460], ["Hyperoxia", "PROBLEM", 569, 578], ["LUNG INJURY", "PROBLEM", 658, 669], ["MODEL SYSTEMSOxygen radicals", "TREATMENT", 670, 698], ["injury", "OBSERVATION", 45, 51], ["secondary", "OBSERVATION_MODIFIER", 80, 89], ["injury", "OBSERVATION", 90, 96], ["injury", "OBSERVATION", 132, 138], ["cecal", "ANATOMY", 156, 161], ["ligation", "OBSERVATION", 162, 170], ["Alveolar Epithelium", "OBSERVATION", 237, 256], ["LUNG", "ANATOMY", 278, 282], ["INJURY", "OBSERVATION", 283, 289], ["oxygen toxicity", "OBSERVATION", 346, 361], ["reactive", "OBSERVATION_MODIFIER", 437, 445], ["oxygen species", "OBSERVATION", 446, 460], ["oxygen", "OBSERVATION_MODIFIER", 509, 515], ["Alveolar Epithelium", "OBSERVATION", 617, 636], ["LUNG", "ANATOMY", 658, 662], ["INJURY", "OBSERVATION", 663, 669], ["orbital", "ANATOMY", 716, 723]]], ["During normal cellular respiration in the mitochondria, a small fraction of oxygen undergoes the addition of a single electron to form the superoxide anion (O2\u2022\u2212).", [["cellular", "ANATOMY", 14, 22], ["mitochondria", "ANATOMY", 42, 54], ["oxygen", "CHEMICAL", 76, 82], ["superoxide", "CHEMICAL", 139, 149], ["O2\u2022\u2212", "CHEMICAL", 157, 161], ["oxygen", "CHEMICAL", 76, 82], ["superoxide", "CHEMICAL", 139, 149], ["O2", "CHEMICAL", 157, 159], ["cellular", "CELL", 14, 22], ["mitochondria", "CELLULAR_COMPONENT", 42, 54], ["oxygen", "SIMPLE_CHEMICAL", 76, 82], ["electron", "SIMPLE_CHEMICAL", 118, 126], ["superoxide anion", "SIMPLE_CHEMICAL", 139, 155], ["O2\u2022\u2212", "SIMPLE_CHEMICAL", 157, 161], ["a single electron", "TREATMENT", 109, 126], ["the superoxide anion (O2\u2022\u2212", "TREATMENT", 135, 161], ["cellular respiration", "OBSERVATION", 14, 34], ["small", "OBSERVATION_MODIFIER", 58, 63], ["fraction", "OBSERVATION_MODIFIER", 64, 72], ["oxygen", "OBSERVATION_MODIFIER", 76, 82]]], ["Superoxide anions can be protonated to perhydroxy radicals (HO2\u00b7) or can react further to form hydrogen peroxide (H2O2).", [["Superoxide", "CHEMICAL", 0, 10], ["HO2\u00b7", "CHEMICAL", 60, 64], ["hydrogen peroxide", "CHEMICAL", 95, 112], ["H2O2", "CHEMICAL", 114, 118], ["Superoxide", "CHEMICAL", 0, 10], ["perhydroxy", "CHEMICAL", 39, 49], ["HO2\u00b7", "CHEMICAL", 60, 64], ["hydrogen peroxide", "CHEMICAL", 95, 112], ["H2O2", "CHEMICAL", 114, 118], ["Superoxide anions", "SIMPLE_CHEMICAL", 0, 17], ["perhydroxy radicals", "SIMPLE_CHEMICAL", 39, 58], ["HO2\u00b7", "SIMPLE_CHEMICAL", 60, 64], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 95, 112], ["H2O2", "SIMPLE_CHEMICAL", 114, 118], ["Superoxide anions", "TREATMENT", 0, 17], ["perhydroxy radicals (HO2\u00b7)", "TREATMENT", 39, 65], ["hydrogen peroxide (H2O2", "TREATMENT", 95, 118]]], ["Hydrogen peroxide and superoxide, in the presence of divalent metals, can react together to form hydroxyl radicals (OH\u00b7), which are extremely reactive.", [["Hydrogen peroxide", "CHEMICAL", 0, 17], ["superoxide", "CHEMICAL", 22, 32], ["hydroxyl", "CHEMICAL", 97, 105], ["OH\u00b7", "CHEMICAL", 116, 119], ["Hydrogen peroxide", "CHEMICAL", 0, 17], ["superoxide", "CHEMICAL", 22, 32], ["hydroxyl", "CHEMICAL", 97, 105], ["OH\u00b7", "CHEMICAL", 116, 119], ["Hydrogen peroxide", "SIMPLE_CHEMICAL", 0, 17], ["superoxide", "SIMPLE_CHEMICAL", 22, 32], ["hydroxyl radicals", "SIMPLE_CHEMICAL", 97, 114], ["OH\u00b7", "SIMPLE_CHEMICAL", 116, 119], ["Hydrogen peroxide", "TREATMENT", 0, 17], ["superoxide", "TREATMENT", 22, 32], ["divalent metals", "TREATMENT", 53, 68], ["divalent metals", "OBSERVATION", 53, 68], ["reactive", "OBSERVATION", 142, 150]]], ["Normally, the small amounts of superoxide and hydrogen peroxide produced during cellular respiration are scavenged by antioxidant enzymes, such as superoxide dismutase, catalase, and glutathione peroxidase (69).", [["cellular", "ANATOMY", 80, 88], ["superoxide", "CHEMICAL", 31, 41], ["hydrogen peroxide", "CHEMICAL", 46, 63], ["superoxide", "CHEMICAL", 147, 157], ["glutathione", "CHEMICAL", 183, 194], ["superoxide", "CHEMICAL", 31, 41], ["hydrogen peroxide", "CHEMICAL", 46, 63], ["superoxide", "CHEMICAL", 147, 157], ["glutathione", "CHEMICAL", 183, 194], ["superoxide", "SIMPLE_CHEMICAL", 31, 41], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 46, 63], ["cellular", "CELL", 80, 88], ["superoxide dismutase", "GENE_OR_GENE_PRODUCT", 147, 167], ["catalase", "SIMPLE_CHEMICAL", 169, 177], ["glutathione peroxidase", "GENE_OR_GENE_PRODUCT", 183, 205], ["antioxidant enzymes", "PROTEIN", 118, 137], ["superoxide dismutase", "PROTEIN", 147, 167], ["catalase", "PROTEIN", 169, 177], ["glutathione peroxidase", "PROTEIN", 183, 205], ["superoxide and hydrogen peroxide", "TREATMENT", 31, 63], ["antioxidant enzymes", "TEST", 118, 137], ["superoxide dismutase", "TEST", 147, 167], ["catalase", "TEST", 169, 177], ["glutathione peroxidase", "TEST", 183, 205], ["small", "OBSERVATION_MODIFIER", 14, 19], ["amounts", "OBSERVATION_MODIFIER", 20, 27], ["hydrogen peroxide", "OBSERVATION", 46, 63], ["cellular respiration", "OBSERVATION", 80, 100]]], ["In the presence of hyperoxia, the mitochondria and other organelles produce increased amounts of superoxide anions (68), which may exceed the capacity of antioxidant enzymes and consume cellular glutathione.", [["mitochondria", "ANATOMY", 34, 46], ["organelles", "ANATOMY", 57, 67], ["cellular", "ANATOMY", 186, 194], ["superoxide", "CHEMICAL", 97, 107], ["glutathione", "CHEMICAL", 195, 206], ["superoxide", "CHEMICAL", 97, 107], ["glutathione", "CHEMICAL", 195, 206], ["mitochondria", "CELLULAR_COMPONENT", 34, 46], ["organelles", "CELLULAR_COMPONENT", 57, 67], ["superoxide", "SIMPLE_CHEMICAL", 97, 107], ["cellular", "CELL", 186, 194], ["glutathione", "SIMPLE_CHEMICAL", 195, 206], ["antioxidant enzymes", "PROTEIN", 154, 173], ["hyperoxia", "PROBLEM", 19, 28], ["superoxide anions", "TREATMENT", 97, 114], ["antioxidant enzymes", "TEST", 154, 173], ["cellular glutathione", "TREATMENT", 186, 206], ["hyperoxia", "OBSERVATION", 19, 28], ["increased", "OBSERVATION_MODIFIER", 76, 85], ["amounts", "OBSERVATION_MODIFIER", 86, 93]]], ["Furthermore, superoxide anions react with NO to form peroxynitrite, a potent oxidizing molecule.", [["superoxide", "CHEMICAL", 13, 23], ["NO", "CHEMICAL", 42, 44], ["peroxynitrite", "CHEMICAL", 53, 66], ["superoxide", "CHEMICAL", 13, 23], ["NO", "CHEMICAL", 42, 44], ["peroxynitrite", "CHEMICAL", 53, 66], ["superoxide anions", "SIMPLE_CHEMICAL", 13, 30], ["NO", "SIMPLE_CHEMICAL", 42, 44], ["peroxynitrite", "SIMPLE_CHEMICAL", 53, 66], ["superoxide anions react", "PROBLEM", 13, 36], ["peroxynitrite", "PROBLEM", 53, 66], ["a potent oxidizing molecule", "PROBLEM", 68, 95], ["peroxynitrite", "OBSERVATION", 53, 66], ["potent", "OBSERVATION_MODIFIER", 70, 76], ["oxidizing molecule", "OBSERVATION", 77, 95]]], ["There is evidence that peroxynitrite is formed in the lungs of hyperoxic humans (202) and animals and that induction of NO synthesis worsens hyperoxic lung injury (90).Hyperoxia. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSThe accumulation of free hydroxyl radicals and peroxynitrite results in oxidation of proteins and peroxidation of membrane lipids and nucleic acids (68).", [["lungs", "ANATOMY", 54, 59], ["lung", "ANATOMY", 151, 155], ["Alveolar Epithelium", "ANATOMY", 216, 235], ["membrane", "ANATOMY", 396, 404], ["peroxynitrite", "CHEMICAL", 23, 36], ["NO", "CHEMICAL", 120, 122], ["lung injury", "DISEASE", 151, 162], ["Hyperoxia", "DISEASE", 168, 177], ["hydroxyl", "CHEMICAL", 307, 315], ["peroxynitrite", "CHEMICAL", 329, 342], ["nucleic acids", "CHEMICAL", 416, 429], ["peroxynitrite", "CHEMICAL", 23, 36], ["NO", "CHEMICAL", 120, 122], ["hydroxyl", "CHEMICAL", 307, 315], ["peroxynitrite", "CHEMICAL", 329, 342], ["peroxynitrite", "SIMPLE_CHEMICAL", 23, 36], ["lungs", "ORGAN", 54, 59], ["humans", "ORGANISM", 73, 79], ["NO", "SIMPLE_CHEMICAL", 120, 122], ["lung", "ORGAN", 151, 155], ["Alveolar Epithelium", "TISSUE", 216, 235], ["free hydroxyl radicals", "SIMPLE_CHEMICAL", 302, 324], ["peroxynitrite", "SIMPLE_CHEMICAL", 329, 342], ["membrane lipids", "CELLULAR_COMPONENT", 396, 411], ["nucleic acids", "SIMPLE_CHEMICAL", 416, 429], ["humans", "SPECIES", 73, 79], ["humans", "SPECIES", 73, 79], ["peroxynitrite", "TREATMENT", 23, 36], ["synthesis worsens hyperoxic lung injury", "PROBLEM", 123, 162], ["Hyperoxia", "PROBLEM", 168, 177], ["LUNG INJURY", "PROBLEM", 257, 268], ["free hydroxyl radicals", "TREATMENT", 302, 324], ["peroxynitrite", "TREATMENT", 329, 342], ["peroxidation of membrane lipids", "TREATMENT", 380, 411], ["nucleic acids", "TEST", 416, 429], ["peroxynitrite", "OBSERVATION", 23, 36], ["lungs", "ANATOMY", 54, 59], ["hyperoxic humans", "OBSERVATION", 63, 79], ["lung", "ANATOMY", 151, 155], ["injury", "OBSERVATION", 156, 162], ["Alveolar Epithelium", "OBSERVATION", 216, 235], ["LUNG", "ANATOMY", 257, 261], ["INJURY", "OBSERVATION", 262, 268]]], ["The mechanism of cellular injury appears to be a combination of necrosis and apoptosis (11, 93), but the importance of apoptosis in the pathogenesis of oxygen-induced injury remains unclear.", [["cellular", "ANATOMY", 17, 25], ["cellular injury", "DISEASE", 17, 32], ["necrosis", "DISEASE", 64, 72], ["oxygen", "CHEMICAL", 152, 158], ["oxygen", "CHEMICAL", 152, 158], ["cellular", "CELL", 17, 25], ["oxygen", "SIMPLE_CHEMICAL", 152, 158], ["cellular injury", "PROBLEM", 17, 32], ["necrosis", "PROBLEM", 64, 72], ["apoptosis", "PROBLEM", 77, 86], ["apoptosis", "PROBLEM", 119, 128], ["induced injury", "PROBLEM", 159, 173], ["cellular injury", "OBSERVATION", 17, 32], ["appears to be", "UNCERTAINTY", 33, 46], ["necrosis", "OBSERVATION", 64, 72], ["apoptosis", "OBSERVATION_MODIFIER", 77, 86], ["apoptosis", "OBSERVATION", 119, 128], ["injury", "OBSERVATION", 167, 173]]], ["The lung epithelial cell line A549 becomes apoptotic in vitro when exposed to oxidants such as H2O2 (65).", [["lung epithelial cell line A549", "ANATOMY", 4, 34], ["H2O2", "CHEMICAL", 95, 99], ["H2O2", "CHEMICAL", 95, 99], ["lung epithelial cell line A549", "CELL", 4, 34], ["H2O2", "SIMPLE_CHEMICAL", 95, 99], ["lung epithelial cell line A549", "CELL_LINE", 4, 34], ["apoptotic", "PROBLEM", 43, 52], ["lung", "ANATOMY", 4, 8], ["epithelial cell line", "OBSERVATION", 9, 29], ["A549", "OBSERVATION_MODIFIER", 30, 34], ["apoptotic", "OBSERVATION_MODIFIER", 43, 52]]], ["However, preexposure to oxygen inhibits the apoptotic response to H2O2, and this is mediated by activation of NF-\u03baB (65).", [["oxygen", "CHEMICAL", 24, 30], ["H2O2", "CHEMICAL", 66, 70], ["oxygen", "CHEMICAL", 24, 30], ["H2O2", "CHEMICAL", 66, 70], ["oxygen", "SIMPLE_CHEMICAL", 24, 30], ["H2O2", "SIMPLE_CHEMICAL", 66, 70], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 110, 115], ["NF-\u03baB", "PROTEIN", 110, 115], ["oxygen", "TREATMENT", 24, 30], ["H2O2", "TREATMENT", 66, 70]]], ["In mice exposed to hyperoxia, neither the number of apoptotic cells nor the severity of injury is attenuated by caspase inhibitors, and Fas-null (lpr) mice and p53 knockout mice are not protected from hyperoxic lung injury (11).", [["cells", "ANATOMY", 62, 67], ["lung", "ANATOMY", 211, 215], ["lung injury", "DISEASE", 211, 222], ["mice", "ORGANISM", 3, 7], ["cells", "CELL", 62, 67], ["caspase", "GENE_OR_GENE_PRODUCT", 112, 119], ["Fas-null", "GENE_OR_GENE_PRODUCT", 136, 144], ["lpr", "GENE_OR_GENE_PRODUCT", 146, 149], ["p53", "GENE_OR_GENE_PRODUCT", 160, 163], ["mice", "ORGANISM", 173, 177], ["lung", "ORGAN", 211, 215], ["apoptotic cells", "CELL_TYPE", 52, 67], ["p53", "PROTEIN", 160, 163], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 151, 155], ["mice", "SPECIES", 173, 177], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 151, 155], ["mice", "SPECIES", 173, 177], ["hyperoxia", "PROBLEM", 19, 28], ["apoptotic cells", "PROBLEM", 52, 67], ["injury", "PROBLEM", 88, 94], ["caspase inhibitors", "TREATMENT", 112, 130], ["Fas-null", "TEST", 136, 144], ["hyperoxic lung injury", "PROBLEM", 201, 222], ["hyperoxia", "OBSERVATION", 19, 28], ["apoptotic cells", "OBSERVATION", 52, 67], ["injury", "OBSERVATION", 88, 94], ["hyperoxic", "OBSERVATION_MODIFIER", 201, 210], ["lung", "ANATOMY", 211, 215], ["injury", "OBSERVATION", 216, 222]]], ["However, disruption of the proapoptotic CD40-CD40 ligand system and overexpression of IL-6 each reduce the number of apoptotic cells and prevent hyperoxic lung injury (2, 233).Hyperoxia. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSHyperoxia increases NF-\u03baB translocation in lung mononuclear cells and the production of proinflammatory mediators such as TNF-\u03b1, IFN-\u03b3, and IL-1\u03b2 (152, 196).", [["cells", "ANATOMY", 127, 132], ["lung", "ANATOMY", 155, 159], ["Alveolar Epithelium", "ANATOMY", 224, 243], ["lung mononuclear cells", "ANATOMY", 333, 355], ["lung injury", "DISEASE", 155, 166], ["Hyperoxia", "DISEASE", 176, 185], ["SYSTEMSHyperoxia", "CHEMICAL", 283, 299], ["CD40", "GENE_OR_GENE_PRODUCT", 40, 44], ["CD40", "GENE_OR_GENE_PRODUCT", 45, 49], ["IL-6", "GENE_OR_GENE_PRODUCT", 86, 90], ["cells", "CELL", 127, 132], ["lung", "ORGAN", 155, 159], ["Alveolar Epithelium", "TISSUE", 224, 243], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 310, 315], ["lung mononuclear cells", "CELL", 333, 355], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 412, 417], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 419, 424], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 430, 435], ["CD40", "PROTEIN", 40, 44], ["CD40", "PROTEIN", 45, 49], ["IL-6", "PROTEIN", 86, 90], ["apoptotic cells", "CELL_TYPE", 117, 132], ["NF-\u03baB", "PROTEIN", 310, 315], ["lung mononuclear cells", "CELL_TYPE", 333, 355], ["proinflammatory mediators", "PROTEIN", 378, 403], ["TNF", "PROTEIN", 412, 415], ["IFN", "PROTEIN", 419, 422], ["overexpression of IL", "TREATMENT", 68, 88], ["apoptotic cells", "PROBLEM", 117, 132], ["hyperoxic lung injury", "PROBLEM", 145, 166], ["Hyperoxia", "PROBLEM", 176, 185], ["LUNG INJURY", "PROBLEM", 265, 276], ["MODEL SYSTEMSHyperoxia", "TEST", 277, 299], ["NF", "PROBLEM", 310, 312], ["B translocation in lung mononuclear cells", "PROBLEM", 314, 355], ["proinflammatory mediators", "TEST", 378, 403], ["TNF", "TEST", 412, 415], ["IFN", "TEST", 419, 422], ["IL", "TEST", 430, 432], ["proapoptotic CD40", "OBSERVATION", 27, 44], ["apoptotic cells", "OBSERVATION", 117, 132], ["prevent", "UNCERTAINTY", 137, 144], ["hyperoxic", "OBSERVATION_MODIFIER", 145, 154], ["lung", "ANATOMY", 155, 159], ["injury", "OBSERVATION", 160, 166], ["Alveolar Epithelium", "OBSERVATION", 224, 243], ["LUNG", "ANATOMY", 265, 269], ["INJURY", "OBSERVATION", 270, 276], ["lung", "ANATOMY", 333, 337], ["mononuclear cells", "OBSERVATION", 338, 355]]], ["However, the role of inflammatory cells such as PMN in hyperoxic injury is controversial.", [["inflammatory cells", "ANATOMY", 21, 39], ["PMN", "ANATOMY", 48, 51], ["hyperoxic injury", "DISEASE", 55, 71], ["inflammatory cells", "CELL", 21, 39], ["PMN", "CELL", 48, 51], ["inflammatory cells", "CELL_TYPE", 21, 39], ["PMN", "CELL_TYPE", 48, 51], ["inflammatory cells", "PROBLEM", 21, 39], ["PMN", "PROBLEM", 48, 51], ["hyperoxic injury", "PROBLEM", 55, 71], ["inflammatory cells", "OBSERVATION", 21, 39], ["PMN", "OBSERVATION_MODIFIER", 48, 51], ["hyperoxic injury", "OBSERVATION", 55, 71]]], ["Although PMN accumulate in hyperoxic injury (63), neutrophil depletion does not prevent either oxygen-induced lung injury or mortality in a rats, rabbits, mice, or lambs (174, 204).", [["PMN", "ANATOMY", 9, 12], ["neutrophil", "ANATOMY", 50, 60], ["lung", "ANATOMY", 110, 114], ["hyperoxic injury", "DISEASE", 27, 43], ["oxygen", "CHEMICAL", 95, 101], ["lung injury", "DISEASE", 110, 121], ["oxygen", "CHEMICAL", 95, 101], ["PMN", "CELL", 9, 12], ["neutrophil", "CELL", 50, 60], ["oxygen", "SIMPLE_CHEMICAL", 95, 101], ["lung", "ORGAN", 110, 114], ["rats", "ORGANISM", 140, 144], ["rabbits", "ORGANISM", 146, 153], ["mice", "ORGANISM", 155, 159], ["PMN", "CELL_TYPE", 9, 12], ["rats", "SPECIES", 140, 144], ["rabbits", "SPECIES", 146, 153], ["mice", "SPECIES", 155, 159], ["rabbits", "SPECIES", 146, 153], ["mice", "SPECIES", 155, 159], ["PMN", "TEST", 9, 12], ["hyperoxic injury", "PROBLEM", 27, 43], ["neutrophil depletion", "PROBLEM", 50, 70], ["oxygen-induced lung injury", "PROBLEM", 95, 121], ["hyperoxic injury", "OBSERVATION", 27, 43], ["neutrophil depletion", "OBSERVATION", 50, 70], ["lung", "ANATOMY", 110, 114], ["injury", "OBSERVATION", 115, 121]]], ["Furthermore, hyperoxia enhances ventilation-induced lung injury by a mechanism independent of cytokine production and lipid peroxidation but involving changes in focal adhesion proteins (45, 201).Hyperoxia. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSTechnique: to create hyperoxia as a cause of ALI, the animals are housed in a sealed cage, with an inflow of O2 sufficient to keep the ambient Po2 at or above the desired level (as measured by an oximeter) and CO2 at ambient levels.", [["lung", "ANATOMY", 52, 56], ["Alveolar Epithelium", "ANATOMY", 244, 263], ["hyperoxia", "CHEMICAL", 13, 22], ["lung injury", "DISEASE", 52, 63], ["Hyperoxia", "DISEASE", 196, 205], ["hyperoxia", "DISEASE", 331, 340], ["ALI", "DISEASE", 355, 358], ["O2", "CHEMICAL", 419, 421], ["CO2", "CHEMICAL", 520, 523], ["O2", "CHEMICAL", 419, 421], ["CO2", "CHEMICAL", 520, 523], ["lung", "ORGAN", 52, 56], ["lipid", "SIMPLE_CHEMICAL", 118, 123], ["focal adhesion proteins", "GENE_OR_GENE_PRODUCT", 162, 185], ["Alveolar Epithelium", "TISSUE", 244, 263], ["O2", "SIMPLE_CHEMICAL", 419, 421], ["CO2", "SIMPLE_CHEMICAL", 520, 523], ["cytokine", "PROTEIN", 94, 102], ["focal adhesion proteins", "PROTEIN", 162, 185], ["hyperoxia enhances ventilation", "PROBLEM", 13, 43], ["lung injury", "PROBLEM", 52, 63], ["cytokine production", "PROBLEM", 94, 113], ["lipid peroxidation", "PROBLEM", 118, 136], ["changes in focal adhesion proteins", "PROBLEM", 151, 185], ["Hyperoxia", "PROBLEM", 196, 205], ["hyperoxia", "PROBLEM", 331, 340], ["ALI", "PROBLEM", 355, 358], ["a sealed cage", "TREATMENT", 386, 399], ["an inflow of O2", "TREATMENT", 406, 421], ["the ambient Po2", "TEST", 441, 456], ["an oximeter", "TEST", 503, 514], ["CO2 at ambient levels", "TEST", 520, 541], ["hyperoxia", "OBSERVATION_MODIFIER", 13, 22], ["enhances ventilation", "OBSERVATION", 23, 43], ["lung", "ANATOMY", 52, 56], ["injury", "OBSERVATION", 57, 63], ["lipid peroxidation", "OBSERVATION", 118, 136], ["focal", "OBSERVATION_MODIFIER", 162, 167], ["adhesion", "OBSERVATION_MODIFIER", 168, 176], ["Alveolar Epithelium", "OBSERVATION", 244, 263], ["LUNG", "ANATOMY", 285, 289], ["INJURY", "OBSERVATION", 290, 296], ["hyperoxia", "OBSERVATION", 331, 340], ["ALI", "OBSERVATION", 355, 358]]], ["The ideal cage allows the investigator to introduce food and remove waste through airlocks without altering the composition of gas in the cage.Hyperoxia. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSCharacteristics of the injury: the exposure to normobaric oxygen is followed within 3\u20134 days by an exudative phase in the lungs, characterized by death of alveolar type I cells, swelling, and necrosis of endothelial cells, interstitial edema, and filling of alveoli with an exudative fluid (38, 109).", [["Alveolar Epithelium", "ANATOMY", 191, 210], ["lungs", "ANATOMY", 379, 384], ["alveolar type I cells", "ANATOMY", 412, 433], ["endothelial cells", "ANATOMY", 461, 478], ["interstitial edema", "ANATOMY", 480, 498], ["alveoli", "ANATOMY", 515, 522], ["exudative fluid", "ANATOMY", 531, 546], ["Hyperoxia", "DISEASE", 143, 152], ["injury", "DISEASE", 280, 286], ["oxygen", "CHEMICAL", 315, 321], ["death", "DISEASE", 403, 408], ["swelling", "DISEASE", 435, 443], ["necrosis", "DISEASE", 449, 457], ["interstitial edema", "DISEASE", 480, 498], ["exudative", "DISEASE", 531, 540], ["oxygen", "CHEMICAL", 315, 321], ["Alveolar Epithelium", "TISSUE", 191, 210], ["oxygen", "SIMPLE_CHEMICAL", 315, 321], ["lungs", "ORGAN", 379, 384], ["alveolar type I cells", "CELL", 412, 433], ["endothelial cells", "CELL", 461, 478], ["interstitial edema", "PATHOLOGICAL_FORMATION", 480, 498], ["alveoli", "MULTI-TISSUE_STRUCTURE", 515, 522], ["alveolar type I cells", "CELL_TYPE", 412, 433], ["endothelial cells", "CELL_TYPE", 461, 478], ["airlocks", "TREATMENT", 82, 90], ["gas in the cage", "PROBLEM", 127, 142], ["Hyperoxia", "PROBLEM", 143, 152], ["LUNG INJURY", "PROBLEM", 232, 243], ["the injury", "PROBLEM", 276, 286], ["normobaric oxygen", "TREATMENT", 304, 321], ["an exudative phase", "TEST", 353, 371], ["alveolar type I cells", "PROBLEM", 412, 433], ["swelling", "PROBLEM", 435, 443], ["necrosis of endothelial cells", "PROBLEM", 449, 478], ["interstitial edema", "PROBLEM", 480, 498], ["filling of alveoli", "PROBLEM", 504, 522], ["an exudative fluid", "PROBLEM", 528, 546], ["gas", "OBSERVATION", 127, 130], ["cage", "ANATOMY", 138, 142], ["Alveolar Epithelium", "OBSERVATION", 191, 210], ["LUNG", "ANATOMY", 232, 236], ["INJURY", "OBSERVATION", 237, 243], ["MODEL SYSTEMSCharacteristics", "OBSERVATION", 244, 272], ["injury", "OBSERVATION", 280, 286], ["normobaric oxygen", "OBSERVATION", 304, 321], ["exudative", "OBSERVATION", 356, 365], ["lungs", "ANATOMY", 379, 384], ["alveolar type I cells", "OBSERVATION", 412, 433], ["swelling", "OBSERVATION", 435, 443], ["necrosis", "OBSERVATION", 449, 457], ["endothelial cells", "OBSERVATION", 461, 478], ["interstitial", "ANATOMY_MODIFIER", 480, 492], ["edema", "OBSERVATION", 493, 498], ["filling", "OBSERVATION_MODIFIER", 504, 511], ["alveoli", "ANATOMY_MODIFIER", 515, 522], ["exudative", "OBSERVATION_MODIFIER", 531, 540], ["fluid", "OBSERVATION", 541, 546]]], ["The initial event appears to be damage to the capillary endothelium, followed by platelet adhesion and PMN accumulation in the capillary vessels and interstitium (13, 82).", [["capillary endothelium", "ANATOMY", 46, 67], ["platelet", "ANATOMY", 81, 89], ["PMN", "ANATOMY", 103, 106], ["capillary vessels", "ANATOMY", 127, 144], ["interstitium", "ANATOMY", 149, 161], ["capillary endothelium", "TISSUE", 46, 67], ["platelet", "CELL", 81, 89], ["PMN", "CELL", 103, 106], ["capillary vessels", "MULTI-TISSUE_STRUCTURE", 127, 144], ["interstitium", "TISSUE", 149, 161], ["PMN", "CELL_TYPE", 103, 106], ["damage to the capillary endothelium", "PROBLEM", 32, 67], ["platelet adhesion", "PROBLEM", 81, 98], ["PMN accumulation in the capillary vessels", "PROBLEM", 103, 144], ["appears to be", "UNCERTAINTY", 18, 31], ["damage", "OBSERVATION", 32, 38], ["capillary endothelium", "ANATOMY", 46, 67], ["platelet adhesion", "OBSERVATION", 81, 98], ["PMN accumulation", "OBSERVATION", 103, 119], ["capillary vessels", "ANATOMY", 127, 144], ["interstitium", "ANATOMY_MODIFIER", 149, 161]]], ["Eventually, alveolar epithelial injury occurs, with an increase in microvascular permeability measured as wet-to-dry (W/D) ratios and migration of neutrophils into the air spaces, as evidenced by increase in total numbers in BAL fluid (18, 20, 102, 148).", [["alveolar epithelial", "ANATOMY", 12, 31], ["microvascular", "ANATOMY", 67, 80], ["neutrophils", "ANATOMY", 147, 158], ["BAL fluid", "ANATOMY", 225, 234], ["alveolar epithelial", "TISSUE", 12, 31], ["microvascular", "TISSUE", 67, 80], ["neutrophils", "CELL", 147, 158], ["BAL fluid", "ORGANISM_SUBSTANCE", 225, 234], ["neutrophils", "CELL_TYPE", 147, 158], ["alveolar epithelial injury", "PROBLEM", 12, 38], ["an increase in microvascular permeability", "PROBLEM", 52, 93], ["W/D) ratios", "TEST", 118, 129], ["migration of neutrophils into the air spaces", "PROBLEM", 134, 178], ["BAL fluid", "TEST", 225, 234], ["alveolar", "ANATOMY_MODIFIER", 12, 20], ["epithelial", "ANATOMY_MODIFIER", 21, 31], ["injury", "OBSERVATION", 32, 38], ["increase", "OBSERVATION_MODIFIER", 55, 63], ["microvascular permeability", "OBSERVATION", 67, 93], ["wet-to-dry", "OBSERVATION_MODIFIER", 106, 116], ["migration", "OBSERVATION_MODIFIER", 134, 143], ["air spaces", "OBSERVATION", 168, 178], ["increase", "OBSERVATION_MODIFIER", 196, 204], ["total", "OBSERVATION_MODIFIER", 208, 213], ["numbers", "OBSERVATION_MODIFIER", 214, 221], ["BAL fluid", "OBSERVATION", 225, 234]]], ["The pulmonary architecture is preserved during this early phase (82).", [["pulmonary", "ANATOMY", 4, 13], ["pulmonary", "ORGAN", 4, 13], ["pulmonary", "ANATOMY", 4, 13], ["architecture", "ANATOMY_MODIFIER", 14, 26], ["preserved", "OBSERVATION", 30, 39]]], ["The initial exudative phase is followed by a proliferative phase, characterized by proliferation of endothelial cells and type 2 pneumocytes, which cover the denuded alveolar basement membrane.", [["endothelial cells", "ANATOMY", 100, 117], ["type 2 pneumocytes", "ANATOMY", 122, 140], ["alveolar basement membrane", "ANATOMY", 166, 192], ["endothelial cells", "CELL", 100, 117], ["type 2 pneumocytes", "CELL", 122, 140], ["alveolar", "MULTI-TISSUE_STRUCTURE", 166, 174], ["basement membrane", "CELLULAR_COMPONENT", 175, 192], ["endothelial cells", "CELL_TYPE", 100, 117], ["type 2 pneumocytes", "CELL_TYPE", 122, 140], ["The initial exudative phase", "TEST", 0, 27], ["a proliferative phase", "TEST", 43, 64], ["endothelial cells", "PROBLEM", 100, 117], ["type 2 pneumocytes", "PROBLEM", 122, 140], ["exudative", "OBSERVATION_MODIFIER", 12, 21], ["proliferation", "OBSERVATION_MODIFIER", 83, 96], ["endothelial cells", "OBSERVATION", 100, 117], ["pneumocytes", "OBSERVATION", 129, 140], ["denuded", "ANATOMY_MODIFIER", 158, 165], ["alveolar", "ANATOMY_MODIFIER", 166, 174], ["basement membrane", "OBSERVATION", 175, 192]]], ["Fibroblast proliferation occurs while the endothelial damage persists.", [["Fibroblast", "ANATOMY", 0, 10], ["endothelial", "ANATOMY", 42, 53], ["Fibroblast", "CELL", 0, 10], ["endothelial", "TISSUE", 42, 53], ["Fibroblast proliferation", "PROBLEM", 0, 24], ["the endothelial damage", "PROBLEM", 38, 60], ["proliferation", "OBSERVATION", 11, 24], ["endothelial", "OBSERVATION_MODIFIER", 42, 53], ["damage", "OBSERVATION", 54, 60]]], ["Recovery from oxygen injury is characterized by a normal-appearing endothelium and epithelium, with only some areas of interstitial scarring (109).", [["endothelium", "ANATOMY", 67, 78], ["epithelium", "ANATOMY", 83, 93], ["interstitial", "ANATOMY", 119, 131], ["oxygen", "CHEMICAL", 14, 20], ["interstitial scarring", "DISEASE", 119, 140], ["oxygen", "CHEMICAL", 14, 20], ["oxygen", "SIMPLE_CHEMICAL", 14, 20], ["endothelium", "TISSUE", 67, 78], ["epithelium", "TISSUE", 83, 93], ["interstitial scarring", "PATHOLOGICAL_FORMATION", 119, 140], ["oxygen injury", "PROBLEM", 14, 27], ["interstitial scarring", "PROBLEM", 119, 140], ["oxygen injury", "OBSERVATION", 14, 27], ["normal", "OBSERVATION", 50, 56], ["endothelium", "ANATOMY_MODIFIER", 67, 78], ["epithelium", "ANATOMY_MODIFIER", 83, 93], ["some", "OBSERVATION_MODIFIER", 105, 109], ["areas", "OBSERVATION_MODIFIER", 110, 115], ["interstitial", "ANATOMY_MODIFIER", 119, 131], ["scarring", "OBSERVATION", 132, 140]]], ["Interestingly, there is synergism between hyperoxia and infection, and the presence of bacterial pneumonia increases the morphological and physiological changes associated with hyperoxia (33).Hyperoxia. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSIn rats and mice, exposure to 100% O2 for 40\u201350 h results in ALI, and longer exposure (60\u201370 h) results in death (13, 18, 63, 148).", [["Alveolar Epithelium", "ANATOMY", 240, 259], ["hyperoxia", "CHEMICAL", 42, 51], ["infection", "DISEASE", 56, 65], ["pneumonia", "DISEASE", 97, 106], ["hyperoxia", "CHEMICAL", 177, 186], ["Hyperoxia", "DISEASE", 192, 201], ["O2", "CHEMICAL", 341, 343], ["ALI", "DISEASE", 367, 370], ["death", "DISEASE", 413, 418], ["O2", "CHEMICAL", 341, 343], ["Alveolar Epithelium", "TISSUE", 240, 259], ["MODEL SYSTEMSIn rats", "ORGANISM", 293, 313], ["mice", "ORGANISM", 318, 322], ["O2", "SIMPLE_CHEMICAL", 341, 343], ["rats", "SPECIES", 309, 313], ["mice", "SPECIES", 318, 322], ["mice", "SPECIES", 318, 322], ["synergism", "PROBLEM", 24, 33], ["hyperoxia", "PROBLEM", 42, 51], ["infection", "PROBLEM", 56, 65], ["bacterial pneumonia", "PROBLEM", 87, 106], ["hyperoxia", "PROBLEM", 177, 186], ["Hyperoxia", "PROBLEM", 192, 201], ["LUNG INJURY", "PROBLEM", 281, 292], ["100% O2", "TREATMENT", 336, 343], ["ALI", "PROBLEM", 367, 370], ["synergism", "OBSERVATION", 24, 33], ["hyperoxia", "OBSERVATION_MODIFIER", 42, 51], ["infection", "OBSERVATION", 56, 65], ["bacterial", "OBSERVATION_MODIFIER", 87, 96], ["pneumonia", "OBSERVATION", 97, 106], ["Alveolar Epithelium", "OBSERVATION", 240, 259], ["LUNG", "ANATOMY", 281, 285], ["INJURY", "OBSERVATION", 286, 292], ["ALI", "ANATOMY", 367, 370]]], ["Survival after exposure to O2 is age dependent, as neonates are more tolerant to hyperoxia and survive for up to 7 days (67).", [["O2", "CHEMICAL", 27, 29], ["hyperoxia", "DISEASE", 81, 90], ["O2", "CHEMICAL", 27, 29], ["O2", "SIMPLE_CHEMICAL", 27, 29], ["neonates", "ORGANISM", 51, 59], ["O2", "TREATMENT", 27, 29]]], ["Older rats (24 mo) are also more tolerant to O2 toxicity (31).", [["O2", "CHEMICAL", 45, 47], ["toxicity", "DISEASE", 48, 56], ["O2", "CHEMICAL", 45, 47], ["rats", "ORGANISM", 6, 10], ["O2", "SIMPLE_CHEMICAL", 45, 47], ["rats", "SPECIES", 6, 10]]], ["Interestingly, exposure to lower levels of O2 (FiO2 = 0.8 or less) is associated with minimal mortality (13).", [["O2", "CHEMICAL", 43, 45], ["O2", "CHEMICAL", 43, 45], ["FiO2", "CHEMICAL", 47, 51], ["O2", "SIMPLE_CHEMICAL", 43, 45], ["lower levels of O2", "TREATMENT", 27, 45], ["FiO2", "TEST", 47, 51]]], ["Rats exposed to 85% O2 for 5\u20137 days can survive subsequent exposures to 100% O2 (13).", [["O2", "CHEMICAL", 20, 22], ["O2", "CHEMICAL", 77, 79], ["O2", "CHEMICAL", 20, 22], ["O2", "CHEMICAL", 77, 79], ["Rats", "ORGANISM", 0, 4], ["O2", "SIMPLE_CHEMICAL", 20, 22], ["Rats", "SPECIES", 0, 4], ["85% O2", "TREATMENT", 16, 22], ["100% O2", "TREATMENT", 72, 79]]], ["This tolerance is not due to a decrease in the production of oxygen radicals (68) but is associated with an increase in the pulmonary concentration of antioxidant enzymes, such as manganese superoxide dismutase and glutathione reductase (67).Hyperoxia. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSStudies in rodents have shown important strain-dependent differences in susceptibility to hyperoxia.", [["pulmonary", "ANATOMY", 124, 133], ["Alveolar Epithelium", "ANATOMY", 290, 309], ["oxygen", "CHEMICAL", 61, 67], ["manganese", "CHEMICAL", 180, 189], ["superoxide", "CHEMICAL", 190, 200], ["glutathione", "CHEMICAL", 215, 226], ["Hyperoxia", "DISEASE", 242, 251], ["hyperoxia", "DISEASE", 446, 455], ["oxygen", "CHEMICAL", 61, 67], ["manganese", "CHEMICAL", 180, 189], ["superoxide", "CHEMICAL", 190, 200], ["glutathione", "CHEMICAL", 215, 226], ["oxygen", "SIMPLE_CHEMICAL", 61, 67], ["pulmonary", "ORGAN", 124, 133], ["manganese superoxide dismutase", "GENE_OR_GENE_PRODUCT", 180, 210], ["glutathione reductase", "GENE_OR_GENE_PRODUCT", 215, 236], ["Alveolar Epithelium", "TISSUE", 290, 309], ["antioxidant enzymes", "PROTEIN", 151, 170], ["manganese superoxide dismutase", "PROTEIN", 180, 210], ["glutathione reductase", "PROTEIN", 215, 236], ["a decrease in the production of oxygen radicals", "PROBLEM", 29, 76], ["antioxidant enzymes", "TEST", 151, 170], ["manganese superoxide dismutase", "TEST", 180, 210], ["glutathione reductase", "TEST", 215, 236], ["Hyperoxia", "PROBLEM", 242, 251], ["LUNG INJURY", "PROBLEM", 331, 342], ["hyperoxia", "TEST", 446, 455], ["not due to", "UNCERTAINTY", 18, 28], ["decrease", "OBSERVATION_MODIFIER", 31, 39], ["increase", "OBSERVATION_MODIFIER", 108, 116], ["pulmonary", "ANATOMY", 124, 133], ["Alveolar Epithelium", "OBSERVATION", 290, 309], ["LUNG", "ANATOMY", 331, 335], ["INJURY", "OBSERVATION", 336, 342], ["dependent", "OBSERVATION_MODIFIER", 403, 412], ["hyperoxia", "OBSERVATION", 446, 455]]], ["Exposure to >95% O2 for 48 and 60 h results in larger pleural effusions with higher total protein content in Fischer rats compared with Sprague-Dawley rats (209).", [["pleural effusions", "ANATOMY", 54, 71], ["O2", "CHEMICAL", 17, 19], ["pleural effusions", "DISEASE", 54, 71], ["O2", "CHEMICAL", 17, 19], ["O2", "SIMPLE_CHEMICAL", 17, 19], ["pleural effusions", "PATHOLOGICAL_FORMATION", 54, 71], ["Fischer rats", "ORGANISM", 109, 121], ["Sprague-Dawley rats", "ORGANISM", 136, 155], ["rats", "SPECIES", 117, 121], ["Sprague-Dawley rats", "SPECIES", 136, 155], ["Sprague-Dawley rats", "SPECIES", 136, 155], ["O2", "TREATMENT", 17, 19], ["larger pleural effusions", "PROBLEM", 47, 71], ["higher total protein content", "PROBLEM", 77, 105], ["larger", "OBSERVATION_MODIFIER", 47, 53], ["pleural", "ANATOMY", 54, 61], ["effusions", "OBSERVATION", 62, 71], ["higher", "OBSERVATION_MODIFIER", 77, 83], ["protein content", "OBSERVATION", 90, 105]]], ["Similarly, C57BL/6 mice are more susceptible to hyperoxia than C3H/HeJ mice.", [["hyperoxia", "DISEASE", 48, 57], ["C57BL/6 mice", "ORGANISM", 11, 23], ["C3H/HeJ mice", "ORGANISM", 63, 75], ["mice", "SPECIES", 19, 23], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 19, 23], ["mice", "SPECIES", 71, 75], ["C57BL/6 mice", "TREATMENT", 11, 23], ["hyperoxia", "PROBLEM", 48, 57], ["C3H/HeJ mice", "TREATMENT", 63, 75]]], ["This difference in susceptibility has recently been linked to the Nrf2I gene (30).Hyperoxia. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSAdvantages/disadvantages: the overall relevance of the hyperoxia injury model to human disease is a matter of controversy because exposure of humans to 100% oxygen for up to 3 days does not result in lung injury (12).", [["Alveolar Epithelium", "ANATOMY", 130, 149], ["lung", "ANATOMY", 396, 400], ["Hyperoxia", "DISEASE", 82, 91], ["hyperoxia injury", "DISEASE", 251, 267], ["human disease", "DISEASE", 277, 290], ["oxygen", "CHEMICAL", 353, 359], ["lung injury", "DISEASE", 396, 407], ["oxygen", "CHEMICAL", 353, 359], ["Nrf2I", "GENE_OR_GENE_PRODUCT", 66, 71], ["Alveolar Epithelium", "TISSUE", 130, 149], ["human", "ORGANISM", 277, 282], ["humans", "ORGANISM", 338, 344], ["oxygen", "SIMPLE_CHEMICAL", 353, 359], ["lung", "ORGAN", 396, 400], ["Nrf2I gene", "DNA", 66, 76], ["human", "SPECIES", 277, 282], ["humans", "SPECIES", 338, 344], ["human", "SPECIES", 277, 282], ["humans", "SPECIES", 338, 344], ["Hyperoxia", "PROBLEM", 82, 91], ["LUNG INJURY", "PROBLEM", 171, 182], ["the hyperoxia injury", "PROBLEM", 247, 267], ["human disease", "PROBLEM", 277, 290], ["100% oxygen", "TREATMENT", 348, 359], ["lung injury", "PROBLEM", 396, 407], ["Alveolar Epithelium", "OBSERVATION", 130, 149], ["LUNG", "ANATOMY", 171, 175], ["INJURY", "OBSERVATION", 176, 182], ["hyperoxia injury", "OBSERVATION", 251, 267], ["lung", "ANATOMY", 396, 400], ["injury", "OBSERVATION", 401, 407]]], ["Furthermore, some studies suggest that BAL fluid from patients with ARDS has antioxidant activity and inhibits lipid peroxidation in vitro (129), whereas other studies report the opposite effect (36).", [["BAL fluid", "ANATOMY", 39, 48], ["ARDS", "DISEASE", 68, 72], ["BAL fluid", "ORGANISM_SUBSTANCE", 39, 48], ["patients", "ORGANISM", 54, 62], ["lipid", "SIMPLE_CHEMICAL", 111, 116], ["patients", "SPECIES", 54, 62], ["some studies", "TEST", 13, 25], ["BAL fluid", "TEST", 39, 48], ["ARDS", "PROBLEM", 68, 72], ["antioxidant activity", "PROBLEM", 77, 97], ["lipid peroxidation", "PROBLEM", 111, 129], ["other studies", "TEST", 154, 167], ["BAL fluid", "OBSERVATION", 39, 48], ["lipid peroxidation", "OBSERVATION", 111, 129]]], ["Despite these limitations, the hyperoxic model, with its well-defined exudative and proliferative phases, provides an excellent model to study lung repair following lung injury.", [["lung", "ANATOMY", 143, 147], ["lung", "ANATOMY", 165, 169], ["lung injury", "DISEASE", 165, 176], ["lung", "ORGAN", 143, 147], ["lung", "ORGAN", 165, 169], ["the hyperoxic model", "TEST", 27, 46], ["study lung repair", "TREATMENT", 137, 154], ["lung injury", "PROBLEM", 165, 176], ["hyperoxic model", "OBSERVATION", 31, 46], ["exudative", "OBSERVATION_MODIFIER", 70, 79], ["proliferative phases", "OBSERVATION", 84, 104], ["lung", "ANATOMY", 143, 147], ["repair", "OBSERVATION", 148, 154], ["lung", "ANATOMY", 165, 169], ["injury", "OBSERVATION", 170, 176]]], ["This model is reproducible but requires specialized equipment and expertise to ensure the delivery of the appropriate concentration of oxygen.Surfactant depletion by saline lavage. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSBasis for the model: the saline lavage model was developed by Lachmann et al. (124) in 1979 based on the observation that ARDS is associated with depletion of surfactant from the air spaces and reduced concentrations of surfactant-associated proteins in BAL fluid.", [["Alveolar Epithelium", "ANATOMY", 218, 237], ["BAL fluid", "ANATOMY", 538, 547], ["oxygen", "CHEMICAL", 135, 141], ["ARDS", "DISEASE", 406, 410], ["oxygen", "CHEMICAL", 135, 141], ["oxygen", "SIMPLE_CHEMICAL", 135, 141], ["Surfactant", "SIMPLE_CHEMICAL", 142, 152], ["Alveolar Epithelium", "TISSUE", 218, 237], ["surfactant", "SIMPLE_CHEMICAL", 504, 514], ["BAL fluid", "ORGANISM_SUBSTANCE", 538, 547], ["surfactant-associated proteins", "PROTEIN", 504, 534], ["the appropriate concentration of oxygen", "TREATMENT", 102, 141], ["Surfactant depletion", "TREATMENT", 142, 162], ["saline lavage", "TREATMENT", 166, 179], ["LUNG INJURY", "PROBLEM", 259, 270], ["the saline lavage model", "TREATMENT", 305, 328], ["ARDS", "PROBLEM", 406, 410], ["surfactant", "TREATMENT", 443, 453], ["the air spaces", "PROBLEM", 459, 473], ["reduced concentrations of surfactant", "PROBLEM", 478, 514], ["associated proteins in BAL fluid", "PROBLEM", 515, 547], ["reproducible", "OBSERVATION_MODIFIER", 14, 26], ["saline lavage", "OBSERVATION", 166, 179], ["Alveolar Epithelium", "OBSERVATION", 218, 237], ["LUNG", "ANATOMY", 259, 263], ["INJURY", "OBSERVATION", 264, 270], ["ARDS", "OBSERVATION", 406, 410], ["surfactant", "OBSERVATION", 443, 453], ["air spaces", "OBSERVATION", 463, 473], ["reduced", "OBSERVATION_MODIFIER", 478, 485], ["concentrations", "OBSERVATION_MODIFIER", 486, 500], ["BAL fluid", "OBSERVATION", 538, 547]]], ["In this model, warmed isotonic saline solution is instilled into the lungs and then removed by aspiration.", [["lungs", "ANATOMY", 69, 74], ["saline", "SIMPLE_CHEMICAL", 31, 37], ["lungs", "ORGAN", 69, 74], ["warmed isotonic saline solution", "TREATMENT", 15, 46], ["aspiration", "PROBLEM", 95, 105], ["lungs", "ANATOMY", 69, 74], ["aspiration", "OBSERVATION", 95, 105]]], ["The lavage is repeated until a target degree of hypoxemia is reached.", [["hypoxemia", "DISEASE", 48, 57], ["lavage", "ORGANISM_SUBSTANCE", 4, 10], ["The lavage", "TEST", 0, 10], ["hypoxemia", "PROBLEM", 48, 57], ["lavage", "OBSERVATION", 4, 10], ["hypoxemia", "OBSERVATION", 48, 57]]], ["Many groups have combined saline lavage with mechanical ventilation, and in many studies it is difficult to determine the extent to which the lung injury is caused by the saline lavage, by the mechanical ventilation, or both.Surfactant depletion by saline lavage. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSMechanism: repeated lavage with saline reduces the surfactant lipid concentration in alveolar lining fluids, altering alveolar surface tension.", [["lung", "ANATOMY", 142, 146], ["Alveolar Epithelium", "ANATOMY", 301, 320], ["alveolar lining fluids", "ANATOMY", 452, 474], ["alveolar surface", "ANATOMY", 485, 501], ["lung injury", "DISEASE", 142, 153], ["lung", "ORGAN", 142, 146], ["Surfactant", "SIMPLE_CHEMICAL", 225, 235], ["Alveolar Epithelium", "TISSUE", 301, 320], ["lavage", "ORGANISM_SUBSTANCE", 387, 393], ["saline", "SIMPLE_CHEMICAL", 399, 405], ["lipid", "SIMPLE_CHEMICAL", 429, 434], ["alveolar lining fluids", "ORGANISM_SUBSTANCE", 452, 474], ["alveolar surface", "MULTI-TISSUE_STRUCTURE", 485, 501], ["combined saline lavage", "TREATMENT", 17, 39], ["mechanical ventilation", "TREATMENT", 45, 67], ["the lung injury", "PROBLEM", 138, 153], ["the saline lavage", "TREATMENT", 167, 184], ["the mechanical ventilation", "TREATMENT", 189, 215], ["Surfactant depletion", "TREATMENT", 225, 245], ["saline lavage", "TREATMENT", 249, 262], ["repeated lavage", "TREATMENT", 378, 393], ["saline", "TREATMENT", 399, 405], ["the surfactant lipid concentration in alveolar lining fluids", "TREATMENT", 414, 474], ["altering alveolar surface tension", "PROBLEM", 476, 509], ["lavage", "OBSERVATION", 33, 39], ["mechanical ventilation", "OBSERVATION", 45, 67], ["lung", "ANATOMY", 142, 146], ["injury", "OBSERVATION", 147, 153], ["saline lavage", "OBSERVATION", 171, 184], ["mechanical ventilation", "OBSERVATION", 193, 215], ["saline lavage", "OBSERVATION", 249, 262], ["Alveolar Epithelium", "OBSERVATION", 301, 320], ["LUNG", "ANATOMY", 342, 346], ["INJURY", "OBSERVATION", 347, 353], ["lavage", "OBSERVATION", 387, 393], ["alveolar", "ANATOMY_MODIFIER", 452, 460], ["lining fluids", "OBSERVATION", 461, 474], ["alveolar", "ANATOMY_MODIFIER", 485, 493], ["surface tension", "OBSERVATION", 494, 509]]], ["Pulmonary surfactant is a complex mixture of phospholipids and proteins that has several important functions (88).", [["Pulmonary", "ANATOMY", 0, 9], ["Pulmonary", "ORGAN", 0, 9], ["phospholipids", "SIMPLE_CHEMICAL", 45, 58], ["Pulmonary surfactant", "TREATMENT", 0, 20], ["phospholipids and proteins", "TREATMENT", 45, 71], ["surfactant", "OBSERVATION", 10, 20]]], ["Surfactant decreases surface tension and prevents collapse of the alveolar spaces at low lung volumes.", [["surface", "ANATOMY", 21, 28], ["alveolar", "ANATOMY", 66, 74], ["lung", "ANATOMY", 89, 93], ["Surfactant", "SIMPLE_CHEMICAL", 0, 10], ["alveolar", "MULTI-TISSUE_STRUCTURE", 66, 74], ["lung", "ORGAN", 89, 93], ["Surfactant", "TREATMENT", 0, 10], ["collapse of the alveolar spaces at low lung volumes", "PROBLEM", 50, 101], ["surface", "OBSERVATION_MODIFIER", 21, 28], ["tension", "OBSERVATION", 29, 36], ["prevents", "UNCERTAINTY", 41, 49], ["collapse", "OBSERVATION", 50, 58], ["alveolar", "ANATOMY_MODIFIER", 66, 74], ["low", "OBSERVATION_MODIFIER", 85, 88], ["lung", "ANATOMY", 89, 93], ["volumes", "ANATOMY_MODIFIER", 94, 101]]], ["Surfactant proteins stabilize surfactant and modulate host defenses in the lungs (243).", [["lungs", "ANATOMY", 75, 80], ["Surfactant proteins", "GENE_OR_GENE_PRODUCT", 0, 19], ["lungs", "ORGAN", 75, 80], ["Surfactant proteins", "PROTEIN", 0, 19], ["Surfactant proteins", "TREATMENT", 0, 19], ["surfactant", "TREATMENT", 30, 40], ["modulate", "OBSERVATION_MODIFIER", 45, 53], ["host defenses", "OBSERVATION", 54, 67], ["lungs", "ANATOMY", 75, 80]]], ["Depletion of surfactant may be associated with lung injury by two mechanisms: first, by facilitating alveolar collapse and increasing the likelihood of mechanical injury to the alveolar walls during repeated cycles of opening/closure during mechanical ventilation, and second, by impairing alveolar host defenses.", [["lung", "ANATOMY", 47, 51], ["alveolar", "ANATOMY", 101, 109], ["alveolar walls", "ANATOMY", 177, 191], ["alveolar", "ANATOMY", 290, 298], ["lung injury", "DISEASE", 47, 58], ["lung", "ORGAN", 47, 51], ["alveolar", "MULTI-TISSUE_STRUCTURE", 101, 109], ["alveolar walls", "MULTI-TISSUE_STRUCTURE", 177, 191], ["alveolar", "MULTI-TISSUE_STRUCTURE", 290, 298], ["Depletion of surfactant", "TREATMENT", 0, 23], ["lung injury", "PROBLEM", 47, 58], ["alveolar collapse", "PROBLEM", 101, 118], ["mechanical injury to the alveolar walls", "PROBLEM", 152, 191], ["opening/closure", "TREATMENT", 218, 233], ["mechanical ventilation", "TREATMENT", 241, 263], ["surfactant", "OBSERVATION", 13, 23], ["may be associated with", "UNCERTAINTY", 24, 46], ["lung", "ANATOMY", 47, 51], ["injury", "OBSERVATION", 52, 58], ["alveolar", "ANATOMY", 101, 109], ["collapse", "OBSERVATION", 110, 118], ["mechanical injury", "OBSERVATION", 152, 169], ["alveolar", "ANATOMY_MODIFIER", 177, 185], ["walls", "ANATOMY_MODIFIER", 186, 191], ["closure", "OBSERVATION", 226, 233], ["mechanical ventilation", "OBSERVATION", 241, 263], ["impairing", "OBSERVATION_MODIFIER", 280, 289], ["alveolar host defenses", "OBSERVATION", 290, 312]]], ["The administration of bovine surfactant and/or synthetic surfactant-related peptides attenuates the injury produced by saline lavage (35, 229).Surfactant depletion by saline lavage. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSCharacteristics of the model: saline lavage (0.9% NaCl) leads to almost immediate hypoxemia and widening of the A-a O2 difference.", [["Alveolar Epithelium", "ANATOMY", 219, 238], ["NaCl", "CHEMICAL", 335, 339], ["hypoxemia", "DISEASE", 367, 376], ["NaCl", "CHEMICAL", 335, 339], ["O2", "CHEMICAL", 401, 403], ["bovine", "ORGANISM", 22, 28], ["surfactant", "SIMPLE_CHEMICAL", 29, 39], ["saline", "SIMPLE_CHEMICAL", 119, 125], ["lavage", "ORGANISM_SUBSTANCE", 126, 132], ["Surfactant", "SIMPLE_CHEMICAL", 143, 153], ["Alveolar Epithelium", "TISSUE", 219, 238], ["saline", "SIMPLE_CHEMICAL", 315, 321], ["lavage", "ORGANISM_SUBSTANCE", 322, 328], ["O2", "SIMPLE_CHEMICAL", 401, 403], ["bovine", "SPECIES", 22, 28], ["bovine", "SPECIES", 22, 28], ["bovine surfactant", "TREATMENT", 22, 39], ["synthetic surfactant", "TREATMENT", 47, 67], ["the injury", "PROBLEM", 96, 106], ["saline lavage", "TREATMENT", 119, 132], ["Surfactant depletion", "TREATMENT", 143, 163], ["saline lavage", "TREATMENT", 167, 180], ["LUNG INJURY", "PROBLEM", 260, 271], ["saline lavage", "TREATMENT", 315, 328], ["0.9% NaCl)", "TREATMENT", 330, 340], ["almost immediate hypoxemia", "PROBLEM", 350, 376], ["a O2 difference", "PROBLEM", 399, 414], ["bovine surfactant", "OBSERVATION", 22, 39], ["saline lavage", "OBSERVATION", 167, 180], ["Alveolar Epithelium", "OBSERVATION", 219, 238], ["LUNG", "ANATOMY", 260, 264], ["INJURY", "OBSERVATION", 265, 271], ["hypoxemia", "OBSERVATION", 367, 376], ["widening", "OBSERVATION_MODIFIER", 381, 389]]], ["These findings are rapidly reversible by recruitment maneuvers such as sustained inflation, suggesting that the gas exchange abnormalities reflect collapsed alveoli with otherwise intact alveolar walls (99, 182).", [["alveoli", "ANATOMY", 157, 164], ["alveolar walls", "ANATOMY", 187, 201], ["alveoli", "MULTI-TISSUE_STRUCTURE", 157, 164], ["alveolar walls", "MULTI-TISSUE_STRUCTURE", 187, 201], ["recruitment maneuvers", "TREATMENT", 41, 62], ["the gas exchange abnormalities", "PROBLEM", 108, 138], ["collapsed alveoli", "PROBLEM", 147, 164], ["rapidly", "OBSERVATION_MODIFIER", 19, 26], ["reversible", "OBSERVATION_MODIFIER", 27, 37], ["recruitment maneuvers", "OBSERVATION", 41, 62], ["sustained", "OBSERVATION_MODIFIER", 71, 80], ["inflation", "OBSERVATION", 81, 90], ["gas exchange", "OBSERVATION", 112, 124], ["collapsed", "OBSERVATION_MODIFIER", 147, 156], ["alveoli", "ANATOMY_MODIFIER", 157, 164], ["otherwise", "OBSERVATION_MODIFIER", 170, 179], ["intact", "OBSERVATION_MODIFIER", 180, 186], ["alveolar", "ANATOMY_MODIFIER", 187, 195], ["walls", "ANATOMY_MODIFIER", 196, 201]]], ["The saline lavage by itself has little consequence in terms of permeability changes or inflammation (71, 182), although TNF-\u03b1 is detectable in lavage fluid (98).", [["lavage fluid", "ANATOMY", 143, 155], ["inflammation", "DISEASE", 87, 99], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 120, 125], ["lavage fluid", "ORGANISM_SUBSTANCE", 143, 155], ["TNF", "PROTEIN", 120, 123], ["The saline lavage", "TREATMENT", 0, 17], ["permeability changes", "PROBLEM", 63, 83], ["inflammation", "PROBLEM", 87, 99], ["TNF", "TEST", 120, 123], ["lavage fluid", "TEST", 143, 155], ["saline lavage", "OBSERVATION", 4, 17], ["permeability", "OBSERVATION", 63, 75], ["inflammation", "OBSERVATION", 87, 99]]], ["When saline lavage is followed by mechanical ventilation with high volumes and no PEEP, a type of lung injury results that is very similar to ARDS in humans.", [["lung", "ANATOMY", 98, 102], ["lung injury", "DISEASE", 98, 109], ["ARDS", "DISEASE", 142, 146], ["lung", "ORGAN", 98, 102], ["humans", "ORGANISM", 150, 156], ["humans", "SPECIES", 150, 156], ["humans", "SPECIES", 150, 156], ["saline lavage", "TREATMENT", 5, 18], ["mechanical ventilation", "TREATMENT", 34, 56], ["PEEP", "TREATMENT", 82, 86], ["lung injury", "PROBLEM", 98, 109], ["ARDS in humans", "PROBLEM", 142, 156], ["lavage", "OBSERVATION", 12, 18], ["lung", "ANATOMY", 98, 102], ["injury", "OBSERVATION", 103, 109], ["ARDS", "OBSERVATION", 142, 146]]], ["The lung injury is dependent on PMN and is characterized by increased protein permeability, PMN infiltration into the air spaces and interstitium, increased cytokine production, and hyaline membrane formation (99, 110, 124).", [["lung", "ANATOMY", 4, 8], ["PMN", "ANATOMY", 32, 35], ["PMN", "ANATOMY", 92, 95], ["air spaces", "ANATOMY", 118, 128], ["interstitium", "ANATOMY", 133, 145], ["hyaline membrane", "ANATOMY", 182, 198], ["lung injury", "DISEASE", 4, 15], ["lung", "ORGAN", 4, 8], ["PMN", "CELL", 32, 35], ["PMN", "CELL", 92, 95], ["interstitium", "MULTI-TISSUE_STRUCTURE", 133, 145], ["hyaline membrane", "CELLULAR_COMPONENT", 182, 198], ["PMN", "CELL_TYPE", 32, 35], ["cytokine", "PROTEIN", 157, 165], ["The lung injury", "PROBLEM", 0, 15], ["dependent on PMN", "PROBLEM", 19, 35], ["increased protein permeability", "PROBLEM", 60, 90], ["PMN infiltration into the air spaces", "PROBLEM", 92, 128], ["interstitium", "PROBLEM", 133, 145], ["increased cytokine production", "PROBLEM", 147, 176], ["hyaline membrane formation", "PROBLEM", 182, 208], ["lung", "ANATOMY", 4, 8], ["injury", "OBSERVATION", 9, 15], ["dependent", "OBSERVATION_MODIFIER", 19, 28], ["increased", "OBSERVATION_MODIFIER", 60, 69], ["protein permeability", "OBSERVATION", 70, 90], ["PMN infiltration", "OBSERVATION", 92, 108], ["air spaces", "OBSERVATION", 118, 128], ["interstitium", "ANATOMY_MODIFIER", 133, 145], ["increased", "OBSERVATION_MODIFIER", 147, 156], ["cytokine production", "OBSERVATION", 157, 176], ["hyaline", "OBSERVATION_MODIFIER", 182, 189], ["membrane formation", "OBSERVATION", 190, 208]]], ["Mechanical ventilation alone, without previous saline lavage, can induce similar findings (53, 145, 220).", [["Mechanical ventilation", "TREATMENT", 0, 22], ["previous saline lavage", "TREATMENT", 38, 60], ["ventilation", "OBSERVATION", 11, 22]]], ["Instilling LPS into the air spaces intensifies the injury response to surfactant depletion (34).", [["LPS", "CHEMICAL", 11, 14], ["LPS", "SIMPLE_CHEMICAL", 11, 14], ["surfactant", "SIMPLE_CHEMICAL", 70, 80], ["Instilling LPS", "TREATMENT", 0, 14], ["the injury", "PROBLEM", 47, 57], ["surfactant depletion", "TREATMENT", 70, 90], ["air spaces", "OBSERVATION", 24, 34], ["injury", "OBSERVATION", 51, 57], ["surfactant depletion", "OBSERVATION", 70, 90]]], ["Rabbits subjected to lung lavage with 0.9% NaCl, five aliquots of 30 ml/kg each, followed immediately by instillation of 0.25 \u03bcg/kg LPS, and then mechanical ventilation with 100% FiO2, develop minimal inflammation at 4 h but progress to significant neutrophilic alveolitis and protein-rich alveolar edema at later times (34).Surfactant depletion by saline lavage. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSComparisons with human ALI/ARDS: surfactant depletion is an important feature of ALI/ARDS in humans, but unlike newborns, surfactant depletion in adults is usually a consequence rather than a primary cause of lung injury (164).", [["lung lavage", "ANATOMY", 21, 32], ["alveolar", "ANATOMY", 290, 298], ["Alveolar Epithelium", "ANATOMY", 401, 420], ["lung", "ANATOMY", 676, 680], ["NaCl", "CHEMICAL", 43, 47], ["LPS", "CHEMICAL", 132, 135], ["FiO2", "CHEMICAL", 179, 183], ["inflammation", "DISEASE", 201, 213], ["alveolitis", "DISEASE", 262, 272], ["alveolar edema", "DISEASE", 290, 304], ["ALI", "DISEASE", 490, 493], ["ARDS", "DISEASE", 494, 498], ["ALI", "DISEASE", 548, 551], ["ARDS", "DISEASE", 552, 556], ["lung injury", "DISEASE", 676, 687], ["NaCl", "CHEMICAL", 43, 47], ["FiO2", "CHEMICAL", 179, 183], ["Rabbits", "ORGANISM", 0, 7], ["lung lavage", "MULTI-TISSUE_STRUCTURE", 21, 32], ["LPS", "SIMPLE_CHEMICAL", 132, 135], ["alveolar edema", "PATHOLOGICAL_FORMATION", 290, 304], ["Surfactant", "SIMPLE_CHEMICAL", 325, 335], ["Alveolar Epithelium", "TISSUE", 401, 420], ["human", "ORGANISM", 484, 489], ["humans", "ORGANISM", 560, 566], ["newborns", "ORGANISM", 579, 587], ["lung", "ORGAN", 676, 680], ["Rabbits", "SPECIES", 0, 7], ["human", "SPECIES", 484, 489], ["humans", "SPECIES", 560, 566], ["human", "SPECIES", 484, 489], ["humans", "SPECIES", 560, 566], ["lung lavage", "TEST", 21, 32], ["0.9% NaCl", "TREATMENT", 38, 47], ["LPS", "TREATMENT", 132, 135], ["mechanical ventilation", "TREATMENT", 146, 168], ["100% FiO2", "TREATMENT", 174, 183], ["minimal inflammation", "PROBLEM", 193, 213], ["significant neutrophilic alveolitis", "PROBLEM", 237, 272], ["protein-rich alveolar edema", "PROBLEM", 277, 304], ["Surfactant depletion", "TREATMENT", 325, 345], ["saline lavage", "TREATMENT", 349, 362], ["LUNG INJURY", "PROBLEM", 442, 453], ["human ALI", "PROBLEM", 484, 493], ["ARDS", "PROBLEM", 494, 498], ["surfactant depletion", "TREATMENT", 500, 520], ["ALI", "PROBLEM", 548, 551], ["ARDS in humans", "PROBLEM", 552, 566], ["surfactant depletion", "PROBLEM", 589, 609], ["lung injury", "PROBLEM", 676, 687], ["lung", "ANATOMY", 21, 25], ["lavage", "OBSERVATION", 26, 32], ["minimal", "OBSERVATION_MODIFIER", 193, 200], ["inflammation", "OBSERVATION", 201, 213], ["significant", "OBSERVATION_MODIFIER", 237, 248], ["neutrophilic", "OBSERVATION_MODIFIER", 249, 261], ["alveolitis", "OBSERVATION", 262, 272], ["rich", "OBSERVATION_MODIFIER", 285, 289], ["alveolar", "ANATOMY_MODIFIER", 290, 298], ["edema", "OBSERVATION", 299, 304], ["saline lavage", "OBSERVATION", 349, 362], ["Alveolar Epithelium", "OBSERVATION", 401, 420], ["LUNG", "ANATOMY", 442, 446], ["INJURY", "OBSERVATION", 447, 453], ["ARDS", "OBSERVATION", 494, 498], ["surfactant depletion", "OBSERVATION", 500, 520], ["ALI", "OBSERVATION", 548, 551], ["ARDS", "OBSERVATION", 552, 556], ["surfactant depletion", "OBSERVATION", 589, 609], ["lung", "ANATOMY", 676, 680], ["injury", "OBSERVATION", 681, 687]]], ["In ALI/ARDS, surfactant abnormalities occur because of injury of the alveolar epithelium and exudation of protein-rich edema fluid into the alveolar spaces.", [["alveolar epithelium", "ANATOMY", 69, 88], ["edema fluid", "ANATOMY", 119, 130], ["alveolar spaces", "ANATOMY", 140, 155], ["ALI", "DISEASE", 3, 6], ["ARDS", "DISEASE", 7, 11], ["surfactant abnormalities", "DISEASE", 13, 37], ["edema", "DISEASE", 119, 124], ["alveolar epithelium", "TISSUE", 69, 88], ["alveolar", "MULTI-TISSUE_STRUCTURE", 140, 148], ["ALI", "PROBLEM", 3, 6], ["ARDS", "PROBLEM", 7, 11], ["surfactant abnormalities", "PROBLEM", 13, 37], ["injury", "PROBLEM", 55, 61], ["the alveolar epithelium", "PROBLEM", 65, 88], ["protein-rich edema fluid into the alveolar spaces", "PROBLEM", 106, 155], ["ALI", "OBSERVATION", 3, 6], ["ARDS", "OBSERVATION", 7, 11], ["surfactant abnormalities", "OBSERVATION", 13, 37], ["injury", "OBSERVATION", 55, 61], ["alveolar", "ANATOMY_MODIFIER", 69, 77], ["epithelium", "ANATOMY_MODIFIER", 78, 88], ["exudation", "OBSERVATION_MODIFIER", 93, 102], ["rich", "OBSERVATION_MODIFIER", 114, 118], ["edema", "OBSERVATION_MODIFIER", 119, 124], ["fluid", "OBSERVATION", 125, 130], ["alveolar", "ANATOMY_MODIFIER", 140, 148]]], ["Saline lavage of the lungs results in surfactant depletion in the absence of major alveolar epithelial damage.", [["lungs", "ANATOMY", 21, 26], ["alveolar epithelial", "ANATOMY", 83, 102], ["lungs", "ORGAN", 21, 26], ["surfactant", "SIMPLE_CHEMICAL", 38, 48], ["alveolar epithelial", "TISSUE", 83, 102], ["Saline lavage", "TEST", 0, 13], ["surfactant depletion", "PROBLEM", 38, 58], ["major alveolar epithelial damage", "PROBLEM", 77, 109], ["lavage", "OBSERVATION", 7, 13], ["lungs", "ANATOMY", 21, 26], ["surfactant depletion", "OBSERVATION", 38, 58], ["major", "OBSERVATION_MODIFIER", 77, 82], ["alveolar epithelial damage", "OBSERVATION", 83, 109]]], ["Epithelial damage occurs only when the saline lavage is followed by an injurious ventilatory strategy.", [["Epithelial", "ANATOMY", 0, 10], ["Epithelial damage", "DISEASE", 0, 17], ["Epithelial", "TISSUE", 0, 10], ["Epithelial damage", "PROBLEM", 0, 17], ["the saline lavage", "TREATMENT", 35, 52], ["an injurious ventilatory strategy", "TREATMENT", 68, 101], ["damage", "OBSERVATION", 11, 17]]], ["Therefore, surfactant depletion followed by mechanical ventilation simulates established ALI/ARDS and provides information about the consequences of surfactant depletion, but it is less useful in modeling the initial pathophysiological mechanisms that lead to ALI/ARDS.Surfactant depletion by saline lavage. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSAdvantages and disadvantages: the main technical disadvantage of the saline lavage model is that the animals require intubation, mechanical ventilation, and general anesthesia.", [["Alveolar Epithelium", "ANATOMY", 345, 364], ["ALI", "DISEASE", 89, 92], ["ARDS", "DISEASE", 93, 97], ["ALI", "DISEASE", 260, 263], ["ARDS", "DISEASE", 264, 268], ["surfactant", "SIMPLE_CHEMICAL", 11, 21], ["surfactant", "SIMPLE_CHEMICAL", 149, 159], ["Surfactant", "SIMPLE_CHEMICAL", 269, 279], ["Alveolar Epithelium", "TISSUE", 345, 364], ["surfactant depletion", "TREATMENT", 11, 31], ["mechanical ventilation", "TREATMENT", 44, 66], ["ARDS", "PROBLEM", 93, 97], ["surfactant depletion", "TREATMENT", 149, 169], ["ALI", "PROBLEM", 260, 263], ["ARDS", "PROBLEM", 264, 268], ["Surfactant depletion", "TREATMENT", 269, 289], ["saline lavage", "TREATMENT", 293, 306], ["LUNG INJURY", "PROBLEM", 386, 397], ["the saline lavage model", "TREATMENT", 476, 499], ["intubation", "TREATMENT", 528, 538], ["mechanical ventilation", "TREATMENT", 540, 562], ["general anesthesia", "TREATMENT", 568, 586], ["surfactant depletion", "OBSERVATION", 11, 31], ["ARDS", "OBSERVATION", 93, 97], ["surfactant depletion", "OBSERVATION", 149, 169], ["ARDS", "OBSERVATION", 264, 268], ["saline lavage", "OBSERVATION", 293, 306], ["Alveolar Epithelium", "OBSERVATION", 345, 364], ["LUNG", "ANATOMY", 386, 390], ["INJURY", "OBSERVATION", 391, 397], ["mechanical ventilation", "OBSERVATION", 540, 562]]], ["The major advantage is that this model provides an ideal way to test the effects of different ventilatory strategies on the development of tissue injury because the tissue injury results more from the ventilatory strategy than from the saline lavage.Mechanical ventilation. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSDuring the 1980s and 1990s, several studies showed that mechanical ventilation can produce lung inflammation and injury in animals, termed ventilator-induced lung injury (VILI) (49, 52).", [["tissue", "ANATOMY", 139, 145], ["tissue", "ANATOMY", 165, 171], ["Alveolar Epithelium", "ANATOMY", 311, 330], ["lung", "ANATOMY", 468, 472], ["lung", "ANATOMY", 535, 539], ["tissue injury", "DISEASE", 139, 152], ["lung inflammation", "DISEASE", 468, 485], ["ventilator-induced lung injury", "DISEASE", 516, 546], ["VILI", "DISEASE", 548, 552], ["tissue", "TISSUE", 139, 145], ["tissue", "TISSUE", 165, 171], ["Alveolar Epithelium", "TISSUE", 311, 330], ["lung", "ORGAN", 468, 472], ["lung", "ORGAN", 535, 539], ["different ventilatory strategies", "TREATMENT", 84, 116], ["tissue injury", "PROBLEM", 139, 152], ["the tissue injury", "PROBLEM", 161, 178], ["the ventilatory strategy", "TREATMENT", 197, 221], ["the saline lavage", "TREATMENT", 232, 249], ["Mechanical ventilation", "TREATMENT", 250, 272], ["LUNG INJURY", "PROBLEM", 352, 363], ["several studies", "TEST", 405, 420], ["mechanical ventilation", "TREATMENT", 433, 455], ["lung inflammation", "PROBLEM", 468, 485], ["injury in animals", "PROBLEM", 490, 507], ["lung injury", "PROBLEM", 535, 546], ["ventilatory strategies", "OBSERVATION", 94, 116], ["tissue", "ANATOMY", 139, 145], ["injury", "OBSERVATION", 146, 152], ["tissue", "ANATOMY", 165, 171], ["injury", "OBSERVATION", 172, 178], ["saline lavage", "OBSERVATION", 236, 249], ["ventilation", "OBSERVATION", 261, 272], ["Alveolar Epithelium", "OBSERVATION", 311, 330], ["LUNG", "ANATOMY", 352, 356], ["INJURY", "OBSERVATION", 357, 363], ["mechanical ventilation", "OBSERVATION", 433, 455], ["lung", "ANATOMY", 468, 472], ["inflammation", "OBSERVATION", 473, 485], ["injury", "OBSERVATION", 490, 496], ["lung", "ANATOMY", 535, 539], ["injury", "OBSERVATION", 540, 546], ["VILI", "OBSERVATION", 548, 552]]], ["These studies provided the basis for a large multicenter study comparing different ventilatory strategies in patients with ALI/ARDS, which changed the clinical management of patients in intensive care units (215).", [["ALI", "DISEASE", 123, 126], ["ARDS", "DISEASE", 127, 131], ["patients", "ORGANISM", 109, 117], ["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 109, 117], ["patients", "SPECIES", 174, 182], ["These studies", "TEST", 0, 13], ["a large multicenter study", "TEST", 37, 62], ["ALI", "PROBLEM", 123, 126], ["ARDS", "PROBLEM", 127, 131], ["ARDS", "OBSERVATION", 127, 131]]], ["The mechanical ventilation model is the only model of lung injury that has affected clinical practice and improved survival in humans.Mechanical ventilation. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSMost animal models of lung injury were developed by reproducing known risk factors for human ARDS.", [["lung", "ANATOMY", 54, 58], ["Alveolar Epithelium", "ANATOMY", 195, 214], ["lung", "ANATOMY", 283, 287], ["lung injury", "DISEASE", 54, 65], ["lung injury", "DISEASE", 283, 294], ["ARDS", "DISEASE", 354, 358], ["lung", "ORGAN", 54, 58], ["humans", "ORGANISM", 127, 133], ["Alveolar Epithelium", "TISSUE", 195, 214], ["lung", "ORGAN", 283, 287], ["human", "ORGANISM", 348, 353], ["humans", "SPECIES", 127, 133], ["human", "SPECIES", 348, 353], ["humans", "SPECIES", 127, 133], ["human", "SPECIES", 348, 353], ["The mechanical ventilation model", "TREATMENT", 0, 32], ["lung injury", "PROBLEM", 54, 65], ["Mechanical ventilation", "TREATMENT", 134, 156], ["LUNG INJURY", "PROBLEM", 236, 247], ["lung injury", "PROBLEM", 283, 294], ["human ARDS", "PROBLEM", 348, 358], ["mechanical", "OBSERVATION", 4, 14], ["ventilation model", "OBSERVATION", 15, 32], ["lung", "ANATOMY", 54, 58], ["injury", "OBSERVATION", 59, 65], ["improved", "OBSERVATION_MODIFIER", 106, 114], ["survival", "OBSERVATION_MODIFIER", 115, 123], ["ventilation", "OBSERVATION", 145, 156], ["Alveolar Epithelium", "OBSERVATION", 195, 214], ["LUNG", "ANATOMY", 236, 240], ["INJURY", "OBSERVATION", 241, 247], ["lung", "ANATOMY", 283, 287], ["injury", "OBSERVATION", 288, 294], ["ARDS", "OBSERVATION", 354, 358]]], ["In contrast, VILI results from applying a treatment, mechanical ventilation.", [["a treatment", "TREATMENT", 40, 51], ["mechanical ventilation", "TREATMENT", 53, 75], ["mechanical ventilation", "OBSERVATION", 53, 75]]], ["In humans with clinical risk factors for ARDS, mechanical ventilation is superimposed on an ongoing inflammatory process in the lungs.", [["lungs", "ANATOMY", 128, 133], ["ARDS", "DISEASE", 41, 45], ["humans", "ORGANISM", 3, 9], ["lungs", "ORGAN", 128, 133], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["ARDS", "PROBLEM", 41, 45], ["mechanical ventilation", "TREATMENT", 47, 69], ["an ongoing inflammatory process in the lungs", "PROBLEM", 89, 133], ["ARDS", "OBSERVATION", 41, 45], ["mechanical ventilation", "OBSERVATION", 47, 69], ["ongoing", "OBSERVATION_MODIFIER", 92, 99], ["inflammatory", "OBSERVATION", 100, 112], ["lungs", "ANATOMY", 128, 133]]], ["It is necessary to distinguish between ventilator-induced lung injury, in which mechanical ventilation is the sole method used to generate injury, and ventilator-associated lung injury, in which mechanical ventilation modifies lung injury due to a clinically relevant cause, such as acid aspiration or sepsis (66).Mechanical ventilation. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSMechanism: the mechanism of VILI involves direct tissue damage due to mechanical stretch and activation of specific intracellular pathways involved in \u201cmechanotransduction\u201d (reviewed in Ref.", [["lung", "ANATOMY", 58, 62], ["lung", "ANATOMY", 173, 177], ["lung", "ANATOMY", 227, 231], ["Alveolar Epithelium", "ANATOMY", 375, 394], ["tissue", "ANATOMY", 490, 496], ["intracellular", "ANATOMY", 557, 570], ["lung injury", "DISEASE", 58, 69], ["lung injury", "DISEASE", 173, 184], ["lung injury", "DISEASE", 227, 238], ["sepsis", "DISEASE", 302, 308], ["VILI", "DISEASE", 469, 473], ["lung", "ORGAN", 58, 62], ["lung", "ORGAN", 173, 177], ["lung", "ORGAN", 227, 231], ["Alveolar Epithelium", "TISSUE", 375, 394], ["tissue", "TISSUE", 490, 496], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 557, 570], ["ventilator", "TREATMENT", 39, 49], ["lung injury", "PROBLEM", 58, 69], ["mechanical ventilation", "TREATMENT", 80, 102], ["injury", "PROBLEM", 139, 145], ["lung injury", "PROBLEM", 173, 184], ["mechanical ventilation", "TREATMENT", 195, 217], ["lung injury", "PROBLEM", 227, 238], ["acid aspiration", "PROBLEM", 283, 298], ["sepsis", "PROBLEM", 302, 308], ["Mechanical ventilation", "TREATMENT", 314, 336], ["LUNG INJURY", "PROBLEM", 416, 427], ["VILI", "PROBLEM", 469, 473], ["direct tissue damage", "PROBLEM", 483, 503], ["mechanical stretch", "TREATMENT", 511, 529], ["lung", "ANATOMY", 58, 62], ["injury", "OBSERVATION", 63, 69], ["mechanical ventilation", "OBSERVATION", 80, 102], ["injury", "OBSERVATION", 139, 145], ["lung", "ANATOMY", 173, 177], ["injury", "OBSERVATION", 178, 184], ["mechanical ventilation", "OBSERVATION", 195, 217], ["lung", "ANATOMY", 227, 231], ["injury", "OBSERVATION", 232, 238], ["sepsis", "OBSERVATION", 302, 308], ["ventilation", "OBSERVATION", 325, 336], ["Alveolar Epithelium", "OBSERVATION", 375, 394], ["LUNG", "ANATOMY", 416, 420], ["INJURY", "OBSERVATION", 421, 427], ["VILI", "OBSERVATION", 469, 473], ["mechanical stretch", "OBSERVATION", 511, 529]]], ["Overstretching of alveolar walls results in endothelial and epithelial breaks and interstitial edema (70).", [["alveolar walls", "ANATOMY", 18, 32], ["endothelial", "ANATOMY", 44, 55], ["epithelial", "ANATOMY", 60, 70], ["interstitial edema", "ANATOMY", 82, 100], ["interstitial edema", "DISEASE", 82, 100], ["alveolar walls", "PATHOLOGICAL_FORMATION", 18, 32], ["endothelial", "CELL", 44, 55], ["epithelial", "TISSUE", 60, 70], ["interstitial edema", "PATHOLOGICAL_FORMATION", 82, 100], ["endothelial and epithelial breaks", "PROBLEM", 44, 77], ["interstitial edema", "PROBLEM", 82, 100], ["alveolar", "ANATOMY_MODIFIER", 18, 26], ["walls", "ANATOMY_MODIFIER", 27, 32], ["endothelial", "ANATOMY", 44, 55], ["epithelial breaks", "OBSERVATION", 60, 77], ["interstitial", "ANATOMY_MODIFIER", 82, 94], ["edema", "OBSERVATION", 95, 100]]], ["Detachment of endothelial cells from the basement membrane and death of epithelial cell with denuding of the epithelial basement membrane become obvious after 20 min of mechanical ventilation with very high tidal volumes (produced by peak pressures of 45 cmH2O in rats) (51).", [["endothelial cells", "ANATOMY", 14, 31], ["basement membrane", "ANATOMY", 41, 58], ["epithelial cell", "ANATOMY", 72, 87], ["epithelial basement membrane", "ANATOMY", 109, 137], ["death", "DISEASE", 63, 68], ["endothelial cells", "CELL", 14, 31], ["basement membrane", "CELLULAR_COMPONENT", 41, 58], ["epithelial cell", "CELL", 72, 87], ["epithelial basement membrane", "CELLULAR_COMPONENT", 109, 137], ["rats", "ORGANISM", 264, 268], ["endothelial cells", "CELL_TYPE", 14, 31], ["epithelial cell", "CELL_TYPE", 72, 87], ["rats", "SPECIES", 264, 268], ["Detachment of endothelial cells", "PROBLEM", 0, 31], ["epithelial cell", "PROBLEM", 72, 87], ["mechanical ventilation", "TREATMENT", 169, 191], ["very high tidal volumes", "PROBLEM", 197, 220], ["peak pressures", "TEST", 234, 248], ["endothelial cells", "OBSERVATION", 14, 31], ["epithelial cell", "OBSERVATION", 72, 87], ["epithelial", "ANATOMY_MODIFIER", 109, 119], ["basement", "ANATOMY_MODIFIER", 120, 128], ["mechanical ventilation", "OBSERVATION", 169, 191], ["very", "OBSERVATION_MODIFIER", 197, 201], ["high", "OBSERVATION_MODIFIER", 202, 206], ["tidal volumes", "OBSERVATION", 207, 220]]], ["However, the development of hyaline membranes and increased permeability require the presence of PMN, suggesting that in addition to mechanical damage, inflammatory damage is also necessary for mechanical ventilation to induce injury (110).", [["hyaline membranes", "ANATOMY", 28, 45], ["PMN", "ANATOMY", 97, 100], ["hyaline membranes", "CELLULAR_COMPONENT", 28, 45], ["PMN", "CELL", 97, 100], ["PMN", "CELL_TYPE", 97, 100], ["hyaline membranes", "PROBLEM", 28, 45], ["increased permeability", "PROBLEM", 50, 72], ["PMN", "PROBLEM", 97, 100], ["mechanical damage", "PROBLEM", 133, 150], ["inflammatory damage", "PROBLEM", 152, 171], ["mechanical ventilation", "TREATMENT", 194, 216], ["injury", "PROBLEM", 227, 233], ["hyaline membranes", "OBSERVATION", 28, 45], ["increased", "OBSERVATION_MODIFIER", 50, 59], ["permeability", "OBSERVATION_MODIFIER", 60, 72], ["mechanical", "OBSERVATION_MODIFIER", 133, 143], ["damage", "OBSERVATION", 144, 150], ["inflammatory", "OBSERVATION", 152, 164]]], ["Mechanical cell deformation can be converted to biochemical changes, including production of proinflammatory cytokines (168, 225) and changes in lipid trafficking (226).", [["cell", "ANATOMY", 11, 15], ["cell", "CELL", 11, 15], ["lipid", "SIMPLE_CHEMICAL", 145, 150], ["proinflammatory cytokines", "PROTEIN", 93, 118], ["Mechanical cell deformation", "PROBLEM", 0, 27], ["biochemical changes", "PROBLEM", 48, 67], ["proinflammatory cytokines", "TEST", 93, 118], ["lipid trafficking", "TEST", 145, 162], ["cell deformation", "OBSERVATION", 11, 27]]], ["The inflammatory component of VILI remains controversial, as studies by Tremblay et al. (218a) showed increased production of inflammatory cytokines in lungs ventilated without PEEP, by a mechanism different from that of LPS (19), whereas studies by Ricard et al. (178) have reported no association between VILI and production of proinflammatory cytokines in the same animal model.Mechanical ventilation. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSOne important aspect of mechanical ventilation-associated lung injury is that the role of stretch appears to be different in normal vs. inflamed lungs.", [["lungs", "ANATOMY", 152, 157], ["Alveolar Epithelium", "ANATOMY", 442, 461], ["lung", "ANATOMY", 566, 570], ["lungs", "ANATOMY", 653, 658], ["VILI", "DISEASE", 30, 34], ["LPS", "CHEMICAL", 221, 224], ["lung injury", "DISEASE", 566, 577], ["lungs", "ORGAN", 152, 157], ["LPS", "SIMPLE_CHEMICAL", 221, 224], ["Alveolar Epithelium", "TISSUE", 442, 461], ["lung", "ORGAN", 566, 570], ["lungs", "ORGAN", 653, 658], ["inflammatory cytokines", "PROTEIN", 126, 148], ["proinflammatory cytokines", "PROTEIN", 330, 355], ["The inflammatory component of VILI", "PROBLEM", 0, 34], ["increased production of inflammatory cytokines in lungs ventilated", "PROBLEM", 102, 168], ["PEEP", "TREATMENT", 177, 181], ["LPS", "TEST", 221, 224], ["VILI", "PROBLEM", 307, 311], ["proinflammatory cytokines", "PROBLEM", 330, 355], ["Mechanical ventilation", "TREATMENT", 381, 403], ["LUNG INJURY", "PROBLEM", 483, 494], ["mechanical ventilation", "TREATMENT", 532, 554], ["lung injury", "PROBLEM", 566, 577], ["inflamed lungs", "PROBLEM", 644, 658], ["inflammatory", "OBSERVATION_MODIFIER", 4, 16], ["VILI", "OBSERVATION", 30, 34], ["increased", "OBSERVATION_MODIFIER", 102, 111], ["production", "OBSERVATION_MODIFIER", 112, 122], ["inflammatory cytokines", "OBSERVATION", 126, 148], ["lungs", "ANATOMY", 152, 157], ["proinflammatory cytokines", "OBSERVATION", 330, 355], ["ventilation", "OBSERVATION", 392, 403], ["Alveolar Epithelium", "OBSERVATION", 442, 461], ["LUNG", "ANATOMY", 483, 487], ["INJURY", "OBSERVATION", 488, 494], ["mechanical ventilation", "OBSERVATION", 532, 554], ["lung", "ANATOMY", 566, 570], ["injury", "OBSERVATION", 571, 577], ["normal", "OBSERVATION", 633, 639], ["lungs", "ANATOMY", 653, 658]]], ["For example, it is clear that in patients with ARDS, the use of high tidal volumes is associated with higher mortality (215).", [["ARDS", "DISEASE", 47, 51], ["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["ARDS", "PROBLEM", 47, 51], ["high tidal volumes", "PROBLEM", 64, 82], ["clear", "OBSERVATION", 19, 24], ["ARDS", "OBSERVATION", 47, 51], ["high", "OBSERVATION_MODIFIER", 64, 68], ["tidal volumes", "OBSERVATION", 69, 82]]], ["However, patients requiring chronic ventilation for neuromuscular disease and normal lungs are routinely ventilated with large tidal volumes, e.g., 10 ml/kg or larger, yet they do not develop ALI.", [["neuromuscular", "ANATOMY", 52, 65], ["lungs", "ANATOMY", 85, 90], ["neuromuscular disease", "DISEASE", 52, 73], ["ALI", "DISEASE", 192, 195], ["patients", "ORGANISM", 9, 17], ["lungs", "ORGAN", 85, 90], ["patients", "SPECIES", 9, 17], ["chronic ventilation", "TREATMENT", 28, 47], ["neuromuscular disease", "PROBLEM", 52, 73], ["large tidal volumes", "TREATMENT", 121, 140], ["ALI", "PROBLEM", 192, 195], ["normal", "OBSERVATION", 78, 84], ["lungs", "ANATOMY", 85, 90], ["large", "OBSERVATION_MODIFIER", 121, 126], ["tidal volumes", "OBSERVATION", 127, 140], ["ALI", "OBSERVATION", 192, 195]]], ["Recent studies have demonstrated that the combination of noninjurious mechanical ventilatory strategies with small doses of LPS or bacteria that cause minimal inflammation results in the development of a form of lung injury characterized by cytokine release, neutrophilic alveolitis, and protein leakage into the air spaces, showing that mechanical ventilation and bacterial products are synergistic in causing lung injury (4, 47, 154).", [["lung", "ANATOMY", 212, 216], ["lung", "ANATOMY", 411, 415], ["LPS", "CHEMICAL", 124, 127], ["inflammation", "DISEASE", 159, 171], ["lung injury", "DISEASE", 212, 223], ["alveolitis", "DISEASE", 272, 282], ["lung injury", "DISEASE", 411, 422], ["LPS", "SIMPLE_CHEMICAL", 124, 127], ["lung", "ORGAN", 212, 216], ["lung", "ORGAN", 411, 415], ["cytokine", "PROTEIN", 241, 249], ["Recent studies", "TEST", 0, 14], ["noninjurious mechanical ventilatory strategies", "TREATMENT", 57, 103], ["LPS", "TREATMENT", 124, 127], ["bacteria", "PROBLEM", 131, 139], ["minimal inflammation", "PROBLEM", 151, 171], ["lung injury", "PROBLEM", 212, 223], ["cytokine release", "PROBLEM", 241, 257], ["neutrophilic alveolitis", "PROBLEM", 259, 282], ["protein leakage into the air spaces", "PROBLEM", 288, 323], ["mechanical ventilation", "TREATMENT", 338, 360], ["bacterial products", "TREATMENT", 365, 383], ["lung injury", "PROBLEM", 411, 422], ["small", "OBSERVATION_MODIFIER", 109, 114], ["minimal", "OBSERVATION_MODIFIER", 151, 158], ["inflammation", "OBSERVATION", 159, 171], ["lung", "ANATOMY", 212, 216], ["injury", "OBSERVATION", 217, 223], ["cytokine release", "OBSERVATION", 241, 257], ["neutrophilic", "OBSERVATION_MODIFIER", 259, 271], ["alveolitis", "OBSERVATION", 272, 282], ["protein leakage", "OBSERVATION", 288, 303], ["air spaces", "OBSERVATION", 313, 323], ["mechanical ventilation", "OBSERVATION", 338, 360], ["bacterial products", "OBSERVATION", 365, 383], ["synergistic", "OBSERVATION_MODIFIER", 388, 399], ["lung", "ANATOMY", 411, 415], ["injury", "OBSERVATION", 416, 422]]], ["The signal transduction pathways activated by mechanical stretch and innate immunity that leads to lung injury need to be clarified.Mechanical ventilation. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSTechnical issues: mechanical ventilation models are challenging, particularly in small animals like mice.", [["lung", "ANATOMY", 99, 103], ["Alveolar Epithelium", "ANATOMY", 193, 212], ["lung injury", "DISEASE", 99, 110], ["lung", "ORGAN", 99, 103], ["Alveolar Epithelium", "TISSUE", 193, 212], ["mice", "ORGANISM", 359, 363], ["mice", "SPECIES", 359, 363], ["mice", "SPECIES", 359, 363], ["The signal transduction pathways", "TREATMENT", 0, 32], ["mechanical stretch and innate immunity", "TREATMENT", 46, 84], ["lung injury", "PROBLEM", 99, 110], ["Mechanical ventilation", "TREATMENT", 132, 154], ["LUNG INJURY", "PROBLEM", 234, 245], ["mechanical ventilation models", "TREATMENT", 277, 306], ["lung", "ANATOMY", 99, 103], ["injury", "OBSERVATION", 104, 110], ["ventilation", "OBSERVATION", 143, 154], ["Alveolar Epithelium", "OBSERVATION", 193, 212], ["LUNG", "ANATOMY", 234, 238], ["INJURY", "OBSERVATION", 239, 245], ["mechanical ventilation", "OBSERVATION", 277, 299]]], ["Several variables must be taken into account, including technical issues like the method of intubation (endotracheal vs. tracheostomy), the type of ventilator, the appropriate physiological monitoring, and the amount of fluid support.", [["endotracheal", "ANATOMY", 104, 116], ["intubation (endotracheal", "TREATMENT", 92, 116], ["tracheostomy", "TREATMENT", 121, 133], ["ventilator", "TREATMENT", 148, 158], ["the appropriate physiological monitoring", "TEST", 160, 200], ["fluid support", "TREATMENT", 220, 233], ["fluid support", "OBSERVATION", 220, 233]]], ["Endotracheal intubation avoids inflammatory responses associated with tracheostomy and can be achieved with practice.", [["Endotracheal", "ANATOMY", 0, 12], ["Endotracheal intubation", "TREATMENT", 0, 23], ["inflammatory responses", "PROBLEM", 31, 53], ["tracheostomy", "TREATMENT", 70, 82], ["inflammatory", "OBSERVATION", 31, 43], ["tracheostomy", "OBSERVATION", 70, 82]]], ["The animals must be anesthetized throughout the ventilation protocol, and this may make it difficult to determine whether the mice are alive or dead unless other variables such as blood pressure, heart rate, or end-dial CO2 are monitored.", [["blood", "ANATOMY", 180, 185], ["heart", "ANATOMY", 196, 201], ["CO2", "CHEMICAL", 220, 223], ["animals", "ORGANISM", 4, 11], ["mice", "ORGANISM", 126, 130], ["blood", "ORGANISM_SUBSTANCE", 180, 185], ["heart", "ORGAN", 196, 201], ["CO2", "SIMPLE_CHEMICAL", 220, 223], ["mice", "SPECIES", 126, 130], ["mice", "SPECIES", 126, 130], ["the ventilation protocol", "TREATMENT", 44, 68], ["blood pressure", "TEST", 180, 194], ["heart rate", "TEST", 196, 206], ["end-dial CO2", "TEST", 211, 223], ["heart", "ANATOMY", 196, 201]]], ["Airway pressures should be monitored, as lung compliance can change as injury develops.", [["Airway", "ANATOMY", 0, 6], ["lung", "ANATOMY", 41, 45], ["Airway", "MULTI-TISSUE_STRUCTURE", 0, 6], ["lung", "ORGAN", 41, 45], ["Airway pressures", "TEST", 0, 16], ["injury", "PROBLEM", 71, 77], ["pressures", "OBSERVATION_MODIFIER", 7, 16], ["lung", "ANATOMY", 41, 45]]], ["Body temperature must be monitored and maintained within a narrow range because mice are extremely sensitive to temperature changes.", [["Body", "ANATOMY", 0, 4], ["Body", "ORGANISM_SUBDIVISION", 0, 4], ["mice", "ORGANISM", 80, 84], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 80, 84], ["Body temperature", "TEST", 0, 16], ["temperature changes", "PROBLEM", 112, 131]]], ["PEEP can be generated with a PEEP valve attached to the end of the ventilator.", [["PEEP", "TREATMENT", 0, 4], ["a PEEP valve", "TREATMENT", 27, 39], ["the ventilator", "TREATMENT", 63, 77]]], ["Fluids can be delivered intraperitoneally either by injection or using an infusion pump.", [["Fluids", "SIMPLE_CHEMICAL", 0, 6], ["Fluids", "TREATMENT", 0, 6], ["an infusion pump", "TREATMENT", 71, 87]]], ["With adequate monitoring and support, mice can be ventilated for 8 h or longer (47).Mechanical ventilation. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSCharacteristics of the lung injury: the severity of lung injury depends on the ventilatory strategy, in particular the tidal volume delivered and the presence or absence of PEEP.", [["Alveolar Epithelium", "ANATOMY", 145, 164], ["lung", "ANATOMY", 234, 238], ["lung", "ANATOMY", 263, 267], ["lung injury", "DISEASE", 234, 245], ["lung injury", "DISEASE", 263, 274], ["mice", "ORGANISM", 38, 42], ["Alveolar Epithelium", "TISSUE", 145, 164], ["lung", "ORGAN", 234, 238], ["lung", "ORGAN", 263, 267], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 38, 42], ["support", "TREATMENT", 29, 36], ["Mechanical ventilation", "TREATMENT", 84, 106], ["LUNG INJURY", "PROBLEM", 186, 197], ["the lung injury", "PROBLEM", 230, 245], ["lung injury", "PROBLEM", 263, 274], ["the ventilatory strategy", "TREATMENT", 286, 310], ["the tidal volume", "TEST", 326, 342], ["PEEP", "TREATMENT", 384, 388], ["ventilation", "OBSERVATION", 95, 106], ["Alveolar", "ANATOMY_MODIFIER", 145, 153], ["Epithelium", "ANATOMY_MODIFIER", 154, 164], ["LUNG", "ANATOMY", 186, 190], ["INJURY", "OBSERVATION", 191, 197], ["MODEL SYSTEMSCharacteristics", "OBSERVATION", 198, 226], ["lung", "ANATOMY", 234, 238], ["injury", "OBSERVATION", 239, 245], ["lung", "ANATOMY", 263, 267], ["injury", "OBSERVATION", 268, 274], ["tidal volume", "OBSERVATION", 330, 342]]], ["Large tidal volume ventilation results in alveolar hemorrhage, hyaline membrane formation, neutrophilic infiltration, decreased compliance, and gas-exchange abnormalities (Fig. 3, E and F).", [["alveolar", "ANATOMY", 42, 50], ["hyaline membrane", "ANATOMY", 63, 79], ["neutrophilic", "ANATOMY", 91, 103], ["hemorrhage", "DISEASE", 51, 61], ["alveolar", "MULTI-TISSUE_STRUCTURE", 42, 50], ["hyaline membrane", "CELLULAR_COMPONENT", 63, 79], ["Large tidal volume ventilation", "TREATMENT", 0, 30], ["alveolar hemorrhage", "PROBLEM", 42, 61], ["hyaline membrane formation", "PROBLEM", 63, 89], ["neutrophilic infiltration", "PROBLEM", 91, 116], ["gas-exchange abnormalities", "PROBLEM", 144, 170], ["tidal", "OBSERVATION", 6, 11], ["volume ventilation", "OBSERVATION", 12, 30], ["alveolar", "ANATOMY", 42, 50], ["hemorrhage", "OBSERVATION", 51, 61], ["hyaline membrane formation", "OBSERVATION", 63, 89], ["neutrophilic infiltration", "OBSERVATION", 91, 116], ["decreased", "OBSERVATION_MODIFIER", 118, 127], ["compliance", "OBSERVATION_MODIFIER", 128, 138]]], ["Mechanical ventilation at tidal volumes of 10 ml/kg and FiO2 = 0.21 is not injurious, but mechanical ventilation combined with low doses of LPS has a synergistic effect, resulting in neutrophilic alveolitis and increased alveolar permeability (3).Mechanical ventilation. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSAdvantages and disadvantages: the main advantage of the mechanical ventilation model is its clinical relevance, which is highlighted by the fact that this is the only model that has led to changes in clinical practice.", [["neutrophilic", "ANATOMY", 183, 195], ["alveolar", "ANATOMY", 221, 229], ["Alveolar Epithelium", "ANATOMY", 308, 327], ["LPS", "CHEMICAL", 140, 143], ["alveolitis", "DISEASE", 196, 206], ["LPS", "SIMPLE_CHEMICAL", 140, 143], ["alveolar", "TISSUE", 221, 229], ["Alveolar Epithelium", "TISSUE", 308, 327], ["Mechanical ventilation", "TREATMENT", 0, 22], ["tidal volumes", "TEST", 26, 39], ["FiO2", "TEST", 56, 60], ["injurious", "PROBLEM", 75, 84], ["mechanical ventilation", "TREATMENT", 90, 112], ["low doses of LPS", "TREATMENT", 127, 143], ["a synergistic effect", "PROBLEM", 148, 168], ["neutrophilic alveolitis", "PROBLEM", 183, 206], ["increased alveolar permeability", "PROBLEM", 211, 242], ["Mechanical ventilation", "TREATMENT", 247, 269], ["LUNG INJURY", "PROBLEM", 349, 360], ["the mechanical ventilation model", "TREATMENT", 426, 458], ["ventilation", "OBSERVATION", 11, 22], ["not", "UNCERTAINTY", 71, 74], ["injurious", "OBSERVATION", 75, 84], ["mechanical ventilation", "OBSERVATION", 90, 112], ["neutrophilic", "OBSERVATION_MODIFIER", 183, 195], ["alveolitis", "OBSERVATION", 196, 206], ["increased", "OBSERVATION_MODIFIER", 211, 220], ["alveolar permeability", "OBSERVATION", 221, 242], ["ventilation", "OBSERVATION", 258, 269], ["Alveolar", "ANATOMY_MODIFIER", 308, 316], ["Epithelium", "ANATOMY_MODIFIER", 317, 327], ["LUNG", "ANATOMY", 349, 353], ["INJURY", "OBSERVATION", 354, 360], ["mechanical ventilation", "OBSERVATION", 430, 452]]], ["The main disadvantage is the complexity of the model.", [["main", "OBSERVATION_MODIFIER", 4, 8], ["disadvantage", "OBSERVATION_MODIFIER", 9, 21]]], ["Furthermore, animals such as mice can only be ventilated for relatively short periods of time, whereas patients require mechanical ventilation for days or weeks.Intratracheal bleomycin. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSThe bleomycin model is usually considered a model of pulmonary fibrosis, but its administration is also associated with features of ALI, and thus we will briefly review it here.", [["Alveolar Epithelium", "ANATOMY", 223, 242], ["pulmonary", "ANATOMY", 342, 351], ["bleomycin", "CHEMICAL", 175, 184], ["bleomycin", "CHEMICAL", 293, 302], ["pulmonary fibrosis", "DISEASE", 342, 360], ["ALI", "DISEASE", 421, 424], ["bleomycin", "CHEMICAL", 175, 184], ["bleomycin", "CHEMICAL", 293, 302], ["mice", "ORGANISM", 29, 33], ["patients", "ORGANISM", 103, 111], ["bleomycin", "SIMPLE_CHEMICAL", 175, 184], ["Alveolar Epithelium", "TISSUE", 223, 242], ["bleomycin", "SIMPLE_CHEMICAL", 293, 302], ["pulmonary", "ORGAN", 342, 351], ["mice", "SPECIES", 29, 33], ["patients", "SPECIES", 103, 111], ["mice", "SPECIES", 29, 33], ["mechanical ventilation", "TREATMENT", 120, 142], ["Intratracheal bleomycin", "TREATMENT", 161, 184], ["LUNG INJURY", "PROBLEM", 264, 275], ["The bleomycin model", "TREATMENT", 289, 308], ["pulmonary fibrosis", "PROBLEM", 342, 360], ["ALI", "PROBLEM", 421, 424], ["bleomycin", "OBSERVATION", 175, 184], ["Alveolar Epithelium", "OBSERVATION", 223, 242], ["LUNG", "ANATOMY", 264, 268], ["INJURY", "OBSERVATION", 269, 275], ["bleomycin", "OBSERVATION", 293, 302], ["pulmonary", "ANATOMY", 342, 351], ["fibrosis", "OBSERVATION", 352, 360], ["ALI", "OBSERVATION", 421, 424]]], ["The bleomycin model has been reviewed in more detail elsewhere in this series (143).", [["bleomycin", "CHEMICAL", 4, 13], ["bleomycin", "CHEMICAL", 4, 13], ["bleomycin", "SIMPLE_CHEMICAL", 4, 13], ["The bleomycin model", "TREATMENT", 0, 19], ["bleomycin", "OBSERVATION", 4, 13]]], ["Bleomycin is an antineoplastic antibiotic drug isolated in 1966 from the actinomycete Streptomyces verticillus (222).", [["antineoplastic", "ANATOMY", 16, 30], ["Bleomycin", "CHEMICAL", 0, 9], ["Bleomycin", "CHEMICAL", 0, 9], ["Bleomycin", "SIMPLE_CHEMICAL", 0, 9], ["Streptomyces verticillus", "ORGANISM", 86, 110], ["Streptomyces verticillus", "SPECIES", 86, 110], ["Streptomyces verticillus", "SPECIES", 86, 110], ["Bleomycin", "TREATMENT", 0, 9], ["an antineoplastic antibiotic drug", "TREATMENT", 13, 46], ["the actinomycete Streptomyces verticillus", "TEST", 69, 110]]], ["Bleomycin forms a complex with oxygen and metals such as Fe2+, leading to the production of oxygen radicals, DNA breaks, and ultimately cell death (26).", [["cell", "ANATOMY", 136, 140], ["Bleomycin", "CHEMICAL", 0, 9], ["oxygen", "CHEMICAL", 31, 37], ["Fe2", "CHEMICAL", 57, 60], ["oxygen", "CHEMICAL", 92, 98], ["death", "DISEASE", 141, 146], ["Bleomycin", "CHEMICAL", 0, 9], ["oxygen", "CHEMICAL", 31, 37], ["Fe2+", "CHEMICAL", 57, 61], ["oxygen", "CHEMICAL", 92, 98], ["Bleomycin", "SIMPLE_CHEMICAL", 0, 9], ["oxygen", "SIMPLE_CHEMICAL", 31, 37], ["metals", "SIMPLE_CHEMICAL", 42, 48], ["Fe2+", "SIMPLE_CHEMICAL", 57, 61], ["oxygen radicals", "SIMPLE_CHEMICAL", 92, 107], ["DNA", "CELLULAR_COMPONENT", 109, 112], ["cell", "CELL", 136, 140], ["Bleomycin", "TREATMENT", 0, 9], ["oxygen and metals", "TREATMENT", 31, 48], ["oxygen radicals", "TREATMENT", 92, 107], ["DNA breaks", "PROBLEM", 109, 119], ["ultimately cell death", "PROBLEM", 125, 146], ["complex", "OBSERVATION_MODIFIER", 18, 25], ["oxygen radicals", "OBSERVATION", 92, 107]]], ["Bleomycin can be inactivated by bleomycin hydrolase, a cysteine protease that shows variable levels of expression in the lungs (194).", [["lungs", "ANATOMY", 121, 126], ["Bleomycin", "CHEMICAL", 0, 9], ["bleomycin", "CHEMICAL", 32, 41], ["Bleomycin", "CHEMICAL", 0, 9], ["bleomycin", "CHEMICAL", 32, 41], ["cysteine", "CHEMICAL", 55, 63], ["Bleomycin", "SIMPLE_CHEMICAL", 0, 9], ["bleomycin hydrolase", "SIMPLE_CHEMICAL", 32, 51], ["lungs", "ORGAN", 121, 126], ["bleomycin hydrolase", "PROTEIN", 32, 51], ["cysteine protease", "PROTEIN", 55, 72], ["Bleomycin", "TREATMENT", 0, 9], ["bleomycin hydrolase", "TREATMENT", 32, 51], ["a cysteine protease", "TREATMENT", 53, 72], ["variable levels of expression in the lungs", "PROBLEM", 84, 126], ["variable", "OBSERVATION_MODIFIER", 84, 92], ["levels", "OBSERVATION_MODIFIER", 93, 99], ["lungs", "ANATOMY", 121, 126]]], ["The susceptibility of the lungs to bleomycin-induced toxicity is largely dependent on the levels of expression of bleomycin hydrolase in the lungs; species with high levels of expression, such as rabbits, are relatively resistant to bleomycin-induced toxicity, whereas species with low levels of expression, such as C57BL/6 mice, are sensitive (126).", [["lungs", "ANATOMY", 26, 31], ["lungs", "ANATOMY", 141, 146], ["bleomycin", "CHEMICAL", 35, 44], ["toxicity", "DISEASE", 53, 61], ["bleomycin", "CHEMICAL", 114, 123], ["bleomycin", "CHEMICAL", 233, 242], ["toxicity", "DISEASE", 251, 259], ["bleomycin", "CHEMICAL", 35, 44], ["bleomycin", "CHEMICAL", 114, 123], ["bleomycin", "CHEMICAL", 233, 242], ["lungs", "ORGAN", 26, 31], ["bleomycin", "SIMPLE_CHEMICAL", 35, 44], ["bleomycin hydrolase", "GENE_OR_GENE_PRODUCT", 114, 133], ["lungs", "ORGAN", 141, 146], ["rabbits", "ORGANISM", 196, 203], ["bleomycin", "SIMPLE_CHEMICAL", 233, 242], ["C57BL/6 mice", "ORGANISM", 316, 328], ["bleomycin hydrolase", "PROTEIN", 114, 133], ["rabbits", "SPECIES", 196, 203], ["mice", "SPECIES", 324, 328], ["rabbits", "SPECIES", 196, 203], ["mice", "SPECIES", 324, 328], ["bleomycin", "TREATMENT", 35, 44], ["induced toxicity", "PROBLEM", 45, 61], ["bleomycin hydrolase in the lungs", "PROBLEM", 114, 146], ["bleomycin-induced toxicity", "PROBLEM", 233, 259], ["lungs", "ANATOMY", 26, 31], ["bleomycin", "OBSERVATION", 35, 44], ["dependent", "OBSERVATION_MODIFIER", 73, 82], ["bleomycin hydrolase", "OBSERVATION", 114, 133], ["lungs", "ANATOMY", 141, 146], ["high levels", "OBSERVATION_MODIFIER", 161, 172], ["low levels", "OBSERVATION_MODIFIER", 282, 292]]], ["In addition to species-related differences in bleomycin susceptibility, there are also differences in strain susceptibility, with C57BL/6 mice being highly sensitive and Balb/c and C3H mice being resistant; however, the differences in strain susceptibility to bleomycin appear to be related more to differential expression of genes involved in apoptosis regulation or oxidative stress than to differences in the expression of bleomycin reductase (87).Intratracheal bleomycin. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSBleomycin can be administered intravenously, intratracheally, intraperitoneally, or subcutaneously (143).", [["Alveolar Epithelium", "ANATOMY", 513, 532], ["intravenously", "ANATOMY", 609, 622], ["intratracheally", "ANATOMY", 624, 639], ["intraperitoneally", "ANATOMY", 641, 658], ["subcutaneously", "ANATOMY", 663, 677], ["bleomycin", "CHEMICAL", 46, 55], ["bleomycin", "CHEMICAL", 260, 269], ["bleomycin", "CHEMICAL", 426, 435], ["bleomycin", "CHEMICAL", 465, 474], ["SYSTEMSBleomycin", "CHEMICAL", 572, 588], ["bleomycin", "CHEMICAL", 46, 55], ["bleomycin", "CHEMICAL", 260, 269], ["bleomycin", "CHEMICAL", 426, 435], ["bleomycin", "CHEMICAL", 465, 474], ["bleomycin", "SIMPLE_CHEMICAL", 46, 55], ["C57BL/6 mice", "ORGANISM", 130, 142], ["Balb/c and C3H mice", "ORGANISM", 170, 189], ["bleomycin", "SIMPLE_CHEMICAL", 260, 269], ["bleomycin reductase", "GENE_OR_GENE_PRODUCT", 426, 445], ["bleomycin", "SIMPLE_CHEMICAL", 465, 474], ["Alveolar Epithelium", "TISSUE", 513, 532], ["SYSTEMSBleomycin", "SIMPLE_CHEMICAL", 572, 588], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 609, 622], ["bleomycin reductase", "PROTEIN", 426, 445], ["mice", "SPECIES", 138, 142], ["mice", "SPECIES", 185, 189], ["mice", "SPECIES", 138, 142], ["mice", "SPECIES", 185, 189], ["species", "PROBLEM", 15, 22], ["bleomycin susceptibility", "PROBLEM", 46, 70], ["strain susceptibility", "TEST", 102, 123], ["C57BL/6 mice", "TREATMENT", 130, 142], ["Balb/c", "TEST", 170, 176], ["strain susceptibility to bleomycin", "PROBLEM", 235, 269], ["apoptosis regulation", "PROBLEM", 344, 364], ["oxidative stress", "PROBLEM", 368, 384], ["bleomycin reductase", "TEST", 426, 445], ["Intratracheal bleomycin", "TREATMENT", 451, 474], ["LUNG INJURY", "PROBLEM", 554, 565], ["MODEL SYSTEMSBleomycin", "TREATMENT", 566, 588], ["bleomycin susceptibility", "OBSERVATION", 46, 70], ["strain susceptibility", "OBSERVATION", 102, 123], ["resistant", "OBSERVATION_MODIFIER", 196, 205], ["oxidative stress", "OBSERVATION", 368, 384], ["bleomycin", "OBSERVATION", 465, 474], ["Alveolar Epithelium", "OBSERVATION", 513, 532], ["LUNG", "ANATOMY", 554, 558], ["INJURY", "OBSERVATION", 559, 565]]], ["The intravenous model mimics the human clinical scenario but requires the administration of the drug twice per week for 4\u20138 wk (1).", [["intravenous", "ANATOMY", 4, 15], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 4, 15], ["human", "ORGANISM", 33, 38], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 33, 38]]], ["In contrast, the intratracheal model requires the administration of one single dose of bleomycin (143).", [["bleomycin", "CHEMICAL", 87, 96], ["bleomycin", "CHEMICAL", 87, 96], ["bleomycin", "SIMPLE_CHEMICAL", 87, 96], ["bleomycin", "TREATMENT", 87, 96], ["intratracheal", "ANATOMY", 17, 30]]], ["It is important to emphasize that although both models result in lung injury and fibrosis, the site of initial injury is different: the endothelium is the primary target of intravenous bleomycin, and the epithelium is the primary target of intratracheal bleomycin.", [["lung", "ANATOMY", 65, 69], ["endothelium", "ANATOMY", 136, 147], ["intravenous", "ANATOMY", 173, 184], ["epithelium", "ANATOMY", 204, 214], ["intratracheal", "ANATOMY", 240, 253], ["lung injury", "DISEASE", 65, 76], ["fibrosis", "DISEASE", 81, 89], ["bleomycin", "CHEMICAL", 185, 194], ["bleomycin", "CHEMICAL", 254, 263], ["bleomycin", "CHEMICAL", 185, 194], ["bleomycin", "CHEMICAL", 254, 263], ["lung", "ORGAN", 65, 69], ["endothelium", "TISSUE", 136, 147], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 173, 184], ["bleomycin", "SIMPLE_CHEMICAL", 185, 194], ["epithelium", "TISSUE", 204, 214], ["bleomycin", "SIMPLE_CHEMICAL", 254, 263], ["lung injury", "PROBLEM", 65, 76], ["fibrosis", "PROBLEM", 81, 89], ["initial injury", "PROBLEM", 103, 117], ["intravenous bleomycin", "TREATMENT", 173, 194], ["intratracheal bleomycin", "TREATMENT", 240, 263], ["lung", "ANATOMY", 65, 69], ["injury", "OBSERVATION", 70, 76], ["fibrosis", "OBSERVATION", 81, 89], ["injury", "OBSERVATION", 111, 117], ["endothelium", "ANATOMY", 136, 147], ["intratracheal bleomycin", "OBSERVATION", 240, 263]]], ["The dose response and pathological changes of the lung to intravenous bleomycin were first described in 1974, and we refer readers to the original Adamson and Bowden report (1).", [["lung", "ANATOMY", 50, 54], ["intravenous", "ANATOMY", 58, 69], ["bleomycin", "CHEMICAL", 70, 79], ["bleomycin", "CHEMICAL", 70, 79], ["lung", "ORGAN", 50, 54], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 58, 69], ["bleomycin", "SIMPLE_CHEMICAL", 70, 79], ["pathological changes", "PROBLEM", 22, 42], ["intravenous bleomycin", "TREATMENT", 58, 79], ["lung", "ANATOMY", 50, 54]]], ["Here we will focus on the intratracheal model, which is the most widely used due to its lower complexity and high reproducibility.Intratracheal bleomycin. ::: Models That Target Primarily the Alveolar Epithelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSThe administration of intratracheal bleomycin is followed by a well-described sequence of events.", [["Alveolar Epithelium", "ANATOMY", 192, 211], ["bleomycin", "CHEMICAL", 144, 153], ["bleomycin", "CHEMICAL", 294, 303], ["bleomycin", "CHEMICAL", 144, 153], ["bleomycin", "CHEMICAL", 294, 303], ["bleomycin", "SIMPLE_CHEMICAL", 144, 153], ["Alveolar Epithelium", "TISSUE", 192, 211], ["bleomycin", "SIMPLE_CHEMICAL", 294, 303], ["the intratracheal model", "TREATMENT", 22, 45], ["Intratracheal bleomycin", "TREATMENT", 130, 153], ["LUNG INJURY", "PROBLEM", 233, 244], ["intratracheal bleomycin", "TREATMENT", 280, 303], ["intratracheal model", "ANATOMY", 26, 45], ["high reproducibility", "OBSERVATION", 109, 129], ["bleomycin", "OBSERVATION", 144, 153], ["Alveolar Epithelium", "OBSERVATION", 192, 211], ["LUNG", "ANATOMY", 233, 237], ["INJURY", "OBSERVATION", 238, 244], ["intratracheal", "ANATOMY", 280, 293], ["bleomycin", "OBSERVATION", 294, 303]]], ["Within 24 h of bleomycin administration, there is an increase in BAL neutrophils, which then normalize towards day 11.", [["BAL neutrophils", "ANATOMY", 65, 80], ["bleomycin", "CHEMICAL", 15, 24], ["bleomycin", "CHEMICAL", 15, 24], ["bleomycin", "SIMPLE_CHEMICAL", 15, 24], ["BAL neutrophils", "CELL", 65, 80], ["BAL neutrophils", "CELL_TYPE", 65, 80], ["bleomycin administration", "TREATMENT", 15, 39], ["an increase in BAL neutrophils", "PROBLEM", 50, 80], ["increase", "OBSERVATION_MODIFIER", 53, 61], ["BAL neutrophils", "OBSERVATION", 65, 80]]], ["The lymphocytic response follows, beginning around day 7 and persisting on day 11.", [["lymphocytic", "ANATOMY", 4, 15], ["lymphocytic", "OBSERVATION", 4, 15]]], ["The fibrotic response becomes detectable in tissues by day 11 and persists by day 20.", [["tissues", "ANATOMY", 44, 51], ["tissues", "TISSUE", 44, 51], ["The fibrotic response", "PROBLEM", 0, 21], ["fibrotic", "OBSERVATION", 4, 12], ["detectable", "OBSERVATION_MODIFIER", 30, 40]]], ["As for cytokines, IL-1\u03b2, KC, IL-6, TNF, and IL-1R1 peak between 6 and 63 h, TGF-\u03b2 R1 and R2 peak towards day 7, and G-CF, GM-CSF, IFN-\u03b3, and IL-4 peak towards day 14 (28, 76, 180, 246).", [["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 18, 23], ["KC", "GENE_OR_GENE_PRODUCT", 25, 27], ["IL-6", "GENE_OR_GENE_PRODUCT", 29, 33], ["TNF", "GENE_OR_GENE_PRODUCT", 35, 38], ["IL-1R1", "GENE_OR_GENE_PRODUCT", 44, 50], ["TGF-\u03b2 R1", "GENE_OR_GENE_PRODUCT", 76, 84], ["G-CF", "GENE_OR_GENE_PRODUCT", 116, 120], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 122, 128], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 130, 135], ["IL-4", "GENE_OR_GENE_PRODUCT", 141, 145], ["cytokines", "PROTEIN", 7, 16], ["KC", "PROTEIN", 25, 27], ["TNF", "PROTEIN", 35, 38], ["TGF", "PROTEIN", 76, 79], ["GM", "PROTEIN", 122, 124], ["CSF", "PROTEIN", 125, 128], ["IFN", "PROTEIN", 130, 133], ["IL", "PROTEIN", 141, 143], ["cytokines", "TEST", 7, 16], ["IL", "TEST", 18, 20], ["KC", "TEST", 25, 27], ["IL", "TEST", 29, 31], ["TNF", "TEST", 35, 38], ["IL", "TEST", 44, 46], ["TGF", "TEST", 76, 79], ["G", "TEST", 116, 117], ["CF", "TEST", 118, 120], ["GM", "TEST", 122, 124], ["CSF", "TEST", 125, 128], ["IFN", "TEST", 130, 133], ["\u03b3", "TEST", 134, 135], ["IL", "TEST", 141, 143], ["CSF", "ANATOMY", 125, 128]]], ["At the tissue level, the early phase is characterized by patchy neutrophilic alveolitis and the late phase by patchy areas of fibrosis, but there is no formation of hyaline membranes (Fig. 3, G and H).", [["tissue", "ANATOMY", 7, 13], ["hyaline membranes", "ANATOMY", 165, 182], ["alveolitis", "DISEASE", 77, 87], ["fibrosis", "DISEASE", 126, 134], ["3, G and H", "CHEMICAL", 189, 199], ["tissue", "TISSUE", 7, 13], ["hyaline membranes", "CELLULAR_COMPONENT", 165, 182], ["patchy neutrophilic alveolitis", "PROBLEM", 57, 87], ["patchy areas of fibrosis", "PROBLEM", 110, 134], ["hyaline membranes", "PROBLEM", 165, 182], ["early phase", "OBSERVATION_MODIFIER", 25, 36], ["patchy", "OBSERVATION_MODIFIER", 57, 63], ["neutrophilic", "OBSERVATION_MODIFIER", 64, 76], ["alveolitis", "OBSERVATION", 77, 87], ["late phase", "OBSERVATION_MODIFIER", 96, 106], ["patchy", "OBSERVATION_MODIFIER", 110, 116], ["areas", "OBSERVATION_MODIFIER", 117, 122], ["fibrosis", "OBSERVATION", 126, 134], ["no formation", "UNCERTAINTY", 149, 161], ["hyaline membranes", "OBSERVATION", 165, 182]]], ["The extent of fibrosis is proportional to the severity of the initial injury (197).", [["fibrosis", "DISEASE", 14, 22], ["fibrosis", "PROBLEM", 14, 22], ["the initial injury", "PROBLEM", 58, 76], ["extent", "OBSERVATION_MODIFIER", 4, 10], ["fibrosis", "OBSERVATION", 14, 22], ["proportional", "OBSERVATION_MODIFIER", 26, 38], ["severity", "OBSERVATION_MODIFIER", 46, 54], ["initial", "OBSERVATION_MODIFIER", 62, 69], ["injury", "OBSERVATION", 70, 76]]], ["Thus, the bleomycin model is relatively technically easy, very reproducible, well standardized, and reproduces the pattern of ALI, with early inflammation that heals with fibrosis.", [["bleomycin", "CHEMICAL", 10, 19], ["ALI", "DISEASE", 126, 129], ["inflammation", "DISEASE", 142, 154], ["fibrosis", "DISEASE", 171, 179], ["bleomycin", "CHEMICAL", 10, 19], ["bleomycin", "SIMPLE_CHEMICAL", 10, 19], ["the bleomycin model", "TREATMENT", 6, 25], ["ALI", "PROBLEM", 126, 129], ["early inflammation", "PROBLEM", 136, 154], ["fibrosis", "PROBLEM", 171, 179], ["bleomycin", "OBSERVATION", 10, 19], ["ALI", "OBSERVATION", 126, 129], ["early", "OBSERVATION_MODIFIER", 136, 141], ["inflammation", "OBSERVATION", 142, 154], ["heals", "OBSERVATION_MODIFIER", 160, 165], ["fibrosis", "OBSERVATION", 171, 179]]], ["The main disadvantage is that the physiological relevance of bleomycin is often questioned, with the argument that intratracheal instillation of bleomycin is an \u201coverwhelming stimulus\u201d that bears little relevance to the clinical setting.", [["intratracheal", "ANATOMY", 115, 128], ["bleomycin", "CHEMICAL", 61, 70], ["bleomycin", "CHEMICAL", 145, 154], ["bleomycin", "CHEMICAL", 61, 70], ["bleomycin", "CHEMICAL", 145, 154], ["bleomycin", "SIMPLE_CHEMICAL", 61, 70], ["intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 115, 128], ["bleomycin", "SIMPLE_CHEMICAL", 145, 154], ["bleomycin", "TREATMENT", 61, 70], ["intratracheal instillation of bleomycin", "TREATMENT", 115, 154], ["main", "OBSERVATION_MODIFIER", 4, 8], ["disadvantage", "OBSERVATION_MODIFIER", 9, 21], ["bleomycin", "OBSERVATION", 61, 70]]], ["Despite these caveats, the bleomycin model remains one of the most commonly used models of ALI in mice.Ischemia/reperfusion models. ::: Models Targeting the Epithelium and Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSIschemia followed by reperfusion (I/R), either in the lungs or in distant vascular beds, can lead to lung injury.", [["Epithelium", "ANATOMY", 157, 167], ["lungs", "ANATOMY", 284, 289], ["vascular", "ANATOMY", 304, 312], ["lung", "ANATOMY", 331, 335], ["bleomycin", "CHEMICAL", 27, 36], ["ALI", "DISEASE", 91, 94], ["Ischemia", "DISEASE", 103, 111], ["SYSTEMSIschemia", "DISEASE", 223, 238], ["lung injury", "DISEASE", 331, 342], ["bleomycin", "CHEMICAL", 27, 36], ["bleomycin", "SIMPLE_CHEMICAL", 27, 36], ["mice", "ORGANISM", 98, 102], ["Epithelium", "TISSUE", 157, 167], ["Endothelium", "TISSUE", 172, 183], ["lungs", "ORGAN", 284, 289], ["vascular", "MULTI-TISSUE_STRUCTURE", 304, 312], ["lung", "ORGAN", 331, 335], ["mice", "SPECIES", 98, 102], ["mice", "SPECIES", 98, 102], ["the bleomycin model", "TREATMENT", 23, 42], ["Ischemia", "PROBLEM", 103, 111], ["reperfusion models", "PROBLEM", 112, 130], ["LUNG INJURY", "PROBLEM", 205, 216], ["MODEL SYSTEMSIschemia", "PROBLEM", 217, 238], ["reperfusion (I/R)", "PROBLEM", 251, 268], ["lung injury", "PROBLEM", 331, 342], ["bleomycin", "OBSERVATION", 27, 36], ["ALI", "OBSERVATION", 91, 94], ["reperfusion models", "OBSERVATION", 112, 130], ["Epithelium", "ANATOMY_MODIFIER", 157, 167], ["LUNG", "ANATOMY", 205, 209], ["INJURY", "OBSERVATION", 210, 216], ["MODEL SYSTEMSIschemia", "OBSERVATION", 217, 238], ["reperfusion", "OBSERVATION", 251, 262], ["lungs", "ANATOMY", 284, 289], ["distant", "ANATOMY_MODIFIER", 296, 303], ["vascular beds", "ANATOMY", 304, 317], ["lung", "ANATOMY", 331, 335], ["injury", "OBSERVATION", 336, 342]]], ["A classic form of injury secondary to lung I/R is the \u201creimplantation response,\u201d a form of lung injury following lung transplantation.", [["lung", "ANATOMY", 38, 42], ["lung", "ANATOMY", 91, 95], ["lung", "ANATOMY", 113, 117], ["lung injury", "DISEASE", 91, 102], ["lung", "ORGAN", 38, 42], ["lung", "ORGAN", 91, 95], ["lung", "ORGAN", 113, 117], ["injury", "PROBLEM", 18, 24], ["lung I/R", "PROBLEM", 38, 46], ["the \u201creimplantation", "TREATMENT", 50, 69], ["lung injury", "PROBLEM", 91, 102], ["lung transplantation", "TREATMENT", 113, 133], ["injury", "OBSERVATION", 18, 24], ["lung", "ANATOMY", 38, 42], ["reimplantation", "OBSERVATION", 55, 69], ["lung", "ANATOMY", 91, 95], ["injury", "OBSERVATION", 96, 102], ["lung", "ANATOMY", 113, 117], ["transplantation", "OBSERVATION", 118, 133]]], ["The reimplantation response is characterized by non-cardiogenic pulmonary edema, inflammatory infiltrates, and hypoxia, and is unrelated to rejection (167, 199).", [["pulmonary", "ANATOMY", 64, 73], ["pulmonary edema", "DISEASE", 64, 79], ["hypoxia", "DISEASE", 111, 118], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 64, 79], ["The reimplantation", "TREATMENT", 0, 18], ["non-cardiogenic pulmonary edema", "PROBLEM", 48, 79], ["inflammatory infiltrates", "PROBLEM", 81, 105], ["hypoxia", "PROBLEM", 111, 118], ["rejection", "PROBLEM", 140, 149], ["reimplantation", "OBSERVATION", 4, 18], ["non-cardiogenic", "OBSERVATION_MODIFIER", 48, 63], ["pulmonary", "ANATOMY", 64, 73], ["edema", "OBSERVATION", 74, 79], ["inflammatory", "OBSERVATION_MODIFIER", 81, 93], ["infiltrates", "OBSERVATION", 94, 105], ["hypoxia", "OBSERVATION", 111, 118], ["rejection", "OBSERVATION", 140, 149]]], ["Lung injury is also associated with ischemia/reperfusion at distant, nonpulmonary sites.", [["Lung", "ANATOMY", 0, 4], ["nonpulmonary sites", "ANATOMY", 69, 87], ["Lung injury", "DISEASE", 0, 11], ["ischemia", "DISEASE", 36, 44], ["Lung", "ORGAN", 0, 4], ["nonpulmonary sites", "MULTI-TISSUE_STRUCTURE", 69, 87], ["Lung injury", "PROBLEM", 0, 11], ["ischemia", "PROBLEM", 36, 44], ["reperfusion at distant, nonpulmonary sites", "PROBLEM", 45, 87], ["injury", "OBSERVATION", 5, 11], ["also associated with", "UNCERTAINTY", 15, 35], ["ischemia", "OBSERVATION", 36, 44], ["reperfusion", "OBSERVATION", 45, 56], ["distant", "OBSERVATION_MODIFIER", 60, 67], ["nonpulmonary", "ANATOMY", 69, 81]]], ["For example, a 20\u201340% incidence of ALI has been reported following repair of thoracoabdominal aortic aneurysms, which involves visceral ischemia and reperfusion (237).", [["thoracoabdominal aortic aneurysms", "ANATOMY", 77, 110], ["visceral", "ANATOMY", 127, 135], ["ALI", "DISEASE", 35, 38], ["thoracoabdominal aortic aneurysms", "DISEASE", 77, 110], ["visceral ischemia", "DISEASE", 127, 144], ["thoracoabdominal aortic", "MULTI-TISSUE_STRUCTURE", 77, 100], ["visceral", "ORGANISM_SUBDIVISION", 127, 135], ["ALI", "PROBLEM", 35, 38], ["repair", "TREATMENT", 67, 73], ["thoracoabdominal aortic aneurysms", "PROBLEM", 77, 110], ["visceral ischemia", "PROBLEM", 127, 144], ["ALI", "OBSERVATION", 35, 38], ["thoracoabdominal aortic", "ANATOMY", 77, 100], ["aneurysms", "OBSERVATION", 101, 110], ["visceral", "ANATOMY", 127, 135], ["ischemia", "OBSERVATION", 136, 144], ["reperfusion", "OBSERVATION_MODIFIER", 149, 160]]], ["This type of injury affects the alveolar epithelium and the capillary endothelium.", [["alveolar epithelium", "ANATOMY", 32, 51], ["capillary endothelium", "ANATOMY", 60, 81], ["alveolar epithelium", "TISSUE", 32, 51], ["capillary endothelium", "TISSUE", 60, 81], ["injury", "PROBLEM", 13, 19], ["injury", "OBSERVATION", 13, 19], ["alveolar", "ANATOMY_MODIFIER", 32, 40], ["epithelium", "ANATOMY_MODIFIER", 41, 51], ["capillary endothelium", "ANATOMY", 60, 81]]], ["It is unclear whether the epithelium and the endothelium are both injured simultaneously or whether the injury occurs primarily in endothelial or epithelial cells.", [["epithelium", "ANATOMY", 26, 36], ["endothelium", "ANATOMY", 45, 56], ["endothelial", "ANATOMY", 131, 142], ["epithelial cells", "ANATOMY", 146, 162], ["epithelium", "TISSUE", 26, 36], ["endothelium", "TISSUE", 45, 56], ["endothelial", "CELL", 131, 142], ["epithelial cells", "CELL", 146, 162], ["endothelial or epithelial cells", "CELL_TYPE", 131, 162], ["the injury", "PROBLEM", 100, 110], ["epithelial cells", "PROBLEM", 146, 162], ["unclear whether", "UNCERTAINTY", 6, 21], ["epithelium", "ANATOMY_MODIFIER", 26, 36], ["endothelium", "ANATOMY", 45, 56], ["injury", "OBSERVATION", 104, 110], ["endothelial", "ANATOMY", 131, 142], ["epithelial cells", "OBSERVATION", 146, 162]]], ["Studies in humans and rabbits show that both types of cells have features compatible with apoptosis and necrosis (59, 186, 208).Ischemia/reperfusion models. ::: Models Targeting the Epithelium and Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSPulmonary models of ischemia reperfusion: in pulmonary models of I/R, the lung is subjected to ischemia for varying periods of time before circulation is reestablished.", [["cells", "ANATOMY", 54, 59], ["Epithelium", "ANATOMY", 182, 192], ["pulmonary", "ANATOMY", 300, 309], ["lung", "ANATOMY", 329, 333], ["necrosis", "DISEASE", 104, 112], ["Ischemia", "DISEASE", 128, 136], ["ischemia", "DISEASE", 275, 283], ["ischemia", "DISEASE", 350, 358], ["humans", "ORGANISM", 11, 17], ["rabbits", "ORGANISM", 22, 29], ["cells", "CELL", 54, 59], ["Epithelium", "TISSUE", 182, 192], ["Endothelium", "TISSUE", 197, 208], ["pulmonary", "ORGAN", 300, 309], ["I/R", "GENE_OR_GENE_PRODUCT", 320, 323], ["lung", "ORGAN", 329, 333], ["humans", "SPECIES", 11, 17], ["rabbits", "SPECIES", 22, 29], ["humans", "SPECIES", 11, 17], ["Studies in humans and rabbits", "TEST", 0, 29], ["apoptosis", "PROBLEM", 90, 99], ["necrosis", "PROBLEM", 104, 112], ["Ischemia", "PROBLEM", 128, 136], ["reperfusion models", "PROBLEM", 137, 155], ["LUNG INJURY", "PROBLEM", 230, 241], ["ischemia reperfusion", "PROBLEM", 275, 295], ["ischemia", "PROBLEM", 350, 358], ["compatible with", "UNCERTAINTY", 74, 89], ["apoptosis", "OBSERVATION", 90, 99], ["necrosis", "OBSERVATION", 104, 112], ["reperfusion models", "OBSERVATION", 137, 155], ["Epithelium", "ANATOMY_MODIFIER", 182, 192], ["LUNG", "ANATOMY", 230, 234], ["INJURY", "OBSERVATION", 235, 241], ["ischemia", "OBSERVATION", 275, 283], ["reperfusion", "OBSERVATION_MODIFIER", 284, 295], ["pulmonary", "ANATOMY", 300, 309], ["lung", "ANATOMY", 329, 333], ["ischemia", "OBSERVATION", 350, 358]]], ["The lungs are perfused by two separate vascular systems, the pulmonary circulation and the bronchial circulation.", [["lungs", "ANATOMY", 4, 9], ["vascular", "ANATOMY", 39, 47], ["pulmonary", "ANATOMY", 61, 70], ["bronchial", "ANATOMY", 91, 100], ["lungs", "ORGAN", 4, 9], ["vascular", "MULTI-TISSUE_STRUCTURE", 39, 47], ["pulmonary", "ORGAN", 61, 70], ["bronchial circulation", "MULTI-TISSUE_STRUCTURE", 91, 112], ["lungs", "ANATOMY", 4, 9], ["perfused", "OBSERVATION", 14, 22], ["two", "OBSERVATION_MODIFIER", 26, 29], ["separate", "OBSERVATION", 30, 38], ["vascular systems", "ANATOMY", 39, 55], ["pulmonary circulation", "ANATOMY", 61, 82], ["bronchial circulation", "ANATOMY", 91, 112]]], ["Ischemia can be produced by clamping the pulmonary artery, which preserves the bronchial circulation, or by clamping the hilum, which stops all circulation.", [["pulmonary artery", "ANATOMY", 41, 57], ["bronchial", "ANATOMY", 79, 88], ["hilum", "ANATOMY", 121, 126], ["Ischemia", "DISEASE", 0, 8], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 41, 57], ["bronchial", "MULTI-TISSUE_STRUCTURE", 79, 88], ["hilum", "MULTI-TISSUE_STRUCTURE", 121, 126], ["Ischemia", "PROBLEM", 0, 8], ["clamping", "OBSERVATION", 28, 36], ["pulmonary artery", "ANATOMY", 41, 57], ["bronchial circulation", "ANATOMY", 79, 100], ["hilum", "ANATOMY", 121, 126], ["all", "OBSERVATION_MODIFIER", 140, 143], ["circulation", "OBSERVATION_MODIFIER", 144, 155]]], ["In a variant of the lung I/R model, ischemia is achieved by lung collapse, followed by reexpansion (101).", [["lung", "ANATOMY", 20, 24], ["lung", "ANATOMY", 60, 64], ["ischemia", "DISEASE", 36, 44], ["lung collapse", "DISEASE", 60, 73], ["lung", "ORGAN", 20, 24], ["lung", "ORGAN", 60, 64], ["ischemia", "PROBLEM", 36, 44], ["lung collapse", "PROBLEM", 60, 73], ["lung", "ANATOMY", 20, 24], ["ischemia", "OBSERVATION", 36, 44], ["lung", "ANATOMY", 60, 64], ["collapse", "OBSERVATION", 65, 73], ["reexpansion", "OBSERVATION_MODIFIER", 87, 98]]], ["Electron microscopic examination of cat lungs treated with 2 h of ischemia (inflated lungs) and 2 h of reperfusion shows structural damage of the alveolar endothelium and epithelium, with separation of type II cells from the basement membrane, thickened vascular endothelium, and disruption of the septal capillary wall (149).", [["lungs", "ANATOMY", 40, 45], ["lungs", "ANATOMY", 85, 90], ["alveolar endothelium", "ANATOMY", 146, 166], ["epithelium", "ANATOMY", 171, 181], ["type II cells", "ANATOMY", 202, 215], ["basement membrane", "ANATOMY", 225, 242], ["vascular endothelium", "ANATOMY", 254, 274], ["septal capillary wall", "ANATOMY", 298, 319], ["ischemia", "DISEASE", 66, 74], ["cat", "ORGANISM", 36, 39], ["lungs", "ORGAN", 40, 45], ["lungs", "ORGAN", 85, 90], ["alveolar endothelium", "TISSUE", 146, 166], ["epithelium", "TISSUE", 171, 181], ["type II cells", "CELL", 202, 215], ["basement membrane", "CELLULAR_COMPONENT", 225, 242], ["vascular endothelium", "TISSUE", 254, 274], ["septal capillary wall", "TISSUE", 298, 319], ["type II cells", "CELL_TYPE", 202, 215], ["Electron microscopic examination", "TEST", 0, 32], ["ischemia (inflated lungs", "PROBLEM", 66, 90], ["reperfusion", "TREATMENT", 103, 114], ["structural damage of the alveolar endothelium and epithelium", "PROBLEM", 121, 181], ["type II cells", "PROBLEM", 202, 215], ["thickened vascular endothelium", "PROBLEM", 244, 274], ["disruption of the septal capillary wall", "PROBLEM", 280, 319], ["lungs", "ANATOMY", 40, 45], ["ischemia", "OBSERVATION", 66, 74], ["lungs", "ANATOMY", 85, 90], ["structural damage", "OBSERVATION", 121, 138], ["alveolar endothelium", "ANATOMY", 146, 166], ["epithelium", "ANATOMY_MODIFIER", 171, 181], ["separation", "OBSERVATION_MODIFIER", 188, 198], ["type II cells", "OBSERVATION", 202, 215], ["basement", "ANATOMY_MODIFIER", 225, 233], ["membrane", "ANATOMY_MODIFIER", 234, 242], ["thickened", "OBSERVATION", 244, 253], ["vascular endothelium", "ANATOMY", 254, 274], ["septal", "ANATOMY_MODIFIER", 298, 304], ["capillary", "ANATOMY_MODIFIER", 305, 314], ["wall", "ANATOMY_MODIFIER", 315, 319]]], ["An interesting feature of this model is that I/R of one lung results in inflammatory changes not only in the occluded lung but also in the contralateral lung (185).", [["lung", "ANATOMY", 56, 60], ["lung", "ANATOMY", 118, 122], ["lung", "ANATOMY", 153, 157], ["I/R", "GENE_OR_GENE_PRODUCT", 45, 48], ["lung", "ORGAN", 56, 60], ["lung", "ORGAN", 118, 122], ["lung", "ORGAN", 153, 157], ["I/R", "PROTEIN", 45, 48], ["inflammatory changes", "PROBLEM", 72, 92], ["lung", "ANATOMY", 56, 60], ["inflammatory", "OBSERVATION", 72, 84], ["occluded", "OBSERVATION", 109, 117], ["lung", "ANATOMY", 118, 122], ["contralateral", "ANATOMY_MODIFIER", 139, 152], ["lung", "ANATOMY", 153, 157]]], ["The injury to the contralateral side, when present, is milder and characterized by permeability changes and PMN infiltration (84, 157).Ischemia/reperfusion models. ::: Models Targeting the Epithelium and Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSFive main variables must be considered in pulmonary I/R models: the inflation state of the lung (deflated vs. inflated), the extent of the ischemic bed (pulmonary, bronchial circulation, venous return), the duration of ischemia and reperfusion, the experimental preparation (in vivo vs. isolated perfused lungs), and the animal species.Ischemia/reperfusion models. ::: Models Targeting the Epithelium and Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSLung inflation: the extent of lung inflation during the ischemic period affects the severity of the injury.", [["PMN", "ANATOMY", 108, 111], ["Epithelium", "ANATOMY", 189, 199], ["pulmonary", "ANATOMY", 304, 313], ["lung", "ANATOMY", 353, 357], ["pulmonary", "ANATOMY", 415, 424], ["bronchial", "ANATOMY", 426, 435], ["venous", "ANATOMY", 449, 455], ["lungs", "ANATOMY", 567, 572], ["Epithelium", "ANATOMY", 652, 662], ["lung", "ANATOMY", 755, 759], ["injury to the contralateral side", "DISEASE", 4, 36], ["Ischemia", "DISEASE", 135, 143], ["ischemia", "DISEASE", 481, 489], ["Ischemia", "DISEASE", 598, 606], ["PMN", "CELL", 108, 111], ["Epithelium", "TISSUE", 189, 199], ["Endothelium", "TISSUE", 204, 215], ["lung", "ORGAN", 353, 357], ["pulmonary", "ORGAN", 415, 424], ["bronchial", "MULTI-TISSUE_STRUCTURE", 426, 435], ["venous", "MULTI-TISSUE_STRUCTURE", 449, 455], ["lungs", "ORGAN", 567, 572], ["Epithelium", "TISSUE", 652, 662], ["Endothelium", "TISSUE", 667, 678], ["lung", "ORGAN", 755, 759], ["The injury to the contralateral side", "PROBLEM", 0, 36], ["permeability changes", "PROBLEM", 83, 103], ["PMN infiltration", "PROBLEM", 108, 124], ["Ischemia", "PROBLEM", 135, 143], ["reperfusion models", "PROBLEM", 144, 162], ["LUNG INJURY", "PROBLEM", 237, 248], ["the ischemic bed (pulmonary, bronchial circulation", "PROBLEM", 397, 447], ["ischemia", "PROBLEM", 481, 489], ["reperfusion", "TREATMENT", 494, 505], ["the experimental preparation", "TREATMENT", 507, 535], ["isolated perfused lungs", "PROBLEM", 549, 572], ["the animal species", "PROBLEM", 579, 597], ["Ischemia", "PROBLEM", 598, 606], ["reperfusion models", "PROBLEM", 607, 625], ["LUNG INJURY", "PROBLEM", 700, 711], ["lung inflation", "PROBLEM", 755, 769], ["the injury", "PROBLEM", 821, 831], ["injury", "OBSERVATION", 4, 10], ["contralateral", "ANATOMY_MODIFIER", 18, 31], ["milder", "OBSERVATION_MODIFIER", 55, 61], ["permeability", "OBSERVATION", 83, 95], ["PMN infiltration", "OBSERVATION", 108, 124], ["reperfusion models", "OBSERVATION", 144, 162], ["Epithelium", "ANATOMY_MODIFIER", 189, 199], ["LUNG", "ANATOMY", 237, 241], ["INJURY", "OBSERVATION", 242, 248], ["pulmonary", "ANATOMY", 304, 313], ["inflation", "OBSERVATION", 330, 339], ["lung", "ANATOMY", 353, 357], ["deflated", "OBSERVATION", 359, 367], ["ischemic", "OBSERVATION", 401, 409], ["pulmonary", "ANATOMY", 415, 424], ["bronchial circulation", "ANATOMY", 426, 447], ["venous", "ANATOMY", 449, 455], ["ischemia", "OBSERVATION", 481, 489], ["reperfusion", "OBSERVATION", 494, 505], ["perfused", "OBSERVATION", 558, 566], ["lungs", "ANATOMY", 567, 572], ["animal", "OBSERVATION_MODIFIER", 583, 589], ["species", "OBSERVATION_MODIFIER", 590, 597], ["reperfusion models", "OBSERVATION", 607, 625], ["Epithelium", "ANATOMY_MODIFIER", 652, 662], ["LUNG", "ANATOMY", 700, 704], ["INJURY", "OBSERVATION", 705, 711], ["SYSTEMSLung inflation", "OBSERVATION", 718, 739], ["extent", "OBSERVATION_MODIFIER", 745, 751], ["lung", "ANATOMY", 755, 759], ["inflation", "OBSERVATION", 760, 769], ["ischemic", "OBSERVATION_MODIFIER", 781, 789], ["severity", "OBSERVATION_MODIFIER", 809, 817], ["injury", "OBSERVATION", 825, 831]]], ["Occlusion of the pulmonary circulation for as long as 7 days results in minimal permeability changes and no macroscopic injury as long as the lungs are kept inflated (16, 94, 162).", [["pulmonary", "ANATOMY", 17, 26], ["lungs", "ANATOMY", 142, 147], ["pulmonary", "ORGAN", 17, 26], ["lungs", "ORGAN", 142, 147], ["Occlusion of the pulmonary circulation", "PROBLEM", 0, 38], ["minimal permeability changes", "PROBLEM", 72, 100], ["macroscopic injury", "PROBLEM", 108, 126], ["pulmonary circulation", "ANATOMY", 17, 38], ["minimal", "OBSERVATION_MODIFIER", 72, 79], ["permeability", "OBSERVATION", 80, 92], ["no", "UNCERTAINTY", 105, 107], ["macroscopic", "OBSERVATION_MODIFIER", 108, 119], ["injury", "OBSERVATION", 120, 126], ["lungs", "ANATOMY", 142, 147], ["inflated", "OBSERVATION", 157, 165]]], ["In contrast, if the lungs are kept deflated during the ischemic period, the resulting injury is severe and characterized by hemorrhage, edema, and inflammation, and there is a marked decrease in bronchial blood flow (21).", [["lungs", "ANATOMY", 20, 25], ["edema", "ANATOMY", 136, 141], ["bronchial blood", "ANATOMY", 195, 210], ["hemorrhage", "DISEASE", 124, 134], ["edema", "DISEASE", 136, 141], ["inflammation", "DISEASE", 147, 159], ["lungs", "ORGAN", 20, 25], ["edema", "PATHOLOGICAL_FORMATION", 136, 141], ["blood", "ORGANISM_SUBSTANCE", 205, 210], ["the resulting injury", "PROBLEM", 72, 92], ["hemorrhage", "PROBLEM", 124, 134], ["edema", "PROBLEM", 136, 141], ["inflammation", "PROBLEM", 147, 159], ["a marked decrease in bronchial blood flow", "PROBLEM", 174, 215], ["lungs", "ANATOMY", 20, 25], ["deflated", "OBSERVATION", 35, 43], ["ischemic", "OBSERVATION_MODIFIER", 55, 63], ["injury", "OBSERVATION", 86, 92], ["severe", "OBSERVATION_MODIFIER", 96, 102], ["hemorrhage", "OBSERVATION", 124, 134], ["edema", "OBSERVATION", 136, 141], ["inflammation", "OBSERVATION", 147, 159], ["marked", "OBSERVATION_MODIFIER", 176, 182], ["decrease", "OBSERVATION_MODIFIER", 183, 191], ["bronchial blood flow", "OBSERVATION", 195, 215]]], ["Persistent lung inflation can also prevent reperfusion injury after interruption of both the pulmonary and bronchial circulation with a hilar clamp (85, 186).Ischemia/reperfusion models. ::: Models Targeting the Epithelium and Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSWhen lung ischemia is followed by reperfusion, inflation of the lung also is an important factor.", [["lung", "ANATOMY", 11, 15], ["pulmonary", "ANATOMY", 93, 102], ["bronchial", "ANATOMY", 107, 116], ["hilar", "ANATOMY", 136, 141], ["Epithelium", "ANATOMY", 212, 222], ["lung", "ANATOMY", 290, 294], ["lung", "ANATOMY", 349, 353], ["Ischemia", "DISEASE", 158, 166], ["lung ischemia", "DISEASE", 290, 303], ["lung", "ORGAN", 11, 15], ["pulmonary", "ORGAN", 93, 102], ["bronchial", "MULTI-TISSUE_STRUCTURE", 107, 116], ["Epithelium", "TISSUE", 212, 222], ["Endothelium", "TISSUE", 227, 238], ["lung", "ORGAN", 290, 294], ["lung", "ORGAN", 349, 353], ["Persistent lung inflation", "PROBLEM", 0, 25], ["reperfusion injury", "PROBLEM", 43, 61], ["a hilar clamp", "TREATMENT", 134, 147], ["Ischemia", "PROBLEM", 158, 166], ["reperfusion models", "PROBLEM", 167, 185], ["LUNG INJURY", "PROBLEM", 260, 271], ["MODEL SYSTEMSWhen lung ischemia", "PROBLEM", 272, 303], ["inflation of the lung", "PROBLEM", 332, 353], ["lung", "ANATOMY", 11, 15], ["inflation", "OBSERVATION", 16, 25], ["reperfusion", "OBSERVATION_MODIFIER", 43, 54], ["injury", "OBSERVATION", 55, 61], ["both", "ANATOMY_MODIFIER", 84, 88], ["pulmonary", "ANATOMY", 93, 102], ["bronchial circulation", "ANATOMY", 107, 128], ["hilar", "ANATOMY", 136, 141], ["reperfusion models", "OBSERVATION", 167, 185], ["Epithelium", "ANATOMY_MODIFIER", 212, 222], ["LUNG", "ANATOMY", 260, 264], ["INJURY", "OBSERVATION", 265, 271], ["lung", "ANATOMY", 290, 294], ["ischemia", "OBSERVATION", 295, 303], ["lung", "ANATOMY", 349, 353]]], ["Sakuma et al. (186) showed that in rabbits, 4 h of unilateral hilar occlusion with lung deflation followed by 1 h of reperfusion resulted in fulminant pulmonary edema and death.", [["hilar", "ANATOMY", 62, 67], ["lung", "ANATOMY", 83, 87], ["pulmonary", "ANATOMY", 151, 160], ["fulminant pulmonary edema", "DISEASE", 141, 166], ["death", "DISEASE", 171, 176], ["rabbits", "ORGANISM", 35, 42], ["hilar", "MULTI-TISSUE_STRUCTURE", 62, 67], ["lung", "ORGAN", 83, 87], ["pulmonary", "ORGAN", 151, 160], ["rabbits", "SPECIES", 35, 42], ["rabbits", "SPECIES", 35, 42], ["unilateral hilar occlusion", "PROBLEM", 51, 77], ["lung deflation", "TREATMENT", 83, 97], ["reperfusion", "TREATMENT", 117, 128], ["fulminant pulmonary edema", "PROBLEM", 141, 166], ["death", "PROBLEM", 171, 176], ["unilateral", "ANATOMY_MODIFIER", 51, 61], ["hilar", "ANATOMY", 62, 67], ["occlusion", "OBSERVATION", 68, 77], ["lung", "ANATOMY", 83, 87], ["deflation", "OBSERVATION", 88, 97], ["fulminant", "OBSERVATION_MODIFIER", 141, 150], ["pulmonary", "ANATOMY", 151, 160], ["edema", "OBSERVATION", 161, 166]]], ["The development of injury in this model was prevented by inflation of the lungs, either with oxygen or nitrogen.", [["lungs", "ANATOMY", 74, 79], ["oxygen", "CHEMICAL", 93, 99], ["nitrogen", "CHEMICAL", 103, 111], ["oxygen", "CHEMICAL", 93, 99], ["nitrogen", "CHEMICAL", 103, 111], ["lungs", "ORGAN", 74, 79], ["oxygen", "SIMPLE_CHEMICAL", 93, 99], ["nitrogen", "SIMPLE_CHEMICAL", 103, 111], ["injury", "PROBLEM", 19, 25], ["oxygen", "TREATMENT", 93, 99], ["nitrogen", "TREATMENT", 103, 111], ["injury", "OBSERVATION", 19, 25], ["inflation", "OBSERVATION", 57, 66], ["lungs", "ANATOMY", 74, 79]]], ["Similar effects have been shown in dogs and rats (85, 227).Ischemia/reperfusion models. ::: Models Targeting the Epithelium and Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSExtent of the ischemic bed: because the lungs are perfused by two separate systems, the pulmonary circulation and the bronchial circulation, occlusion of the pulmonary artery alone results in milder injury than occlusion of both the pulmonary artery and the bronchial circulation (85, 161).", [["Epithelium", "ANATOMY", 113, 123], ["lungs", "ANATOMY", 226, 231], ["pulmonary", "ANATOMY", 274, 283], ["bronchial", "ANATOMY", 304, 313], ["pulmonary artery", "ANATOMY", 344, 360], ["pulmonary artery", "ANATOMY", 419, 435], ["bronchial", "ANATOMY", 444, 453], ["Ischemia", "DISEASE", 59, 67], ["dogs", "ORGANISM", 35, 39], ["rats", "ORGANISM", 44, 48], ["Epithelium", "TISSUE", 113, 123], ["Endothelium", "TISSUE", 128, 139], ["lungs", "ORGAN", 226, 231], ["pulmonary", "ORGAN", 274, 283], ["bronchial", "MULTI-TISSUE_STRUCTURE", 304, 313], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 344, 360], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 419, 435], ["bronchial circulation", "MULTI-TISSUE_STRUCTURE", 444, 465], ["dogs", "SPECIES", 35, 39], ["rats", "SPECIES", 44, 48], ["Ischemia", "PROBLEM", 59, 67], ["reperfusion models", "PROBLEM", 68, 86], ["LUNG INJURY", "PROBLEM", 161, 172], ["occlusion of the pulmonary artery", "PROBLEM", 327, 360], ["milder injury", "PROBLEM", 378, 391], ["reperfusion models", "OBSERVATION", 68, 86], ["Epithelium", "ANATOMY_MODIFIER", 113, 123], ["LUNG", "ANATOMY", 161, 165], ["INJURY", "OBSERVATION", 166, 172], ["ischemic", "OBSERVATION", 200, 208], ["lungs", "ANATOMY", 226, 231], ["perfused", "OBSERVATION", 236, 244], ["pulmonary circulation", "ANATOMY", 274, 295], ["bronchial circulation", "ANATOMY", 304, 325], ["occlusion", "OBSERVATION", 327, 336], ["pulmonary artery", "ANATOMY", 344, 360], ["milder", "OBSERVATION_MODIFIER", 378, 384], ["injury", "OBSERVATION", 385, 391], ["occlusion", "OBSERVATION", 397, 406], ["both", "ANATOMY_MODIFIER", 410, 414], ["pulmonary artery", "ANATOMY", 419, 435], ["bronchial circulation", "ANATOMY", 444, 465]]], ["Reverse pulmonary venous flow from the left atrium can occur if the hilum is not clamped, leading to less injury than complete occlusion of the hilum (43, 84, 155).", [["pulmonary venous", "ANATOMY", 8, 24], ["left atrium", "ANATOMY", 39, 50], ["hilum", "ANATOMY", 68, 73], ["hilum", "ANATOMY", 144, 149], ["pulmonary venous", "MULTI-TISSUE_STRUCTURE", 8, 24], ["left atrium", "MULTI-TISSUE_STRUCTURE", 39, 50], ["hilum", "MULTI-TISSUE_STRUCTURE", 68, 73], ["hilum", "MULTI-TISSUE_STRUCTURE", 144, 149], ["Reverse pulmonary venous flow from the left atrium", "PROBLEM", 0, 50], ["less injury than complete occlusion of the hilum", "PROBLEM", 101, 149], ["pulmonary venous", "ANATOMY", 8, 24], ["flow", "OBSERVATION", 25, 29], ["left atrium", "ANATOMY", 39, 50], ["hilum", "ANATOMY", 68, 73], ["not", "UNCERTAINTY", 77, 80], ["clamped", "OBSERVATION", 81, 88], ["less", "OBSERVATION_MODIFIER", 101, 105], ["injury", "OBSERVATION", 106, 112], ["complete", "OBSERVATION_MODIFIER", 118, 126], ["occlusion", "OBSERVATION", 127, 136], ["hilum", "ANATOMY", 144, 149]]], ["The extent of ischemia is also affected by whether oxygenated air continues to ventilate the lungs while the circulation is blocked.Ischemia/reperfusion models. ::: Models Targeting the Epithelium and Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSDuration of ischemic and reperfusion periods: although the effect of the duration of the ischemia and reperfusion periods is difficult to evaluate because of the many different protocols used, some generalizations can be made.", [["lungs", "ANATOMY", 93, 98], ["Epithelium", "ANATOMY", 186, 196], ["ischemia", "DISEASE", 14, 22], ["Ischemia", "DISEASE", 132, 140], ["ischemia", "DISEASE", 348, 356], ["lungs", "ORGAN", 93, 98], ["Epithelium", "TISSUE", 186, 196], ["Endothelium", "TISSUE", 201, 212], ["ischemia", "PROBLEM", 14, 22], ["oxygenated air", "PROBLEM", 51, 65], ["Ischemia", "PROBLEM", 132, 140], ["reperfusion models", "PROBLEM", 141, 159], ["LUNG INJURY", "PROBLEM", 234, 245], ["ischemic", "PROBLEM", 271, 279], ["the ischemia", "PROBLEM", 344, 356], ["reperfusion periods", "TREATMENT", 361, 380], ["extent", "OBSERVATION_MODIFIER", 4, 10], ["ischemia", "OBSERVATION", 14, 22], ["oxygenated air", "OBSERVATION", 51, 65], ["lungs", "ANATOMY", 93, 98], ["blocked", "OBSERVATION", 124, 131], ["reperfusion models", "OBSERVATION", 141, 159], ["Epithelium", "ANATOMY_MODIFIER", 186, 196], ["LUNG", "ANATOMY", 234, 238], ["INJURY", "OBSERVATION", 239, 245], ["ischemic", "OBSERVATION_MODIFIER", 271, 279], ["reperfusion periods", "OBSERVATION", 284, 303], ["ischemia", "OBSERVATION", 348, 356], ["reperfusion", "OBSERVATION", 361, 372]]], ["Ischemia alone, in the absence of reperfusion, may or may not result in injury, depending on the extent of inflation of the ischemic bed (21, 94).", [["Ischemia", "DISEASE", 0, 8], ["Ischemia", "PROBLEM", 0, 8], ["reperfusion", "PROBLEM", 34, 45], ["injury", "PROBLEM", 72, 78], ["inflation of the ischemic bed", "PROBLEM", 107, 136], ["reperfusion", "OBSERVATION", 34, 45], ["may not result", "UNCERTAINTY", 54, 68], ["injury", "OBSERVATION", 72, 78], ["extent", "OBSERVATION_MODIFIER", 97, 103], ["inflation", "OBSERVATION", 107, 116], ["ischemic", "OBSERVATION_MODIFIER", 124, 132]]], ["When ischemic time is varied (45 min to 4 h) and the reperfusion time remains constant, longer ischemic times result in worse lung injury (186, 227).", [["lung", "ANATOMY", 126, 130], ["lung injury", "DISEASE", 126, 137], ["lung", "ORGAN", 126, 130], ["worse lung injury", "PROBLEM", 120, 137], ["ischemic", "OBSERVATION", 5, 13], ["reperfusion", "OBSERVATION", 53, 64], ["worse", "OBSERVATION_MODIFIER", 120, 125], ["lung", "ANATOMY", 126, 130], ["injury", "OBSERVATION", 131, 137]]], ["When the ischemic time is kept constant and the reperfusion time is varied (30 min to 2 h), the severity of injury increases with longer reperfusion times (113, 149).", [["injury", "PROBLEM", 108, 114], ["ischemic", "OBSERVATION", 9, 17], ["injury", "OBSERVATION", 108, 114]]], ["Thus, ischemia and reperfusion times each affect the severity of the subsequent injury.Ischemia/reperfusion models. ::: Models Targeting the Epithelium and Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSExperimental preparation: I/R can be performed either in vivo or in isolated lung preparations, and the experimental method does not seem to affect the development of injury. in vivo models allow the study of secondary changes in the contralateral lung.Ischemia/reperfusion models. ::: Models Targeting the Epithelium and Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSSpecies variability: the results of I/R injury vary among species.", [["Epithelium", "ANATOMY", 141, 151], ["lung", "ANATOMY", 291, 295], ["lung", "ANATOMY", 462, 466], ["Epithelium", "ANATOMY", 521, 531], ["ischemia", "DISEASE", 6, 14], ["Ischemia", "DISEASE", 87, 95], ["Ischemia", "DISEASE", 467, 475], ["Epithelium", "TISSUE", 141, 151], ["Endothelium", "TISSUE", 156, 167], ["I/R", "GENE_OR_GENE_PRODUCT", 240, 243], ["lung", "ORGAN", 291, 295], ["lung", "ORGAN", 462, 466], ["Epithelium", "TISSUE", 521, 531], ["Endothelium", "TISSUE", 536, 547], ["I/R", "GENE_OR_GENE_PRODUCT", 630, 633], ["ischemia", "PROBLEM", 6, 14], ["the subsequent injury", "PROBLEM", 65, 86], ["Ischemia", "PROBLEM", 87, 95], ["reperfusion models", "PROBLEM", 96, 114], ["LUNG INJURY", "PROBLEM", 189, 200], ["isolated lung preparations", "TREATMENT", 282, 308], ["injury", "PROBLEM", 381, 387], ["the study", "TEST", 410, 419], ["secondary changes in the contralateral lung", "PROBLEM", 423, 466], ["Ischemia", "PROBLEM", 467, 475], ["reperfusion models", "PROBLEM", 476, 494], ["LUNG INJURY", "PROBLEM", 569, 580], ["I/R injury vary among species", "PROBLEM", 630, 659], ["ischemia", "OBSERVATION", 6, 14], ["reperfusion", "OBSERVATION", 19, 30], ["injury", "OBSERVATION", 80, 86], ["reperfusion models", "OBSERVATION", 96, 114], ["Epithelium", "ANATOMY_MODIFIER", 141, 151], ["LUNG", "ANATOMY", 189, 193], ["INJURY", "OBSERVATION", 194, 200], ["lung", "ANATOMY", 291, 295], ["injury", "OBSERVATION", 381, 387], ["contralateral", "ANATOMY_MODIFIER", 448, 461], ["lung", "ANATOMY", 462, 466], ["reperfusion models", "OBSERVATION", 476, 494], ["Epithelium", "ANATOMY_MODIFIER", 521, 531], ["LUNG", "ANATOMY", 569, 573], ["INJURY", "OBSERVATION", 574, 580]]], ["Rabbits have been most widely used in pulmonary I/R models, followed by rats and dogs; sheep, pigs, cats, and ferrets have also been used.", [["pulmonary", "ANATOMY", 38, 47], ["Rabbits", "ORGANISM", 0, 7], ["rats", "ORGANISM", 72, 76], ["dogs", "ORGANISM", 81, 85], ["sheep", "ORGANISM", 87, 92], ["pigs", "ORGANISM", 94, 98], ["cats", "ORGANISM", 100, 104], ["ferrets", "ORGANISM", 110, 117], ["Rabbits", "SPECIES", 0, 7], ["rats", "SPECIES", 72, 76], ["dogs", "SPECIES", 81, 85], ["sheep", "SPECIES", 87, 92], ["pigs", "SPECIES", 94, 98], ["cats", "SPECIES", 100, 104], ["ferrets", "SPECIES", 110, 117], ["sheep", "SPECIES", 87, 92], ["pigs", "SPECIES", 94, 98], ["ferrets", "SPECIES", 110, 117], ["cats", "TREATMENT", 100, 104], ["ferrets", "TREATMENT", 110, 117], ["most widely", "OBSERVATION_MODIFIER", 18, 29], ["pulmonary", "ANATOMY", 38, 47]]], ["In the dog, the major change after lung reperfusion is a large increase in pulmonary postcapillary resistance (101).", [["lung", "ANATOMY", 35, 39], ["pulmonary postcapillary", "ANATOMY", 75, 98], ["dog", "ORGANISM", 7, 10], ["lung", "ORGAN", 35, 39], ["pulmonary postcapillary", "MULTI-TISSUE_STRUCTURE", 75, 98], ["dog", "SPECIES", 7, 10], ["lung reperfusion", "TREATMENT", 35, 51], ["a large increase in pulmonary postcapillary resistance", "PROBLEM", 55, 109], ["major", "OBSERVATION_MODIFIER", 16, 21], ["change", "OBSERVATION", 22, 28], ["lung", "ANATOMY", 35, 39], ["reperfusion", "OBSERVATION", 40, 51], ["large", "OBSERVATION_MODIFIER", 57, 62], ["increase", "OBSERVATION_MODIFIER", 63, 71], ["pulmonary", "ANATOMY", 75, 84], ["postcapillary resistance", "OBSERVATION", 85, 109]]], ["In rats, pulmonary edema is due mostly to an increase in the permeability of the postalveolar venules (114).", [["pulmonary edema", "ANATOMY", 9, 24], ["postalveolar venules", "ANATOMY", 81, 101], ["pulmonary edema", "DISEASE", 9, 24], ["rats", "ORGANISM", 3, 7], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 9, 24], ["postalveolar venules", "MULTI-TISSUE_STRUCTURE", 81, 101], ["rats", "SPECIES", 3, 7], ["pulmonary edema", "PROBLEM", 9, 24], ["pulmonary", "ANATOMY", 9, 18], ["edema", "OBSERVATION", 19, 24], ["increase", "OBSERVATION_MODIFIER", 45, 53], ["permeability", "OBSERVATION_MODIFIER", 61, 73], ["postalveolar venules", "ANATOMY", 81, 101]]], ["Rabbits seem to be more sensitive than dogs to I/R.Ischemia/reperfusion models. ::: Models Targeting the Epithelium and Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSIn summary, lung ischemia followed by reperfusion results in lung injury characterized by increased pulmonary vascular permeability and edema, PMN infiltration, and sometimes hemorrhage.", [["Epithelium", "ANATOMY", 105, 115], ["lung", "ANATOMY", 190, 194], ["lung", "ANATOMY", 239, 243], ["pulmonary vascular", "ANATOMY", 278, 296], ["edema", "ANATOMY", 314, 319], ["PMN", "ANATOMY", 321, 324], ["Ischemia", "DISEASE", 51, 59], ["lung ischemia", "DISEASE", 190, 203], ["lung injury", "DISEASE", 239, 250], ["edema", "DISEASE", 314, 319], ["hemorrhage", "DISEASE", 353, 363], ["Rabbits", "ORGANISM", 0, 7], ["dogs", "ORGANISM", 39, 43], ["Epithelium", "TISSUE", 105, 115], ["Endothelium", "TISSUE", 120, 131], ["lung", "ORGAN", 190, 194], ["lung", "ORGAN", 239, 243], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 278, 296], ["edema", "PATHOLOGICAL_FORMATION", 314, 319], ["PMN", "CELL", 321, 324], ["Rabbits", "SPECIES", 0, 7], ["dogs", "SPECIES", 39, 43], ["Ischemia", "PROBLEM", 51, 59], ["reperfusion models", "PROBLEM", 60, 78], ["LUNG INJURY", "PROBLEM", 153, 164], ["lung ischemia", "PROBLEM", 190, 203], ["lung injury", "PROBLEM", 239, 250], ["increased pulmonary vascular permeability", "PROBLEM", 268, 309], ["edema", "PROBLEM", 314, 319], ["PMN infiltration", "PROBLEM", 321, 337], ["hemorrhage", "PROBLEM", 353, 363], ["Ischemia", "OBSERVATION", 51, 59], ["reperfusion models", "OBSERVATION", 60, 78], ["Epithelium", "ANATOMY_MODIFIER", 105, 115], ["LUNG", "ANATOMY", 153, 157], ["INJURY", "OBSERVATION", 158, 164], ["lung", "ANATOMY", 190, 194], ["ischemia", "OBSERVATION", 195, 203], ["lung", "ANATOMY", 239, 243], ["injury", "OBSERVATION", 244, 250], ["increased", "OBSERVATION_MODIFIER", 268, 277], ["pulmonary vascular", "ANATOMY", 278, 296], ["permeability", "OBSERVATION_MODIFIER", 297, 309], ["edema", "OBSERVATION", 314, 319], ["PMN infiltration", "OBSERVATION", 321, 337], ["hemorrhage", "OBSERVATION", 353, 363]]], ["The severity of injury is worse when the lungs remain deflated during the ischemic period and when the pulmonary and bronchial circulations are occluded together.Ischemia/reperfusion models. ::: Models Targeting the Epithelium and Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSNonpulmonary I/R: the nonpulmonary I/R model has been used mainly in rats and mice, although there are some studies in rabbits (8, 150) and sheep (116, 195).", [["lungs", "ANATOMY", 41, 46], ["pulmonary", "ANATOMY", 103, 112], ["bronchial circulations", "ANATOMY", 117, 139], ["Epithelium", "ANATOMY", 216, 226], ["Ischemia", "DISEASE", 162, 170], ["lungs", "ORGAN", 41, 46], ["pulmonary", "ORGAN", 103, 112], ["bronchial circulations", "MULTI-TISSUE_STRUCTURE", 117, 139], ["Epithelium", "TISSUE", 216, 226], ["Endothelium", "TISSUE", 231, 242], ["I/R", "GENE_OR_GENE_PRODUCT", 324, 327], ["rats", "ORGANISM", 358, 362], ["mice", "ORGANISM", 367, 371], ["rabbits", "ORGANISM", 408, 415], ["sheep", "ORGANISM", 429, 434], ["rats", "SPECIES", 358, 362], ["mice", "SPECIES", 367, 371], ["rabbits", "SPECIES", 408, 415], ["sheep", "SPECIES", 429, 434], ["mice", "SPECIES", 367, 371], ["rabbits", "SPECIES", 408, 415], ["sheep", "SPECIES", 429, 434], ["injury", "PROBLEM", 16, 22], ["Ischemia", "PROBLEM", 162, 170], ["reperfusion models", "PROBLEM", 171, 189], ["LUNG INJURY", "PROBLEM", 264, 275], ["the nonpulmonary I/R model", "TEST", 307, 333], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["injury", "OBSERVATION", 16, 22], ["worse", "OBSERVATION_MODIFIER", 26, 31], ["lungs", "ANATOMY", 41, 46], ["deflated", "OBSERVATION", 54, 62], ["ischemic", "OBSERVATION_MODIFIER", 74, 82], ["pulmonary", "ANATOMY", 103, 112], ["bronchial circulations", "ANATOMY", 117, 139], ["occluded", "OBSERVATION", 144, 152], ["reperfusion models", "OBSERVATION", 171, 189], ["Epithelium", "ANATOMY_MODIFIER", 216, 226], ["LUNG", "ANATOMY", 264, 268], ["INJURY", "OBSERVATION", 269, 275], ["nonpulmonary", "ANATOMY", 311, 323]]], ["Models differ in terms of the anatomic area subjected to ischemia, e.g., gut, liver, kidneys, lower torso, the duration of the ischemic period, and the duration of reperfusion.", [["gut", "ANATOMY", 73, 76], ["liver", "ANATOMY", 78, 83], ["kidneys", "ANATOMY", 85, 92], ["lower torso", "ANATOMY", 94, 105], ["ischemia", "DISEASE", 57, 65], ["gut", "ORGANISM_SUBDIVISION", 73, 76], ["liver", "ORGAN", 78, 83], ["kidneys", "ORGAN", 85, 92], ["lower", "ORGANISM_SUBDIVISION", 94, 99], ["torso", "ORGANISM_SUBDIVISION", 100, 105], ["ischemia", "PROBLEM", 57, 65], ["e.g., gut, liver, kidneys, lower torso", "PROBLEM", 67, 105], ["reperfusion", "TREATMENT", 164, 175], ["ischemia", "OBSERVATION", 57, 65], ["gut", "ANATOMY", 73, 76], ["liver", "ANATOMY", 78, 83], ["kidneys", "ANATOMY", 85, 92], ["lower", "ANATOMY_MODIFIER", 94, 99], ["torso", "ANATOMY", 100, 105], ["ischemic", "OBSERVATION", 127, 135], ["reperfusion", "OBSERVATION", 164, 175]]], ["In general, the severity of lung injury is more closely related to the volume of ischemic tissue than to the duration of ischemia.", [["lung", "ANATOMY", 28, 32], ["tissue", "ANATOMY", 90, 96], ["lung injury", "DISEASE", 28, 39], ["ischemia", "DISEASE", 121, 129], ["lung", "ORGAN", 28, 32], ["tissue", "TISSUE", 90, 96], ["lung injury", "PROBLEM", 28, 39], ["ischemic tissue", "PROBLEM", 81, 96], ["ischemia", "PROBLEM", 121, 129], ["lung", "ANATOMY", 28, 32], ["injury", "OBSERVATION", 33, 39], ["ischemic tissue", "OBSERVATION", 81, 96], ["ischemia", "OBSERVATION", 121, 129]]], ["Furthermore, the lung injury is mild and temporary unless a second intrapulmonary stimulus such as intratracheal LPS is added (120).Ischemia/reperfusion models. ::: Models Targeting the Epithelium and Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSTechnical considerations: I/R in nonpulmonary vascular beds is generally achieved by isolating and clamping a specific artery for a period of time and then removing the clamp and restoring perfusion.", [["lung", "ANATOMY", 17, 21], ["intrapulmonary", "ANATOMY", 67, 81], ["intratracheal", "ANATOMY", 99, 112], ["Epithelium", "ANATOMY", 186, 196], ["nonpulmonary vascular beds", "ANATOMY", 292, 318], ["artery", "ANATOMY", 378, 384], ["lung injury", "DISEASE", 17, 28], ["LPS", "CHEMICAL", 113, 116], ["Ischemia", "DISEASE", 132, 140], ["lung", "ORGAN", 17, 21], ["LPS", "SIMPLE_CHEMICAL", 113, 116], ["Epithelium", "TISSUE", 186, 196], ["Endothelium", "TISSUE", 201, 212], ["I/R", "GENE_OR_GENE_PRODUCT", 285, 288], ["vascular", "MULTI-TISSUE_STRUCTURE", 305, 313], ["artery", "MULTI-TISSUE_STRUCTURE", 378, 384], ["the lung injury", "PROBLEM", 13, 28], ["a second intrapulmonary stimulus", "TEST", 58, 90], ["intratracheal LPS", "TEST", 99, 116], ["Ischemia", "PROBLEM", 132, 140], ["reperfusion models", "PROBLEM", 141, 159], ["LUNG INJURY", "PROBLEM", 234, 245], ["nonpulmonary vascular beds", "TREATMENT", 292, 318], ["the clamp", "TREATMENT", 424, 433], ["lung", "ANATOMY", 17, 21], ["injury", "OBSERVATION", 22, 28], ["mild", "OBSERVATION_MODIFIER", 32, 36], ["reperfusion models", "OBSERVATION", 141, 159], ["Epithelium", "ANATOMY_MODIFIER", 186, 196], ["LUNG", "ANATOMY", 234, 238], ["INJURY", "OBSERVATION", 239, 245], ["nonpulmonary", "ANATOMY_MODIFIER", 292, 304], ["vascular beds", "ANATOMY", 305, 318], ["artery", "ANATOMY", 378, 384]]], ["The most commonly used vascular bed in large animals is the superior mesenteric artery, whereas in mice hindlimb ischemia has been achieved either by surgical occlusion of the supraceliac aorta or without surgery by applying tourniquets to the extremities (57, 73, 103, 116, 119, 237).", [["vascular bed", "ANATOMY", 23, 35], ["superior mesenteric artery", "ANATOMY", 60, 86], ["hindlimb", "ANATOMY", 104, 112], ["supraceliac aorta", "ANATOMY", 176, 193], ["extremities", "ANATOMY", 244, 255], ["hindlimb ischemia", "DISEASE", 104, 121], ["vascular bed", "MULTI-TISSUE_STRUCTURE", 23, 35], ["superior mesenteric artery", "MULTI-TISSUE_STRUCTURE", 60, 86], ["mice", "ORGANISM", 99, 103], ["hindlimb", "ORGANISM_SUBDIVISION", 104, 112], ["aorta", "MULTI-TISSUE_STRUCTURE", 188, 193], ["extremities", "ORGANISM_SUBDIVISION", 244, 255], ["mice", "SPECIES", 99, 103], ["mice", "SPECIES", 99, 103], ["mice hindlimb ischemia", "PROBLEM", 99, 121], ["surgery", "TREATMENT", 205, 212], ["vascular", "ANATOMY", 23, 31], ["large", "OBSERVATION_MODIFIER", 39, 44], ["animals", "OBSERVATION", 45, 52], ["superior mesenteric artery", "ANATOMY", 60, 86], ["hindlimb", "ANATOMY", 104, 112], ["ischemia", "OBSERVATION", 113, 121], ["surgical", "OBSERVATION_MODIFIER", 150, 158], ["occlusion", "OBSERVATION", 159, 168], ["supraceliac aorta", "ANATOMY", 176, 193], ["without", "UNCERTAINTY", 197, 204], ["surgery", "OBSERVATION", 205, 212], ["extremities", "ANATOMY", 244, 255]]], ["In abdominal I/R, the abdominal cavity is left open during the ischemic period and covered by a plastic wrap.", [["abdominal", "ANATOMY", 3, 12], ["abdominal cavity", "ANATOMY", 22, 38], ["abdominal cavity", "MULTI-TISSUE_STRUCTURE", 22, 38], ["the abdominal cavity", "PROBLEM", 18, 38], ["a plastic wrap", "TREATMENT", 94, 108], ["abdominal", "ANATOMY", 3, 12], ["abdominal cavity", "ANATOMY", 22, 38], ["left", "ANATOMY_MODIFIER", 42, 46], ["open", "OBSERVATION", 47, 51], ["ischemic", "OBSERVATION_MODIFIER", 63, 71], ["plastic wrap", "OBSERVATION", 96, 108]]], ["At the end of the ischemic period, the clamp is removed, and reperfusion is initiated.", [["the clamp", "TREATMENT", 35, 44], ["reperfusion", "TREATMENT", 61, 72], ["ischemic", "OBSERVATION", 18, 26]]], ["Surgery can be avoided by applying tourniquets to the extremities to create variable periods of tissue ischemia.Ischemia/reperfusion models. ::: Models Targeting the Epithelium and Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSSpecific models: in nonpulmonary I/R models in rats, mice, sheep, and other species, reperfusion following ischemic periods ranging from 30 to 120 min is associated with a systemic response characterized by decreased cardiac output and hypotension, metabolic acidosis, and PMN activation (73, 119) (245).", [["extremities", "ANATOMY", 54, 65], ["tissue", "ANATOMY", 96, 102], ["Epithelium", "ANATOMY", 166, 176], ["cardiac", "ANATOMY", 456, 463], ["PMN", "ANATOMY", 512, 515], ["ischemia", "DISEASE", 103, 111], ["Ischemia", "DISEASE", 112, 120], ["decreased cardiac output", "DISEASE", 446, 470], ["hypotension", "DISEASE", 475, 486], ["metabolic acidosis", "DISEASE", 488, 506], ["extremities", "ORGANISM_SUBDIVISION", 54, 65], ["tissue", "TISSUE", 96, 102], ["Epithelium", "TISSUE", 166, 176], ["Endothelium", "TISSUE", 181, 192], ["I/R", "GENE_OR_GENE_PRODUCT", 272, 275], ["rats", "ORGANISM", 286, 290], ["mice", "ORGANISM", 292, 296], ["sheep", "ORGANISM", 298, 303], ["cardiac", "ORGAN", 456, 463], ["PMN", "CELL", 512, 515], ["rats", "SPECIES", 286, 290], ["mice", "SPECIES", 292, 296], ["sheep", "SPECIES", 298, 303], ["mice", "SPECIES", 292, 296], ["sheep", "SPECIES", 298, 303], ["Surgery", "TREATMENT", 0, 7], ["tourniquets", "TREATMENT", 35, 46], ["tissue ischemia", "PROBLEM", 96, 111], ["Ischemia", "PROBLEM", 112, 120], ["reperfusion models", "PROBLEM", 121, 139], ["LUNG INJURY", "PROBLEM", 214, 225], ["nonpulmonary I/R models", "TEST", 259, 282], ["ischemic periods", "PROBLEM", 346, 362], ["a systemic response", "PROBLEM", 409, 428], ["decreased cardiac output", "PROBLEM", 446, 470], ["hypotension", "PROBLEM", 475, 486], ["metabolic acidosis", "PROBLEM", 488, 506], ["PMN activation", "TEST", 512, 526], ["extremities", "ANATOMY", 54, 65], ["tissue", "ANATOMY", 96, 102], ["ischemia", "OBSERVATION", 103, 111], ["reperfusion models", "OBSERVATION", 121, 139], ["Epithelium", "ANATOMY_MODIFIER", 166, 176], ["LUNG", "ANATOMY", 214, 218], ["INJURY", "OBSERVATION", 219, 225], ["nonpulmonary", "ANATOMY", 259, 271], ["reperfusion", "OBSERVATION", 324, 335], ["ischemic", "OBSERVATION_MODIFIER", 346, 354], ["decreased", "OBSERVATION_MODIFIER", 446, 455], ["cardiac output", "OBSERVATION", 456, 470], ["hypotension", "OBSERVATION", 475, 486], ["metabolic acidosis", "OBSERVATION", 488, 506], ["PMN activation", "OBSERVATION", 512, 526]]], ["In the lungs, PMN sequestration begins within 90 min of reperfusion (245) and is followed 1 h later by increases in pulmonary microvascular permeability, which peak after 4\u20136 h (119, 212).", [["lungs", "ANATOMY", 7, 12], ["PMN", "ANATOMY", 14, 17], ["pulmonary microvascular", "ANATOMY", 116, 139], ["lungs", "ORGAN", 7, 12], ["PMN", "CELL", 14, 17], ["pulmonary microvascular", "TISSUE", 116, 139], ["PMN", "CELL_TYPE", 14, 17], ["PMN sequestration", "PROBLEM", 14, 31], ["reperfusion", "TEST", 56, 67], ["increases in pulmonary microvascular permeability", "PROBLEM", 103, 152], ["lungs", "ANATOMY", 7, 12], ["PMN sequestration", "OBSERVATION", 14, 31], ["reperfusion", "OBSERVATION_MODIFIER", 56, 67], ["increases", "OBSERVATION_MODIFIER", 103, 112], ["pulmonary", "ANATOMY", 116, 125], ["microvascular permeability", "OBSERVATION", 126, 152], ["peak", "OBSERVATION_MODIFIER", 160, 164]]], ["After 12\u201318 h, lung permeability returns to baseline levels (120, 212).", [["lung", "ANATOMY", 15, 19], ["lung", "ORGAN", 15, 19], ["lung permeability", "TEST", 15, 32], ["lung", "ANATOMY", 15, 19], ["permeability", "OBSERVATION", 20, 32]]], ["Lung histology shows microvascular sequestration of PMN and proteinaceous alveolar exudates (116).", [["Lung", "ANATOMY", 0, 4], ["microvascular", "ANATOMY", 21, 34], ["PMN", "ANATOMY", 52, 55], ["alveolar exudates", "ANATOMY", 74, 91], ["Lung", "ORGAN", 0, 4], ["microvascular", "MULTI-TISSUE_STRUCTURE", 21, 34], ["PMN", "CELL", 52, 55], ["proteinaceous alveolar exudates", "TISSUE", 60, 91], ["PMN", "CELL_TYPE", 52, 55], ["Lung histology", "TEST", 0, 14], ["microvascular sequestration of PMN", "PROBLEM", 21, 55], ["proteinaceous alveolar exudates", "PROBLEM", 60, 91], ["histology", "OBSERVATION", 5, 14], ["microvascular sequestration", "OBSERVATION", 21, 48], ["PMN", "OBSERVATION_MODIFIER", 52, 55], ["proteinaceous", "OBSERVATION_MODIFIER", 60, 73], ["alveolar exudates", "OBSERVATION", 74, 91]]], ["The lung injury in this model depends on circulating PMN (132).Ischemia/reperfusion models. ::: Models Targeting the Epithelium and Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSThe administration of 2.5 mg/kg iv LPS to rats 6 h after 45 min of mesenteric ischemia results in a more severe form of injury, with a sustained increase in alveolar permeability for up to 18 h following reperfusion, and the development of alveolar edema, alveolar hemorrhage, and fibrinous exudates (120, 212).", [["lung", "ANATOMY", 4, 8], ["PMN", "ANATOMY", 53, 56], ["Epithelium", "ANATOMY", 117, 127], ["mesenteric", "ANATOMY", 257, 267], ["alveolar", "ANATOMY", 347, 355], ["alveolar edema", "ANATOMY", 430, 444], ["alveolar", "ANATOMY", 446, 454], ["fibrinous exudates", "ANATOMY", 471, 489], ["lung injury", "DISEASE", 4, 15], ["Ischemia", "DISEASE", 63, 71], ["LPS", "CHEMICAL", 225, 228], ["mesenteric ischemia", "DISEASE", 257, 276], ["alveolar edema", "DISEASE", 430, 444], ["alveolar hemorrhage", "DISEASE", 446, 465], ["lung", "ORGAN", 4, 8], ["PMN", "CELL", 53, 56], ["Epithelium", "TISSUE", 117, 127], ["Endothelium", "TISSUE", 132, 143], ["LPS", "SIMPLE_CHEMICAL", 225, 228], ["rats", "ORGANISM", 232, 236], ["mesenteric", "MULTI-TISSUE_STRUCTURE", 257, 267], ["alveolar", "TISSUE", 347, 355], ["alveolar edema", "PATHOLOGICAL_FORMATION", 430, 444], ["alveolar", "MULTI-TISSUE_STRUCTURE", 446, 454], ["fibrinous exudates", "PATHOLOGICAL_FORMATION", 471, 489], ["circulating PMN", "CELL_TYPE", 41, 56], ["rats", "SPECIES", 232, 236], ["The lung injury", "PROBLEM", 0, 15], ["circulating PMN", "TEST", 41, 56], ["Ischemia", "PROBLEM", 63, 71], ["reperfusion models", "PROBLEM", 72, 90], ["LUNG INJURY", "PROBLEM", 165, 176], ["mesenteric ischemia", "PROBLEM", 257, 276], ["injury", "PROBLEM", 310, 316], ["a sustained increase in alveolar permeability", "PROBLEM", 323, 368], ["reperfusion", "TREATMENT", 394, 405], ["alveolar edema", "PROBLEM", 430, 444], ["alveolar hemorrhage", "PROBLEM", 446, 465], ["fibrinous exudates", "PROBLEM", 471, 489], ["lung", "ANATOMY", 4, 8], ["injury", "OBSERVATION", 9, 15], ["reperfusion models", "OBSERVATION", 72, 90], ["Epithelium", "ANATOMY_MODIFIER", 117, 127], ["LUNG", "ANATOMY", 165, 169], ["INJURY", "OBSERVATION", 170, 176], ["mesenteric", "ANATOMY", 257, 267], ["ischemia", "OBSERVATION", 268, 276], ["more severe", "OBSERVATION_MODIFIER", 290, 301], ["injury", "OBSERVATION", 310, 316], ["sustained", "OBSERVATION_MODIFIER", 325, 334], ["increase", "OBSERVATION_MODIFIER", 335, 343], ["alveolar permeability", "OBSERVATION", 347, 368], ["alveolar", "ANATOMY_MODIFIER", 430, 438], ["edema", "OBSERVATION", 439, 444], ["alveolar", "ANATOMY_MODIFIER", 446, 454], ["hemorrhage", "OBSERVATION", 455, 465], ["fibrinous", "OBSERVATION_MODIFIER", 471, 480], ["exudates", "OBSERVATION_MODIFIER", 481, 489]]], ["As in models of VILI, nonpulmonary ischemia and circulating LPS appear to have synergistic effects on the development of lung injury.Ischemia/reperfusion models. ::: Models Targeting the Epithelium and Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSAdvantages and disadvantages: the main advantage of the nonpulmonary ischemia reperfusion models is that they reproduce a known clinical phenomenon, the development of lung injury after intestinal or peripheral ischemia and reperfusion in humans.", [["nonpulmonary", "ANATOMY", 22, 34], ["lung", "ANATOMY", 121, 125], ["Epithelium", "ANATOMY", 187, 197], ["nonpulmonary", "ANATOMY", 316, 328], ["lung", "ANATOMY", 428, 432], ["intestinal", "ANATOMY", 446, 456], ["VILI", "DISEASE", 16, 20], ["ischemia", "DISEASE", 35, 43], ["LPS", "CHEMICAL", 60, 63], ["lung injury", "DISEASE", 121, 132], ["Ischemia", "DISEASE", 133, 141], ["ischemia", "DISEASE", 329, 337], ["lung injury", "DISEASE", 428, 439], ["peripheral ischemia", "DISEASE", 460, 479], ["LPS", "SIMPLE_CHEMICAL", 60, 63], ["lung", "ORGAN", 121, 125], ["Epithelium", "TISSUE", 187, 197], ["Endothelium", "TISSUE", 202, 213], ["lung", "ORGAN", 428, 432], ["intestinal", "ORGAN", 446, 456], ["humans", "ORGANISM", 499, 505], ["humans", "SPECIES", 499, 505], ["humans", "SPECIES", 499, 505], ["VILI", "PROBLEM", 16, 20], ["nonpulmonary ischemia", "PROBLEM", 22, 43], ["circulating LPS", "PROBLEM", 48, 63], ["synergistic effects", "PROBLEM", 79, 98], ["lung injury", "PROBLEM", 121, 132], ["Ischemia", "PROBLEM", 133, 141], ["reperfusion models", "PROBLEM", 142, 160], ["LUNG INJURY", "PROBLEM", 235, 246], ["the nonpulmonary ischemia reperfusion models", "PROBLEM", 312, 356], ["a known clinical phenomenon", "PROBLEM", 380, 407], ["lung injury", "PROBLEM", 428, 439], ["intestinal or peripheral ischemia", "PROBLEM", 446, 479], ["reperfusion in humans", "PROBLEM", 484, 505], ["VILI", "OBSERVATION", 16, 20], ["nonpulmonary", "ANATOMY", 22, 34], ["ischemia", "OBSERVATION", 35, 43], ["lung", "ANATOMY", 121, 125], ["injury", "OBSERVATION", 126, 132], ["reperfusion models", "OBSERVATION", 142, 160], ["Epithelium", "ANATOMY_MODIFIER", 187, 197], ["LUNG", "ANATOMY", 235, 239], ["INJURY", "OBSERVATION", 240, 246], ["nonpulmonary", "ANATOMY", 316, 328], ["ischemia", "OBSERVATION", 329, 337], ["lung", "ANATOMY", 428, 432], ["injury", "OBSERVATION", 433, 439], ["intestinal", "ANATOMY", 446, 456], ["peripheral", "ANATOMY_MODIFIER", 460, 470], ["ischemia", "OBSERVATION", 471, 479], ["reperfusion", "OBSERVATION_MODIFIER", 484, 495]]], ["I/R can be performed in a variety of large and small animal species, including mice.", [["I/R", "GENE_OR_GENE_PRODUCT", 0, 3], ["mice", "ORGANISM", 79, 83], ["I/R", "PROTEIN", 0, 3], ["mice", "SPECIES", 79, 83], ["mice", "SPECIES", 79, 83], ["large and small animal species", "PROBLEM", 37, 67], ["large", "OBSERVATION_MODIFIER", 37, 42], ["small", "OBSERVATION_MODIFIER", 47, 52], ["animal species", "OBSERVATION", 53, 67]]], ["However, when I/R of nonpulmonary beds is the only stimulus, the lung injury is mild, and secondary stimuli (such as LPS) are required to cause significant lung injury.", [["lung", "ANATOMY", 65, 69], ["lung", "ANATOMY", 156, 160], ["lung injury", "DISEASE", 65, 76], ["LPS", "CHEMICAL", 117, 120], ["lung injury", "DISEASE", 156, 167], ["I/R", "GENE_OR_GENE_PRODUCT", 14, 17], ["lung", "ORGAN", 65, 69], ["LPS", "SIMPLE_CHEMICAL", 117, 120], ["lung", "ORGAN", 156, 160], ["nonpulmonary beds", "TREATMENT", 21, 38], ["the lung injury", "PROBLEM", 61, 76], ["secondary stimuli", "PROBLEM", 90, 107], ["significant lung injury", "PROBLEM", 144, 167], ["nonpulmonary beds", "ANATOMY", 21, 38], ["lung", "ANATOMY", 65, 69], ["injury", "OBSERVATION", 70, 76], ["mild", "OBSERVATION_MODIFIER", 80, 84], ["significant", "OBSERVATION_MODIFIER", 144, 155], ["lung", "ANATOMY", 156, 160], ["injury", "OBSERVATION", 161, 167]]], ["Abdominal surgery is required in the intestinal I/R model, which induces an inflammatory response that must be controlled for in the experimental design.Models of lung injury due to sepsis. ::: Models Targeting the Epithelium and Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSSepsis is one of the main risk factors for ARDS (95), and many animal models of sepsis have been developed to study ALI.", [["Abdominal", "ANATOMY", 0, 9], ["intestinal", "ANATOMY", 37, 47], ["lung", "ANATOMY", 163, 167], ["Epithelium", "ANATOMY", 215, 225], ["lung injury", "DISEASE", 163, 174], ["sepsis", "DISEASE", 182, 188], ["ARDS", "DISEASE", 331, 335], ["sepsis", "DISEASE", 368, 374], ["ALI", "DISEASE", 404, 407], ["Abdominal", "ORGAN", 0, 9], ["intestinal", "ORGAN", 37, 47], ["lung", "ORGAN", 163, 167], ["Epithelium", "TISSUE", 215, 225], ["Endothelium", "TISSUE", 230, 241], ["Abdominal surgery", "TREATMENT", 0, 17], ["the intestinal I/R model", "TREATMENT", 33, 57], ["an inflammatory response", "PROBLEM", 73, 97], ["lung injury", "PROBLEM", 163, 174], ["sepsis", "PROBLEM", 182, 188], ["LUNG INJURY", "PROBLEM", 263, 274], ["ARDS", "PROBLEM", 331, 335], ["sepsis", "PROBLEM", 368, 374], ["surgery", "OBSERVATION", 10, 17], ["intestinal", "ANATOMY", 37, 47], ["inflammatory", "OBSERVATION", 76, 88], ["lung", "ANATOMY", 163, 167], ["injury", "OBSERVATION", 168, 174], ["sepsis", "OBSERVATION", 182, 188], ["Epithelium", "ANATOMY_MODIFIER", 215, 225], ["LUNG", "ANATOMY", 263, 267], ["INJURY", "OBSERVATION", 268, 274], ["ARDS", "OBSERVATION", 331, 335], ["sepsis", "OBSERVATION", 368, 374]]], ["Three main strategies have been used to induce sepsis: 1) the administration of live bacteria, 2) the creation of an endogenous infection, e.g., cecal ligation and puncture, and 3) the administration of bacterial products, such as endotoxin.", [["cecal", "ANATOMY", 145, 150], ["sepsis", "DISEASE", 47, 53], ["infection", "DISEASE", 128, 137], ["endotoxin", "CHEMICAL", 231, 240], ["endotoxin", "SIMPLE_CHEMICAL", 231, 240], ["endotoxin", "PROTEIN", 231, 240], ["sepsis", "PROBLEM", 47, 53], ["live bacteria", "PROBLEM", 80, 93], ["an endogenous infection", "PROBLEM", 114, 137], ["cecal ligation", "TREATMENT", 145, 159], ["puncture", "TREATMENT", 164, 172], ["bacterial products", "TREATMENT", 203, 221], ["endotoxin", "TREATMENT", 231, 240], ["sepsis", "OBSERVATION", 47, 53], ["endogenous", "OBSERVATION_MODIFIER", 117, 127], ["infection", "OBSERVATION", 128, 137], ["cecal", "ANATOMY", 145, 150], ["ligation", "OBSERVATION", 151, 159], ["bacterial products", "OBSERVATION", 203, 221]]], ["The following sections address models that use live bacteria, because LPS models have been discussed in Endotoxin.", [["sections", "ANATOMY", 14, 22], ["LPS", "CHEMICAL", 70, 73], ["Endotoxin", "CHEMICAL", 104, 113], ["LPS", "SIMPLE_CHEMICAL", 70, 73], ["Endotoxin", "SIMPLE_CHEMICAL", 104, 113], ["Endotoxin", "PROTEIN", 104, 113], ["live bacteria", "PROBLEM", 47, 60], ["LPS models", "TEST", 70, 80]]], ["Important variables in live bacteria models of ALI include: the route of administration, the size of the bacterial inoculum, the bacterial species, and the animal species.", [["ALI", "DISEASE", 47, 50], ["administration", "TREATMENT", 73, 87], ["the bacterial inoculum", "PROBLEM", 101, 123], ["the bacterial species", "PROBLEM", 125, 146], ["the animal species", "PROBLEM", 152, 170], ["size", "OBSERVATION_MODIFIER", 93, 97], ["bacterial inoculum", "OBSERVATION", 105, 123], ["bacterial species", "OBSERVATION", 129, 146]]], ["In general, more severe responses are seen in species with PIM than in those without PIM.Models of lung injury due to sepsis. ::: Models Targeting the Epithelium and Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSIntravenous bacteria: intravenous bacteria can be administered as a bolus or as a continuous infusion.", [["lung", "ANATOMY", 99, 103], ["Epithelium", "ANATOMY", 151, 161], ["intravenous", "ANATOMY", 246, 257], ["PIM", "DISEASE", 59, 62], ["PIM", "DISEASE", 85, 88], ["lung injury", "DISEASE", 99, 110], ["sepsis", "DISEASE", 118, 124], ["lung", "ORGAN", 99, 103], ["Epithelium", "TISSUE", 151, 161], ["Endothelium", "TISSUE", 166, 177], ["intravenous bacteria", "SIMPLE_CHEMICAL", 246, 266], ["more severe responses", "PROBLEM", 12, 33], ["lung injury", "PROBLEM", 99, 110], ["sepsis", "PROBLEM", 118, 124], ["LUNG INJURY", "PROBLEM", 199, 210], ["MODEL SYSTEMSIntravenous bacteria", "PROBLEM", 211, 244], ["intravenous bacteria", "TREATMENT", 246, 266], ["a bolus", "TREATMENT", 290, 297], ["a continuous infusion", "TREATMENT", 304, 325], ["lung", "ANATOMY", 99, 103], ["injury", "OBSERVATION", 104, 110], ["sepsis", "OBSERVATION", 118, 124], ["Epithelium", "ANATOMY_MODIFIER", 151, 161], ["LUNG", "ANATOMY", 199, 203], ["INJURY", "OBSERVATION", 204, 210]]], ["The administration of an intravenous bolus of bacteria is followed within an hour by an initial phase of hypotension and leukopenia, which can progress to septic shock, intravascular coagulation, and death if the inoculum is high.", [["intravenous", "ANATOMY", 25, 36], ["intravascular", "ANATOMY", 169, 182], ["hypotension", "DISEASE", 105, 116], ["leukopenia", "DISEASE", 121, 131], ["septic shock", "DISEASE", 155, 167], ["intravascular coagulation", "DISEASE", 169, 194], ["death", "DISEASE", 200, 205], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 25, 36], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 169, 182], ["an intravenous bolus of bacteria", "TREATMENT", 22, 54], ["hypotension", "PROBLEM", 105, 116], ["leukopenia", "PROBLEM", 121, 131], ["septic shock", "PROBLEM", 155, 167], ["intravascular coagulation", "PROBLEM", 169, 194], ["death", "PROBLEM", 200, 205], ["the inoculum", "PROBLEM", 209, 221], ["hypotension", "OBSERVATION", 105, 116], ["leukopenia", "OBSERVATION", 121, 131], ["septic shock", "OBSERVATION", 155, 167], ["high", "OBSERVATION_MODIFIER", 225, 229]]], ["If the animals survive, the initial phase is followed between 1 and 3 h later by a brief period of hemodynamic stabilization and then by a phase of microvascular injury with PMN sequestration in the lungs, an increase in pulmonary microvascular permeability, interstitial edema, an increase in shunt fraction and pulmonary arterial pressure, and intravascular thrombosis (238).", [["microvascular", "ANATOMY", 148, 161], ["PMN", "ANATOMY", 174, 177], ["lungs", "ANATOMY", 199, 204], ["pulmonary microvascular", "ANATOMY", 221, 244], ["interstitial", "ANATOMY", 259, 271], ["pulmonary arterial", "ANATOMY", 313, 331], ["intravascular", "ANATOMY", 346, 359], ["microvascular injury", "DISEASE", 148, 168], ["interstitial edema", "DISEASE", 259, 277], ["intravascular thrombosis", "DISEASE", 346, 370], ["animals", "ORGANISM", 7, 14], ["microvascular", "TISSUE", 148, 161], ["PMN", "CELL", 174, 177], ["lungs", "ORGAN", 199, 204], ["pulmonary microvascular", "TISSUE", 221, 244], ["interstitial edema", "PATHOLOGICAL_FORMATION", 259, 277], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 313, 331], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 346, 359], ["hemodynamic stabilization", "TREATMENT", 99, 124], ["microvascular injury", "PROBLEM", 148, 168], ["PMN sequestration in the lungs", "PROBLEM", 174, 204], ["pulmonary microvascular permeability", "PROBLEM", 221, 257], ["interstitial edema", "PROBLEM", 259, 277], ["an increase in shunt fraction", "PROBLEM", 279, 308], ["pulmonary arterial pressure", "TEST", 313, 340], ["intravascular thrombosis", "PROBLEM", 346, 370], ["hemodynamic stabilization", "OBSERVATION", 99, 124], ["microvascular", "ANATOMY", 148, 161], ["injury", "OBSERVATION", 162, 168], ["PMN sequestration", "OBSERVATION", 174, 191], ["lungs", "ANATOMY", 199, 204], ["increase", "OBSERVATION_MODIFIER", 209, 217], ["pulmonary", "ANATOMY", 221, 230], ["microvascular permeability", "OBSERVATION", 231, 257], ["interstitial", "ANATOMY_MODIFIER", 259, 271], ["edema", "OBSERVATION", 272, 277], ["increase", "OBSERVATION_MODIFIER", 282, 290], ["shunt fraction", "OBSERVATION", 294, 308], ["pulmonary arterial", "ANATOMY", 313, 331], ["pressure", "OBSERVATION_MODIFIER", 332, 340], ["intravascular thrombosis", "OBSERVATION", 346, 370]]], ["However, the alveolar epithelium is relatively resistant to intravenous bacteria, and unless the inoculum is very high, there is little neutrophilic alveolitis or intra-alveolar edema formation (166, 239).", [["alveolar epithelium", "ANATOMY", 13, 32], ["intravenous", "ANATOMY", 60, 71], ["intra-alveolar edema", "ANATOMY", 163, 183], ["alveolitis", "DISEASE", 149, 159], ["edema", "DISEASE", 178, 183], ["alveolar epithelium", "TISSUE", 13, 32], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 60, 71], ["intra-alveolar edema", "PATHOLOGICAL_FORMATION", 163, 183], ["the alveolar epithelium", "PROBLEM", 9, 32], ["intravenous bacteria", "PROBLEM", 60, 80], ["the inoculum", "TEST", 93, 105], ["little neutrophilic alveolitis", "PROBLEM", 129, 159], ["intra-alveolar edema formation", "PROBLEM", 163, 193], ["alveolar", "ANATOMY_MODIFIER", 13, 21], ["epithelium", "ANATOMY_MODIFIER", 22, 32], ["relatively", "OBSERVATION_MODIFIER", 36, 46], ["resistant", "OBSERVATION_MODIFIER", 47, 56], ["intravenous bacteria", "OBSERVATION", 60, 80], ["very", "OBSERVATION_MODIFIER", 109, 113], ["high", "OBSERVATION_MODIFIER", 114, 118], ["little", "OBSERVATION_MODIFIER", 129, 135], ["neutrophilic", "OBSERVATION_MODIFIER", 136, 148], ["alveolitis", "OBSERVATION", 149, 159], ["intra-alveolar", "ANATOMY_MODIFIER", 163, 177], ["edema", "OBSERVATION", 178, 183]]], ["Thus, experimental bacteremia is not associated with the full histopathological picture of ARDS, including epithelial damage and hyaline membrane formation.", [["epithelial", "ANATOMY", 107, 117], ["hyaline membrane", "ANATOMY", 129, 145], ["bacteremia", "DISEASE", 19, 29], ["ARDS", "DISEASE", 91, 95], ["epithelial", "TISSUE", 107, 117], ["hyaline membrane", "CELLULAR_COMPONENT", 129, 145], ["experimental bacteremia", "PROBLEM", 6, 29], ["ARDS", "PROBLEM", 91, 95], ["epithelial damage", "PROBLEM", 107, 124], ["hyaline membrane formation", "PROBLEM", 129, 155], ["bacteremia", "OBSERVATION", 19, 29], ["not associated with", "UNCERTAINTY", 33, 52], ["ARDS", "OBSERVATION", 91, 95], ["epithelial damage", "OBSERVATION", 107, 124], ["hyaline membrane formation", "OBSERVATION", 129, 155]]], ["In humans, the relationship between bacteremia, sepsis, and ARDS is not clear.", [["bacteremia", "DISEASE", 36, 46], ["sepsis", "DISEASE", 48, 54], ["ARDS", "DISEASE", 60, 64], ["humans", "ORGANISM", 3, 9], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["bacteremia", "PROBLEM", 36, 46], ["sepsis", "PROBLEM", 48, 54], ["ARDS", "PROBLEM", 60, 64], ["bacteremia", "OBSERVATION", 36, 46], ["sepsis", "OBSERVATION", 48, 54], ["ARDS", "OBSERVATION", 60, 64], ["not", "UNCERTAINTY", 68, 71], ["clear", "OBSERVATION", 72, 77]]], ["Although sepsis is a major risk factor for ARDS, less than 50% of patients with clinically defined sepsis syndrome have detectable bacteremia, and when present, the bacteremia is usually less severe than that seen in most animal models (142).", [["sepsis", "DISEASE", 9, 15], ["ARDS", "DISEASE", 43, 47], ["sepsis", "DISEASE", 99, 105], ["bacteremia", "DISEASE", 131, 141], ["bacteremia", "DISEASE", 165, 175], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["sepsis", "PROBLEM", 9, 15], ["ARDS", "PROBLEM", 43, 47], ["clinically defined sepsis syndrome", "PROBLEM", 80, 114], ["detectable bacteremia", "PROBLEM", 120, 141], ["the bacteremia", "PROBLEM", 161, 175], ["sepsis", "OBSERVATION", 9, 15], ["ARDS", "OBSERVATION", 43, 47], ["sepsis", "OBSERVATION", 99, 105], ["detectable", "OBSERVATION_MODIFIER", 120, 130], ["bacteremia", "OBSERVATION", 131, 141], ["bacteremia", "OBSERVATION", 165, 175], ["less severe", "OBSERVATION_MODIFIER", 187, 198]]], ["Furthermore, bacteremia alone (in the absence of sepsis syndrome) is associated with an extremely low risk of ARDS (62).", [["bacteremia", "DISEASE", 13, 23], ["sepsis", "DISEASE", 49, 55], ["ARDS", "DISEASE", 110, 114], ["bacteremia", "PROBLEM", 13, 23], ["sepsis syndrome", "PROBLEM", 49, 64], ["ARDS", "PROBLEM", 110, 114], ["bacteremia", "OBSERVATION", 13, 23], ["sepsis", "OBSERVATION", 49, 55], ["extremely", "OBSERVATION_MODIFIER", 88, 97], ["low", "OBSERVATION_MODIFIER", 98, 101], ["ARDS", "OBSERVATION", 110, 114]]], ["Thus, the relevance of bacteremia models for human lung injury is unclear.", [["lung", "ANATOMY", 51, 55], ["bacteremia", "DISEASE", 23, 33], ["lung injury", "DISEASE", 51, 62], ["human", "ORGANISM", 45, 50], ["lung", "ORGAN", 51, 55], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 45, 50], ["bacteremia models", "PROBLEM", 23, 40], ["human lung injury", "PROBLEM", 45, 62], ["bacteremia", "OBSERVATION", 23, 33], ["lung", "ANATOMY", 51, 55], ["injury", "OBSERVATION", 56, 62]]], ["Investigators have tried to address these concerns by inducing primary infections that lead to sepsis and lung injury.Models of lung injury secondary to peritonitis: cecal ligation and puncture. ::: Models Targeting the Epithelium and Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSBecause many cases of human sepsis follow intraperitoneal infections (25), animal models have been developed in which peritonitis is followed by sepsis and lung injury.", [["lung", "ANATOMY", 106, 110], ["lung", "ANATOMY", 128, 132], ["cecal", "ANATOMY", 166, 171], ["Epithelium", "ANATOMY", 220, 230], ["intraperitoneal", "ANATOMY", 335, 350], ["lung", "ANATOMY", 449, 453], ["primary infections", "DISEASE", 63, 81], ["sepsis", "DISEASE", 95, 101], ["lung injury", "DISEASE", 106, 117], ["lung injury", "DISEASE", 128, 139], ["peritonitis", "DISEASE", 153, 164], ["sepsis", "DISEASE", 321, 327], ["infections", "DISEASE", 351, 361], ["peritonitis", "DISEASE", 411, 422], ["sepsis", "DISEASE", 438, 444], ["lung injury", "DISEASE", 449, 460], ["lung", "ORGAN", 106, 110], ["lung", "ORGAN", 128, 132], ["cecal", "ORGANISM_SUBDIVISION", 166, 171], ["Epithelium", "TISSUE", 220, 230], ["Endothelium", "TISSUE", 235, 246], ["human", "ORGANISM", 315, 320], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 335, 350], ["lung", "ORGAN", 449, 453], ["human", "SPECIES", 315, 320], ["human", "SPECIES", 315, 320], ["primary infections", "PROBLEM", 63, 81], ["sepsis", "PROBLEM", 95, 101], ["lung injury", "PROBLEM", 106, 117], ["lung injury", "PROBLEM", 128, 139], ["peritonitis", "PROBLEM", 153, 164], ["cecal ligation", "TREATMENT", 166, 180], ["puncture", "TREATMENT", 185, 193], ["LUNG INJURY", "PROBLEM", 268, 279], ["human sepsis", "PROBLEM", 315, 327], ["intraperitoneal infections", "PROBLEM", 335, 361], ["peritonitis", "PROBLEM", 411, 422], ["sepsis", "PROBLEM", 438, 444], ["lung injury", "PROBLEM", 449, 460], ["sepsis", "OBSERVATION", 95, 101], ["lung", "ANATOMY", 106, 110], ["injury", "OBSERVATION", 111, 117], ["lung", "ANATOMY", 128, 132], ["injury", "OBSERVATION", 133, 139], ["peritonitis", "OBSERVATION", 153, 164], ["cecal", "ANATOMY", 166, 171], ["ligation", "OBSERVATION", 172, 180], ["Epithelium", "ANATOMY_MODIFIER", 220, 230], ["LUNG", "ANATOMY", 268, 272], ["INJURY", "OBSERVATION", 273, 279], ["sepsis", "OBSERVATION_MODIFIER", 321, 327], ["peritonitis", "OBSERVATION", 411, 422], ["sepsis", "OBSERVATION", 438, 444], ["lung", "ANATOMY", 449, 453], ["injury", "OBSERVATION", 454, 460]]], ["Experimental peritonitis can be induced surgically by ligating and perforating the cecum (cecal ligation and puncture; CLP), or, alternatively, the bacteria can be incorporated into a carrier vehicle such as a fibrin clot or a sponge placed in the peritoneum (55, 135).", [["cecum", "ANATOMY", 83, 88], ["cecal", "ANATOMY", 90, 95], ["clot", "ANATOMY", 217, 221], ["sponge", "ANATOMY", 227, 233], ["peritoneum", "ANATOMY", 248, 258], ["peritonitis", "DISEASE", 13, 24], ["cecum", "MULTI-TISSUE_STRUCTURE", 83, 88], ["cecal", "MULTI-TISSUE_STRUCTURE", 90, 95], ["fibrin", "GENE_OR_GENE_PRODUCT", 210, 216], ["peritoneum", "MULTI-TISSUE_STRUCTURE", 248, 258], ["Experimental peritonitis", "PROBLEM", 0, 24], ["perforating the cecum", "PROBLEM", 67, 88], ["cecal ligation", "TREATMENT", 90, 104], ["puncture", "TREATMENT", 109, 117], ["CLP", "PROBLEM", 119, 122], ["the bacteria", "PROBLEM", 144, 156], ["a fibrin clot", "PROBLEM", 208, 221], ["a sponge", "TREATMENT", 225, 233], ["peritonitis", "OBSERVATION", 13, 24], ["cecum", "ANATOMY", 83, 88], ["cecal", "ANATOMY", 90, 95], ["ligation", "OBSERVATION", 96, 104], ["fibrin", "OBSERVATION_MODIFIER", 210, 216], ["clot", "OBSERVATION", 217, 221], ["sponge", "OBSERVATION", 227, 233], ["peritoneum", "ANATOMY", 248, 258]]], ["The inoculation of live bacteria directly into the peritoneal cavity is seldom used because the bacteria are either cleared rapidly by local host defense systems, or, if the inoculum is high, cause rapid death by sepsis (115).", [["peritoneal cavity", "ANATOMY", 51, 68], ["death", "DISEASE", 204, 209], ["sepsis", "DISEASE", 213, 219], ["peritoneal cavity", "MULTI-TISSUE_STRUCTURE", 51, 68], ["The inoculation of live bacteria", "PROBLEM", 0, 32], ["the bacteria", "PROBLEM", 92, 104], ["the inoculum", "PROBLEM", 170, 182], ["rapid death", "PROBLEM", 198, 209], ["sepsis", "PROBLEM", 213, 219], ["peritoneal cavity", "ANATOMY", 51, 68], ["bacteria", "OBSERVATION", 96, 104], ["sepsis", "OBSERVATION", 213, 219]]], ["In either case, there is very little lung injury.Models of lung injury secondary to peritonitis: cecal ligation and puncture. ::: Models Targeting the Epithelium and Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSCLP is the most widely used model of peritonitis.", [["lung", "ANATOMY", 37, 41], ["lung", "ANATOMY", 59, 63], ["cecal", "ANATOMY", 97, 102], ["Epithelium", "ANATOMY", 151, 161], ["lung injury", "DISEASE", 37, 48], ["lung injury", "DISEASE", 59, 70], ["peritonitis", "DISEASE", 84, 95], ["peritonitis", "DISEASE", 261, 272], ["lung", "ORGAN", 37, 41], ["lung", "ORGAN", 59, 63], ["cecal", "ORGANISM_SUBDIVISION", 97, 102], ["Epithelium", "TISSUE", 151, 161], ["Endothelium", "TISSUE", 166, 177], ["very little lung injury", "PROBLEM", 25, 48], ["lung injury", "PROBLEM", 59, 70], ["peritonitis", "PROBLEM", 84, 95], ["cecal ligation", "TREATMENT", 97, 111], ["puncture", "TREATMENT", 116, 124], ["LUNG INJURY", "PROBLEM", 199, 210], ["MODEL SYSTEMSCLP", "TREATMENT", 211, 227], ["peritonitis", "PROBLEM", 261, 272], ["very", "OBSERVATION_MODIFIER", 25, 29], ["little", "OBSERVATION_MODIFIER", 30, 36], ["lung", "ANATOMY", 37, 41], ["injury", "OBSERVATION", 42, 48], ["lung", "ANATOMY", 59, 63], ["injury", "OBSERVATION", 64, 70], ["peritonitis", "OBSERVATION", 84, 95], ["cecal", "ANATOMY", 97, 102], ["ligation", "OBSERVATION", 103, 111], ["Epithelium", "ANATOMY_MODIFIER", 151, 161], ["LUNG", "ANATOMY", 199, 203], ["INJURY", "OBSERVATION", 204, 210], ["MODEL SYSTEMSCLP", "OBSERVATION", 211, 227], ["most widely", "OBSERVATION_MODIFIER", 235, 246], ["peritonitis", "OBSERVATION", 261, 272]]], ["In CLP, the cecum is ligated and punctured three to five times with a needle.", [["cecum", "ANATOMY", 12, 17], ["cecum", "ORGAN", 12, 17], ["a needle", "TREATMENT", 68, 76], ["CLP", "OBSERVATION", 3, 6], ["cecum", "ANATOMY", 12, 17], ["ligated", "OBSERVATION", 21, 28]]], ["The severity of the injury depends on the number of holes in the cecum and on the size of the needle used to make the holes (228).", [["cecum", "ANATOMY", 65, 70], ["cecum", "ORGAN", 65, 70], ["the injury", "PROBLEM", 16, 26], ["the needle", "TREATMENT", 90, 100], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["injury", "OBSERVATION", 20, 26], ["cecum", "ANATOMY", 65, 70], ["size", "OBSERVATION_MODIFIER", 82, 86]]], ["In contrast to models using LPS and live bacteria, in which the effects are almost immediate, the effects of CLP develop over days, and the onset is less abrupt.", [["LPS", "CHEMICAL", 28, 31], ["LPS", "SIMPLE_CHEMICAL", 28, 31], ["LPS", "TREATMENT", 28, 31], ["live bacteria", "PROBLEM", 36, 49], ["CLP", "PROBLEM", 109, 112], ["CLP", "OBSERVATION", 109, 112], ["less", "OBSERVATION_MODIFIER", 149, 153], ["abrupt", "OBSERVATION_MODIFIER", 154, 160]]], ["Leukopenia develops within 24\u201330 h of surgery; pulmonary hypertension develops within 24\u201330 h; and lung injury develops within 18\u201372 h (79).", [["pulmonary", "ANATOMY", 47, 56], ["lung", "ANATOMY", 99, 103], ["Leukopenia", "DISEASE", 0, 10], ["pulmonary hypertension", "DISEASE", 47, 69], ["lung injury", "DISEASE", 99, 110], ["pulmonary", "ORGAN", 47, 56], ["lung", "ORGAN", 99, 103], ["Leukopenia", "PROBLEM", 0, 10], ["surgery", "TREATMENT", 38, 45], ["pulmonary hypertension", "PROBLEM", 47, 69], ["lung injury", "PROBLEM", 99, 110], ["pulmonary", "ANATOMY", 47, 56], ["hypertension", "OBSERVATION", 57, 69], ["lung", "ANATOMY", 99, 103], ["injury", "OBSERVATION", 104, 110]]], ["The main features of CLP-associated lung injury are hypoxemia, neutrophilic inflammation, and interstitial and alveolar edema (77, 128, 223) (Fig. 5).", [["lung", "ANATOMY", 36, 40], ["neutrophilic", "ANATOMY", 63, 75], ["interstitial", "ANATOMY", 94, 106], ["alveolar", "ANATOMY", 111, 119], ["CLP", "DISEASE", 21, 24], ["lung injury", "DISEASE", 36, 47], ["hypoxemia", "DISEASE", 52, 61], ["inflammation", "DISEASE", 76, 88], ["interstitial and alveolar edema", "DISEASE", 94, 125], ["lung", "ORGAN", 36, 40], ["alveolar edema", "PATHOLOGICAL_FORMATION", 111, 125], ["CLP", "PROBLEM", 21, 24], ["lung injury", "PROBLEM", 36, 47], ["hypoxemia", "PROBLEM", 52, 61], ["neutrophilic inflammation", "PROBLEM", 63, 88], ["interstitial and alveolar edema", "PROBLEM", 94, 125], ["main", "OBSERVATION_MODIFIER", 4, 8], ["CLP", "OBSERVATION", 21, 24], ["lung", "ANATOMY", 36, 40], ["injury", "OBSERVATION", 41, 47], ["hypoxemia", "OBSERVATION", 52, 61], ["neutrophilic", "OBSERVATION_MODIFIER", 63, 75], ["inflammation", "OBSERVATION", 76, 88], ["interstitial", "ANATOMY_MODIFIER", 94, 106], ["alveolar", "ANATOMY_MODIFIER", 111, 119], ["edema", "OBSERVATION", 120, 125]]], ["Blood cultures are usually positive for multiple organisms, the most common being enteric gram-negative rods such as serratia, enterobacter, and bacteroides species (77).", [["Blood cultures", "ANATOMY", 0, 14], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["enterobacter", "CANCER", 127, 139], ["bacteroides species", "ORGANISM", 145, 164], ["Blood cultures", "TEST", 0, 14], ["multiple organisms", "PROBLEM", 40, 58], ["enteric gram-negative rods", "PROBLEM", 82, 108], ["serratia", "PROBLEM", 117, 125], ["enterobacter", "PROBLEM", 127, 139], ["bacteroides species", "PROBLEM", 145, 164], ["most common", "OBSERVATION_MODIFIER", 64, 75], ["negative rods", "OBSERVATION", 95, 108]]], ["Mortality is high, ranging from 25% at 18 h to 70\u201390% within 30 h of the operation (79, 223).Models of lung injury secondary to peritonitis: cecal ligation and puncture. ::: Models Targeting the Epithelium and Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSThus, CLP results in mild lung injury similar to ALI/ARDS, although with less impressive intra-alveolar inflammation and hyaline membrane formation.", [["lung", "ANATOMY", 103, 107], ["cecal", "ANATOMY", 141, 146], ["Epithelium", "ANATOMY", 195, 205], ["lung", "ANATOMY", 294, 298], ["intra-alveolar", "ANATOMY", 357, 371], ["hyaline membrane", "ANATOMY", 389, 405], ["lung injury", "DISEASE", 103, 114], ["peritonitis", "DISEASE", 128, 139], ["lung injury", "DISEASE", 294, 305], ["ALI", "DISEASE", 317, 320], ["ARDS", "DISEASE", 321, 325], ["inflammation", "DISEASE", 372, 384], ["lung", "ORGAN", 103, 107], ["cecal", "ORGANISM_SUBDIVISION", 141, 146], ["Epithelium", "TISSUE", 195, 205], ["Endothelium", "TISSUE", 210, 221], ["lung", "ORGAN", 294, 298], ["intra-alveolar inflammation", "PATHOLOGICAL_FORMATION", 357, 384], ["hyaline membrane", "CELLULAR_COMPONENT", 389, 405], ["Mortality", "TEST", 0, 9], ["the operation", "TREATMENT", 69, 82], ["lung injury", "PROBLEM", 103, 114], ["peritonitis", "PROBLEM", 128, 139], ["cecal ligation", "TREATMENT", 141, 155], ["puncture", "TREATMENT", 160, 168], ["LUNG INJURY", "PROBLEM", 243, 254], ["mild lung injury", "PROBLEM", 289, 305], ["ALI", "PROBLEM", 317, 320], ["ARDS", "PROBLEM", 321, 325], ["impressive intra-alveolar inflammation", "PROBLEM", 346, 384], ["hyaline membrane formation", "PROBLEM", 389, 415], ["high", "OBSERVATION_MODIFIER", 13, 17], ["lung", "ANATOMY", 103, 107], ["injury", "OBSERVATION", 108, 114], ["peritonitis", "OBSERVATION", 128, 139], ["cecal", "ANATOMY", 141, 146], ["ligation", "OBSERVATION", 147, 155], ["Epithelium", "ANATOMY_MODIFIER", 195, 205], ["LUNG", "ANATOMY", 243, 247], ["INJURY", "OBSERVATION", 248, 254], ["mild", "OBSERVATION_MODIFIER", 289, 293], ["lung", "ANATOMY", 294, 298], ["injury", "OBSERVATION", 299, 305], ["ALI", "OBSERVATION", 317, 320], ["ARDS", "OBSERVATION", 321, 325], ["less", "OBSERVATION_MODIFIER", 341, 345], ["impressive", "OBSERVATION_MODIFIER", 346, 356], ["intra-alveolar", "OBSERVATION_MODIFIER", 357, 371], ["inflammation", "OBSERVATION", 372, 384], ["hyaline membrane formation", "OBSERVATION", 389, 415]]], ["It is probably the single best animal model of sepsis and organ injury, but the main disadvantage is the requirement for major surgery.", [["organ", "ANATOMY", 58, 63], ["sepsis", "DISEASE", 47, 53], ["organ injury", "DISEASE", 58, 70], ["organ", "ORGAN", 58, 63], ["sepsis", "PROBLEM", 47, 53], ["organ injury", "PROBLEM", 58, 70], ["major surgery", "TREATMENT", 121, 134], ["sepsis", "OBSERVATION", 47, 53], ["organ", "ANATOMY", 58, 63], ["injury", "OBSERVATION", 64, 70], ["main", "OBSERVATION_MODIFIER", 80, 84], ["surgery", "OBSERVATION", 127, 134]]], ["In addition, the actual bacterial inoculum in CLP is unknown, and the model could be affected by differences in colonic flora among animals, resulting in significant variability.Models of lung injury secondary to peritonitis: cecal ligation and puncture. ::: Models Targeting the Epithelium and Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSLocal administration of live bacteria into the lungs: pulmonary infections are the main risk factor of ALI/ARDS in 46\u201351% of patients (184).", [["colonic flora", "ANATOMY", 112, 125], ["lung", "ANATOMY", 188, 192], ["cecal", "ANATOMY", 226, 231], ["Epithelium", "ANATOMY", 280, 290], ["lungs", "ANATOMY", 400, 405], ["pulmonary", "ANATOMY", 407, 416], ["lung injury", "DISEASE", 188, 199], ["peritonitis", "DISEASE", 213, 224], ["pulmonary infections", "DISEASE", 407, 427], ["ALI", "DISEASE", 456, 459], ["ARDS", "DISEASE", 460, 464], ["colonic flora", "MULTI-TISSUE_STRUCTURE", 112, 125], ["lung", "ORGAN", 188, 192], ["cecal", "ORGANISM_SUBDIVISION", 226, 231], ["Epithelium", "TISSUE", 280, 290], ["Endothelium", "TISSUE", 295, 306], ["lungs", "ORGAN", 400, 405], ["pulmonary", "ORGAN", 407, 416], ["patients", "ORGANISM", 478, 486], ["patients", "SPECIES", 478, 486], ["the actual bacterial inoculum in CLP", "PROBLEM", 13, 49], ["colonic flora", "PROBLEM", 112, 125], ["significant variability", "PROBLEM", 154, 177], ["lung injury", "PROBLEM", 188, 199], ["peritonitis", "PROBLEM", 213, 224], ["cecal ligation", "TREATMENT", 226, 240], ["puncture", "TREATMENT", 245, 253], ["LUNG INJURY", "PROBLEM", 328, 339], ["MODEL SYSTEMSLocal administration", "TREATMENT", 340, 373], ["pulmonary infections", "PROBLEM", 407, 427], ["ALI", "PROBLEM", 456, 459], ["ARDS", "PROBLEM", 460, 464], ["bacterial", "OBSERVATION_MODIFIER", 24, 33], ["inoculum", "OBSERVATION", 34, 42], ["CLP", "OBSERVATION", 46, 49], ["colonic", "ANATOMY", 112, 119], ["flora", "OBSERVATION", 120, 125], ["significant", "OBSERVATION_MODIFIER", 154, 165], ["variability", "OBSERVATION_MODIFIER", 166, 177], ["lung", "ANATOMY", 188, 192], ["injury", "OBSERVATION", 193, 199], ["peritonitis", "OBSERVATION", 213, 224], ["cecal", "ANATOMY", 226, 231], ["ligation", "OBSERVATION", 232, 240], ["Epithelium", "ANATOMY_MODIFIER", 280, 290], ["LUNG", "ANATOMY", 328, 332], ["INJURY", "OBSERVATION", 333, 339], ["lungs", "ANATOMY", 400, 405], ["pulmonary", "ANATOMY", 407, 416], ["infections", "OBSERVATION", 417, 427], ["ALI", "OBSERVATION", 456, 459], ["ARDS", "OBSERVATION", 460, 464]]], ["In animals, local administration of bacteria into the lungs can be achieved by using an intratracheal catheter, by transtracheal instillation, by direct intrabronchial instillation using a bronchoscope, or by aerosolization (64, 86, 147).", [["lungs", "ANATOMY", 54, 59], ["transtracheal", "ANATOMY", 115, 128], ["intrabronchial", "ANATOMY", 153, 167], ["lungs", "ORGAN", 54, 59], ["bacteria into the lungs", "PROBLEM", 36, 59], ["an intratracheal catheter", "TREATMENT", 85, 110], ["transtracheal instillation", "TREATMENT", 115, 141], ["direct intrabronchial instillation", "TREATMENT", 146, 180], ["a bronchoscope", "TREATMENT", 187, 201], ["lungs", "ANATOMY", 54, 59], ["intratracheal catheter", "OBSERVATION", 88, 110], ["transtracheal", "ANATOMY", 115, 128], ["intrabronchial", "ANATOMY", 153, 167]]], ["Intratracheal instillation of bacteria results in a localized area of pneumonia, whereas aerosolization results in diffuse infection (Fig. 3, E and F).", [["Intratracheal", "ANATOMY", 0, 13], ["pneumonia", "DISEASE", 70, 79], ["infection", "DISEASE", 123, 132], ["Intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["Intratracheal instillation", "TREATMENT", 0, 26], ["bacteria", "PROBLEM", 30, 38], ["pneumonia", "PROBLEM", 70, 79], ["diffuse infection", "PROBLEM", 115, 132], ["bacteria", "OBSERVATION", 30, 38], ["pneumonia", "OBSERVATION", 70, 79], ["diffuse", "OBSERVATION_MODIFIER", 115, 122], ["infection", "OBSERVATION", 123, 132]]], ["Aerosolization has two main advantages: there is no need to anesthetize the animal, and a large number of animals can be treated simultaneously in an aerosol chamber (179).", [["animals", "ORGANISM", 106, 113], ["Aerosolization", "TREATMENT", 0, 14], ["an aerosol chamber", "TREATMENT", 147, 165], ["two", "OBSERVATION_MODIFIER", 19, 22], ["main", "OBSERVATION_MODIFIER", 23, 27], ["advantages", "OBSERVATION_MODIFIER", 28, 38], ["no need to", "UNCERTAINTY", 49, 59], ["large", "OBSERVATION_MODIFIER", 90, 95], ["number", "OBSERVATION_MODIFIER", 96, 102]]], ["A recent article in this series has extensively reviewed animal models of pneumonia (140), and, therefore, here we will only present a very succinct commentary of some key features of this model.Models of lung injury secondary to peritonitis: cecal ligation and puncture. ::: Models Targeting the Epithelium and Endothelium ::: AGENTS TO INDUCE LUNG INJURY/MODEL SYSTEMSThe local administration of bacteria results in pneumonia, and, depending on the size of the bacterial inoculum, systemic manifestations of sepsis.", [["lung", "ANATOMY", 205, 209], ["cecal", "ANATOMY", 243, 248], ["Epithelium", "ANATOMY", 297, 307], ["pneumonia", "DISEASE", 74, 83], ["lung injury", "DISEASE", 205, 216], ["peritonitis", "DISEASE", 230, 241], ["pneumonia", "DISEASE", 418, 427], ["sepsis", "DISEASE", 510, 516], ["lung", "ORGAN", 205, 209], ["cecal", "ORGANISM_SUBDIVISION", 243, 248], ["Epithelium", "TISSUE", 297, 307], ["Endothelium", "TISSUE", 312, 323], ["pneumonia", "PROBLEM", 74, 83], ["lung injury", "PROBLEM", 205, 216], ["peritonitis", "PROBLEM", 230, 241], ["cecal ligation", "TREATMENT", 243, 257], ["puncture", "TREATMENT", 262, 270], ["LUNG INJURY", "PROBLEM", 345, 356], ["bacteria", "PROBLEM", 398, 406], ["pneumonia", "PROBLEM", 418, 427], ["the bacterial inoculum", "PROBLEM", 459, 481], ["sepsis", "PROBLEM", 510, 516], ["pneumonia", "OBSERVATION", 74, 83], ["lung", "ANATOMY", 205, 209], ["injury", "OBSERVATION", 210, 216], ["peritonitis", "OBSERVATION", 230, 241], ["cecal", "ANATOMY", 243, 248], ["ligation", "OBSERVATION", 249, 257], ["Epithelium", "ANATOMY_MODIFIER", 297, 307], ["LUNG", "ANATOMY", 345, 349], ["INJURY", "OBSERVATION", 350, 356], ["pneumonia", "OBSERVATION", 418, 427], ["size", "OBSERVATION_MODIFIER", 451, 455], ["bacterial inoculum", "OBSERVATION", 463, 481], ["systemic", "OBSERVATION_MODIFIER", 483, 491], ["sepsis", "OBSERVATION", 510, 516]]], ["In rabbits, the intrapulmonary instillation of Escherichia coli at doses ranging from 1 \u00d7 107 to 1 \u00d7 1010 CFU/ml into the right lower lobe via a catheter produced local and systemic inflammatory responses (64).", [["intrapulmonary", "ANATOMY", 16, 30], ["right lower lobe", "ANATOMY", 122, 138], ["rabbits", "ORGANISM", 3, 10], ["intrapulmonary", "IMMATERIAL_ANATOMICAL_ENTITY", 16, 30], ["Escherichia coli", "ORGANISM", 47, 63], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 128, 138], ["rabbits", "SPECIES", 3, 10], ["Escherichia coli", "SPECIES", 47, 63], ["rabbits", "SPECIES", 3, 10], ["Escherichia coli", "SPECIES", 47, 63], ["the intrapulmonary instillation of Escherichia coli", "TREATMENT", 12, 63], ["a catheter", "TREATMENT", 143, 153], ["systemic inflammatory responses", "TEST", 173, 204], ["intrapulmonary", "ANATOMY", 16, 30], ["instillation", "OBSERVATION", 31, 43], ["Escherichia coli", "OBSERVATION", 47, 63], ["right lower lobe", "ANATOMY", 122, 138], ["catheter", "OBSERVATION", 145, 153], ["local", "OBSERVATION_MODIFIER", 163, 168], ["systemic", "OBSERVATION_MODIFIER", 173, 181], ["inflammatory", "OBSERVATION_MODIFIER", 182, 194]]], ["At low bacterial doses, the systemic changes were minimal.", [["low bacterial doses", "TREATMENT", 3, 22], ["the systemic changes", "PROBLEM", 24, 44], ["bacterial doses", "OBSERVATION_MODIFIER", 7, 22], ["systemic", "OBSERVATION", 28, 36], ["minimal", "OBSERVATION_MODIFIER", 50, 57]]], ["At high bacterial doses, the animals developed severe localized pneumonia with epithelial injury and empyema and severe systemic manifestations including shock (64, 240).", [["epithelial", "ANATOMY", 79, 89], ["pneumonia", "DISEASE", 64, 73], ["epithelial injury", "DISEASE", 79, 96], ["empyema", "DISEASE", 101, 108], ["shock", "DISEASE", 154, 159], ["epithelial", "TISSUE", 79, 89], ["high bacterial doses", "TREATMENT", 3, 23], ["severe localized pneumonia", "PROBLEM", 47, 73], ["epithelial injury", "PROBLEM", 79, 96], ["empyema", "PROBLEM", 101, 108], ["severe systemic manifestations", "PROBLEM", 113, 143], ["shock", "PROBLEM", 154, 159], ["bacterial doses", "OBSERVATION_MODIFIER", 8, 23], ["severe", "OBSERVATION_MODIFIER", 47, 53], ["localized", "OBSERVATION_MODIFIER", 54, 63], ["pneumonia", "OBSERVATION", 64, 73], ["epithelial injury", "OBSERVATION", 79, 96], ["empyema", "OBSERVATION", 101, 108], ["severe", "OBSERVATION_MODIFIER", 113, 119], ["systemic", "OBSERVATION_MODIFIER", 120, 128], ["manifestations", "OBSERVATION", 129, 143], ["shock", "OBSERVATION_MODIFIER", 154, 159]]], ["Interestingly, bacterial pneumonia due to Pseudomonas aeruginosa and also to E. coli is associated with an increase in alveolar fluid clearance, indicating that alveolar epithelial function is partly preserved (177, 210).", [["alveolar fluid", "ANATOMY", 119, 133], ["alveolar epithelial", "ANATOMY", 161, 180], ["pneumonia", "DISEASE", 25, 34], ["Pseudomonas aeruginosa", "ORGANISM", 42, 64], ["E. coli", "ORGANISM", 77, 84], ["alveolar fluid", "ORGANISM_SUBSTANCE", 119, 133], ["alveolar epithelial", "TISSUE", 161, 180], ["Pseudomonas aeruginosa", "SPECIES", 42, 64], ["E. coli", "SPECIES", 77, 84], ["Pseudomonas aeruginosa", "SPECIES", 42, 64], ["E. coli", "SPECIES", 77, 84], ["bacterial pneumonia", "PROBLEM", 15, 34], ["Pseudomonas aeruginosa", "PROBLEM", 42, 64], ["E. coli", "PROBLEM", 77, 84], ["an increase in alveolar fluid clearance", "PROBLEM", 104, 143], ["alveolar epithelial function", "TEST", 161, 189], ["bacterial", "OBSERVATION_MODIFIER", 15, 24], ["pneumonia", "OBSERVATION", 25, 34], ["Pseudomonas aeruginosa", "OBSERVATION", 42, 64], ["E. coli", "OBSERVATION_MODIFIER", 77, 84], ["associated with", "UNCERTAINTY", 88, 103], ["increase", "OBSERVATION_MODIFIER", 107, 115], ["alveolar", "ANATOMY_MODIFIER", 119, 127], ["fluid clearance", "OBSERVATION", 128, 143], ["alveolar", "ANATOMY_MODIFIER", 161, 169], ["epithelial function", "OBSERVATION", 170, 189]]], ["Histologically, the intratracheal administration of bacteria results in localized pneumonia (rather than ARDS) in the instilled lung.", [["intratracheal", "ANATOMY", 20, 33], ["lung", "ANATOMY", 128, 132], ["pneumonia", "DISEASE", 82, 91], ["ARDS", "DISEASE", 105, 109], ["lung", "ORGAN", 128, 132], ["the intratracheal administration", "TREATMENT", 16, 48], ["bacteria", "PROBLEM", 52, 60], ["localized pneumonia", "PROBLEM", 72, 91], ["ARDS) in the instilled lung", "PROBLEM", 105, 132], ["intratracheal", "ANATOMY", 20, 33], ["localized", "OBSERVATION_MODIFIER", 72, 81], ["pneumonia", "OBSERVATION", 82, 91], ["instilled", "ANATOMY_MODIFIER", 118, 127], ["lung", "ANATOMY", 128, 132]]], ["However, unilateral administration of bacteria can result in lung injury in the contralateral lung, depending on the bacterial dose.", [["lung", "ANATOMY", 61, 65], ["lung", "ANATOMY", 94, 98], ["lung injury", "DISEASE", 61, 72], ["lung", "ORGAN", 61, 65], ["lung", "ORGAN", 94, 98], ["bacteria", "PROBLEM", 38, 46], ["lung injury in the contralateral lung", "PROBLEM", 61, 98], ["the bacterial dose", "TREATMENT", 113, 131], ["lung", "ANATOMY", 61, 65], ["injury", "OBSERVATION", 66, 72], ["contralateral", "ANATOMY_MODIFIER", 80, 93], ["lung", "ANATOMY", 94, 98]]], ["In rats, the administration of 1 \u00d7 106 CFU/ml P. aeruginosa to the right lung results 4 h later in an ipsilateral increase in inflammatory cytokines (TNF-\u03b1 and CINC) but not in neutrophil sequestration or permeability changes (214).", [["right lung", "ANATOMY", 67, 77], ["neutrophil", "ANATOMY", 177, 187], ["rats", "ORGANISM", 3, 7], ["P. aeruginosa", "ORGANISM", 46, 59], ["lung", "ORGAN", 73, 77], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 150, 155], ["CINC", "GENE_OR_GENE_PRODUCT", 160, 164], ["neutrophil", "CELL", 177, 187], ["inflammatory cytokines", "PROTEIN", 126, 148], ["TNF", "PROTEIN", 150, 153], ["CINC", "PROTEIN", 160, 164], ["neutrophil", "CELL_TYPE", 177, 187], ["rats", "SPECIES", 3, 7], ["P. aeruginosa", "SPECIES", 46, 59], ["P. aeruginosa", "SPECIES", 46, 59], ["an ipsilateral increase", "PROBLEM", 99, 122], ["inflammatory cytokines", "TEST", 126, 148], ["TNF", "TEST", 150, 153], ["CINC", "TEST", 160, 164], ["neutrophil sequestration", "PROBLEM", 177, 201], ["permeability changes", "PROBLEM", 205, 225], ["right", "ANATOMY_MODIFIER", 67, 72], ["lung", "ANATOMY", 73, 77], ["ipsilateral", "OBSERVATION_MODIFIER", 102, 113], ["increase", "OBSERVATION_MODIFIER", 114, 122], ["inflammatory cytokines", "OBSERVATION", 126, 148], ["not in", "UNCERTAINTY", 170, 176], ["neutrophil sequestration", "OBSERVATION", 177, 201], ["permeability changes", "OBSERVATION", 205, 225]]], ["A higher dose, 1 \u00d7 107 CFU/ml, results in bilateral increases in permeability and PMN sequestration as well as an increase in plasma cytokines.SUMMARY AND CONCLUSIONSIn summary, this review discusses several animal models of ALI with the goal of helping investigators choose the model best suited to specific scientific questions.", [["PMN", "ANATOMY", 82, 85], ["plasma", "ANATOMY", 126, 132], ["ALI", "DISEASE", 225, 228], ["PMN", "CELL", 82, 85], ["plasma", "ORGANISM_SUBSTANCE", 126, 132], ["plasma cytokines", "PROTEIN", 126, 142], ["bilateral increases in permeability", "PROBLEM", 42, 77], ["PMN sequestration", "PROBLEM", 82, 99], ["an increase in plasma cytokines", "TREATMENT", 111, 142], ["bilateral", "ANATOMY_MODIFIER", 42, 51], ["increases", "OBSERVATION_MODIFIER", 52, 61], ["permeability", "OBSERVATION_MODIFIER", 65, 77], ["PMN sequestration", "OBSERVATION", 82, 99], ["increase", "OBSERVATION_MODIFIER", 114, 122], ["plasma cytokines", "OBSERVATION", 126, 142]]], ["However, none of these models of ALI adequately reproduces the full characteristics of human ALI/ARDS, namely an acute neutrophilic alveolitis with hyaline membrane formation and intravascular microthrombi, and, therefore, the choice of a particular model should be made after considering the specific features of each model.SUMMARY AND CONCLUSIONSSeveral limitations are common to all models of ALI.", [["hyaline membrane", "ANATOMY", 148, 164], ["intravascular", "ANATOMY", 179, 192], ["ALI", "DISEASE", 33, 36], ["ALI", "DISEASE", 93, 96], ["ARDS", "DISEASE", 97, 101], ["alveolitis", "DISEASE", 132, 142], ["intravascular microthrombi", "DISEASE", 179, 205], ["ALI", "DISEASE", 396, 399], ["human", "ORGANISM", 87, 92], ["hyaline membrane", "TISSUE", 148, 164], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 179, 192], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 87, 92], ["ALI", "PROBLEM", 33, 36], ["human ALI", "PROBLEM", 87, 96], ["ARDS", "PROBLEM", 97, 101], ["an acute neutrophilic alveolitis", "PROBLEM", 110, 142], ["hyaline membrane formation", "PROBLEM", 148, 174], ["intravascular microthrombi", "PROBLEM", 179, 205], ["ALI", "PROBLEM", 396, 399], ["ALI", "OBSERVATION", 33, 36], ["ALI", "OBSERVATION", 93, 96], ["ARDS", "OBSERVATION", 97, 101], ["acute", "OBSERVATION_MODIFIER", 113, 118], ["neutrophilic", "OBSERVATION_MODIFIER", 119, 131], ["alveolitis", "OBSERVATION", 132, 142], ["hyaline membrane formation", "OBSERVATION", 148, 174], ["intravascular microthrombi", "OBSERVATION", 179, 205], ["ALI", "OBSERVATION", 396, 399]]], ["Most models are based on one, or, at most, two methods to cause injury.", [["injury", "PROBLEM", 64, 70], ["injury", "OBSERVATION", 64, 70]]], ["However, human ALI/ARDS is seldom caused by any single event.", [["ALI", "DISEASE", 15, 18], ["ARDS", "DISEASE", 19, 23], ["human", "ORGANISM", 9, 14], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14], ["human ALI", "PROBLEM", 9, 18], ["ARDS", "PROBLEM", 19, 23], ["ALI", "OBSERVATION", 15, 18], ["ARDS", "OBSERVATION", 19, 23]]], ["More often, ARDS in humans is associated with complex interactions between primary risk factors such as sepsis and oropharyngeal aspiration; comorbidities, such as diabetes, alcoholism, and underlying lung disease; and additional factors inherent to the host, such as genetic determinants.", [["oropharyngeal", "ANATOMY", 115, 128], ["lung", "ANATOMY", 201, 205], ["ARDS", "DISEASE", 12, 16], ["sepsis", "DISEASE", 104, 110], ["oropharyngeal aspiration", "DISEASE", 115, 139], ["diabetes", "DISEASE", 164, 172], ["alcoholism", "DISEASE", 174, 184], ["lung disease", "DISEASE", 201, 213], ["humans", "ORGANISM", 20, 26], ["oropharyngeal", "ORGANISM_SUBDIVISION", 115, 128], ["lung", "ORGAN", 201, 205], ["humans", "SPECIES", 20, 26], ["humans", "SPECIES", 20, 26], ["ARDS", "PROBLEM", 12, 16], ["primary risk factors", "PROBLEM", 75, 95], ["sepsis", "PROBLEM", 104, 110], ["oropharyngeal aspiration", "PROBLEM", 115, 139], ["comorbidities", "PROBLEM", 141, 154], ["diabetes", "PROBLEM", 164, 172], ["alcoholism", "PROBLEM", 174, 184], ["underlying lung disease", "PROBLEM", 190, 213], ["ARDS", "OBSERVATION", 12, 16], ["sepsis", "OBSERVATION", 104, 110], ["oropharyngeal", "ANATOMY", 115, 128], ["aspiration", "OBSERVATION", 129, 139], ["alcoholism", "OBSERVATION", 174, 184], ["lung", "ANATOMY", 201, 205], ["disease", "OBSERVATION", 206, 213]]], ["Another shortcoming of animal models is that interspecies variability in innate immunity and other responses may affect the relevance of animal data for humans.", [["humans", "ORGANISM", 153, 159], ["humans", "SPECIES", 153, 159], ["humans", "SPECIES", 153, 159]]], ["Finally, most models target a primary tissue, the alveolar epithelium, the alveolar endothelium, or both, but the primary target tissue in human ALI/ARDS remains unknown.", [["primary tissue", "ANATOMY", 30, 44], ["alveolar epithelium", "ANATOMY", 50, 69], ["alveolar endothelium", "ANATOMY", 75, 95], ["tissue", "ANATOMY", 129, 135], ["ALI", "DISEASE", 145, 148], ["ARDS", "DISEASE", 149, 153], ["tissue", "TISSUE", 38, 44], ["alveolar epithelium", "TISSUE", 50, 69], ["alveolar endothelium", "TISSUE", 75, 95], ["tissue", "TISSUE", 129, 135], ["human", "ORGANISM", 139, 144], ["human", "SPECIES", 139, 144], ["human", "SPECIES", 139, 144], ["ARDS", "PROBLEM", 149, 153], ["most models", "OBSERVATION_MODIFIER", 9, 20], ["primary tissue", "OBSERVATION", 30, 44], ["alveolar", "ANATOMY_MODIFIER", 50, 58], ["epithelium", "ANATOMY_MODIFIER", 59, 69], ["alveolar endothelium", "ANATOMY", 75, 95], ["both", "OBSERVATION_MODIFIER", 100, 104], ["primary", "OBSERVATION_MODIFIER", 114, 121], ["target tissue", "OBSERVATION", 122, 135], ["human", "ANATOMY", 139, 144], ["ALI", "OBSERVATION", 145, 148], ["ARDS", "OBSERVATION", 149, 153]]], ["These shortcomings, alone or in combination, are probably responsible for the fact that animal models have often yielded different or even contradictory results and that therapeutic approaches effective in animals are not always successful in humans.", [["animals", "ORGANISM", 206, 213], ["humans", "ORGANISM", 243, 249], ["humans", "SPECIES", 243, 249], ["humans", "SPECIES", 243, 249], ["therapeutic approaches", "TREATMENT", 170, 192], ["probably responsible for", "UNCERTAINTY", 49, 73]]], ["However, despite these limitations, studies using animal models of ALI/ARDS remain essential because at the present time there is no substitute for animal models as tools to generate information about the pathophysiology of lung injury and to test novel therapeutic interventions in complex biological systems.SUMMARY AND CONCLUSIONSTo overcome these shortcomings, investigators must pay special attention to choosing the model best suited to test their hypothesis and should be aware of the differences between the model used and human ALI/ARDS.", [["lung", "ANATOMY", 224, 228], ["ALI", "DISEASE", 67, 70], ["ARDS", "DISEASE", 71, 75], ["lung injury", "DISEASE", 224, 235], ["ALI", "DISEASE", 537, 540], ["ARDS", "DISEASE", 541, 545], ["lung", "ORGAN", 224, 228], ["human", "ORGANISM", 531, 536], ["human", "SPECIES", 531, 536], ["human", "SPECIES", 531, 536], ["studies", "TEST", 36, 43], ["ALI/ARDS", "PROBLEM", 67, 75], ["lung injury", "PROBLEM", 224, 235], ["therapeutic interventions", "TREATMENT", 254, 279], ["ARDS", "PROBLEM", 541, 545], ["ARDS", "OBSERVATION", 71, 75], ["no substitute", "UNCERTAINTY", 130, 143], ["lung", "ANATOMY", 224, 228], ["injury", "OBSERVATION", 229, 235], ["ALI", "OBSERVATION", 537, 540], ["ARDS", "OBSERVATION", 541, 545]]], ["Of the models discussed in this review, the models that most consistently approach the features of human ARDS, at least those observed during the acute phase, include oleic acid instillation, acid aspiration, and hyperoxia.", [["ARDS", "DISEASE", 105, 109], ["oleic acid", "CHEMICAL", 167, 177], ["oleic acid", "CHEMICAL", 167, 177], ["human", "ORGANISM", 99, 104], ["oleic acid", "SIMPLE_CHEMICAL", 167, 177], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104], ["human ARDS", "PROBLEM", 99, 109], ["oleic acid instillation", "TREATMENT", 167, 190], ["acid aspiration", "PROBLEM", 192, 207], ["hyperoxia", "PROBLEM", 213, 222], ["ARDS", "OBSERVATION", 105, 109], ["hyperoxia", "OBSERVATION_MODIFIER", 213, 222]]], ["Unfortunately, only a fraction of cases of ARDS is caused by long bone trauma (modeled by oleic acid instillation), humans seldom aspirate gastric juice with pH 1.5 or less, and hyperoxia has not been shown to cause ALI/ARDS in humans (42).", [["bone", "ANATOMY", 66, 70], ["gastric juice", "ANATOMY", 139, 152], ["ARDS", "DISEASE", 43, 47], ["bone trauma", "DISEASE", 66, 77], ["oleic acid", "CHEMICAL", 90, 100], ["hyperoxia", "CHEMICAL", 178, 187], ["ALI", "DISEASE", 216, 219], ["ARDS", "DISEASE", 220, 224], ["oleic acid", "CHEMICAL", 90, 100], ["bone", "TISSUE", 66, 70], ["oleic acid", "SIMPLE_CHEMICAL", 90, 100], ["humans", "ORGANISM", 116, 122], ["gastric juice", "ORGANISM_SUBSTANCE", 139, 152], ["humans", "ORGANISM", 228, 234], ["humans", "SPECIES", 116, 122], ["humans", "SPECIES", 228, 234], ["humans", "SPECIES", 116, 122], ["humans", "SPECIES", 228, 234], ["ARDS", "PROBLEM", 43, 47], ["long bone trauma", "PROBLEM", 61, 77], ["oleic acid instillation", "TREATMENT", 90, 113], ["gastric juice", "TEST", 139, 152], ["pH", "TEST", 158, 160], ["hyperoxia", "TEST", 178, 187], ["ALI", "PROBLEM", 216, 219], ["ARDS", "PROBLEM", 220, 224], ["ARDS", "OBSERVATION", 43, 47], ["long", "OBSERVATION_MODIFIER", 61, 65], ["bone", "ANATOMY", 66, 70], ["trauma", "OBSERVATION", 71, 77], ["gastric", "ANATOMY", 139, 146], ["juice", "OBSERVATION", 147, 152], ["ARDS", "OBSERVATION", 220, 224]]], ["Surfactant depletion by saline lavage results in a decrease in lung compliance and hypoxemia, but not in alveolar epithelial injury or neutrophilic alveolitis unless a second injury, such as bacterial endotoxin or mechanical ventilation, is added.", [["lung", "ANATOMY", 63, 67], ["alveolar epithelial", "ANATOMY", 105, 124], ["hypoxemia", "DISEASE", 83, 92], ["alveolar epithelial injury", "DISEASE", 105, 131], ["alveolitis", "DISEASE", 148, 158], ["Surfactant", "SIMPLE_CHEMICAL", 0, 10], ["lung", "ORGAN", 63, 67], ["alveolar epithelial", "TISSUE", 105, 124], ["Surfactant depletion", "TREATMENT", 0, 20], ["saline lavage", "TREATMENT", 24, 37], ["a decrease in lung compliance", "PROBLEM", 49, 78], ["hypoxemia", "PROBLEM", 83, 92], ["alveolar epithelial injury", "PROBLEM", 105, 131], ["neutrophilic alveolitis", "PROBLEM", 135, 158], ["a second injury", "PROBLEM", 166, 181], ["bacterial endotoxin", "TREATMENT", 191, 210], ["mechanical ventilation", "TREATMENT", 214, 236], ["saline lavage", "OBSERVATION", 24, 37], ["decrease", "OBSERVATION_MODIFIER", 51, 59], ["lung", "ANATOMY", 63, 67], ["compliance", "OBSERVATION", 68, 78], ["hypoxemia", "OBSERVATION", 83, 92], ["not in", "UNCERTAINTY", 98, 104], ["alveolar", "ANATOMY_MODIFIER", 105, 113], ["epithelial", "ANATOMY", 114, 124], ["injury", "OBSERVATION", 125, 131], ["neutrophilic", "OBSERVATION_MODIFIER", 135, 147], ["alveolitis", "OBSERVATION", 148, 158], ["mechanical ventilation", "OBSERVATION", 214, 236]]], ["Sepsis is one of the most common causes of ARDS in humans, but attempts at modeling sepsis by treating animals with bacteria or bacterial products systemically is usually associated with only mild alveolar neutrophilia and minimal changes in alveolar-capillary permeability.SUMMARY AND CONCLUSIONSBecause of the difficulties in modeling human ALI/ARDS in animals, and because of differences among species, extrapolating the results of animal studies to humans must be done with a great deal of care.", [["alveolar", "ANATOMY", 197, 205], ["alveolar", "ANATOMY", 242, 250], ["capillary", "ANATOMY", 251, 260], ["Sepsis", "DISEASE", 0, 6], ["ARDS", "DISEASE", 43, 47], ["sepsis", "DISEASE", 84, 90], ["neutrophilia", "DISEASE", 206, 218], ["ALI", "DISEASE", 343, 346], ["ARDS", "DISEASE", 347, 351], ["humans", "ORGANISM", 51, 57], ["alveolar", "MULTI-TISSUE_STRUCTURE", 197, 205], ["alveolar-capillary", "TISSUE", 242, 260], ["human", "ORGANISM", 337, 342], ["humans", "ORGANISM", 453, 459], ["humans", "SPECIES", 51, 57], ["human", "SPECIES", 337, 342], ["humans", "SPECIES", 453, 459], ["humans", "SPECIES", 51, 57], ["human", "SPECIES", 337, 342], ["humans", "SPECIES", 453, 459], ["Sepsis", "PROBLEM", 0, 6], ["ARDS in humans", "PROBLEM", 43, 57], ["modeling sepsis", "PROBLEM", 75, 90], ["bacteria", "PROBLEM", 116, 124], ["bacterial products systemically", "PROBLEM", 128, 159], ["mild alveolar neutrophilia", "PROBLEM", 192, 218], ["minimal changes in alveolar-capillary permeability", "PROBLEM", 223, 273], ["the difficulties in modeling human ALI", "PROBLEM", 308, 346], ["ARDS", "PROBLEM", 347, 351], ["animal studies", "TEST", 435, 449], ["one of the most common", "OBSERVATION_MODIFIER", 10, 32], ["ARDS", "OBSERVATION", 43, 47], ["sepsis", "OBSERVATION", 84, 90], ["bacterial products", "OBSERVATION", 128, 146], ["mild", "OBSERVATION_MODIFIER", 192, 196], ["alveolar", "ANATOMY_MODIFIER", 197, 205], ["neutrophilia", "OBSERVATION", 206, 218], ["minimal", "OBSERVATION_MODIFIER", 223, 230], ["alveolar", "ANATOMY_MODIFIER", 242, 250], ["capillary permeability", "OBSERVATION", 251, 273], ["ARDS", "OBSERVATION", 347, 351]]], ["Ideally, findings from animal models should be reproduced in more than one mammalian species before human experimentation.", [["human", "ORGANISM", 100, 105], ["human", "SPECIES", 100, 105], ["human", "SPECIES", 100, 105]]], ["This is particularly relevant for studies in mice, which differ in important ways from humans, as described in unique characteristics of animal species in modeling human lung injury.", [["lung", "ANATOMY", 170, 174], ["lung injury", "DISEASE", 170, 181], ["mice", "ORGANISM", 45, 49], ["humans", "ORGANISM", 87, 93], ["human", "ORGANISM", 164, 169], ["lung", "ORGAN", 170, 174], ["mice", "SPECIES", 45, 49], ["humans", "SPECIES", 87, 93], ["human", "SPECIES", 164, 169], ["mice", "SPECIES", 45, 49], ["humans", "SPECIES", 87, 93], ["human", "SPECIES", 164, 169], ["animal species", "PROBLEM", 137, 151], ["modeling human lung injury", "PROBLEM", 155, 181], ["animal species", "OBSERVATION", 137, 151], ["lung", "ANATOMY", 170, 174], ["injury", "OBSERVATION", 175, 181]]], ["In addition, scientific reports should pay special attention to describing the actual features of the \u201clung injury\u201d observed in the model, including measurements of alveolar-capillary permeability and the inflammatory response.SUMMARY AND CONCLUSIONSIn conclusion, studies in animal models are essential to our understanding of the pathophysiology of ALI and the development of novel therapeutic strategies for human ALI/ARDS even though none of the animal models available fully reproduces the findings of human disease.", [["lung", "ANATOMY", 103, 107], ["alveolar-capillary", "ANATOMY", 165, 183], ["lung injury", "DISEASE", 103, 114], ["ALI", "DISEASE", 351, 354], ["ALI", "DISEASE", 417, 420], ["ARDS", "DISEASE", 421, 425], ["lung", "ORGAN", 103, 107], ["alveolar-capillary", "TISSUE", 165, 183], ["human", "ORGANISM", 411, 416], ["human", "ORGANISM", 507, 512], ["human", "SPECIES", 411, 416], ["human", "SPECIES", 507, 512], ["human", "SPECIES", 411, 416], ["human", "SPECIES", 507, 512], ["the \u201clung injury", "PROBLEM", 98, 114], ["alveolar-capillary permeability", "TEST", 165, 196], ["the inflammatory response", "PROBLEM", 201, 226], ["ALI", "PROBLEM", 351, 354], ["novel therapeutic strategies", "TREATMENT", 378, 406], ["human ALI", "PROBLEM", 411, 420], ["ARDS", "PROBLEM", 421, 425], ["human disease", "PROBLEM", 507, 520], ["lung", "ANATOMY", 103, 107], ["injury", "OBSERVATION", 108, 114], ["alveolar", "ANATOMY_MODIFIER", 165, 173], ["capillary permeability", "OBSERVATION", 174, 196], ["inflammatory response", "OBSERVATION", 205, 226], ["ARDS", "OBSERVATION", 421, 425], ["human disease", "OBSERVATION", 507, 520]]], ["Further attempts to develop standardized criteria for defining lung injury in animals would help in the selection of animal models for specific experimental protocols and improve the usefulness of data generated in different animal models of lung injury.GRANTSThis work was supported by National Heart, Lung, and Blood Institute Grants HL-083044 (G. Matute-Bello) and HL-081764 (T. R. Martin) and the Research Service of the Veterans Administration Puget Sound Healthcare System.", [["lung", "ANATOMY", 63, 67], ["lung", "ANATOMY", 242, 246], ["Lung", "ANATOMY", 303, 307], ["lung injury", "DISEASE", 63, 74], ["lung injury", "DISEASE", 242, 253], ["HL-083044", "CHEMICAL", 336, 345], ["HL-081764", "CHEMICAL", 368, 377], ["lung", "ORGAN", 63, 67], ["lung", "ORGAN", 242, 246], ["Lung", "ORGAN", 303, 307], ["Blood", "ORGANISM_SUBSTANCE", 313, 318], ["HL-081764", "CELL", 368, 377], ["standardized criteria", "TEST", 28, 49], ["defining lung injury", "PROBLEM", 54, 74], ["specific experimental protocols", "TREATMENT", 135, 166], ["lung injury", "PROBLEM", 242, 253], ["lung", "ANATOMY", 63, 67], ["injury", "OBSERVATION", 68, 74], ["lung", "ANATOMY", 242, 246], ["injury", "OBSERVATION", 247, 253], ["Heart", "ANATOMY", 296, 301], ["Lung", "ANATOMY", 303, 307]]]], "PMC3091528": [["IntroductionLSECtin is one of a group of glycan-binding receptors encoded near the end of human chromosome 19 (Liu et al. 2004).", [["chromosome", "ANATOMY", 96, 106], ["IntroductionLSECtin", "CHEMICAL", 0, 19], ["glycan-binding receptors", "GENE_OR_GENE_PRODUCT", 41, 65], ["human", "ORGANISM", 90, 95], ["chromosome 19", "CELLULAR_COMPONENT", 96, 109], ["glycan-binding receptors", "PROTEIN", 41, 65], ["human chromosome 19", "DNA", 90, 109], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 90, 95], ["glycan-binding receptors", "TREATMENT", 41, 65]]], ["Other receptors in the cluster include the dendritic and endothelial cell receptors dendritic cell-intercellular adhesion molecule 1 grabbing nonintegrin (DC-SIGN) and DC-SIGN related receptor (DC-SIGNR) (L-SIGN) and the structurally related Fc-binding receptor CD23 (Soilleux et al. 2000).", [["dendritic", "ANATOMY", 43, 52], ["endothelial cell", "ANATOMY", 57, 73], ["dendritic", "CELL", 43, 52], ["endothelial cell", "CELL", 57, 73], ["dendritic cell-intercellular adhesion molecule 1", "GENE_OR_GENE_PRODUCT", 84, 132], ["nonintegrin", "GENE_OR_GENE_PRODUCT", 142, 153], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 155, 162], ["DC-SIGN related receptor", "GENE_OR_GENE_PRODUCT", 168, 192], ["DC-SIGNR", "GENE_OR_GENE_PRODUCT", 194, 202], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 205, 211], ["CD23", "GENE_OR_GENE_PRODUCT", 262, 266], ["dendritic and endothelial cell receptors dendritic cell-intercellular adhesion molecule 1", "PROTEIN", 43, 132], ["nonintegrin", "PROTEIN", 142, 153], ["DC", "PROTEIN", 155, 157], ["SIGN", "PROTEIN", 158, 162], ["DC-SIGN related receptor", "PROTEIN", 168, 192], ["DC", "PROTEIN", 194, 196], ["SIGNR", "PROTEIN", 197, 202], ["L", "PROTEIN", 205, 206], ["SIGN", "PROTEIN", 207, 211], ["Fc-binding receptor CD23", "PROTEIN", 242, 266], ["the dendritic and endothelial cell receptors", "TREATMENT", 39, 83], ["intercellular adhesion molecule", "TREATMENT", 99, 130], ["the structurally related Fc", "PROBLEM", 217, 244], ["dendritic", "OBSERVATION_MODIFIER", 43, 52], ["endothelial cell receptors", "OBSERVATION", 57, 83], ["dendritic cell", "OBSERVATION", 84, 98], ["intercellular adhesion", "OBSERVATION", 99, 121]]], ["All of these receptors contain C-type carbohydrate-recognition domains (CRDs).", [["carbohydrate", "CHEMICAL", 38, 50], ["C-type carbohydrate-recognition domains", "PROTEIN", 31, 70], ["CRDs", "PROTEIN", 72, 76]]], ["Although a related cluster is found in the syntenic region of chromosome 8 in mouse, there are major differences in the organization of several of the genes, with eight mouse DC-SIGN-related genes replacing the two human genes (Powlesland et al. 2006).", [["chromosome 8", "ANATOMY", 62, 74], ["DC", "ANATOMY", 175, 177], ["syntenic region", "CELLULAR_COMPONENT", 43, 58], ["chromosome 8", "CELLULAR_COMPONENT", 62, 74], ["mouse", "ORGANISM", 78, 83], ["mouse", "ORGANISM", 169, 174], ["SIGN", "GENE_OR_GENE_PRODUCT", 178, 182], ["human", "ORGANISM", 215, 220], ["syntenic region", "DNA", 43, 58], ["chromosome 8", "DNA", 62, 74], ["mouse DC-SIGN-related genes", "DNA", 169, 196], ["human genes", "DNA", 215, 226], ["mouse", "SPECIES", 78, 83], ["mouse", "SPECIES", 169, 174], ["human", "SPECIES", 215, 220], ["mouse", "SPECIES", 78, 83], ["mouse", "SPECIES", 169, 174], ["human", "SPECIES", 215, 220], ["cluster", "OBSERVATION_MODIFIER", 19, 26], ["syntenic", "ANATOMY_MODIFIER", 43, 51], ["region", "ANATOMY_MODIFIER", 52, 58], ["chromosome 8", "ANATOMY_MODIFIER", 62, 74], ["major", "OBSERVATION_MODIFIER", 95, 100], ["differences", "OBSERVATION_MODIFIER", 101, 112]]], ["These differences make it difficult to identify clear mouse-human orthologs.", [["mouse", "ORGANISM", 54, 59], ["human", "ORGANISM", 60, 65], ["mouse-human orthologs", "DNA", 54, 75], ["mouse", "SPECIES", 54, 59], ["human", "SPECIES", 60, 65], ["mouse", "SPECIES", 54, 59], ["human", "SPECIES", 60, 65]]], ["In contrast, the human and mouse LSECtin genes appear to be much more closely related, although the two sequences differ at key residues that have been proposed to be involved in selective binding of ligands (Powlesland et al. 2008; Tang et al. 2009).IntroductionThe mRNA for LSECtin is found in a restricted pattern, with the primary sites of expression being sinusoidal endothelial cells in liver and lymph nodes (Liu et al. 2004), although expression has also been reported in suitably stimulated dendritic cells and macrophages in vitro and in the Kupffer cells (Dom\u00ednguez-Soto et al. 2007; Dom\u00ednguez-Soto et al. 2009).", [["sinusoidal endothelial cells", "ANATOMY", 361, 389], ["liver", "ANATOMY", 393, 398], ["lymph nodes", "ANATOMY", 403, 414], ["dendritic cells", "ANATOMY", 500, 515], ["macrophages", "ANATOMY", 520, 531], ["Kupffer cells", "ANATOMY", 552, 565], ["human", "ORGANISM", 17, 22], ["mouse", "ORGANISM", 27, 32], ["LSECtin", "GENE_OR_GENE_PRODUCT", 33, 40], ["LSECtin", "GENE_OR_GENE_PRODUCT", 276, 283], ["sinusoidal endothelial cells", "CELL", 361, 389], ["liver", "ORGAN", 393, 398], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 403, 414], ["dendritic cells", "CELL", 500, 515], ["macrophages", "CELL", 520, 531], ["Kupffer cells", "CELL", 552, 565], ["human and mouse LSECtin genes", "DNA", 17, 46], ["mRNA", "RNA", 267, 271], ["LSECtin", "PROTEIN", 276, 283], ["sinusoidal endothelial cells", "CELL_TYPE", 361, 389], ["stimulated dendritic cells", "CELL_TYPE", 489, 515], ["macrophages", "CELL_TYPE", 520, 531], ["Kupffer cells", "CELL_TYPE", 552, 565], ["human", "SPECIES", 17, 22], ["mouse", "SPECIES", 27, 32], ["human", "SPECIES", 17, 22], ["mouse", "SPECIES", 27, 32], ["sinusoidal endothelial cells in liver and lymph nodes", "PROBLEM", 361, 414], ["sinusoidal endothelial cells", "OBSERVATION", 361, 389], ["liver", "ANATOMY", 393, 398], ["lymph nodes", "OBSERVATION", 403, 414], ["dendritic cells", "OBSERVATION", 500, 515], ["Kupffer cells", "ANATOMY", 552, 565]]], ["Unlike many glycan-binding receptors, LSECtin does not appear to function in clathrin-mediated endocytosis (Gramberg et al. 2008; Powlesland et al. 2008), although it can undergo antibody-induced internalization in myeloid cells (Dom\u00ednguez-Soto et al. 2007).", [["myeloid cells", "ANATOMY", 215, 228], ["LSECtin", "GENE_OR_GENE_PRODUCT", 38, 45], ["clathrin", "GENE_OR_GENE_PRODUCT", 77, 85], ["myeloid cells", "CELL", 215, 228], ["glycan-binding receptors", "PROTEIN", 12, 36], ["LSECtin", "PROTEIN", 38, 45], ["clathrin", "PROTEIN", 77, 85], ["myeloid cells", "CELL_TYPE", 215, 228], ["mediated endocytosis", "PROBLEM", 86, 106], ["antibody", "TEST", 179, 187], ["myeloid cells", "PROBLEM", 215, 228], ["myeloid cells", "OBSERVATION", 215, 228]]], ["Several biological functions for LSECtin mediated by its ability to interact with specific glycans have been investigated.", [["LSECtin", "CHEMICAL", 33, 40], ["LSECtin", "GENE_OR_GENE_PRODUCT", 33, 40], ["LSECtin", "PROTEIN", 33, 40], ["LSECtin mediated", "TREATMENT", 33, 49], ["specific glycans", "TREATMENT", 82, 98]]], ["In vitro studies demonstrate that human LSECtin can provide a route for Ebola virus and SARS coronavirus infection of cells initiated by binding of LSECtin to glycans of the viral envelope glycoproteins (Gramberg et al. 2005; Dom\u00ednguez-Soto et al. 2007; Powlesland et al. 2008).", [["cells", "ANATOMY", 118, 123], ["LSECtin", "CHEMICAL", 40, 47], ["SARS coronavirus infection", "DISEASE", 88, 114], ["human", "ORGANISM", 34, 39], ["LSECtin", "GENE_OR_GENE_PRODUCT", 40, 47], ["Ebola virus", "ORGANISM", 72, 83], ["SARS coronavirus", "ORGANISM", 88, 104], ["cells", "CELL", 118, 123], ["LSECtin", "GENE_OR_GENE_PRODUCT", 148, 155], ["human LSECtin", "PROTEIN", 34, 47], ["LSECtin", "PROTEIN", 148, 155], ["viral envelope glycoproteins", "PROTEIN", 174, 202], ["human", "SPECIES", 34, 39], ["Ebola virus", "SPECIES", 72, 83], ["human", "SPECIES", 34, 39], ["Ebola virus", "SPECIES", 72, 83], ["SARS coronavirus", "SPECIES", 88, 104], ["vitro studies", "TEST", 3, 16], ["human LSECtin", "TREATMENT", 34, 47], ["Ebola virus", "PROBLEM", 72, 83], ["SARS coronavirus infection of cells", "PROBLEM", 88, 123]]], ["Studies in mice indicate that mouse LSECtin is able to bind T cells through glycans on the CD44 T-cell surface marker (Tang et al. 2010).", [["T cells", "ANATOMY", 60, 67], ["CD44 T-cell surface", "ANATOMY", 91, 110], ["mice", "ORGANISM", 11, 15], ["mouse", "ORGANISM", 30, 35], ["LSECtin", "GENE_OR_GENE_PRODUCT", 36, 43], ["T cells", "CELL", 60, 67], ["CD44", "GENE_OR_GENE_PRODUCT", 91, 95], ["mouse LSECtin", "PROTEIN", 30, 43], ["T cells", "CELL_TYPE", 60, 67], ["CD44", "PROTEIN", 91, 95], ["mice", "SPECIES", 11, 15], ["mouse", "SPECIES", 30, 35], ["mice", "SPECIES", 11, 15], ["mouse", "SPECIES", 30, 35], ["Studies", "TEST", 0, 7]]], ["This interaction leads to suppression of T-cell responses and knockout mice lacking LSECtin show increased sensitivity to liver damage mediated by T cells following acute injury, suggesting that LSECtin plays a role in protection of the liver from immune attack (Tang et al. 2009).", [["T-cell", "ANATOMY", 41, 47], ["liver", "ANATOMY", 122, 127], ["T cells", "ANATOMY", 147, 154], ["liver", "ANATOMY", 237, 242], ["liver damage", "DISEASE", 122, 134], ["acute injury", "DISEASE", 165, 177], ["LSECtin", "CHEMICAL", 195, 202], ["T-cell", "CELL", 41, 47], ["mice", "ORGANISM", 71, 75], ["LSECtin", "GENE_OR_GENE_PRODUCT", 84, 91], ["liver", "ORGAN", 122, 127], ["T cells", "CELL", 147, 154], ["LSECtin", "GENE_OR_GENE_PRODUCT", 195, 202], ["liver", "ORGAN", 237, 242], ["LSECtin", "PROTEIN", 84, 91], ["T cells", "CELL_TYPE", 147, 154], ["LSECtin", "PROTEIN", 195, 202], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 71, 75], ["T-cell responses", "TEST", 41, 57], ["knockout mice lacking LSECtin", "PROBLEM", 62, 91], ["increased sensitivity", "PROBLEM", 97, 118], ["liver damage", "PROBLEM", 122, 134], ["acute injury", "PROBLEM", 165, 177], ["immune attack", "PROBLEM", 248, 261], ["increased", "OBSERVATION_MODIFIER", 97, 106], ["liver", "ANATOMY", 122, 127], ["damage", "OBSERVATION", 128, 134], ["acute", "OBSERVATION_MODIFIER", 165, 170], ["injury", "OBSERVATION", 171, 177], ["liver", "ANATOMY", 237, 242]]], ["Finally, it has been suggested that receptor expressed on myeloid cells could be involved in antigen capture and presentation (Dom\u00ednguez-Soto et al. 2007).IntroductionUse of the knockout mice (Tang et al. 2009) and other mouse-specific tools to model interactions of the human receptor is based on the assumption that the human and mouse proteins function similarly.", [["myeloid cells", "ANATOMY", 58, 71], ["myeloid cells", "CELL", 58, 71], ["mice", "ORGANISM", 187, 191], ["mouse", "ORGANISM", 221, 226], ["human", "ORGANISM", 271, 276], ["human", "ORGANISM", 322, 327], ["mouse", "ORGANISM", 332, 337], ["myeloid cells", "CELL_TYPE", 58, 71], ["human receptor", "PROTEIN", 271, 285], ["human and mouse proteins", "PROTEIN", 322, 346], ["mice", "SPECIES", 187, 191], ["mouse", "SPECIES", 221, 226], ["human", "SPECIES", 271, 276], ["human", "SPECIES", 322, 327], ["mouse", "SPECIES", 332, 337], ["mice", "SPECIES", 187, 191], ["mouse", "SPECIES", 221, 226], ["human", "SPECIES", 271, 276], ["human", "SPECIES", 322, 327], ["mouse", "SPECIES", 332, 337], ["myeloid cells", "PROBLEM", 58, 71], ["the knockout mice", "TREATMENT", 174, 191], ["the human receptor", "TREATMENT", 267, 285], ["myeloid cells", "OBSERVATION", 58, 71]]], ["From the work with DC-SIGN and its homologues, which provides precedent for rapid evolution of function in this region of the genome, as well as the presence of some potentially important differences in the sequences of human and mouse LSECtin, there is need for empirical evidence comparing the biochemical properties of the two receptors in order to provide a foundation for extrapolating results from mice to humans.IntroductionIn the studies described in this manuscript, biochemical characterization of mouse LSECtin is presented and close similarity in the sugar-binding properties of the two receptors, and their ability to interact with Ebola virus glycoprotein, is documented.", [["DC", "ANATOMY", 19, 21], ["sugar", "CHEMICAL", 563, 568], ["genome", "CELLULAR_COMPONENT", 126, 132], ["human", "ORGANISM", 220, 225], ["mouse", "ORGANISM", 230, 235], ["LSECtin", "GENE_OR_GENE_PRODUCT", 236, 243], ["mice", "ORGANISM", 404, 408], ["humans", "ORGANISM", 412, 418], ["mouse", "ORGANISM", 508, 513], ["LSECtin", "GENE_OR_GENE_PRODUCT", 514, 521], ["sugar", "SIMPLE_CHEMICAL", 563, 568], ["Ebola virus glycoprotein", "ORGANISM", 645, 669], ["DC", "CELL_TYPE", 19, 21], ["SIGN", "PROTEIN", 22, 26], ["mouse LSECtin", "PROTEIN", 508, 521], ["Ebola virus glycoprotein", "PROTEIN", 645, 669], ["human", "SPECIES", 220, 225], ["mouse", "SPECIES", 230, 235], ["mice", "SPECIES", 404, 408], ["humans", "SPECIES", 412, 418], ["mouse", "SPECIES", 508, 513], ["Ebola virus", "SPECIES", 645, 656], ["human", "SPECIES", 220, 225], ["mouse", "SPECIES", 230, 235], ["mice", "SPECIES", 404, 408], ["humans", "SPECIES", 412, 418], ["mouse", "SPECIES", 508, 513], ["Ebola virus", "SPECIES", 645, 656], ["the studies", "TEST", 434, 445], ["Ebola virus glycoprotein", "TREATMENT", 645, 669], ["genome", "OBSERVATION", 126, 132]]], ["In addition, it is demonstrated that the simple disaccharide GlcNAc\u03b21-2Man acts as an effective inhibitor of binding to the viral glycoprotein at micromolar concentrations.Expression and characterization of the CRD from mouse LSECtin ::: ResultsLSECtin is a type 2 transmembrane protein in which the C-type CRD resides at the C-terminal end of the protein (Figure 1A).", [["GlcNAc", "CHEMICAL", 61, 67], ["\u03b21-2Man", "CHEMICAL", 67, 74], ["GlcNAc", "CHEMICAL", 61, 67], ["C", "CHEMICAL", 326, 327], ["GlcNAc\u03b21-2", "GENE_OR_GENE_PRODUCT", 61, 71], ["CRD", "GENE_OR_GENE_PRODUCT", 211, 214], ["mouse", "ORGANISM", 220, 225], ["ResultsLSECtin", "GENE_OR_GENE_PRODUCT", 238, 252], ["C-type CRD", "GENE_OR_GENE_PRODUCT", 300, 310], ["viral glycoprotein", "PROTEIN", 124, 142], ["CRD", "PROTEIN", 211, 214], ["ResultsLSECtin", "PROTEIN", 238, 252], ["type 2 transmembrane protein", "PROTEIN", 258, 286], ["C-type CRD", "PROTEIN", 300, 310], ["C-terminal end", "PROTEIN", 326, 340], ["Figure 1A", "PROTEIN", 357, 366], ["mouse", "SPECIES", 220, 225], ["mouse", "SPECIES", 220, 225], ["the simple disaccharide GlcNAc\u03b21", "TREATMENT", 37, 69], ["an effective inhibitor", "TREATMENT", 83, 105], ["a type 2 transmembrane protein", "PROBLEM", 256, 286], ["the C-type CRD", "PROBLEM", 296, 310], ["terminal", "ANATOMY_MODIFIER", 328, 336]]], ["An initial survey of the distribution of LSECtin expression was undertaken using the polymerase chain reaction to amplify the LSECtin-coding region from a panel of cDNAs with a pair of primers that lie just outside the protein-coding region at each end (Figure 1B).", [["LSECtin", "GENE_OR_GENE_PRODUCT", 41, 48], ["LSECtin", "DNA", 41, 48], ["LSECtin-coding region", "DNA", 126, 147], ["cDNAs", "DNA", 164, 169], ["protein-coding region", "DNA", 219, 240], ["LSECtin expression", "TREATMENT", 41, 59], ["the polymerase chain reaction", "TREATMENT", 81, 110], ["a pair of primers", "TREATMENT", 175, 192]]], ["Expression was detected exclusively in the liver, as was previously observed for human LSECtin in a survey of a similar set of human tissues (Liu et al. 2004).", [["liver", "ANATOMY", 43, 48], ["tissues", "ANATOMY", 133, 140], ["liver", "ORGAN", 43, 48], ["human", "ORGANISM", 81, 86], ["LSECtin", "GENE_OR_GENE_PRODUCT", 87, 94], ["human", "ORGANISM", 127, 132], ["tissues", "TISSUE", 133, 140], ["human LSECtin", "PROTEIN", 81, 94], ["human", "SPECIES", 81, 86], ["human", "SPECIES", 127, 132], ["human", "SPECIES", 81, 86], ["human", "SPECIES", 127, 132], ["human LSECtin", "TREATMENT", 81, 94], ["liver", "ANATOMY", 43, 48], ["human tissues", "ANATOMY", 127, 140]]], ["This distribution is consistent with the idea that mouse LSECtin performs a function similar to human LSECtin in sinusoidal endothelial cells, although it was not possible to document expression in lymph node as well because of the difficulty of obtaining a suitable cDNA library.", [["sinusoidal endothelial cells", "ANATOMY", 113, 141], ["lymph node", "ANATOMY", 198, 208], ["mouse", "ORGANISM", 51, 56], ["LSECtin", "GENE_OR_GENE_PRODUCT", 57, 64], ["human", "ORGANISM", 96, 101], ["LSECtin", "CELL", 102, 109], ["sinusoidal endothelial cells", "CELL", 113, 141], ["lymph node", "MULTI-TISSUE_STRUCTURE", 198, 208], ["mouse LSECtin", "PROTEIN", 51, 64], ["human LSECtin", "PROTEIN", 96, 109], ["sinusoidal endothelial cells", "CELL_TYPE", 113, 141], ["cDNA library", "DNA", 267, 279], ["mouse", "SPECIES", 51, 56], ["human", "SPECIES", 96, 101], ["mouse", "SPECIES", 51, 56], ["human", "SPECIES", 96, 101], ["human LSECtin in sinusoidal endothelial cells", "TREATMENT", 96, 141], ["expression in lymph node", "PROBLEM", 184, 208], ["consistent with", "UNCERTAINTY", 21, 36], ["sinusoidal endothelial cells", "OBSERVATION", 113, 141], ["lymph node", "OBSERVATION", 198, 208]]]], "8318896fad2acf22ac94d15d6d571dd2f7cf121d": [["Many patients shared common exposure and family transmission.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13]]]], "b1015c91fc17f53167eff10558b7cc0df84999a2": [["needs and granted administrators a streamlined connection to a previously decentralized volunteer network.", [["volunteer network", "MULTI-TISSUE_STRUCTURE", 88, 105]]]], "30dece6583758d5936ab4697f79747095ccf9d6d": [["T he 2015 Ebola virus epidemic in West Africa renewed worldwide attention on the ability of health-care entities to handle highly infectious patients.", [["Ebola virus", "DISEASE", 10, 21], ["Ebola virus", "ORGANISM", 10, 21], ["patients", "ORGANISM", 141, 149], ["Ebola virus", "SPECIES", 10, 21], ["patients", "SPECIES", 141, 149], ["Ebola virus", "SPECIES", 10, 21], ["infectious", "OBSERVATION", 130, 140]]], ["Development and implementation of hospital protocols to prepare for Ebola and other exposures requiring high-level personal protective equipment (PPE) occurred throughout the United States and worldwide.", [["Ebola", "DISEASE", 68, 73], ["Ebola", "ORGANISM", 68, 73], ["Ebola", "SPECIES", 68, 73], ["hospital protocols", "TREATMENT", 34, 52], ["Ebola", "PROBLEM", 68, 73], ["high-level personal protective equipment", "TREATMENT", 104, 144]]], ["1,2 These efforts included training health-care providers (HCPs) to care for infected HCPs being evacuated for treatment in their native countries.", [["1,2", "CHEMICAL", 0, 3], ["treatment", "TREATMENT", 111, 120]]], ["Following chemical attacks in the United Kingdom and Syria, attention has also increased on the protection of HCPs in scenarios involving mass poisonings.", [["poisonings", "DISEASE", 143, 153], ["mass poisonings", "PROBLEM", 138, 153], ["chemical attacks", "OBSERVATION", 10, 26], ["mass", "OBSERVATION", 138, 142]]], ["In 2020, these preparations now include protecting HCPs from the novel coronavirus.", [["coronavirus", "DISEASE", 71, 82], ["coronavirus", "ORGANISM", 71, 82]]], ["PPE refers to barrier clothing, gloves, and/or headgear designed to protect an individual from exposure to biologic, chemical, radiological, or environmental hazards in the prehospital or hospital environment.", [["PPE", "TREATMENT", 0, 3], ["barrier clothing", "TREATMENT", 14, 30], ["gloves", "TREATMENT", 32, 38], ["headgear", "TREATMENT", 47, 55]]], ["The key focus of PPE in health care is to provide a barrier for muco-cutaneous and/or respiratory protection, with a wide spectrum of equipment.", [["cutaneous", "ANATOMY", 69, 78], ["respiratory", "ANATOMY", 86, 97], ["a barrier", "TREATMENT", 50, 59], ["muco-cutaneous", "TREATMENT", 64, 78], ["respiratory protection", "TREATMENT", 86, 108], ["a wide spectrum of equipment", "TREATMENT", 115, 143], ["cutaneous", "ANATOMY", 69, 78]]], ["The selection of the appropriate level of PPE for HCPs is based on the specific biohazard and environment in which the patient is treated, and for which an appropriate combination of respiratory and/or chemical protection should be anticipated, classified as Levels A through D from most to least protective.", [["patient", "ORGANISM", 119, 126], ["patient", "SPECIES", 119, 126], ["chemical protection", "TREATMENT", 202, 221]]], ["3 As front-line medical professionals, prehospital providers (PHPs) have an important role to safely care for patients with potentially transmissible illness.", [["transmissible illness", "DISEASE", 136, 157], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["transmissible illness", "PROBLEM", 136, 157]]], ["When the identity of a prehospital hazardous material is unknown, fully encapsulating nonpermeable, gastight protective gear (Level A) is recommended.", [["a prehospital hazardous material", "PROBLEM", 21, 53]]], ["4 Level B PPE is visually similar to Level A gear, but used for the highest degrees of respiratory protection when a substance is known.", [["respiratory", "ANATOMY", 87, 98], ["Level B PPE", "TEST", 2, 13], ["respiratory protection", "TREATMENT", 87, 109], ["respiratory protection", "OBSERVATION", 87, 109]]], ["Both of these forms of PPE are bulky, limit tactile and auditory feedback, and restrict mobility.", [["PPE", "GENE_OR_GENE_PRODUCT", 23, 26], ["PPE", "OBSERVATION", 23, 26], ["bulky", "OBSERVATION", 31, 36]]], ["5 A few publications on adult resuscitation describe the decreased ability of providers to perform resuscitation procedures in PPE, 6, 7 but research on the impact of PPE on procedural performance by PHPs caring for children remains limited.", [["children", "ORGANISM", 216, 224], ["children", "SPECIES", 216, 224], ["adult resuscitation", "TREATMENT", 24, 43], ["resuscitation procedures", "TREATMENT", 99, 123], ["few", "OBSERVATION_MODIFIER", 4, 7], ["publications", "OBSERVATION", 8, 20]]], ["It is also unknown as to whether or how specific elements of care delivery should be modified when providers must wear PPE to resuscitate pediatric patients.", [["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 148, 156], ["care delivery", "TREATMENT", 61, 74]]]], "PMC7189178": [["IntroductionSince its first documented human infection in Wuhan, China, in the winter of 2019, SARS-CoV-2, the causal agent of COronaVIrus Disease 2019 (COVID-19) that manifests as an aggressive viral pneumonia, has spread at unprecedented speed and scale resulting in a global pandemic [1].", [["human infection", "DISEASE", 39, 54], ["SARS", "DISEASE", 95, 99], ["COronaVIrus Disease", "DISEASE", 127, 146], ["COVID-19", "CHEMICAL", 153, 161], ["viral pneumonia", "DISEASE", 195, 210], ["human", "ORGANISM", 39, 44], ["SARS-CoV-2", "ORGANISM", 95, 105], ["COVID-19", "CELL", 153, 161], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44], ["SARS-CoV", "SPECIES", 95, 103], ["COronaVIrus Disease 2019 (COVID-19", "SPECIES", 127, 161], ["human infection", "PROBLEM", 39, 54], ["COronaVIrus Disease", "PROBLEM", 127, 146], ["an aggressive viral pneumonia", "PROBLEM", 181, 210], ["infection", "OBSERVATION", 45, 54], ["COronaVIrus Disease", "OBSERVATION", 127, 146], ["aggressive", "OBSERVATION_MODIFIER", 184, 194], ["viral", "OBSERVATION_MODIFIER", 195, 200], ["pneumonia", "OBSERVATION", 201, 210]]], ["Despite drastic interventions implemented around the world to contain its spread, COVID-19 has progressed worldwide with significant resultant morbidity and mortality while stretching medical systems to their limits.", [["COVID-19", "CHEMICAL", 82, 90], ["drastic interventions", "TREATMENT", 8, 29], ["COVID", "TEST", 82, 87], ["significant resultant morbidity", "PROBLEM", 121, 152], ["drastic", "OBSERVATION_MODIFIER", 8, 15], ["significant", "OBSERVATION_MODIFIER", 121, 132], ["resultant", "OBSERVATION_MODIFIER", 133, 142], ["morbidity", "OBSERVATION", 143, 152]]], ["An exponential increase of COVID-19 cases has also been observed in the USA, with over 200,000 patients confirmed as of 4/1/2020 and rapid daily growth [2].", [["patients", "ORGANISM", 95, 103], ["COVID", "PROTEIN", 27, 32], ["patients", "SPECIES", 95, 103], ["COVID", "TEST", 27, 32], ["exponential", "OBSERVATION_MODIFIER", 3, 14], ["increase", "OBSERVATION_MODIFIER", 15, 23]]], ["Thus, efforts are urgently needed to better understand the epidemiology and pathobiology of this illness to limit its impact.IntroductionThe overall case fatality rate (CFR) of COVID-19 is estimated to be approximately 3\u20134%, although large variabilities exist with the highest reported in Italy (11.9%) and the lowest in Germany (1.2%) [3].", [["this illness", "PROBLEM", 92, 104], ["COVID", "TEST", 177, 182], ["large variabilities", "PROBLEM", 234, 253], ["large", "OBSERVATION_MODIFIER", 234, 239], ["variabilities", "OBSERVATION", 240, 253], ["highest", "OBSERVATION_MODIFIER", 269, 276], ["lowest", "OBSERVATION_MODIFIER", 311, 317]]], ["Early epidemiologic studies emerging from China point to a strong association between advanced age and severity of illness [4].", [["illness", "DISEASE", 115, 122], ["Early epidemiologic studies", "TEST", 0, 27], ["illness", "PROBLEM", 115, 122]]], ["Similar observations were made in Italy, where up to 20% CFR was noted among patients greater than 80 years old [5].", [["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85]]], ["Numerous important age-associated cardiovascular comorbidities, such as hypertension and coronary heart disease, have also been linked to increased risk for worse outcomes including higher rates of ICU admissions and death [6\u20138].", [["cardiovascular", "ANATOMY", 34, 48], ["coronary", "ANATOMY", 89, 97], ["heart", "ANATOMY", 98, 103], ["cardiovascular comorbidities", "DISEASE", 34, 62], ["hypertension", "DISEASE", 72, 84], ["coronary heart disease", "DISEASE", 89, 111], ["death", "DISEASE", 217, 222], ["cardiovascular", "ANATOMICAL_SYSTEM", 34, 48], ["heart", "ORGAN", 98, 103], ["associated cardiovascular comorbidities", "PROBLEM", 23, 62], ["hypertension", "PROBLEM", 72, 84], ["coronary heart disease", "PROBLEM", 89, 111], ["worse outcomes", "PROBLEM", 157, 171], ["death", "PROBLEM", 217, 222], ["cardiovascular", "ANATOMY", 34, 48], ["comorbidities", "OBSERVATION", 49, 62], ["hypertension", "OBSERVATION", 72, 84], ["coronary heart", "ANATOMY", 89, 103], ["disease", "OBSERVATION", 104, 111]]], ["Whether these epidemiological associations are attributed to high risk of infection among the elderly or lesser ability to recover from SARS-CoV-2 infection remain to be clarified.IntroductionIn this review, we aim to highlight the pathobiology of SARS-CoV-2 and discuss its potential implications in the cardiovascular system.", [["cardiovascular system", "ANATOMY", 305, 326], ["infection", "DISEASE", 74, 83], ["SARS", "DISEASE", 136, 140], ["infection", "DISEASE", 147, 156], ["SARS", "DISEASE", 248, 252], ["SARS-CoV-2", "ORGANISM", 136, 146], ["SARS-CoV-2", "ORGANISM", 248, 258], ["cardiovascular", "ANATOMICAL_SYSTEM", 305, 319], ["system", "ANATOMICAL_SYSTEM", 320, 326], ["CoV-2", "SPECIES", 141, 146], ["SARS-CoV-2", "SPECIES", 136, 146], ["SARS-CoV", "SPECIES", 248, 256], ["infection", "PROBLEM", 74, 83], ["SARS", "PROBLEM", 136, 140], ["CoV", "PROBLEM", 141, 144], ["2 infection", "PROBLEM", 145, 156], ["CoV", "TEST", 253, 256], ["infection", "OBSERVATION", 74, 83], ["infection", "OBSERVATION", 147, 156], ["cardiovascular system", "ANATOMY", 305, 326]]], ["We then summarize the available epidemiological data with particular attention paid to cardiovascular comorbidities and outcomes.", [["cardiovascular", "ANATOMY", 87, 101], ["cardiovascular comorbidities", "DISEASE", 87, 115], ["cardiovascular", "ANATOMICAL_SYSTEM", 87, 101], ["cardiovascular comorbidities", "PROBLEM", 87, 115]]], ["Finally, we discuss various cardiac manifestations of COVID-19.SARS-CoV-2 Biology and Clinical ImplicationsCoronaviridae, a family of positive strand RNA viruses causing human respiratory infections, was named for the crown-shaped outer coat seen on the electron-microscopy.", [["cardiac", "ANATOMY", 28, 35], ["respiratory", "ANATOMY", 176, 187], ["SARS", "DISEASE", 63, 67], ["respiratory infections", "DISEASE", 176, 198], ["COVID-19", "CHEMICAL", 54, 62], ["cardiac", "ORGAN", 28, 35], ["human", "ORGANISM", 170, 175], ["human", "SPECIES", 170, 175], ["human", "SPECIES", 170, 175], ["COVID", "TEST", 54, 59], ["Coronaviridae", "TREATMENT", 107, 120], ["positive strand RNA viruses", "PROBLEM", 134, 161], ["human respiratory infections", "PROBLEM", 170, 198], ["the crown-shaped outer coat", "PROBLEM", 214, 241], ["the electron-microscopy", "TEST", 250, 273], ["respiratory infections", "OBSERVATION", 176, 198], ["shaped", "OBSERVATION_MODIFIER", 224, 230], ["outer", "OBSERVATION_MODIFIER", 231, 236], ["coat", "OBSERVATION", 237, 241]]], ["First discovered in the 1960s, it received great attention during the 2003 SARS coronavirus (SARS-CoV) outbreak.", [["SARS coronavirus", "DISEASE", 75, 91], ["SARS-CoV)", "DISEASE", 93, 102], ["2003 SARS coronavirus", "ORGANISM", 70, 91], ["SARS-CoV", "ORGANISM", 93, 101], ["SARS coronavirus", "SPECIES", 75, 91], ["SARS-CoV", "SPECIES", 93, 101], ["outbreak", "PROBLEM", 103, 111]]], ["There is approximately an 80% nucleotide sequence similarity [9] between SARS-CoV and SARS-CoV-2, the pathogen of COVID-19.", [["nucleotide", "CHEMICAL", 30, 40], ["SARS-CoV", "ORGANISM", 73, 81], ["SARS-CoV-2", "ORGANISM", 86, 96], ["COVID-19", "DNA", 114, 122], ["SARS-CoV", "SPECIES", 73, 81], ["SARS-CoV", "SPECIES", 86, 94], ["nucleotide sequence similarity", "TEST", 30, 60], ["SARS", "TEST", 73, 77], ["CoV", "TEST", 78, 81], ["SARS", "TEST", 86, 90], ["CoV", "TEST", 91, 94], ["COVID", "TEST", 114, 119]]], ["Hence, most of our understanding of the biology of SARS-CoV-2 has been extrapolated from prior research on the original SARS virus.SARS-CoV-2 Biology and Clinical ImplicationsThe \u201ccrown\u201d seen on electron microscopy are protruding proteins called \u201cspike proteins\u201d which are essential to viral entry into human cells (Fig. 1a).", [["cells", "ANATOMY", 309, 314], ["SARS", "DISEASE", 51, 55], ["SARS", "DISEASE", 120, 124], ["SARS", "DISEASE", 131, 135], ["SARS-CoV-2", "ORGANISM", 51, 61], ["SARS virus", "ORGANISM", 120, 130], ["\u201cspike proteins", "GENE_OR_GENE_PRODUCT", 246, 261], ["human", "ORGANISM", 303, 308], ["cells", "CELL", 309, 314], ["Fig. 1a", "ORGANISM", 316, 323], ["protruding proteins", "PROTEIN", 219, 238], ["\u201cspike proteins", "PROTEIN", 246, 261], ["human cells", "CELL_TYPE", 303, 314], ["human", "SPECIES", 303, 308], ["SARS-CoV", "SPECIES", 51, 59], ["SARS virus", "SPECIES", 120, 130], ["human", "SPECIES", 303, 308], ["SARS", "PROBLEM", 51, 55], ["the original SARS virus", "PROBLEM", 107, 130], ["electron microscopy", "TEST", 195, 214], ["protruding proteins", "PROBLEM", 219, 238], ["spike proteins", "PROBLEM", 247, 261]]], ["Studies in mice and human cells demonstrated that the SARS virus enters into the cell via contact between the spike protein and angiotensin-converting enzyme 2 (ACE2) [10], a regulator of the renin/angiotensin pathway expressed on a subset of cell surfaces.", [["cells", "ANATOMY", 26, 31], ["cell", "ANATOMY", 81, 85], ["cell surfaces", "ANATOMY", 243, 256], ["SARS", "DISEASE", 54, 58], ["angiotensin", "CHEMICAL", 128, 139], ["angiotensin", "CHEMICAL", 198, 209], ["mice", "ORGANISM", 11, 15], ["human", "ORGANISM", 20, 25], ["cells", "CELL", 26, 31], ["SARS virus", "ORGANISM", 54, 64], ["cell", "CELL", 81, 85], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 128, 159], ["ACE2) [10", "GENE_OR_GENE_PRODUCT", 161, 170], ["renin", "GENE_OR_GENE_PRODUCT", 192, 197], ["angiotensin", "GENE_OR_GENE_PRODUCT", 198, 209], ["cell surfaces", "CELLULAR_COMPONENT", 243, 256], ["human cells", "CELL_TYPE", 20, 31], ["spike protein", "PROTEIN", 110, 123], ["angiotensin-converting enzyme 2", "PROTEIN", 128, 159], ["ACE2", "PROTEIN", 161, 165], ["renin", "PROTEIN", 192, 197], ["mice", "SPECIES", 11, 15], ["human", "SPECIES", 20, 25], ["mice", "SPECIES", 11, 15], ["human", "SPECIES", 20, 25], ["SARS virus", "SPECIES", 54, 64], ["Studies", "TEST", 0, 7], ["human cells", "TEST", 20, 31], ["the SARS virus", "PROBLEM", 50, 64], ["the spike protein", "TEST", 106, 123], ["angiotensin", "TEST", 128, 139], ["converting enzyme", "TEST", 140, 157], ["the renin/angiotensin pathway", "TREATMENT", 188, 217], ["cell surfaces", "OBSERVATION", 243, 256]]], ["The contact of these two proteins triggers cleavage of the viral spike protein via an enzyme transmembrane protease, serine 2 (TMPRSS2), which then activates a cascade of molecular events leading to the fusion of the viral membrane envelope with the plasma membrane of the host cells and subsequent entry of viral contents into the cytoplasm [11].", [["membrane", "ANATOMY", 223, 231], ["plasma membrane", "ANATOMY", 250, 265], ["cells", "ANATOMY", 278, 283], ["cytoplasm", "ANATOMY", 332, 341], ["serine", "CHEMICAL", 117, 123], ["transmembrane protease, serine 2", "GENE_OR_GENE_PRODUCT", 93, 125], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 127, 134], ["plasma membrane", "CELLULAR_COMPONENT", 250, 265], ["host cells", "CELL", 273, 283], ["cytoplasm", "ORGANISM_SUBSTANCE", 332, 341], ["viral spike protein", "PROTEIN", 59, 78], ["enzyme transmembrane protease", "PROTEIN", 86, 115], ["serine 2", "PROTEIN", 117, 125], ["TMPRSS2", "PROTEIN", 127, 134], ["host cells", "CELL_TYPE", 273, 283], ["the viral spike protein", "TEST", 55, 78], ["an enzyme transmembrane protease", "TEST", 83, 115], ["TMPRSS2", "TEST", 127, 134], ["molecular events", "PROBLEM", 171, 187], ["the fusion", "TREATMENT", 199, 209], ["the viral membrane envelope", "PROBLEM", 213, 240], ["viral membrane", "OBSERVATION", 217, 231], ["host cells", "OBSERVATION", 273, 283], ["viral contents", "OBSERVATION", 308, 322]]], ["The spike protein of SARS-CoV and SARS-CoV-2 shares 76% of amino acid sequence and an overall conservation of structure [12].", [["amino acid", "CHEMICAL", 59, 69], ["amino acid", "CHEMICAL", 59, 69], ["SARS-CoV", "ORGANISM", 21, 29], ["SARS-CoV-2", "ORGANISM", 34, 44], ["amino acid", "AMINO_ACID", 59, 69], ["spike protein", "PROTEIN", 4, 17], ["SARS-CoV", "SPECIES", 21, 29], ["SARS-CoV", "SPECIES", 34, 42], ["The spike protein", "TEST", 0, 17], ["SARS", "TEST", 21, 25], ["CoV", "TEST", 26, 29], ["SARS", "TEST", 34, 38], ["CoV", "TEST", 39, 42], ["amino acid sequence", "TEST", 59, 78]]], ["In vitro studies suggest SARS-CoV-2 may have an even higher affinity towards binding of ACE2 [12], which may partially explain its higher transmission rate compared to SARS-CoV.", [["SARS", "DISEASE", 168, 172], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 25, 35], ["ACE2 [12]", "GENE_OR_GENE_PRODUCT", 88, 97], ["SARS-CoV", "ORGANISM", 168, 176], ["ACE2", "PROTEIN", 88, 92], ["SARS-CoV", "SPECIES", 25, 33], ["SARS-CoV", "SPECIES", 168, 176], ["vitro studies", "TEST", 3, 16], ["SARS", "PROBLEM", 25, 29], ["CoV", "TEST", 30, 33], ["ACE2", "TEST", 88, 92], ["may partially explain", "UNCERTAINTY", 105, 126]]], ["As in SARS-CoV, in vitro studies showed SARS-CoV-2 enters the cell through ACE2, and inhibitors of the protease TMPRSS2 impairs viral entry [13\u2022\u2022].", [["cell", "ANATOMY", 62, 66], ["SARS", "DISEASE", 6, 10], ["SARS-CoV", "ORGANISM", 6, 14], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 40, 50], ["cell", "CELL", 62, 66], ["ACE2", "GENE_OR_GENE_PRODUCT", 75, 79], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 112, 119], ["ACE2", "PROTEIN", 75, 79], ["protease TMPRSS2", "PROTEIN", 103, 119], ["SARS-CoV", "SPECIES", 6, 14], ["SARS", "PROBLEM", 6, 10], ["vitro studies", "TEST", 19, 32], ["SARS", "PROBLEM", 40, 44], ["CoV", "TEST", 45, 48], ["ACE2", "TEST", 75, 79], ["inhibitors", "TREATMENT", 85, 95], ["the protease TMPRSS2", "TREATMENT", 99, 119]]], ["It is most likely that ACE2 is the primary receptor by which viral entry occurs, but whether additional receptors exist for SARS-CoV-2 remains unknown.SARS-CoV-2 Biology and Clinical ImplicationsGiven the likely importance of ACE2 in pathogenesis of COVID19 and the respiratory tract being the primary site of viral entry into the body, investigators have focused on type 2 pneumocytes in alveoli as the presumed target cells of SARS-CoV-2, given that these cells express the highest level of ACE2 and TMPRSS2 in the human lung [14].", [["respiratory tract", "ANATOMY", 266, 283], ["body", "ANATOMY", 331, 335], ["type 2 pneumocytes", "ANATOMY", 367, 385], ["alveoli", "ANATOMY", 389, 396], ["cells", "ANATOMY", 420, 425], ["cells", "ANATOMY", 458, 463], ["lung", "ANATOMY", 523, 527], ["SARS", "DISEASE", 124, 128], ["SARS", "DISEASE", 151, 155], ["respiratory tract", "DISEASE", 266, 283], ["ACE2", "GENE_OR_GENE_PRODUCT", 23, 27], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 124, 134], ["ACE2", "GENE_OR_GENE_PRODUCT", 226, 230], ["COVID19", "GENE_OR_GENE_PRODUCT", 250, 257], ["respiratory tract", "ORGANISM_SUBDIVISION", 266, 283], ["body", "ORGANISM_SUBDIVISION", 331, 335], ["type 2 pneumocytes", "CELL", 367, 385], ["alveoli", "MULTI-TISSUE_STRUCTURE", 389, 396], ["cells", "CELL", 420, 425], ["SARS-CoV-2", "ORGANISM", 429, 439], ["cells", "CELL", 458, 463], ["ACE2", "GENE_OR_GENE_PRODUCT", 493, 497], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 502, 509], ["human", "ORGANISM", 517, 522], ["lung", "ORGAN", 523, 527], ["ACE2", "PROTEIN", 23, 27], ["ACE2", "PROTEIN", 226, 230], ["type 2 pneumocytes", "CELL_TYPE", 367, 385], ["ACE2", "PROTEIN", 493, 497], ["TMPRSS2", "PROTEIN", 502, 509], ["human", "SPECIES", 517, 522], ["SARS-CoV", "SPECIES", 429, 437], ["human", "SPECIES", 517, 522], ["SARS", "TEST", 124, 128], ["CoV", "TEST", 129, 132], ["COVID19", "TREATMENT", 250, 257], ["the respiratory tract", "TREATMENT", 262, 283], ["type 2 pneumocytes in alveoli", "PROBLEM", 367, 396], ["SARS", "TEST", 429, 433], ["CoV", "TEST", 434, 437], ["these cells", "TEST", 452, 463], ["ACE2", "TEST", 493, 497], ["most likely", "UNCERTAINTY", 6, 17], ["respiratory tract", "ANATOMY", 266, 283], ["viral", "OBSERVATION", 310, 315], ["body", "ANATOMY", 331, 335], ["alveoli", "ANATOMY", 389, 396], ["presumed", "UNCERTAINTY", 404, 412], ["target cells", "OBSERVATION", 413, 425], ["human lung", "ANATOMY", 517, 527]]], ["The viral infection and injury of these pneumocytes are thought to be central to the prominent diffuse alveolar damage seen on pathology of patients with COVID19.", [["pneumocytes", "ANATOMY", 40, 51], ["alveolar", "ANATOMY", 103, 111], ["viral infection", "DISEASE", 4, 19], ["alveolar damage", "DISEASE", 103, 118], ["pneumocytes", "CELL", 40, 51], ["alveolar", "TISSUE", 103, 111], ["patients", "ORGANISM", 140, 148], ["pneumocytes", "CELL_TYPE", 40, 51], ["patients", "SPECIES", 140, 148], ["The viral infection", "PROBLEM", 0, 19], ["injury of these pneumocytes", "PROBLEM", 24, 51], ["the prominent diffuse alveolar damage", "PROBLEM", 81, 118], ["COVID19", "TREATMENT", 154, 161], ["viral", "OBSERVATION_MODIFIER", 4, 9], ["infection", "OBSERVATION", 10, 19], ["injury", "OBSERVATION", 24, 30], ["pneumocytes", "OBSERVATION", 40, 51], ["thought to be", "UNCERTAINTY", 56, 69], ["prominent", "OBSERVATION_MODIFIER", 85, 94], ["diffuse", "OBSERVATION_MODIFIER", 95, 102], ["alveolar damage", "OBSERVATION", 103, 118]]], ["Interestingly, ACE2 expression is low in the lower airways [15], but more elevated in nasal ciliated and goblet cells, which may explain the symptom of anosmia which has been recently reported by Brann et al. [16].", [["lower airways", "ANATOMY", 45, 58], ["nasal ciliated", "ANATOMY", 86, 100], ["goblet cells", "ANATOMY", 105, 117], ["anosmia", "DISEASE", 152, 159], ["ACE2", "GENE_OR_GENE_PRODUCT", 15, 19], ["nasal ciliated", "CELL", 86, 100], ["goblet cells", "CELL", 105, 117], ["ACE2", "PROTEIN", 15, 19], ["nasal ciliated and goblet cells", "CELL_TYPE", 86, 117], ["ACE2 expression", "TEST", 15, 30], ["elevated in nasal ciliated and goblet cells", "PROBLEM", 74, 117], ["anosmia", "PROBLEM", 152, 159], ["low", "OBSERVATION_MODIFIER", 34, 37], ["lower", "ANATOMY_MODIFIER", 45, 50], ["airways", "ANATOMY", 51, 58], ["elevated", "OBSERVATION_MODIFIER", 74, 82], ["nasal ciliated", "ANATOMY", 86, 100], ["goblet cells", "OBSERVATION", 105, 117]]], ["At the organ level, however, respiratory tissue carries significantly less ACE2 (by 10\u2013100-fold) than the digestive organs, kidneys, and heart (Fig. 1b) [17].", [["organ", "ANATOMY", 7, 12], ["respiratory tissue", "ANATOMY", 29, 47], ["digestive organs", "ANATOMY", 106, 122], ["kidneys", "ANATOMY", 124, 131], ["heart", "ANATOMY", 137, 142], ["organ", "ORGAN", 7, 12], ["respiratory tissue", "TISSUE", 29, 47], ["ACE2", "GENE_OR_GENE_PRODUCT", 75, 79], ["digestive organs", "ORGAN", 106, 122], ["kidneys", "ORGAN", 124, 131], ["heart", "ORGAN", 137, 142], ["ACE2", "PROTEIN", 75, 79], ["the organ level", "TEST", 3, 18], ["organ", "ANATOMY", 7, 12], ["respiratory tissue", "OBSERVATION", 29, 47], ["digestive organs", "ANATOMY", 106, 122], ["kidneys", "ANATOMY", 124, 131], ["heart", "ANATOMY", 137, 142]]], ["The high expression of ACE2 in the GI tract was thought to explain the frequent occurrence of GI symptoms with SARS.", [["GI tract", "ANATOMY", 35, 43], ["GI", "ANATOMY", 94, 96], ["SARS", "DISEASE", 111, 115], ["ACE2", "GENE_OR_GENE_PRODUCT", 23, 27], ["GI tract", "ORGAN", 35, 43], ["GI", "ORGANISM_SUBDIVISION", 94, 96], ["ACE2", "PROTEIN", 23, 27], ["ACE2 in the GI tract", "PROBLEM", 23, 43], ["GI symptoms", "PROBLEM", 94, 105], ["SARS", "PROBLEM", 111, 115], ["high", "OBSERVATION_MODIFIER", 4, 8], ["expression", "OBSERVATION_MODIFIER", 9, 19], ["GI tract", "ANATOMY", 35, 43]]], ["However, while GI symptoms are present in COVID-19 patients, they do not appear to be as frequent compared to SARS [18], suggesting key vector-specific differences in tissue tropism.", [["GI", "ANATOMY", 15, 17], ["tissue", "ANATOMY", 167, 173], ["SARS", "DISEASE", 110, 114], ["patients", "ORGANISM", 51, 59], ["tissue", "TISSUE", 167, 173], ["patients", "SPECIES", 51, 59], ["GI symptoms", "PROBLEM", 15, 26], ["SARS", "TEST", 110, 114], ["key vector-specific differences in tissue tropism", "PROBLEM", 132, 181], ["tissue tropism", "OBSERVATION", 167, 181]]], ["There are reports, however, of detection of viral RNA in the stool of asymptomatic patients, which raises the possibility of additional routes of asymptomatic spread [19].", [["stool", "ANATOMY", 61, 66], ["stool", "ORGANISM_SUBSTANCE", 61, 66], ["patients", "ORGANISM", 83, 91], ["viral RNA", "RNA", 44, 53], ["patients", "SPECIES", 83, 91], ["viral RNA", "PROBLEM", 44, 53], ["asymptomatic spread", "PROBLEM", 146, 165], ["viral RNA", "OBSERVATION", 44, 53], ["raises the possibility of", "UNCERTAINTY", 99, 124]]], ["The relatively elevated expression of ACE2 levels in the heart compared to the lungs also lends biological plausibility for the perceived elevated incidence of cardiac injuries seen in COVID-19 patients.SARS-CoV-2 Biology and Clinical ImplicationsThe central role of ACE2 in viral entry in combination with reported worse outcomes seen in patients with hypertension and diabetes fueled much of the speculation that ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), both commonly used by hypertensive or diabetic patients, may play a role in the observed increased risk.", [["heart", "ANATOMY", 57, 62], ["lungs", "ANATOMY", 79, 84], ["cardiac", "ANATOMY", 160, 167], ["cardiac injuries", "DISEASE", 160, 176], ["SARS", "DISEASE", 203, 207], ["hypertension", "DISEASE", 353, 365], ["diabetes", "DISEASE", 370, 378], ["ACE inhibitors", "CHEMICAL", 415, 429], ["ACEIs", "CHEMICAL", 431, 436], ["angiotensin receptor blockers", "CHEMICAL", 442, 471], ["ARBs", "CHEMICAL", 473, 477], ["hypertensive", "DISEASE", 502, 514], ["diabetic", "DISEASE", 518, 526], ["ACE2", "GENE_OR_GENE_PRODUCT", 38, 42], ["heart", "ORGAN", 57, 62], ["lungs", "ORGAN", 79, 84], ["cardiac", "ORGAN", 160, 167], ["patients", "ORGANISM", 194, 202], ["ACE2", "GENE_OR_GENE_PRODUCT", 267, 271], ["patients", "ORGANISM", 339, 347], ["ACE", "GENE_OR_GENE_PRODUCT", 415, 418], ["ACEIs", "SIMPLE_CHEMICAL", 431, 436], ["angiotensin receptor blockers", "SIMPLE_CHEMICAL", 442, 471], ["ARBs", "SIMPLE_CHEMICAL", 473, 477], ["patients", "ORGANISM", 527, 535], ["ACE2", "PROTEIN", 38, 42], ["ACE2", "PROTEIN", 267, 271], ["patients", "SPECIES", 194, 202], ["patients", "SPECIES", 339, 347], ["patients", "SPECIES", 527, 535], ["The relatively elevated expression of ACE2 levels in the heart", "PROBLEM", 0, 62], ["cardiac injuries", "PROBLEM", 160, 176], ["COVID", "TEST", 185, 190], ["ACE2 in viral entry", "TREATMENT", 267, 286], ["hypertension", "PROBLEM", 353, 365], ["diabetes", "PROBLEM", 370, 378], ["ACE inhibitors", "TREATMENT", 415, 429], ["ACEIs)", "TREATMENT", 431, 437], ["angiotensin receptor blockers", "TREATMENT", 442, 471], ["ARBs", "TREATMENT", 473, 477], ["relatively", "OBSERVATION_MODIFIER", 4, 14], ["elevated", "OBSERVATION_MODIFIER", 15, 23], ["expression", "OBSERVATION", 24, 34], ["ACE2 levels", "OBSERVATION", 38, 49], ["heart", "ANATOMY", 57, 62], ["lungs", "ANATOMY", 79, 84], ["cardiac", "ANATOMY", 160, 167], ["injuries", "OBSERVATION", 168, 176], ["viral entry", "OBSERVATION", 275, 286], ["hypertension", "OBSERVATION", 353, 365]]], ["The evidence was mostly based on studies that have demonstrated a moderate increase in Ace2 expression in the mouse heart treated with ACEIs [20].", [["heart", "ANATOMY", 116, 121], ["ACEIs", "CHEMICAL", 135, 140], ["Ace2", "GENE_OR_GENE_PRODUCT", 87, 91], ["mouse", "ORGANISM", 110, 115], ["heart", "ORGAN", 116, 121], ["Ace2", "PROTEIN", 87, 91], ["mouse", "SPECIES", 110, 115], ["mouse", "SPECIES", 110, 115], ["studies", "TEST", 33, 40], ["a moderate increase in Ace2 expression", "PROBLEM", 64, 102], ["ACEIs", "TREATMENT", 135, 140], ["moderate", "OBSERVATION_MODIFIER", 66, 74], ["increase", "OBSERVATION_MODIFIER", 75, 83], ["Ace2 expression", "OBSERVATION", 87, 102], ["heart", "ANATOMY", 116, 121]]], ["However, there is no such report of ACE2 level alterations in the lungs thus far.", [["lungs", "ANATOMY", 66, 71], ["ACE2", "GENE_OR_GENE_PRODUCT", 36, 40], ["lungs", "ORGAN", 66, 71], ["ACE2", "PROTEIN", 36, 40], ["ACE2 level alterations in the lungs", "PROBLEM", 36, 71], ["no", "UNCERTAINTY", 18, 20], ["lungs", "ANATOMY", 66, 71]]], ["While theoretically, increased ACE2 expression in the lungs may lead to worsened viral entry, the potential worsening of respiratory status and progression to ARDS in hypertensive and diabetic patients taking ACE inhibitors remains speculative.", [["lungs", "ANATOMY", 54, 59], ["respiratory", "ANATOMY", 121, 132], ["ARDS", "DISEASE", 159, 163], ["hypertensive", "DISEASE", 167, 179], ["diabetic", "DISEASE", 184, 192], ["ACE2", "GENE_OR_GENE_PRODUCT", 31, 35], ["lungs", "ORGAN", 54, 59], ["patients", "ORGANISM", 193, 201], ["ACE", "GENE_OR_GENE_PRODUCT", 209, 212], ["ACE2", "PROTEIN", 31, 35], ["patients", "SPECIES", 193, 201], ["increased ACE2 expression in the lungs", "PROBLEM", 21, 59], ["worsened viral entry", "PROBLEM", 72, 92], ["respiratory status", "PROBLEM", 121, 139], ["ARDS", "PROBLEM", 159, 163], ["hypertensive and diabetic patients", "PROBLEM", 167, 201], ["ACE inhibitors", "TREATMENT", 209, 223], ["increased", "OBSERVATION_MODIFIER", 21, 30], ["ACE2 expression", "OBSERVATION", 31, 46], ["lungs", "ANATOMY", 54, 59], ["may lead to", "UNCERTAINTY", 60, 71], ["worsened", "OBSERVATION_MODIFIER", 72, 80], ["viral", "OBSERVATION", 81, 86], ["worsening", "OBSERVATION_MODIFIER", 108, 117], ["respiratory status", "OBSERVATION", 121, 139], ["ARDS", "OBSERVATION", 159, 163]]], ["In addition, ACE2 is thought to be potentially protective in acute lung injury and ARDS, as the genetic knockout of Ace2 in rodents results in worsened lung injury, and overexpression of Ace2 in the lung is protective [21].", [["lung", "ANATOMY", 67, 71], ["lung", "ANATOMY", 152, 156], ["lung", "ANATOMY", 199, 203], ["acute lung injury", "DISEASE", 61, 78], ["ARDS", "DISEASE", 83, 87], ["Ace2", "CHEMICAL", 116, 120], ["lung injury", "DISEASE", 152, 163], ["ACE2", "GENE_OR_GENE_PRODUCT", 13, 17], ["lung", "ORGAN", 67, 71], ["Ace2", "GENE_OR_GENE_PRODUCT", 116, 120], ["lung", "ORGAN", 152, 156], ["Ace2", "GENE_OR_GENE_PRODUCT", 187, 191], ["lung", "ORGAN", 199, 203], ["ACE2", "PROTEIN", 13, 17], ["Ace2", "PROTEIN", 116, 120], ["Ace2", "PROTEIN", 187, 191], ["ACE2", "PROBLEM", 13, 17], ["acute lung injury", "PROBLEM", 61, 78], ["ARDS", "PROBLEM", 83, 87], ["worsened lung injury", "PROBLEM", 143, 163], ["thought to be potentially", "UNCERTAINTY", 21, 46], ["protective", "OBSERVATION_MODIFIER", 47, 57], ["acute", "OBSERVATION_MODIFIER", 61, 66], ["lung", "ANATOMY", 67, 71], ["injury", "OBSERVATION", 72, 78], ["ARDS", "OBSERVATION", 83, 87], ["worsened", "OBSERVATION_MODIFIER", 143, 151], ["lung", "ANATOMY", 152, 156], ["injury", "OBSERVATION", 157, 163], ["lung", "ANATOMY", 199, 203]]], ["This protective role of ACE2 is hypothesized to be due to modulation of the angiotensin response to lung, immune, and vascular cells within the pulmonary system [22].", [["lung", "ANATOMY", 100, 104], ["vascular cells", "ANATOMY", 118, 132], ["pulmonary system", "ANATOMY", 144, 160], ["angiotensin", "CHEMICAL", 76, 87], ["ACE2", "GENE_OR_GENE_PRODUCT", 24, 28], ["angiotensin", "GENE_OR_GENE_PRODUCT", 76, 87], ["lung", "ORGAN", 100, 104], ["vascular cells", "CELL", 118, 132], ["pulmonary", "ORGAN", 144, 153], ["ACE2", "PROTEIN", 24, 28], ["vascular cells", "CELL_TYPE", 118, 132], ["the angiotensin response", "TEST", 72, 96], ["lung", "ANATOMY", 100, 104], ["vascular cells", "ANATOMY", 118, 132], ["pulmonary system", "ANATOMY", 144, 160]]], ["To address the role of angiotensin in lung injury, there is an ongoing clinical trial to examine whether losartan treatment affects outcomes in COVID-19 associated ARDS (NCT04312009).", [["lung", "ANATOMY", 38, 42], ["angiotensin", "CHEMICAL", 23, 34], ["lung injury", "DISEASE", 38, 49], ["losartan", "CHEMICAL", 105, 113], ["ARDS", "DISEASE", 164, 168], ["losartan", "CHEMICAL", 105, 113], ["angiotensin", "SIMPLE_CHEMICAL", 23, 34], ["lung", "ORGAN", 38, 42], ["losartan", "SIMPLE_CHEMICAL", 105, 113], ["angiotensin in lung injury", "PROBLEM", 23, 49], ["losartan treatment", "TREATMENT", 105, 123], ["COVID", "TEST", 144, 149], ["ARDS", "PROBLEM", 164, 168], ["lung", "ANATOMY", 38, 42], ["injury", "OBSERVATION", 43, 49], ["ARDS", "OBSERVATION", 164, 168]]], ["Given the known benefit of ACEI/ARB treatment in patients with diabetes mellitus, heart failure, and hypertension, many societies including the American College of Cardiology, American Heart Association, Heart Failure Society of American, and the European Society of Cardiology have released statements to advise against discontinuation of these medications in COVID-19 patients until more data are available [23].Myocardial Injury and Heart Failure ::: Cardiac Complications of COVID-19 ::: Cardiovascular Comorbidities and COVID-19 OutcomesSeveral published and unpublished case series have documented elevated serum troponin levels in a significant fraction (5\u20137%) of hospitalized COVID-19 patients [1, 8].", [["heart", "ANATOMY", 82, 87], ["Myocardial", "ANATOMY", 414, 424], ["Heart", "ANATOMY", 436, 441], ["Cardiac", "ANATOMY", 454, 461], ["Cardiovascular", "ANATOMY", 492, 506], ["serum", "ANATOMY", 613, 618], ["ACEI", "CHEMICAL", 27, 31], ["ARB", "CHEMICAL", 32, 35], ["diabetes mellitus", "DISEASE", 63, 80], ["heart failure", "DISEASE", 82, 95], ["hypertension", "DISEASE", 101, 113], ["Heart Failure", "DISEASE", 204, 217], ["Myocardial Injury", "DISEASE", 414, 431], ["Heart Failure", "DISEASE", 436, 449], ["Cardiovascular Comorbidities", "DISEASE", 492, 520], ["COVID-19", "CHEMICAL", 479, 487], ["ACEI", "SIMPLE_CHEMICAL", 27, 31], ["ARB", "SIMPLE_CHEMICAL", 32, 35], ["patients", "ORGANISM", 49, 57], ["heart", "ORGAN", 82, 87], ["patients", "ORGANISM", 370, 378], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 414, 424], ["Cardiac", "ORGAN", 454, 461], ["serum", "ORGANISM_SUBSTANCE", 613, 618], ["troponin", "GENE_OR_GENE_PRODUCT", 619, 627], ["patients", "ORGANISM", 693, 701], ["troponin", "PROTEIN", 619, 627], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 370, 378], ["patients", "SPECIES", 693, 701], ["ACEI", "TREATMENT", 27, 31], ["ARB treatment", "TREATMENT", 32, 45], ["diabetes mellitus", "PROBLEM", 63, 80], ["heart failure", "PROBLEM", 82, 95], ["hypertension", "PROBLEM", 101, 113], ["these medications", "TREATMENT", 340, 357], ["Myocardial Injury", "PROBLEM", 414, 431], ["Heart Failure", "PROBLEM", 436, 449], ["COVID", "TEST", 479, 484], ["Cardiovascular Comorbidities", "PROBLEM", 492, 520], ["COVID", "TEST", 525, 530], ["elevated serum troponin levels", "PROBLEM", 604, 634], ["COVID", "TEST", 684, 689], ["heart", "ANATOMY", 82, 87], ["failure", "OBSERVATION", 88, 95], ["hypertension", "OBSERVATION", 101, 113], ["Heart", "ANATOMY", 185, 190], ["Heart", "ANATOMY", 204, 209], ["Failure", "OBSERVATION", 210, 217], ["Injury", "OBSERVATION", 425, 431], ["Heart", "ANATOMY", 436, 441], ["Failure", "OBSERVATION", 442, 449], ["Complications", "OBSERVATION", 462, 475], ["Cardiovascular", "ANATOMY", 492, 506], ["Comorbidities", "OBSERVATION", 507, 520]]], ["While the degree of troponin elevation was mild in the majority of cases, the presence of myocardial injury (as manifested by troponins above the upper range of normal) was associated with a significantly worse prognosis [28\u2022].", [["myocardial", "ANATOMY", 90, 100], ["myocardial injury", "DISEASE", 90, 107], ["troponin", "GENE_OR_GENE_PRODUCT", 20, 28], ["myocardial", "MULTI-TISSUE_STRUCTURE", 90, 100], ["troponin", "PROTEIN", 20, 28], ["troponins", "PROTEIN", 126, 135], ["troponin elevation", "PROBLEM", 20, 38], ["myocardial injury", "PROBLEM", 90, 107], ["troponins", "TEST", 126, 135], ["a significantly worse prognosis", "PROBLEM", 189, 220], ["troponin elevation", "OBSERVATION", 20, 38], ["mild", "OBSERVATION_MODIFIER", 43, 47], ["myocardial", "ANATOMY", 90, 100], ["injury", "OBSERVATION", 101, 107], ["upper range", "OBSERVATION_MODIFIER", 146, 157]]], ["It remains unclear whether the association with worse outcomes is simply reflective of selection of an older, sicker population more prone to demand ischemia with metabolic compromise during critical illness or direct myocardial injury caused by the virus or its inflammatory sequelae (Fig. 2).", [["myocardial", "ANATOMY", 218, 228], ["ischemia", "DISEASE", 149, 157], ["myocardial injury", "DISEASE", 218, 235], ["myocardial", "MULTI-TISSUE_STRUCTURE", 218, 228], ["demand ischemia", "PROBLEM", 142, 157], ["metabolic compromise", "PROBLEM", 163, 183], ["critical illness", "PROBLEM", 191, 207], ["direct myocardial injury", "PROBLEM", 211, 235], ["the virus", "PROBLEM", 246, 255], ["its inflammatory sequelae", "PROBLEM", 259, 284], ["metabolic compromise", "OBSERVATION", 163, 183], ["myocardial", "ANATOMY", 218, 228], ["injury", "OBSERVATION", 229, 235], ["inflammatory", "OBSERVATION_MODIFIER", 263, 275]]], ["Relatively high levels of ACE2 protein expression on cardiomyocytes may theoretically lead to increased risk of viral susceptibility and virus mediated injury.", [["cardiomyocytes", "ANATOMY", 53, 67], ["ACE2", "GENE_OR_GENE_PRODUCT", 26, 30], ["cardiomyocytes", "CELL", 53, 67], ["ACE2", "PROTEIN", 26, 30], ["cardiomyocytes", "CELL_TYPE", 53, 67], ["ACE2 protein expression on cardiomyocytes", "PROBLEM", 26, 67], ["viral susceptibility", "PROBLEM", 112, 132], ["virus mediated injury", "PROBLEM", 137, 158], ["cardiomyocytes", "ANATOMY", 53, 67], ["viral susceptibility", "OBSERVATION", 112, 132]]], ["However, while there are anecdotal reports of clinical presentations consistent with myocarditis [29\u2022], significant incidence of myocarditis has not been reported in any larger case series thus far.", [["myocarditis", "DISEASE", 85, 96], ["myocarditis", "DISEASE", 129, 140], ["myocarditis", "PROBLEM", 85, 96], ["myocarditis", "PROBLEM", 129, 140], ["consistent with", "UNCERTAINTY", 69, 84], ["myocarditis", "OBSERVATION", 85, 96], ["significant", "OBSERVATION_MODIFIER", 104, 115], ["myocarditis", "OBSERVATION", 129, 140]]], ["To date, there has been very limited pathologic or radiologic proof of myocarditis as a direct sequelae of COVID-19.", [["myocarditis", "DISEASE", 71, 82], ["COVID-19", "CHEMICAL", 107, 115], ["myocarditis", "PROBLEM", 71, 82], ["COVID", "TEST", 107, 112], ["myocarditis", "OBSERVATION", 71, 82]]], ["Alternatively, the observed incidence of myocardial injury could be due to the increased risk of myocardial ischemic insult due to the poorly understood pleiotropic pro-thrombotic inflammatory sequelae from viral infections.", [["myocardial", "ANATOMY", 41, 51], ["myocardial", "ANATOMY", 97, 107], ["myocardial injury", "DISEASE", 41, 58], ["myocardial ischemic insult", "DISEASE", 97, 123], ["viral infections", "DISEASE", 207, 223], ["myocardial", "MULTI-TISSUE_STRUCTURE", 41, 51], ["myocardial", "MULTI-TISSUE_STRUCTURE", 97, 107], ["myocardial injury", "PROBLEM", 41, 58], ["myocardial ischemic insult", "PROBLEM", 97, 123], ["pleiotropic pro-thrombotic inflammatory sequelae", "PROBLEM", 153, 201], ["viral infections", "PROBLEM", 207, 223], ["myocardial", "ANATOMY", 41, 51], ["injury", "OBSERVATION", 52, 58], ["increased", "OBSERVATION_MODIFIER", 79, 88], ["myocardial", "ANATOMY", 97, 107], ["ischemic", "OBSERVATION", 108, 116], ["pro-thrombotic", "OBSERVATION_MODIFIER", 165, 179], ["inflammatory", "OBSERVATION_MODIFIER", 180, 192], ["viral", "OBSERVATION_MODIFIER", 207, 212], ["infections", "OBSERVATION", 213, 223]]], ["An increased risk of myocardial infarction as determined by serological evidence of myocardial injuries has been well-documented in influenza infections at similar prevalence [30\u201332].", [["myocardial", "ANATOMY", 21, 31], ["myocardial", "ANATOMY", 84, 94], ["myocardial infarction", "DISEASE", 21, 42], ["myocardial injuries", "DISEASE", 84, 103], ["influenza infections", "DISEASE", 132, 152], ["myocardial", "MULTI-TISSUE_STRUCTURE", 21, 31], ["myocardial", "MULTI-TISSUE_STRUCTURE", 84, 94], ["myocardial infarction", "PROBLEM", 21, 42], ["myocardial injuries", "PROBLEM", 84, 103], ["influenza infections", "PROBLEM", 132, 152], ["increased", "OBSERVATION_MODIFIER", 3, 12], ["myocardial", "ANATOMY", 21, 31], ["infarction", "OBSERVATION", 32, 42], ["myocardial", "ANATOMY", 84, 94], ["injuries", "OBSERVATION", 95, 103]]], ["This would suggest that the intravascular prothrombotic effect observed in COVID-19 patients is the consequence of the overall inflammatory state rather than a COVID19-specific phenomenon.Myocardial Injury and Heart Failure ::: Cardiac Complications of COVID-19 ::: Cardiovascular Comorbidities and COVID-19 OutcomesRegardless of the cause of myocardial injuries, early case reports of critically ill patients have found a significant fraction of patients developing clinical heart failure.", [["intravascular", "ANATOMY", 28, 41], ["Myocardial", "ANATOMY", 188, 198], ["Heart", "ANATOMY", 210, 215], ["Cardiac", "ANATOMY", 228, 235], ["Cardiovascular", "ANATOMY", 266, 280], ["myocardial", "ANATOMY", 343, 353], ["heart", "ANATOMY", 476, 481], ["Myocardial Injury", "DISEASE", 188, 205], ["Heart Failure", "DISEASE", 210, 223], ["Cardiovascular Comorbidities", "DISEASE", 266, 294], ["myocardial injuries", "DISEASE", 343, 362], ["critically ill", "DISEASE", 386, 400], ["heart failure", "DISEASE", 476, 489], ["COVID-19", "CHEMICAL", 253, 261], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 28, 41], ["patients", "ORGANISM", 84, 92], ["COVID19", "GENE_OR_GENE_PRODUCT", 160, 167], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 188, 198], ["Cardiac", "ORGAN", 228, 235], ["myocardial", "MULTI-TISSUE_STRUCTURE", 343, 353], ["patients", "ORGANISM", 401, 409], ["patients", "ORGANISM", 447, 455], ["heart", "ORGAN", 476, 481], ["COVID19", "PROTEIN", 160, 167], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 401, 409], ["patients", "SPECIES", 447, 455], ["the intravascular prothrombotic effect", "PROBLEM", 24, 62], ["COVID", "TEST", 75, 80], ["the overall inflammatory state", "PROBLEM", 115, 145], ["a COVID19-specific phenomenon", "PROBLEM", 158, 187], ["Myocardial Injury", "PROBLEM", 188, 205], ["Heart Failure", "PROBLEM", 210, 223], ["Cardiovascular Comorbidities", "PROBLEM", 266, 294], ["COVID", "TEST", 299, 304], ["myocardial injuries", "PROBLEM", 343, 362], ["clinical heart failure", "PROBLEM", 467, 489], ["intravascular", "OBSERVATION_MODIFIER", 28, 41], ["prothrombotic", "OBSERVATION", 42, 55], ["inflammatory", "OBSERVATION", 127, 139], ["Injury", "OBSERVATION", 199, 205], ["Heart", "ANATOMY", 210, 215], ["Failure", "OBSERVATION", 216, 223], ["Complications", "OBSERVATION", 236, 249], ["myocardial", "ANATOMY", 343, 353], ["injuries", "OBSERVATION", 354, 362], ["heart", "ANATOMY", 476, 481], ["failure", "OBSERVATION", 482, 489]]], ["Zhou et al. from Wuhan found that 28/54 of those who succumbed to the disease had heart failure\u2014albeit the definition of \u201cheart failure\u201d employed was not stated, and a broad definition of acute cardiac injury (cardiac biomarkers > 99th percentile of the upper reference limit or new abnormalities on EKG or echocardiography) was used in this study.", [["heart", "ANATOMY", 82, 87], ["heart", "ANATOMY", 122, 127], ["cardiac", "ANATOMY", 194, 201], ["cardiac", "ANATOMY", 210, 217], ["heart failure\u2014albeit", "DISEASE", 82, 102], ["heart failure", "DISEASE", 122, 135], ["cardiac injury", "DISEASE", 194, 208], ["heart", "ORGAN", 82, 87], ["heart", "ORGAN", 122, 127], ["cardiac", "ORGAN", 194, 201], ["cardiac", "ORGAN", 210, 217], ["heart failure\u2014albeit", "PROBLEM", 82, 102], ["\u201cheart failure", "PROBLEM", 121, 135], ["acute cardiac injury", "PROBLEM", 188, 208], ["cardiac biomarkers", "TEST", 210, 228], ["new abnormalities", "PROBLEM", 279, 296], ["EKG", "TEST", 300, 303], ["echocardiography", "TEST", 307, 323], ["this study", "TEST", 337, 347], ["heart", "ANATOMY", 82, 87], ["failure\u2014albeit", "OBSERVATION", 88, 102], ["heart", "ANATOMY", 122, 127], ["failure", "OBSERVATION", 128, 135], ["acute", "OBSERVATION_MODIFIER", 188, 193], ["cardiac", "ANATOMY", 194, 201], ["injury", "OBSERVATION", 202, 208]]], ["The case series of critically ill patients from Seattle showed cardiomyopathy in 7/21 patients, as defined by globally reduced left ventricular ejection function or decreased central venous saturation to < 70% [25].", [["left ventricular", "ANATOMY", 127, 143], ["central venous", "ANATOMY", 175, 189], ["critically ill", "DISEASE", 19, 33], ["cardiomyopathy", "DISEASE", 63, 77], ["patients", "ORGANISM", 34, 42], ["patients", "ORGANISM", 86, 94], ["ventricular", "MULTI-TISSUE_STRUCTURE", 132, 143], ["venous", "MULTI-TISSUE_STRUCTURE", 183, 189], ["patients", "SPECIES", 34, 42], ["patients", "SPECIES", 86, 94], ["cardiomyopathy", "PROBLEM", 63, 77], ["globally reduced left ventricular ejection function", "PROBLEM", 110, 161], ["decreased central venous saturation", "PROBLEM", 165, 200], ["cardiomyopathy", "OBSERVATION", 63, 77], ["reduced", "OBSERVATION", 119, 126], ["left ventricular", "ANATOMY", 127, 143], ["ejection function", "OBSERVATION", 144, 161], ["decreased", "OBSERVATION_MODIFIER", 165, 174], ["central", "ANATOMY_MODIFIER", 175, 182], ["venous", "ANATOMY", 183, 189]]], ["While the frequency of patient with cardiac dysfunction is notable in these reports, some limitations such as small sample size, very high (44%) baseline history of \u201cCHF\u201d, and the lack of clearly defined criteria for heart failure limit the generalizability of these studies.", [["cardiac", "ANATOMY", 36, 43], ["heart", "ANATOMY", 217, 222], ["cardiac dysfunction", "DISEASE", 36, 55], ["CHF", "DISEASE", 166, 169], ["heart failure", "DISEASE", 217, 230], ["patient", "ORGANISM", 23, 30], ["cardiac", "ORGAN", 36, 43], ["heart", "ORGAN", 217, 222], ["patient", "SPECIES", 23, 30], ["cardiac dysfunction", "PROBLEM", 36, 55], ["small sample size", "PROBLEM", 110, 127], ["\u201cCHF", "PROBLEM", 165, 169], ["heart failure", "PROBLEM", 217, 230], ["these studies", "TEST", 261, 274], ["cardiac", "ANATOMY", 36, 43], ["dysfunction", "OBSERVATION", 44, 55], ["small", "OBSERVATION_MODIFIER", 110, 115], ["sample", "OBSERVATION_MODIFIER", 116, 122], ["size", "OBSERVATION_MODIFIER", 123, 127], ["very", "OBSERVATION_MODIFIER", 129, 133], ["high", "OBSERVATION_MODIFIER", 134, 138], ["CHF", "OBSERVATION", 166, 169], ["heart", "ANATOMY", 217, 222], ["failure", "OBSERVATION", 223, 230]]], ["It is worth noting that high incidence of heart failure was not mentioned in a larger case series from China [26\u2022\u2022] nor in the Italian experience thus far [33].Arrhythmia ::: Cardiac Complications of COVID-19 ::: Cardiovascular Comorbidities and COVID-19 OutcomesA published study and additional anecdotal reports have highlighted the presence of arrhythmia and even sudden cardiac death in critically ill COVID-19 patients.", [["heart", "ANATOMY", 42, 47], ["Cardiac", "ANATOMY", 175, 182], ["Cardiovascular", "ANATOMY", 213, 227], ["cardiac", "ANATOMY", 374, 381], ["heart failure", "DISEASE", 42, 55], ["Arrhythmia", "DISEASE", 160, 170], ["arrhythmia", "DISEASE", 347, 357], ["sudden cardiac death", "DISEASE", 367, 387], ["critically ill", "DISEASE", 391, 405], ["COVID-19", "CHEMICAL", 200, 208], ["heart", "ORGAN", 42, 47], ["Cardiac", "ORGAN", 175, 182], ["cardiac", "ORGAN", 374, 381], ["patients", "ORGANISM", 415, 423], ["patients", "SPECIES", 415, 423], ["heart failure", "PROBLEM", 42, 55], ["Arrhythmia", "PROBLEM", 160, 170], ["Cardiovascular Comorbidities", "PROBLEM", 213, 241], ["COVID", "TEST", 246, 251], ["OutcomesA published study", "TEST", 255, 280], ["arrhythmia", "PROBLEM", 347, 357], ["sudden cardiac death", "PROBLEM", 367, 387], ["heart", "ANATOMY", 42, 47], ["failure", "OBSERVATION", 48, 55], ["Complications", "OBSERVATION", 183, 196], ["Comorbidities", "OBSERVATION", 228, 241], ["arrhythmia", "OBSERVATION", 347, 357], ["cardiac", "ANATOMY", 374, 381], ["death", "OBSERVATION", 382, 387]]], ["The first case series out of Wuhan documented 16.7% and 44% incidence of arrhythmia in those hospitalized for COVID-19 and admitted to the ICU respectively [8].", [["arrhythmia", "DISEASE", 73, 83], ["arrhythmia", "PROBLEM", 73, 83], ["COVID", "TEST", 110, 115], ["arrhythmia", "OBSERVATION", 73, 83]]], ["Unfortunately, the exact nature of the arrhythmias was not detailed in this study.", [["arrhythmias", "DISEASE", 39, 50], ["the arrhythmias", "PROBLEM", 35, 50], ["this study", "TEST", 71, 81], ["arrhythmias", "OBSERVATION", 39, 50]]], ["Interestingly, a high incidence of arrhythmias was not reported in several subsequent larger case series from China [26\u2022\u2022].", [["arrhythmias", "DISEASE", 35, 46], ["arrhythmias", "PROBLEM", 35, 46], ["arrhythmias", "OBSERVATION", 35, 46]]], ["One would expect a majority of the reported arrhythmias are atrial, as similarly elevated rates of atrial arrhythmia were seen in longitudinal studies on Medicare patients hospitalized with sepsis [34].", [["atrial", "ANATOMY", 60, 66], ["atrial", "ANATOMY", 99, 105], ["arrhythmias", "DISEASE", 44, 55], ["atrial arrhythmia", "DISEASE", 99, 116], ["sepsis", "DISEASE", 190, 196], ["atrial", "MULTI-TISSUE_STRUCTURE", 60, 66], ["atrial", "MULTI-TISSUE_STRUCTURE", 99, 105], ["patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 163, 171], ["the reported arrhythmias", "PROBLEM", 31, 55], ["atrial", "PROBLEM", 60, 66], ["atrial arrhythmia", "PROBLEM", 99, 116], ["sepsis", "PROBLEM", 190, 196], ["arrhythmias", "OBSERVATION", 44, 55], ["atrial", "ANATOMY", 60, 66], ["elevated", "OBSERVATION_MODIFIER", 81, 89], ["atrial", "ANATOMY", 99, 105], ["arrhythmia", "OBSERVATION", 106, 116], ["sepsis", "OBSERVATION", 190, 196]]], ["It remains to be determined whether a significant portion of COVID-19 patients have hemodynamically significant ventricular arrhythmias.", [["ventricular", "ANATOMY", 112, 123], ["ventricular arrhythmias", "DISEASE", 112, 135], ["patients", "ORGANISM", 70, 78], ["ventricular", "MULTI-TISSUE_STRUCTURE", 112, 123], ["patients", "SPECIES", 70, 78], ["COVID", "TEST", 61, 66], ["hemodynamically significant ventricular arrhythmias", "PROBLEM", 84, 135], ["significant", "OBSERVATION_MODIFIER", 100, 111], ["ventricular", "ANATOMY", 112, 123], ["arrhythmias", "OBSERVATION", 124, 135]]], ["The high prevalence of myocardial injury may itself increase life-threatening arrhythmias and contribute to worse outcomes.", [["myocardial", "ANATOMY", 23, 33], ["myocardial injury", "DISEASE", 23, 40], ["arrhythmias", "DISEASE", 78, 89], ["myocardial", "MULTI-TISSUE_STRUCTURE", 23, 33], ["myocardial injury", "PROBLEM", 23, 40], ["threatening arrhythmias", "PROBLEM", 66, 89], ["worse outcomes", "PROBLEM", 108, 122], ["high", "OBSERVATION_MODIFIER", 4, 8], ["myocardial", "ANATOMY", 23, 33], ["injury", "OBSERVATION", 34, 40]]], ["Of note, some of the therapies empirically used to treat SARS-CoV-2 infections such as chloroquine, have known effects on myocyte repolarization [35], resulting in increased risk of QT prolongation and subsequent arrhythmia.", [["myocyte", "ANATOMY", 122, 129], ["SARS", "DISEASE", 57, 61], ["infections", "DISEASE", 68, 78], ["chloroquine", "CHEMICAL", 87, 98], ["QT prolongation", "DISEASE", 182, 197], ["arrhythmia", "DISEASE", 213, 223], ["chloroquine", "CHEMICAL", 87, 98], ["SARS-CoV-2", "ORGANISM", 57, 67], ["chloroquine", "SIMPLE_CHEMICAL", 87, 98], ["myocyte", "CELL", 122, 129], ["SARS-CoV", "SPECIES", 57, 65], ["the therapies", "TREATMENT", 17, 30], ["SARS", "PROBLEM", 57, 61], ["CoV-2 infections", "PROBLEM", 62, 78], ["chloroquine", "TREATMENT", 87, 98], ["myocyte repolarization", "TREATMENT", 122, 144], ["QT prolongation", "PROBLEM", 182, 197], ["subsequent arrhythmia", "PROBLEM", 202, 223], ["increased", "OBSERVATION_MODIFIER", 164, 173], ["QT prolongation", "OBSERVATION", 182, 197]]], ["Given the high incidence of electrolyte abnormalities in ill patients, high vigilance by the treatment teams is required to avoid iatrogenic harm.ConclusionCOVID 19, the viral illness caused by SARS-CoV2, continues to spread across the world with alarming speed and a reported case fatality rate of ~ 3\u20134% worldwide without any proven therapies.", [["electrolyte abnormalities", "DISEASE", 28, 53], ["ill", "DISEASE", 57, 60], ["viral illness", "DISEASE", 170, 183], ["SARS-CoV2", "DISEASE", 194, 203], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["electrolyte abnormalities", "PROBLEM", 28, 53], ["iatrogenic harm", "PROBLEM", 130, 145], ["ConclusionCOVID", "TEST", 146, 161], ["the viral illness", "PROBLEM", 166, 183], ["SARS-CoV2", "PROBLEM", 194, 203], ["electrolyte abnormalities", "OBSERVATION", 28, 53], ["ill patients", "OBSERVATION_MODIFIER", 57, 69], ["viral illness", "OBSERVATION", 170, 183]]], ["The virus\u2019s port of entry into human cells, ACE2, is expressed in the myocardium, but whether direct viral damage is contributing to the disease remains unknown.", [["cells", "ANATOMY", 37, 42], ["myocardium", "ANATOMY", 70, 80], ["viral damage", "DISEASE", 101, 113], ["human", "ORGANISM", 31, 36], ["cells", "CELL", 37, 42], ["ACE2", "GENE_OR_GENE_PRODUCT", 44, 48], ["myocardium", "ORGAN", 70, 80], ["human cells", "CELL_TYPE", 31, 42], ["ACE2", "PROTEIN", 44, 48], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 31, 36], ["The virus", "TREATMENT", 0, 9], ["ACE2", "TEST", 44, 48], ["direct viral damage", "PROBLEM", 94, 113], ["the disease", "PROBLEM", 133, 144], ["virus", "OBSERVATION", 4, 9], ["human cells", "OBSERVATION", 31, 42], ["myocardium", "ANATOMY", 70, 80], ["viral damage", "OBSERVATION", 101, 113]]], ["Anecdotal reports and small case series have suggested an increased risk of myocardial injury, arrhythmia, and heart failure as sequelae of the disease, but more concrete epidemiological evidence is required to confirm these findings.", [["myocardial", "ANATOMY", 76, 86], ["heart", "ANATOMY", 111, 116], ["myocardial injury", "DISEASE", 76, 93], ["arrhythmia", "DISEASE", 95, 105], ["heart failure", "DISEASE", 111, 124], ["myocardial", "MULTI-TISSUE_STRUCTURE", 76, 86], ["heart", "ORGAN", 111, 116], ["small case series", "PROBLEM", 22, 39], ["myocardial injury", "PROBLEM", 76, 93], ["arrhythmia", "PROBLEM", 95, 105], ["heart failure", "PROBLEM", 111, 124], ["the disease", "PROBLEM", 140, 151], ["small", "OBSERVATION_MODIFIER", 22, 27], ["increased", "OBSERVATION_MODIFIER", 58, 67], ["myocardial", "ANATOMY", 76, 86], ["injury", "OBSERVATION", 87, 93], ["arrhythmia", "OBSERVATION", 95, 105], ["heart", "ANATOMY", 111, 116], ["failure", "OBSERVATION", 117, 124], ["disease", "OBSERVATION", 144, 151]]], ["There is strong evidence that those with underlying cardiovascular disease and risk factors are at much higher risk for worse outcomes from SARS-CoV-2 infections, but whether this is causal or simply an association remains elusive.", [["cardiovascular", "ANATOMY", 52, 66], ["cardiovascular disease", "DISEASE", 52, 74], ["SARS-CoV-2 infections", "DISEASE", 140, 161], ["cardiovascular", "ANATOMICAL_SYSTEM", 52, 66], ["SARS-CoV-2", "ORGANISM", 140, 150], ["underlying cardiovascular disease", "PROBLEM", 41, 74], ["risk factors", "PROBLEM", 79, 91], ["SARS", "PROBLEM", 140, 144], ["CoV-2 infections", "PROBLEM", 145, 161], ["cardiovascular", "ANATOMY", 52, 66], ["disease", "OBSERVATION", 67, 74], ["infections", "OBSERVATION", 151, 161]]], ["Given that we currently have no proven effective therapy against SARS-CoV2, understanding the root cause of this association is particularly critical, as it may lead to avenues for intervention.", [["root", "ANATOMY", 94, 98], ["SARS-CoV2", "DISEASE", 65, 74], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 65, 74], ["root", "ORGAN", 94, 98], ["SARS", "PROBLEM", 65, 69], ["intervention", "TREATMENT", 181, 193]]], ["In the meantime, keeping human-to-human transmission rates as low as possible through numerous interventions around the world is our only hope to prevent healthcare systems from being overwhelmed and to buy us time for effective therapies to be developed.", [["human", "ORGANISM", 25, 30], ["human", "ORGANISM", 34, 39], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 34, 39], ["effective therapies", "TREATMENT", 219, 238]]]], "00701ae954da043431769fd67e8eba8df7667e29": [["I n December 2019, a series of cases of pneumonia of unknown cause was reported in Wuhan, Hubei Province, China.", [["pneumonia", "DISEASE", 40, 49], ["pneumonia", "PROBLEM", 40, 49], ["pneumonia", "OBSERVATION", 40, 49]]], ["On January 7, 2020, the causative pathogen was identified as a virus subsequently named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1) (2) (3) .", [["acute respiratory syndrome coronavirus", "DISEASE", 95, 133], ["severe acute respiratory syndrome coronavirus", "SPECIES", 88, 133], ["the causative pathogen", "PROBLEM", 20, 42], ["a virus", "PROBLEM", 61, 68], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 88, 133], ["severe", "OBSERVATION_MODIFIER", 88, 94], ["acute", "OBSERVATION_MODIFIER", 95, 100], ["respiratory syndrome", "OBSERVATION", 101, 121]]], ["We report a case of co-infection with SARS-CoV-2 and influenza A virus in China.", [["SARS", "DISEASE", 38, 42], ["influenza A virus", "DISEASE", 53, 70], ["SARS-CoV-2", "ORGANISM", 38, 48], ["influenza A virus", "ORGANISM", 53, 70], ["CoV-2", "SPECIES", 43, 48], ["influenza A virus", "SPECIES", 53, 70], ["SARS-CoV-2", "SPECIES", 38, 48], ["influenza A virus", "SPECIES", 53, 70], ["co-infection", "PROBLEM", 20, 32], ["SARS", "PROBLEM", 38, 42], ["CoV", "TEST", 43, 46], ["influenza", "PROBLEM", 53, 62], ["co-infection", "OBSERVATION", 20, 32]]]], "PMC7079891": [["HintergrundAlexander Langmuir definierte 1963 die \u201eSurveillance von Krankheiten\u201c als \u201eeine kontinuierliche Beobachtung von Verteilung, Trends und Inzidenz durch systematische Sammlung, Konsolidierung und Evaluation von Berichten \u00fcber Morbidit\u00e4t, Mortalit\u00e4t und anderer relevanter Daten\u201c.", [["HintergrundAlexander Langmuir definierte 1963 die \u201eSurveillance von Krankheiten\u201c als \u201eeine kontinuierliche Beobachtung von Verteilung, Trends und Inzidenz durch systematische Sammlung, Konsolidierung und Evaluation von Berichten \u00fcber Morbidit\u00e4t, Mortalit\u00e4t und anderer relevanter", "SPECIES", 0, 279]]], ["Weltgesundheitsversammlung bez\u00fcglich der nationalen und globalen Surveillance \u00fcbertragbarer Krankheiten zum Aspekt der Datenverbreitung hinzugef\u00fcgt, dass die Daten zu Einrichtungen gelangen sollten, die Public-Health-Ma\u00dfnahmen initiieren k\u00f6nnen [2].", [["Weltgesundheitsversammlung bez\u00fcglich der nationalen und globalen Surveillance \u00fcbertragbarer Krankheiten zum Aspekt der Datenverbreitung hinzugef\u00fcgt, dass die Daten zu Einrichtungen gelangen sollten, die Public-Health-Ma\u00dfnahmen initiieren k\u00f6nnen", "SPECIES", 0, 244], ["Weltgesundheitsversammlung bez\u00fcglich der nationalen", "TREATMENT", 0, 51]]], ["Hierzu geh\u00f6rt die Kapazit\u00e4t, Daten zu sammeln, zu analysieren sowie die Weitergabe von Daten an Public-Health-Programme [3].HintergrundDie aktive Form der epidemiologischen Surveillance beinhaltet, dass die Daten von der Institution, die die Surveillance durchf\u00fchrt, zum Beispiel per E-Mail oder Telefon angefordert werden.", [["Hierzu geh\u00f6rt die Kapazit\u00e4t", "TREATMENT", 0, 27]]], ["Bei der passiven Form eines epidemiologischen Surveillance-Systems werden F\u00e4lle von im Gesundheitswesen t\u00e4tigen oder anderen autorisierten Personen gemeldet, ohne dass aktiv nachgefragt wurde.", [["Bei der passiven Form eines epidemiologischen Surveillance-Systems werden F\u00e4lle von im Gesundheitswesen t\u00e4tigen oder anderen autorisierten Personen gemeldet, ohne dass aktiv nachgefragt wurde", "SPECIES", 0, 191], ["Surveillance", "TEST", 46, 58]]], ["Die IGV bilden das v\u00f6lkerrechtliche Fundament zur internationalen Bek\u00e4mpfung von Infektionskrankheiten; neben verbindlichen Verpflichtungen enthalten sie eine Reihe ma\u00dfnahmenorientierter Empfehlungen der Weltgesundheitsorganisation (WHO).", [["Die IGV bilden das v\u00f6lkerrechtliche Fundament zur internationalen Bek\u00e4mpfung von Infektionskrankheiten; neben verbindlichen Verpflichtungen enthalten sie eine Reihe ma\u00dfnahmenorientierter Empfehlungen der Weltgesundheitsorganisation (WHO)", "SPECIES", 0, 237]]], ["Dazu geh\u00f6ren Empfehlungen, die nach Feststellung einer gesundheitlichen Notlage von internationaler Tragweite (GNIT) oder bei Vorliegen einer bestimmten Gefahr von der WHO ausgesprochen werden k\u00f6nnen.", [["Dazu geh\u00f6ren Empfehlungen, die nach Feststellung einer gesundheitlichen Notlage von internationaler Tragweite (GNIT) oder bei Vorliegen einer bestimmten Gefahr von der WHO ausgesprochen werden k\u00f6nnen", "SPECIES", 0, 199], ["Dazu geh\u00f6ren Empfehlungen", "TREATMENT", 0, 25]]], ["Liegt ein solches Ereignis vor, so ist dieses immer gemeinsam mit den bereits durchgef\u00fchrten Ma\u00dfnahmen innerhalb von 24 Stunden nach der Bewertung an die WHO zu melden (Artikel 6 IGV) [4].", [["Liegt ein solches Ereignis vor, so ist dieses immer gemeinsam mit den bereits durchgef\u00fchrten Ma\u00dfnahmen innerhalb von 24 Stunden nach der Bewertung an die WHO zu melden (Artikel 6 IGV", "SPECIES", 0, 182]]], ["Im Rahmen der IGV gibt es auch eine aktive Komponente; sie besteht aus einer vorgeschriebenen R\u00fcckmeldung des Vertragsstaates auf WHO-Anfragen f\u00fcr die Best\u00e4tigung (oder Widerlegung) von Ereignissen, die der WHO weder durch Meldung noch durch Konsultation bekannt sind (Artikel 9.1 und 10 IGV) [5].HintergrundIndikatorbasierte Surveillance-Systeme beruhen auf einer strukturierten Datensammlung durch Routine-Surveillance, zum Beispiel Meldesysteme.", [["besteht aus einer vorgeschriebenen R\u00fcckmeldung des Vertragsstaates auf WHO-Anfragen f\u00fcr die Best\u00e4tigung (oder Widerlegung) von Ereignissen, die der WHO weder durch Meldung noch durch Konsultation bekannt sind (Artikel 9.1 und 10 IGV", "SPECIES", 59, 291]]], ["Zum Beispiel k\u00f6nnen webbasierte Informationsquellen zu einem fr\u00fchen Erkennen von Ausbr\u00fcchen und einer Sensibilisierung der \u00d6ffentlichkeit beitragen [9].", [["Zum Beispiel k\u00f6nnen webbasierte Informationsquellen zu einem fr\u00fchen Erkennen von Ausbr\u00fcchen und einer Sensibilisierung der \u00d6ffentlichkeit beitragen", "SPECIES", 0, 147], ["Zum", "TREATMENT", 0, 3]]], ["Im November 2002 erschien in einer chinesischen Zeitung ein Artikel, der ungew\u00f6hnlich hohe Fallzahlen an Patienten mit akuten respiratorischen Erkrankungen in Rettungsstellen von Krankenh\u00e4usern in der Provinz Guangdong beschrieb.", [["Guangdong beschrieb", "SPECIES", 209, 228]]], ["Nach diesem fr\u00fchen Hinweis auf SARS (Severe Acute Respiratory Syndrome) berichteten chinesische Medien in der Folge von respiratorischen Erkrankungen bei Krankenhauspersonal.", [["SARS", "DISEASE", 31, 35], ["Respiratory Syndrome", "DISEASE", 50, 70], ["Nach diesem fr\u00fchen Hinweis auf SARS (Severe Acute Respiratory Syndrome) berichteten chinesische Medien in der Folge von respiratorischen Erkrankungen bei Krankenhauspersonal", "SPECIES", 0, 173], ["Nach diesem", "TREATMENT", 0, 11], ["auf SARS (Severe Acute Respiratory Syndrome", "PROBLEM", 27, 70], ["berichteten chinesische", "TREATMENT", 72, 95], ["Severe", "OBSERVATION_MODIFIER", 37, 43], ["Acute", "OBSERVATION_MODIFIER", 44, 49], ["Respiratory Syndrome", "OBSERVATION", 50, 70]]], ["Die WHO erhielt den ersten offiziellen Bericht aus China am 11.", [["Die WHO erhielt den ersten offiziellen Bericht aus China am 11", "SPECIES", 0, 62]]], ["Um ad\u00e4quat auf neue Bedrohungen reagieren zu k\u00f6nnen, kann sich der \u00d6ffentliche Gesundheitsdienst (\u00d6GD) nicht mehr ausschlie\u00dflich auf traditionelle Surveillance-Systeme verlassen [15, 16].", [["kann sich der \u00d6ffentliche Gesundheitsdienst (\u00d6GD) nicht mehr ausschlie\u00dflich auf traditionelle Surveillance-Systeme verlassen", "SPECIES", 53, 177]]], ["Am 13.", [["Am 13", "PROTEIN", 0, 5]]], ["Januar 2009 wurde von der Abteilung f\u00fcr Infektionsepidemiologie am Robert Koch-Institut (RKI) eine w\u00f6chentliche telefonische epidemiologische Bund-L\u00e4nder-Lagekonferenz (EpiLag) eingef\u00fchrt, an der \u00fcberwiegend Vertreter der oberen Landesgesundheitsbeh\u00f6rden und des RKI, dar\u00fcber hinaus gelegentlich Referenten f\u00fcr Infektionsschutz der obersten Landesgesundheitsbeh\u00f6rden und Vertreter der Bundeswehr teilnehmen.", [["Januar 2009 wurde von der Abteilung f\u00fcr Infektionsepidemiologie am Robert Koch-Institut (RKI) eine w\u00f6chentliche telefonische epidemiologische Bund-L\u00e4nder-Lagekonferenz (EpiLag) eingef\u00fchrt, an der \u00fcberwiegend Vertreter der oberen Landesgesundheitsbeh\u00f6rden und des RKI, dar\u00fcber hinaus gelegentlich Referenten f\u00fcr Infektionsschutz der obersten Landesgesundheitsbeh\u00f6rden und Vertreter der Bundeswehr teilnehmen", "SPECIES", 0, 406], ["Lagekonferenz (EpiLag)", "TREATMENT", 154, 176]]], ["Ziel war es, f\u00fcr den \u00d6GD auf L\u00e4nder- und Bundesebene eine Plattform zur Diskussion aktueller infektionsepidemiologischer Ereignisse zu schaffen und unabh\u00e4ngig von der Meldepflicht den Austausch \u00fcber relevante Ereignisse zu verbessern.", [["f\u00fcr den \u00d6GD auf L\u00e4nder- und Bundesebene eine Plattform zur Diskussion aktueller infektionsepidemiologischer Ereignisse zu schaffen und unabh\u00e4ngig von der Meldepflicht den Austausch \u00fcber relevante Ereignisse zu verbessern", "SPECIES", 13, 233], ["infektionsepidemiologischer", "PROBLEM", 93, 120]]], ["Hierzu z\u00e4hlen neben Ereignissen mit potenziell \u00fcberregionaler infektionsepidemiologischer Relevanz auch Ereignisse, die ungew\u00f6hnlich sind oder bei denen Diskussionsbedarf besteht.", [["Hierzu z\u00e4hlen", "TREATMENT", 0, 13]]], ["Beiden Surveillance-Komponenten soll Beachtung geschenkt werden, da Signale von beiden zu Public-Health-Ma\u00dfnahmen f\u00fchren k\u00f6nnen [2].HintergrundZiel des vorliegenden Beitrages ist es, die Organisation, die Durchf\u00fchrung und den Inhalt der w\u00f6chentlichen EpiLag zu beschreiben und ihren infektionsepidemiologischen Nutzen f\u00fcr den \u00d6GD und damit f\u00fcr die Bev\u00f6lkerung darzustellen.Inhalt ::: Die TelefonkonferenzDie EpiLag bietet den Teilnehmern einen strukturierten, w\u00f6chentlichen und damit regelm\u00e4\u00dfigen Austausch \u00fcber aktuelle infektionsepidemiologische Ereignisse.", [["von beiden zu Public-Health-Ma\u00dfnahmen f\u00fchren k\u00f6nnen", "SPECIES", 76, 127], ["HintergrundZiel des vorliegenden Beitrages ist es, die Organisation, die Durchf\u00fchrung und den Inhalt der w\u00f6chentlichen EpiLag zu beschreiben und ihren infektionsepidemiologischen Nutzen f\u00fcr den \u00d6GD und damit f\u00fcr die Bev\u00f6lkerung darzustellen", "SPECIES", 132, 372], ["Surveillance", "TEST", 7, 19], ["HintergrundZiel des", "TREATMENT", 132, 151], ["Die", "PROBLEM", 384, 387]]], ["Ereignisse k\u00f6nnen auch in mehreren Telefonkonferenzen diskutiert werden.Organisation und Durchf\u00fchrung ::: Die TelefonkonferenzDie Organisation und Durchf\u00fchrung der EpiLag erfolgt durch die Abteilung f\u00fcr Infektionsepidemiologie am RKI (Abb.", [["Die TelefonkonferenzDie Organisation und Durchf\u00fchrung der EpiLag erfolgt durch die Abteilung f\u00fcr Infektionsepidemiologie am RKI", "SPECIES", 106, 233]]], ["1) zu wochenaktuellen, nationalen und internationalen infektionsepidemiologischen Ereignissen und Informationen befragt.Organisation und Durchf\u00fchrung ::: Die TelefonkonferenzWeitere Informationen werden dem Weekly Threat Report des Europ\u00e4ischen Zentrums f\u00fcr die Pr\u00e4vention und Kontrolle von Krankheiten (ECDC) sowie der IGV Event Information Page der WHO entnommen.", [["Die TelefonkonferenzWeitere Informationen werden dem Weekly Threat Report des Europ\u00e4ischen Zentrums f\u00fcr die Pr\u00e4vention und Kontrolle von Krankheiten (ECDC) sowie der IGV Event Information Page der WHO entnommen", "SPECIES", 154, 364]]], ["1).Organisation und Durchf\u00fchrung ::: Die TelefonkonferenzDie Vorbereitung auf die EpiLag und die Erstellung des Protokolls beanspruchen pro Woche zwischen f\u00fcnf und neun Stunden.", [["Die TelefonkonferenzDie Vorbereitung auf die EpiLag und die Erstellung des Protokolls beanspruchen pro Woche zwischen f\u00fcnf und neun Stunden", "SPECIES", 37, 176], ["Die", "PROBLEM", 37, 40]]], ["Der gesamte zeitliche Aufwand f\u00fcr das RKI liegt also zwischen f\u00fcnf und zehn Stunden.", [["Der gesamte zeitliche Aufwand f\u00fcr das RKI liegt also zwischen f\u00fcnf und zehn Stunden", "SPECIES", 0, 83]]], ["F\u00fcr die w\u00f6chentliche Vor- und Nachbereitung der EpiLag ist je ein im Turnus wechselnder Mitarbeiter der Abteilung f\u00fcr Infektionsepidemiologie verantwortlich.", [["F\u00fcr die w\u00f6chentliche Vor- und Nachbereitung der EpiLag ist je ein im Turnus wechselnder Mitarbeiter der Abteilung f\u00fcr Infektionsepidemiologie verantwortlich", "SPECIES", 0, 156]]], ["Bei der Konferenz selbst sind vom RKI zumindest der f\u00fcr das Sammeln und Zusammenstellen der Informationen verantwortliche Mitarbeiter und ein leitender Moderator anwesend.", [["Bei der Konferenz selbst sind vom RKI zumindest der f\u00fcr das Sammeln und Zusammenstellen der Informationen verantwortliche Mitarbeiter und ein leitender Moderator anwesend", "SPECIES", 0, 170]]], ["Die Teilnehmer der EpiLag w\u00e4hlen sich in die Telefon-Konferenz ein.Auswertung der Protokolle ::: MethodeDie w\u00f6chentlichen EpiLag-Protokolle der ersten drei Quartale 2009 wurden hinsichtlich Beteiligung, H\u00e4ufigkeit diskutierter infektionsepidemiologischer Ereignisse und ihrer Informationsquellen ausgewertet.Evaluation der Konferenz ::: MethodeUm die Qualit\u00e4t der EpiLag zu evaluieren, f\u00fchrte das RKI zwischen dem 23.6. und dem 1.7.2009 einen Online-Survey (http://www.surveymonkey.com) durch.", [["MethodeDie w\u00f6chentlichen EpiLag", "TREATMENT", 97, 128], ["Evaluation", "TEST", 308, 318]]], ["Es wurden 23 Fragen zu den Themen Logistik (zehn Fragen), Inhalt (f\u00fcnf Fragen) und Qualit\u00e4t (acht Fragen) der Telefonkonferenz gestellt.", [["Logistik (zehn Fragen)", "TREATMENT", 34, 56], ["Inhalt (f\u00fcnf Fragen)", "TREATMENT", 58, 78]]], ["Die \u00fcberwiegende Zahl der Fragen konnte mit den vorgegebenen Antwortkategorien \u201estimme voll zu/stimme zu/neutral/stimme nicht zu/stimme gar nicht zu\u201c, \u201esehr gut/gut/weniger gut/unzufrieden\u201c, \u201eja/nein\u201c oder einem freien Textfeld beantwortet werden.Teilnahme ::: ErgebnisseSeit Einf\u00fchrung der EpiLag am 13.1.2009 lag die durchschnittliche Beteiligung der oberen Landesgesundheitsbeh\u00f6rden in den ersten drei Quartalen 2009 bei 78%.", [["Teilnahme", "CHEMICAL", 247, 256], ["Teilnahme", "SIMPLE_CHEMICAL", 247, 256], ["Die \u00fcberwiegende Zahl der Fragen konnte mit den vorgegebenen Antwortkategorien \u201estimme voll zu/stimme zu/neutral/stimme nicht zu/stimme gar nicht zu\u201c, \u201esehr gut/gut/weniger gut/unzufrieden\u201c, \u201eja/nein\u201c oder einem freien Textfeld beantwortet werden", "SPECIES", 0, 246], ["den ersten drei Quartalen 2009 bei 78", "SPECIES", 389, 426], ["gut", "ANATOMY", 161, 164]]], ["An den w\u00f6chentlichen Telefonkonferenzen nahmen in unregelm\u00e4\u00dfigen Abst\u00e4nden auch Vertreter der Bundeswehr sowie einzelne Referenten f\u00fcr Infektionsschutz der Bundesl\u00e4nder als Vertreter der obersten Landesgesundheitsbeh\u00f6rden teil.In der EpiLag diskutierte Ereignisse ::: ErgebnisseIn der EpiLag wurde bisher \u00fcber das Auftreten von insgesamt 46 verschiedenen Infektionskrankheiten (darunter auch H\u00e4ufungen, bei denen kein Erreger diagnostiziert worden war) diskutiert.", [["ErgebnisseIn der EpiLag wurde bisher \u00fcber das Auftreten von insgesamt 46 verschiedenen Infektionskrankheiten (darunter auch H\u00e4ufungen, bei denen kein Erreger diagnostiziert worden war) diskutiert", "SPECIES", 268, 463], ["An den w\u00f6chentlichen Telefonkonferenzen nahmen", "TREATMENT", 0, 46]]], ["Die mit Abstand h\u00e4ufigsten infektionsepidemiologischen Ereignisse, von denen berichtet wurde, waren Masern und Meningokokken-Meningitis (Tab.", [["Meningitis", "DISEASE", 125, 135], ["Meningitis", "PROBLEM", 125, 135], ["Meningitis", "OBSERVATION", 125, 135]]], ["\u00dcber Mumps, h\u00e4morrhagisches Fieber und CJK (Creutzfeldt-Jakob-Krankheit) wurde \u00fcberwiegend international berichtet; Infektionskrankheiten wie Pest, avi\u00e4re Influenza, saisonale Influenza oder Poliomyelitis wurden im Rahmen von Updates \u00fcber die globale epidemiologische Situation behandelt.In der EpiLag diskutierte Ereignisse ::: ErgebnisseInfektionsepidemiologisch relevante Ereignisse wurden teilweise \u00fcber mehrere aufeinanderfolgende Wochen in der EpiLag thematisiert.", [["h\u00e4morrhagisches Fieber und CJK (Creutzfeldt-Jakob-Krankheit)", "SPECIES", 12, 72], ["h\u00e4morrhagisches", "TEST", 12, 27], ["CJK", "TEST", 39, 42], ["Creutzfeldt", "TEST", 44, 55], ["Jakob", "TEST", 56, 61], ["Influenza", "PROBLEM", 155, 164]]], ["Dazu z\u00e4hlte zum Beispiel ein schwer zu kontrollierender Masern-Ausbruch in Hamburg, der \u00fcber 22 Kalenderwochen (KW) diskutiert wurde und auch zu F\u00e4llen in Niedersachsen, Nordrhein-Westfalen und Baden-W\u00fcrttemberg f\u00fchrte.", [["Dazu z\u00e4hlte zum Beispiel ein schwer zu kontrollierender Masern-Ausbruch in Hamburg, der \u00fcber 22 Kalenderwochen (KW) diskutiert wurde und auch zu F\u00e4llen in Niedersachsen, Nordrhein-Westfalen und Baden-W\u00fcrttemberg f\u00fchrte", "SPECIES", 0, 218], ["Dazu z\u00e4hlte zum", "TREATMENT", 0, 15]]], ["Ein Hepatitis-A-Ausbruch in Lettland wurde \u00fcber einen Zeitraum von 10 KW in der Telekonferenz behandelt.", [["Hepatitis-A-Ausbruch", "DISEASE", 4, 24], ["Ein Hepatitis-A-Ausbruch", "PROBLEM", 0, 24], ["Hepatitis", "OBSERVATION", 4, 13]]], ["\u00dcber Chikungunya-Ausbr\u00fcche im Indischen Ozean, S\u00fcdostasien und Ostasien wurde \u00fcber einen Zeitraum von acht KW berichtet.", [["Chikungunya", "PROBLEM", 5, 16]]], ["KW ein Chikungunya-Ausbruch in Thailand besprochen: F\u00fcnf der acht bis zum 4.", [["Chikungunya-Ausbruch", "DISEASE", 7, 27]]], ["KW wurde vom ersten Chikungunya-Ausbruch auf der Insel La R\u00e9union nach dem Ausbruch von 2005/2006 berichtet; im Sommer 2007 kam es in Italien zur ersten lokalen \u00dcbertragung des Chikungunya-Virus in Europa [18].In der EpiLag diskutierte Ereignisse ::: ErgebnisseAls Beispiel f\u00fcr eine nicht-meldepflichtige Erkrankung, die in der EpiLag diskutiert wurde und damit einen raschen und regelm\u00e4\u00dfigen Austausch zwischen den zust\u00e4ndigen Landesgesundheitsbeh\u00f6rden erm\u00f6glichte, z\u00e4hlt ein Kuhpocken-Ausbruch mit Erkrankungsf\u00e4llen in Frankreich und mehreren Bundesl\u00e4ndern Deutschlands.", [["Chikungunya-Virus", "DISEASE", 177, 194], ["Chikungunya-Ausbruch auf der Insel La R\u00e9union nach dem Ausbruch von 2005/2006 berichtet; im Sommer 2007 kam es in Italien zur ersten lokalen \u00dcbertragung des Chikungunya-Virus", "SPECIES", 20, 194], ["ErgebnisseAls Beispiel f\u00fcr eine nicht-meldepflichtige Erkrankung, die in der EpiLag diskutiert wurde und damit einen raschen und regelm\u00e4\u00dfigen Austausch zwischen den zust\u00e4ndigen Landesgesundheitsbeh\u00f6rden erm\u00f6glichte, z\u00e4hlt ein Kuhpocken-Ausbruch mit Erkrankungsf\u00e4llen in Frankreich und mehreren Bundesl\u00e4ndern Deutschlands", "SPECIES", 251, 571], ["Chikungunya", "PROBLEM", 20, 31], ["Italien zur ersten", "TREATMENT", 134, 152]]], ["Kleintiernager sind das nat\u00fcrliche Reservoir der Kuhpockenviren und k\u00f6nnen von infizierten Tieren auf den Menschen \u00fcbertragen werden.", [["Kleintiernager sind das nat\u00fcrliche Reservoir der Kuhpockenviren und k\u00f6nnen von infizierten Tieren auf den Menschen \u00fcbertragen werden", "SPECIES", 0, 132], ["Kleintiernager sind das nat\u00fcrliche Reservoir", "TREATMENT", 0, 44]]], ["KW 2009 wurden in der EpiLag erstmals Kuhpocken-F\u00e4lle in Bayern und Nordrhein-Westfalen (NRW) diskutiert, danach wurde auch von F\u00e4llen in Frankreich berichtet.", [["Kuhpocken", "TEST", 38, 47]]], ["Die F\u00e4lle in Frankreich und NRW konnten auf Heimtierratten (\u201eSchmuseratten\u201c) zur\u00fcckgef\u00fchrt werden, die von einem H\u00e4ndler aus Tschechien exportiert wurden.", [["auf Heimtierratten (\u201eSchmuseratten\u201c)", "TREATMENT", 40, 76]]], ["Jedoch ergab sich bei diesem H\u00e4ndler und seinen Zulieferern kein Hinweis auf eine Kuhpocken-Infektion der Tiere.", [["Jedoch ergab sich bei diesem H\u00e4ndler und seinen Zulieferern kein Hinweis auf eine Kuhpocken-Infektion der Tiere", "SPECIES", 0, 111], ["Jedoch ergab sich bei diesem", "TREATMENT", 0, 28]]], ["Die Kuhpocken-F\u00e4lle in Bayern konnten auf einen bayerischen Rattenz\u00fcchter zur\u00fcckgef\u00fchrt werden, bei dem die zust\u00e4ndige Veterin\u00e4rbeh\u00f6rde 17 von 31 Heimtierratten positiv testete.In der EpiLag diskutierte Ereignisse ::: ErgebnisseIn der 29.", [["Die Kuhpocken-F\u00e4lle in Bayern konnten auf einen bayerischen Rattenz\u00fcchter zur\u00fcckgef\u00fchrt werden, bei dem die zust\u00e4ndige Veterin\u00e4rbeh\u00f6rde 17 von 31 Heimtierratten positiv testete", "SPECIES", 0, 176]]], ["KW kam es erneut zu einem Kuhpockenausbruch, der durch tiefgefrorene Futterratten \u00fcbertragen wurde, die aus einem polnischen Zuchtbetrieb stammten.", [["KW kam es erneut zu einem Kuhpockenausbruch", "TREATMENT", 0, 43], ["der durch tiefgefrorene Futterratten \u00fcbertragen wurde", "TREATMENT", 45, 98]]], ["Baden-W\u00fcrttemberg konnte als erstbetroffenes Bundesland mithilfe der EpiLag andere Bundesl\u00e4nder zeitnah benachrichtigen: Das RKI erhielt aus Baden-W\u00fcrttemberg eine Empf\u00e4ngerliste der Futterratten des H\u00e4ndlers, leitete sie an die betroffenen Bundesl\u00e4nder weiter, die wiederum den Gesundheits\u00e4mtern die Lieferadressen mitteilen konnten.In der EpiLag diskutierte Ereignisse ::: ErgebnisseAm 1.7.2009 wurde in Deutschland die Meldepflicht f\u00fcr MRSA eingef\u00fchrt.", [["MRSA", "SPECIES", 439, 443], ["Baden-W\u00fcrttemberg konnte als erstbetroffenes Bundesland mithilfe der EpiLag andere Bundesl\u00e4nder zeitnah benachrichtigen: Das RKI erhielt aus Baden-W\u00fcrttemberg eine Empf\u00e4ngerliste der Futterratten des H\u00e4ndlers, leitete sie an die betroffenen Bundesl\u00e4nder weiter, die wiederum den Gesundheits\u00e4mtern die Lieferadressen mitteilen konnten", "SPECIES", 0, 333], ["MRSA eingef\u00fchrt", "PROBLEM", 439, 454]]], ["Die EpiLag behandelte dieses Thema intermittierend \u00fcber insgesamt sieben KW: Inhalte waren die MRSA-Falldefinition, die Art der Meldung, die provisorische Erfassung, die technischen Vorgehensweisen sowie die \u00dcbermittlung der F\u00e4lle mit SurvNet, einer Software, die der Eingabe von Fallmeldungen entsprechend IfSG sowie der Weiterleitung (\u00dcbermittlung) der erfassten Daten von der Peripherie (Gesundheits\u00e4mter) \u00fcber die zust\u00e4ndigen Landesgesundheitsbeh\u00f6rden an das RKI dient.", [["MRSA", "SPECIES", 95, 99], ["Thema intermittierend \u00fcber insgesamt sieben KW: Inhalte waren die MRSA-Falldefinition, die Art der Meldung, die provisorische Erfassung, die technischen Vorgehensweisen sowie die \u00dcbermittlung der F\u00e4lle mit SurvNet, einer Software, die der Eingabe von Fallmeldungen entsprechend IfSG sowie der Weiterleitung (\u00dcbermittlung) der erfassten Daten von der Peripherie (Gesundheits\u00e4mter) \u00fcber die zust\u00e4ndigen Landesgesundheitsbeh\u00f6rden an das RKI dient", "SPECIES", 29, 472], ["MRSA", "PROBLEM", 95, 99]]], ["Alle 16 oberen Landesgesundheitsbeh\u00f6rden waren vertreten, und s\u00e4mtliche Befragten hatten eine ihr Bundesland repr\u00e4sentierende Funktion.Ergebnisse der Evaluation ::: ErgebnisseMit der Logistik der w\u00f6chentlichen EpiLag waren die Teilnehmer generell zufrieden.", [["Ergebnisse", "CHEMICAL", 165, 175], ["Mit der Logistik der w\u00f6chentlichen EpiLag", "TREATMENT", 175, 216]]], ["\u00dcber 90% der Befragten gaben an, die Koordination der Telefonkonferenzen durch das RKI sei vollst\u00e4ndig und ausreichend, und es gebe ausreichend Zeit, Fragen zu stellen sowie \u00fcber relevante Vorkommnisse in der Region zu berichten.", [["Region zu berichten", "SPECIES", 209, 228]]], ["\u00dcber 90% gaben an, die Protokolle seien in einem geeigneten Format (PDF), und \u00fcber 80% begr\u00fc\u00dften die M\u00f6glichkeit, dem RKI Feedback zu den Protokollen geben zu k\u00f6nnen.", [["dem RKI Feedback zu den Protokollen geben zu k\u00f6nnen", "SPECIES", 114, 165]]], ["Insgesamt 85% der Teilnehmer gaben an, dass die Anmerkungen der L\u00e4nder w\u00e4hrend der Telefonkonferenzen im Protokoll exakt wiedergegeben worden seien.", [["Insgesamt", "TREATMENT", 0, 9]]], ["Die Informationen zur aktuellen epidemiologischen Lage wurden von 91% der Teilnehmer als ausreichend angesehen.", [["Die Informationen zur aktuellen epidemiologischen Lage wurden von 91% der Teilnehmer als ausreichend angesehen", "SPECIES", 0, 110]]], ["95% der Teilnehmer betrachten die Telefonkonferenz als eine Informationsquelle, und 85% nutzen die Informationen der Konferenz f\u00fcr interne Zwecke.Ergebnisse der Evaluation ::: ErgebnisseDie allgemeine Qualit\u00e4t der EpiLag hinsichtlich Durchf\u00fchrung, Inhalt und Format der Protokolle sowie die Qualit\u00e4t der l\u00e4nderspezifischen Informationen wurde von allen Teilnehmern mit entweder \u201egut\u201c oder \u201esehr gut\u201c bewertet.", [["ErgebnisseDie allgemeine Qualit\u00e4t der EpiLag hinsichtlich Durchf\u00fchrung, Inhalt und Format der Protokolle sowie die Qualit\u00e4t der l\u00e4nderspezifischen Informationen wurde von allen Teilnehmern mit entweder \u201egut\u201c oder \u201esehr gut\u201c bewertet", "SPECIES", 176, 408], ["ErgebnisseDie", "TREATMENT", 176, 189]]], ["Die Wichtigkeit der internationalen Ereignisse bezeichneten 85% der Teilnehmer zumindest als \u201ehoch\u201c.", [["bezeichneten", "TREATMENT", 47, 59]]], ["Zum Zeitpunkt der Evaluation wurden die Informationen aus dem Lagebericht von vier zust\u00e4ndigen Landesgesundheitsbeh\u00f6rden an die zugeordneten Gesundheits\u00e4mter und von f\u00fcnf zust\u00e4ndigen Landesgesundheitsbeh\u00f6rden an ihre Landesministerien weitergeleitet.", [["Zum Zeitpunkt der Evaluation wurden die Informationen aus dem Lagebericht von vier zust\u00e4ndigen Landesgesundheitsbeh\u00f6rden an die zugeordneten Gesundheits\u00e4mter und von f\u00fcnf zust\u00e4ndigen Landesgesundheitsbeh\u00f6rden an ihre Landesministerien weitergeleitet", "SPECIES", 0, 249]]], ["Das Protokoll wird aber auch als Diskussionsgrundlage oder als Hilfe zur Bearbeitung aktueller infektionsepidemiologischer Probleme genutzt.Ergebnisse der Evaluation ::: ErgebnisseDie Kommentare der Teilnehmer hinsichtlich weiterer Vorschl\u00e4ge f\u00fcr die EpiLag bezogen sich \u00fcberwiegend auf die seit Ende April 2009 in Deutschland auftretende pandemische Influenza (H1N1) 2009, die bis Ende Juni 2009 in der Telefonkonferenz nicht behandelt wurde.", [["Das Protokoll wird aber auch als Diskussionsgrundlage oder als Hilfe zur Bearbeitung aktueller infektionsepidemiologischer Probleme genutzt", "SPECIES", 0, 139], ["ErgebnisseDie Kommentare der Teilnehmer hinsichtlich weiterer Vorschl\u00e4ge f\u00fcr die EpiLag bezogen sich \u00fcberwiegend auf die seit Ende April 2009 in Deutschland auftretende pandemische Influenza (H1N1) 2009, die bis Ende Juni 2009 in der Telefonkonferenz nicht behandelt wurde", "SPECIES", 170, 442], ["Influenza", "PROBLEM", 351, 360]]], ["Die Besprechung des Themas in der EpiLag wurde von den Teilnehmern f\u00fcr wichtig gehalten.DiskussionVor Einrichtung der EpiLag gab es zwischen Bund und L\u00e4ndern keinen strukturierten, h\u00e4ufigen und regelm\u00e4\u00dfigen Austausch \u00fcber aktuelle infektionsepidemiologische Ereignisse.", [["DiskussionVor Einrichtung der EpiLag gab es zwischen Bund und L\u00e4ndern keinen strukturierten", "SPECIES", 88, 179]]], ["Von Beginn an wurde die EpiLag vom RKI im Rahmen des \u201eEpidemic Intelligence\u201c-Ansatzes (EI) konzipiert.", [["Von Beginn an wurde die EpiLag vom RKI im Rahmen des \u201eEpidemic Intelligence\u201c-Ansatzes (EI) konzipiert", "SPECIES", 0, 101], ["an wurde die EpiLag", "TREATMENT", 11, 30], ["konzipiert", "TREATMENT", 91, 101]]], ["Die konstant hohe Beteiligung der oberen Landesgesundheitsbeh\u00f6rden l\u00e4sst darauf schlie\u00dfen, dass eine L\u00fccke geschlossen und das EI-Konzept von den Teilnehmern angenommen wurde.", [["Die konstant hohe Beteiligung der oberen Landesgesundheitsbeh\u00f6rden l\u00e4sst darauf schlie\u00dfen, dass eine L\u00fccke geschlossen und das EI-Konzept von den Teilnehmern angenommen wurde", "SPECIES", 0, 174]]], ["Die Weiterleitung des epidemiologischen EpiLag-Protokolles an die Gesundheits\u00e4mter und Landesministerien durch einige Teilnehmer ist ein weiterer Beleg f\u00fcr die Qualit\u00e4t und Relevanz der Konferenz und Protokolle.DiskussionBerichte \u00fcber nationale Ereignisse wurden bei der Evaluation zu 85% als relevant eingestuft.", [["Die Weiterleitung des epidemiologischen EpiLag-Protokolles an die Gesundheits\u00e4mter und Landesministerien durch einige Teilnehmer ist ein weiterer Beleg f\u00fcr die Qualit\u00e4t und Relevanz der Konferenz und Protokolle", "SPECIES", 0, 210], ["DiskussionBerichte \u00fcber nationale Ereignisse wurden bei der Evaluation zu 85", "SPECIES", 211, 287], ["Weiterleitung des epidemiologischen EpiLag", "TREATMENT", 4, 46]]], ["Die Relevanz internationaler Ereignisse wurde von 85% der Teilnehmer zumindest als \u201ehoch\u201c bezeichnet; 88% nutzen die EpiLag auch dazu, sich \u00fcber die internationale Situation zu informieren, 71% betrachten die internationalen Informationen als relevant f\u00fcr ihre t\u00e4gliche Arbeit.", [["bezeichnet", "TREATMENT", 90, 100]]], ["Die Aussagen lassen den Schluss zu, dass das Informationsbed\u00fcrfnis \u00fcber internationale Ereignisse h\u00f6her ist als der praktische Nutzen f\u00fcr die t\u00e4gliche Arbeit.DiskussionDie pandemische Influenza (H1N1) 2009 war zun\u00e4chst in der EpiLag ausgespart worden, um inhaltliche Dopplungen und \u00dcberschneidungen mit anderen Konferenzen zu vermeiden.", [["Influenza", "DISEASE", 184, 193], ["Die Aussagen lassen den Schluss zu, dass das Informationsbed\u00fcrfnis \u00fcber internationale Ereignisse h\u00f6her ist als der praktische Nutzen f\u00fcr die t\u00e4gliche Arbeit", "SPECIES", 0, 157], ["DiskussionDie pandemische Influenza (H1N1) 2009 war zun\u00e4chst in der EpiLag ausgespart worden, um inhaltliche Dopplungen und \u00dcberschneidungen mit anderen Konferenzen zu vermeiden", "SPECIES", 158, 335], ["Influenza", "PROBLEM", 184, 193]]], ["In der Folge wurde die pandemische Influenza (H1N1) 2009 wieder in die EpiLag aufgenommen.", [["Influenza", "DISEASE", 35, 44], ["Influenza", "PROBLEM", 35, 44]]], ["Die EpiLag soll jedoch nicht als Ersatzforum f\u00fcr eine regelm\u00e4\u00dfige Abstimmung der Managementstrategien zwischen RKI und den Referenten f\u00fcr Infektionsschutz der einzelnen Bundesl\u00e4nder dienen.DiskussionDurch die EpiLag haben die zust\u00e4ndigen Landesgesundheitsbeh\u00f6rden die M\u00f6glichkeit, vom RKI \u00fcber infektionsepidemiologisch relevante internationale Informationen aus dem EWRS und dem CDTR des ECDC informiert zu werden \u2013 nationale Anlaufstelle f\u00fcr dieses System ist das RKI.", [["Die EpiLag soll jedoch nicht als Ersatzforum f\u00fcr eine regelm\u00e4\u00dfige Abstimmung der Managementstrategien zwischen RKI und den Referenten f\u00fcr Infektionsschutz der einzelnen Bundesl\u00e4nder dienen", "SPECIES", 0, 188], ["DiskussionDurch die EpiLag haben die zust\u00e4ndigen Landesgesundheitsbeh\u00f6rden die M\u00f6glichkeit, vom RKI \u00fcber infektionsepidemiologisch relevante internationale Informationen aus dem EWRS und dem CDTR des ECDC informiert zu werden \u2013 nationale Anlaufstelle f\u00fcr dieses System ist das RKI", "SPECIES", 189, 469], ["Die", "PROBLEM", 0, 3]]], ["Das RKI hat wiederum durch die EpiLag die M\u00f6glichkeit, relevante Informationen an die zust\u00e4ndigen Landesgesundheitsbeh\u00f6rden weiterzugeben sowie Informationen von ihnen zu erhalten.DiskussionDie EpiLag erleichtert den horizontalen Informationsaustausch zwischen den Bundesl\u00e4ndern, wie sich vor allem am Beispiel der Kuhpockenausbr\u00fcche durch Schmuse- und Futterratten zeigte.DiskussionGenerell bietet eine Telefonkonferenz den Vorteil, dass die teilweise zeit- und kostenaufwendige An- und Abfahrt wegf\u00e4llt und somit die zeitlichen und finanziellen Ressourcen aller Teilnehmer effektiver genutzt werden k\u00f6nnen.", [["DiskussionDie EpiLag erleichtert den horizontalen Informationsaustausch zwischen den Bundesl\u00e4ndern, wie sich vor allem am Beispiel der Kuhpockenausbr\u00fcche durch Schmuse- und Futterratten zeigte", "SPECIES", 180, 372], ["DiskussionGenerell bietet eine Telefonkonferenz den Vorteil, dass die teilweise zeit- und kostenaufwendige An- und Abfahrt wegf\u00e4llt und somit die zeitlichen und finanziellen Ressourcen aller Teilnehmer effektiver genutzt werden k\u00f6nnen", "SPECIES", 373, 607], ["zeitlichen", "TREATMENT", 519, 529]]], ["Durch standardisierte Arbeitsweise konnte seit Einf\u00fchrung der EpiLag der w\u00f6chentliche zeitliche Aufwand bei der Vorbereitung reduziert werden.SchlussfolgerungDas Epidemic Intelligence (EI)-Konzept der EpiLag stellt den Teilnehmern Meldungen \u00fcber Ereignisse aus der indikatorbasierten Surveillance sowie aus der eventbasierten Surveillance aus unterschiedlichen Quellen zur Verf\u00fcgung.", [["Konzept der EpiLag stellt", "TREATMENT", 189, 214]]], ["Mit Einf\u00fchrung der EpiLag wurde eine Informationsl\u00fccke geschlossen.SchlussfolgerungDie Implementierung eines nationalen EI-Surveillance-Systems sollte spezifisch auf Monitoring und Evaluation von Infektionskrankheiten, die die Gesundheit der Bev\u00f6lkerung bedrohen, zugeschnitten sein [19].", [["SchlussfolgerungDie Implementierung eines nationalen EI-Surveillance-Systems sollte spezifisch auf Monitoring und Evaluation von Infektionskrankheiten, die die Gesundheit der Bev\u00f6lkerung bedrohen, zugeschnitten sein", "SPECIES", 67, 282], ["auf Monitoring", "TEST", 162, 176]]], ["Da sich die EpiLag als infektionsepidemiologische Plattform zwischen nationaler Ebene (RKI) und den zust\u00e4ndigen Landesgesundheitsbeh\u00f6rden bew\u00e4hrt hat, k\u00f6nnten auch zwischen den zust\u00e4ndigen Landesgesundheitsbeh\u00f6rden und lokalen Gesundheits\u00e4mtern Telefonkonferenzen eingerichtet werden, auf denen die Teilnehmer regelm\u00e4\u00dfig, strukturiert und zeitnah infektionsepidemiologische Ereignisse diskutieren.", [["Da sich die EpiLag als infektionsepidemiologische Plattform zwischen nationaler Ebene (RKI) und den zust\u00e4ndigen Landesgesundheitsbeh\u00f6rden bew\u00e4hrt hat, k\u00f6nnten auch zwischen den zust\u00e4ndigen Landesgesundheitsbeh\u00f6rden und lokalen Gesundheits\u00e4mtern Telefonkonferenzen eingerichtet werden, auf denen die Teilnehmer regelm\u00e4\u00dfig, strukturiert und zeitnah infektionsepidemiologische Ereignisse diskutieren", "SPECIES", 0, 396], ["Da sich die", "TREATMENT", 0, 11], ["EpiLag als infektionsepidemiologische", "TREATMENT", 12, 49], ["Plattform zwischen nationaler Ebene (RKI)", "TREATMENT", 50, 91]]]], "PMC5423899": [["IntroductionDietary recommendation for the management of chronic gastroenteropathy in cats has included the use of both veterinary therapeutic elimination and veterinary therapeutic gastrointestinal formulas (1\u20133).", [["gastrointestinal", "ANATOMY", 182, 198], ["gastroenteropathy", "DISEASE", 65, 82], ["cats", "ORGANISM", 86, 90], ["gastrointestinal", "ORGANISM_SUBDIVISION", 182, 198], ["cats", "SPECIES", 86, 90], ["chronic gastroenteropathy in cats", "PROBLEM", 57, 90], ["both veterinary therapeutic elimination", "TREATMENT", 115, 154], ["veterinary therapeutic gastrointestinal formulas", "TREATMENT", 159, 207], ["chronic", "OBSERVATION_MODIFIER", 57, 64], ["gastroenteropathy", "OBSERVATION", 65, 82]]], ["Veterinary elimination diets are designed to limit dietary antigens by incorporating uncommon or hydrolyzed protein ingredients and are utilized to diagnose and manage gastrointestinal and/or dermatologic conditions with an underlying food intolerance or food allergy.", [["gastrointestinal", "ANATOMY", 168, 184], ["food intolerance", "DISEASE", 235, 251], ["food allergy", "DISEASE", 255, 267], ["gastrointestinal", "ORGAN", 168, 184], ["Veterinary elimination diets", "TREATMENT", 0, 28], ["hydrolyzed protein ingredients", "TREATMENT", 97, 127], ["gastrointestinal and/or dermatologic conditions", "PROBLEM", 168, 215], ["an underlying food intolerance", "PROBLEM", 221, 251], ["food allergy", "PROBLEM", 255, 267]]], ["Veterinary gastrointestinal formulas differ in that they do not necessarily utilize unique or hydrolyzed protein sources but are designed with highly digestible ingredients to facilitate digestion and absorption of nutrients within a compromised gastrointestinal tract.", [["gastrointestinal", "ANATOMY", 11, 27], ["gastrointestinal tract", "ANATOMY", 246, 268], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 246, 268], ["Veterinary gastrointestinal formulas", "TREATMENT", 0, 36], ["hydrolyzed protein sources", "PROBLEM", 94, 120], ["highly digestible ingredients", "TREATMENT", 143, 172], ["a compromised gastrointestinal tract", "PROBLEM", 232, 268], ["gastrointestinal", "ANATOMY", 11, 27], ["gastrointestinal tract", "ANATOMY", 246, 268]]], ["Veterinary gastrointestinal formulas may also incorporate other dietary modifications such as adjustment of macronutrient distribution, fatty acid composition, and inclusion of dietary fibers and prebiotics.IntroductionWhile nutritional intervention is commonly utilized to manage chronic gastroenteropathy in cats, there have only been a handful of reported studies evaluating the efficacy of nutritional intervention in naturally occurring disease (4\u20137).", [["gastrointestinal", "ANATOMY", 11, 27], ["fatty acid", "CHEMICAL", 136, 146], ["gastroenteropathy", "DISEASE", 289, 306], ["fatty acid", "CHEMICAL", 136, 146], ["fatty acid", "SIMPLE_CHEMICAL", 136, 146], ["cats", "ORGANISM", 310, 314], ["cats", "SPECIES", 310, 314], ["Veterinary gastrointestinal formulas", "TREATMENT", 0, 36], ["dietary modifications", "TREATMENT", 64, 85], ["macronutrient distribution", "TREATMENT", 108, 134], ["fatty acid composition", "TREATMENT", 136, 158], ["dietary fibers", "TREATMENT", 177, 191], ["prebiotics", "TREATMENT", 196, 206], ["nutritional intervention", "TREATMENT", 225, 249], ["chronic gastroenteropathy in cats", "PROBLEM", 281, 314], ["nutritional intervention", "TREATMENT", 394, 418], ["naturally occurring disease", "PROBLEM", 422, 449], ["gastrointestinal", "ANATOMY", 11, 27]]], ["Guilford et al. showed that 49% of 55 cats with chronic gastrointestinal disease were responsive to dietary change, and 29% of the 55 demonstrated a food allergy or sensitivity with recrudescence of clinical signs upon diet re-challenge (4).", [["gastrointestinal", "ANATOMY", 56, 72], ["chronic gastrointestinal disease", "DISEASE", 48, 80], ["food allergy", "DISEASE", 149, 161], ["cats", "ORGANISM", 38, 42], ["gastrointestinal", "ORGAN", 56, 72], ["cats", "SPECIES", 38, 42], ["chronic gastrointestinal disease", "PROBLEM", 48, 80], ["dietary change", "TEST", 100, 114], ["a food allergy", "PROBLEM", 147, 161], ["sensitivity", "PROBLEM", 165, 176], ["chronic", "OBSERVATION_MODIFIER", 48, 55], ["gastrointestinal", "ANATOMY", 56, 72], ["disease", "OBSERVATION", 73, 80]]], ["In another study, eight cats with chronic diarrhea and/or vomiting responded to dietary therapy with a hydrolyzed diet after other medical and dietary interventions were unsuccessful (5).", [["diarrhea", "DISEASE", 42, 50], ["vomiting", "DISEASE", 58, 66], ["cats", "ORGANISM", 24, 28], ["cats", "SPECIES", 24, 28], ["another study", "TEST", 3, 16], ["chronic diarrhea", "PROBLEM", 34, 50], ["vomiting", "PROBLEM", 58, 66], ["dietary therapy", "TREATMENT", 80, 95], ["a hydrolyzed diet", "TREATMENT", 101, 118], ["dietary interventions", "TREATMENT", 143, 164], ["chronic", "OBSERVATION_MODIFIER", 34, 41], ["diarrhea", "OBSERVATION", 42, 50]]], ["Laflamme et al. demonstrated improvement in fecal score in 78.2% of 55 cats with chronic diarrhea fed either a low-fat (23% ME) or high-fat (45.1% ME) dry diet containing common ingredients (6).", [["fecal", "ANATOMY", 44, 49], ["diarrhea", "DISEASE", 89, 97], ["fecal", "ORGANISM_SUBSTANCE", 44, 49], ["cats", "ORGANISM", 71, 75], ["fat", "TISSUE", 115, 118], ["fat", "TISSUE", 136, 139], ["cats", "SPECIES", 71, 75], ["fecal score", "TEST", 44, 55], ["chronic diarrhea", "PROBLEM", 81, 97], ["improvement", "OBSERVATION_MODIFIER", 29, 40], ["fecal", "ANATOMY", 44, 49], ["chronic", "OBSERVATION_MODIFIER", 81, 88], ["diarrhea", "OBSERVATION", 89, 97]]], ["Additionally, two canned therapeutic gastrointestinal formulas containing common ingredients were evaluated for the management of naturally occurring chronic diarrhea, demonstrating resolution to a normal fecal score in up to 46.7% of 15 cats (7).IntroductionWhile recent studies have focused on chronic diarrhea, less is known regarding dietary intervention with chronic vomiting.", [["gastrointestinal", "ANATOMY", 37, 53], ["fecal", "ANATOMY", 205, 210], ["diarrhea", "DISEASE", 158, 166], ["chronic diarrhea", "DISEASE", 296, 312], ["chronic vomiting", "DISEASE", 364, 380], ["fecal", "ORGANISM_SUBDIVISION", 205, 210], ["two canned therapeutic gastrointestinal formulas", "TREATMENT", 14, 62], ["common ingredients", "TREATMENT", 74, 92], ["the management", "TREATMENT", 112, 126], ["chronic diarrhea", "PROBLEM", 150, 166], ["recent studies", "TEST", 265, 279], ["chronic diarrhea", "PROBLEM", 296, 312], ["dietary intervention", "TREATMENT", 338, 358], ["chronic vomiting", "PROBLEM", 364, 380], ["therapeutic", "OBSERVATION_MODIFIER", 25, 36], ["gastrointestinal", "ANATOMY", 37, 53], ["chronic", "OBSERVATION_MODIFIER", 150, 157], ["diarrhea", "OBSERVATION", 158, 166], ["resolution", "OBSERVATION_MODIFIER", 182, 192], ["normal", "OBSERVATION", 198, 204], ["fecal score", "OBSERVATION_MODIFIER", 205, 216], ["chronic", "OBSERVATION_MODIFIER", 296, 303], ["diarrhea", "OBSERVATION", 304, 312], ["chronic", "OBSERVATION_MODIFIER", 364, 371], ["vomiting", "OBSERVATION", 372, 380]]], ["Vomiting is the primary clinical sign recognized in feline patients with chronic gastroenteropathy (4, 8, 9).", [["Vomiting", "DISEASE", 0, 8], ["gastroenteropathy", "DISEASE", 81, 98], ["feline", "ORGANISM", 52, 58], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["Vomiting", "PROBLEM", 0, 8], ["chronic gastroenteropathy", "PROBLEM", 73, 98], ["chronic", "OBSERVATION_MODIFIER", 73, 80], ["gastroenteropathy", "OBSERVATION", 81, 98]]], ["In the Guilford\u2019s study, vomiting was present in 51.4% of the cats, diarrhea in 31.4%, and vomiting and diarrhea in 17.1% (4).", [["vomiting", "DISEASE", 25, 33], ["diarrhea", "DISEASE", 68, 76], ["vomiting", "DISEASE", 91, 99], ["diarrhea", "DISEASE", 104, 112], ["cats", "ORGANISM", 62, 66], ["cats", "SPECIES", 62, 66], ["the Guilford\u2019s study", "TEST", 3, 23], ["vomiting", "PROBLEM", 25, 33], ["the cats", "TEST", 58, 66], ["diarrhea", "PROBLEM", 68, 76], ["vomiting", "PROBLEM", 91, 99], ["diarrhea", "PROBLEM", 104, 112]]], ["Of patient visits to Banfield Pet Hospital\u00ae between 2008 and 2012, 1.4% of total feline visits per annum presented with chronic vomiting alone, 0.4% with chronic diarrhea alone, and 0.1% with both chronic vomiting and chronic diarrhea (8).", [["chronic vomiting", "DISEASE", 120, 136], ["diarrhea", "DISEASE", 162, 170], ["chronic vomiting", "DISEASE", 197, 213], ["diarrhea", "DISEASE", 226, 234], ["patient", "ORGANISM", 3, 10], ["feline", "ORGANISM", 81, 87], ["patient", "SPECIES", 3, 10], ["chronic vomiting", "PROBLEM", 120, 136], ["chronic diarrhea", "PROBLEM", 154, 170], ["both chronic vomiting", "PROBLEM", 192, 213], ["chronic diarrhea", "PROBLEM", 218, 234], ["chronic", "OBSERVATION_MODIFIER", 197, 204], ["vomiting", "OBSERVATION", 205, 213], ["chronic", "OBSERVATION_MODIFIER", 218, 225], ["diarrhea", "OBSERVATION", 226, 234]]], ["An evaluation of 100 feline cases of chronic small bowel disease suggested that diagnostic evaluation and implementation of dietary management is indicated in cats with vomiting as infrequently as two times per month (9).", [["bowel", "ANATOMY", 51, 56], ["small bowel disease", "DISEASE", 45, 64], ["vomiting", "DISEASE", 169, 177], ["feline", "ORGANISM", 21, 27], ["bowel", "ORGAN", 51, 56], ["cats", "ORGANISM", 159, 163], ["cats", "SPECIES", 159, 163], ["An evaluation", "TEST", 0, 13], ["chronic small bowel disease", "PROBLEM", 37, 64], ["diagnostic evaluation", "TEST", 80, 101], ["dietary management", "TREATMENT", 124, 142], ["vomiting", "PROBLEM", 169, 177], ["chronic", "OBSERVATION_MODIFIER", 37, 44], ["small", "OBSERVATION_MODIFIER", 45, 50], ["bowel", "ANATOMY", 51, 56], ["disease", "OBSERVATION", 57, 64]]], ["While the use of elimination diets containing novel and hydrolyzed protein sources has been evaluated (4, 5), to the authors\u2019 knowledge, no studies to date have evaluated the efficacy of feeding a non-specific gastrointestinal therapeutic diet to cats with chronic gastroenteropathy with vomiting included as one of the primary clinical signs.Study Population ::: Materials and MethodsCats with chronic vomiting and/or diarrhea were recruited by a multi-center group of primary care veterinarians in the greater Cincinnati region.", [["gastrointestinal", "ANATOMY", 210, 226], ["chronic gastroenteropathy", "DISEASE", 257, 282], ["vomiting", "DISEASE", 288, 296], ["chronic vomiting", "DISEASE", 395, 411], ["diarrhea", "DISEASE", 419, 427], ["gastrointestinal", "ORGANISM_SUBDIVISION", 210, 226], ["cats", "ORGANISM", 247, 251], ["cats", "SPECIES", 247, 251], ["elimination diets", "TREATMENT", 17, 34], ["hydrolyzed protein sources", "PROBLEM", 56, 82], ["a non-specific gastrointestinal therapeutic diet", "TREATMENT", 195, 243], ["chronic gastroenteropathy", "PROBLEM", 257, 282], ["vomiting", "PROBLEM", 288, 296], ["MethodsCats", "TREATMENT", 378, 389], ["chronic vomiting", "PROBLEM", 395, 411], ["diarrhea", "PROBLEM", 419, 427], ["chronic", "OBSERVATION_MODIFIER", 395, 402], ["vomiting", "OBSERVATION", 403, 411]]], ["Cats with at least one episode of vomiting and/or diarrhea per week for a minimum duration of 3 weeks, with no more than three episodes of vomiting daily were included.", [["vomiting", "DISEASE", 34, 42], ["diarrhea", "DISEASE", 50, 58], ["vomiting", "DISEASE", 139, 147], ["vomiting", "PROBLEM", 34, 42], ["diarrhea", "PROBLEM", 50, 58], ["vomiting", "PROBLEM", 139, 147], ["at least", "OBSERVATION_MODIFIER", 10, 18], ["vomiting", "OBSERVATION", 34, 42]]], ["The vomitus excluded those defined as hairball only but could include hair material if present in addition to food and/or bile.", [["hair material", "ANATOMY", 70, 83], ["bile", "ANATOMY", 122, 126], ["hair material", "MULTI-TISSUE_STRUCTURE", 70, 83], ["bile", "MULTI-TISSUE_STRUCTURE", 122, 126], ["The vomitus", "PROBLEM", 0, 11], ["hair material", "PROBLEM", 70, 83], ["vomitus", "OBSERVATION", 4, 11], ["bile", "ANATOMY", 122, 126]]], ["Cats were at least 1 year of age, with a body condition score (BCS) between 2 and 4 on a 5-point scale, and housed exclusively indoors.", [["body", "ANATOMY", 41, 45], ["body", "ORGANISM_SUBDIVISION", 41, 45], ["a body condition score", "TEST", 39, 61], ["BCS", "TEST", 63, 66]]], ["Cats were excluded if they were fed a veterinary therapeutic diet; had a known food allergy; had a history of undesired weight loss in excess of 10% over the last 2 months; had received antibiotic therapy within the last month; received long-acting immunosuppressive drugs within the past 6 weeks; or had received any immunosuppressive drugs within 3 weeks prior to enrollment.Study Population ::: Materials and MethodsCat owners were required to be at least 18 years of age, be the primary caregiver of the cat, be able to monitor the frequency of vomiting and/or diarrhea, and be able to report the daily occurrences via a daily automated phone call from an Interactive Voice Response System (IVRS).", [["food allergy", "DISEASE", 79, 91], ["weight loss", "DISEASE", 120, 131], ["vomiting", "DISEASE", 549, 557], ["diarrhea", "DISEASE", 565, 573], ["Cat", "ORGANISM", 419, 422], ["cat", "ORGANISM", 508, 511], ["a veterinary therapeutic diet", "TREATMENT", 36, 65], ["a known food allergy", "PROBLEM", 71, 91], ["undesired weight loss in excess", "PROBLEM", 110, 141], ["antibiotic therapy", "TREATMENT", 186, 204], ["long-acting immunosuppressive drugs", "TREATMENT", 237, 272], ["any immunosuppressive drugs", "TREATMENT", 314, 341], ["vomiting", "PROBLEM", 549, 557], ["diarrhea", "PROBLEM", 565, 573]]], ["Cats from multi-cat households (up to four cats maximum) could be included, but only one cat was eligible to participate in the study and all cats in the house-hold were required to be fed the same study diet.", [["cat", "ORGANISM", 16, 19], ["cats", "ORGANISM", 43, 47], ["cat", "ORGANISM", 89, 92], ["cats", "ORGANISM", 142, 146], ["cats", "SPECIES", 142, 146], ["the study", "TEST", 124, 133]]], ["Additionally, the owner had to be able to monitor the frequency and occurrence of vomiting and/or diarrhea from the cat participating in the study.Clinical Screening ::: Materials and MethodsOn day 0, all cats underwent a baseline physical examination and blood was submitted for complete blood count, serum chemistry panel, total serum thyroxine concentration (Total T4), feline pancreas-specific lipase (Spec fPL), and serum cobalamin and folate testing.", [["blood", "ANATOMY", 256, 261], ["blood", "ANATOMY", 289, 294], ["serum", "ANATOMY", 302, 307], ["serum", "ANATOMY", 331, 336], ["pancreas", "ANATOMY", 380, 388], ["serum", "ANATOMY", 421, 426], ["vomiting", "DISEASE", 82, 90], ["diarrhea", "DISEASE", 98, 106], ["thyroxine", "CHEMICAL", 337, 346], ["cobalamin", "CHEMICAL", 427, 436], ["folate", "CHEMICAL", 441, 447], ["thyroxine", "CHEMICAL", 337, 346], ["cobalamin", "CHEMICAL", 427, 436], ["folate", "CHEMICAL", 441, 447], ["cat", "ORGANISM", 116, 119], ["cats", "ORGANISM", 205, 209], ["blood", "ORGANISM_SUBSTANCE", 256, 261], ["blood", "ORGANISM_SUBSTANCE", 289, 294], ["serum", "ORGANISM_SUBSTANCE", 302, 307], ["serum", "ORGANISM_SUBSTANCE", 331, 336], ["thyroxine", "SIMPLE_CHEMICAL", 337, 346], ["T4", "SIMPLE_CHEMICAL", 368, 370], ["feline", "ORGANISM", 373, 379], ["pancreas", "ORGAN", 380, 388], ["lipase", "GENE_OR_GENE_PRODUCT", 398, 404], ["Spec fPL", "GENE_OR_GENE_PRODUCT", 406, 414], ["serum", "ORGANISM_SUBSTANCE", 421, 426], ["cobalamin", "SIMPLE_CHEMICAL", 427, 436], ["folate", "SIMPLE_CHEMICAL", 441, 447], ["feline pancreas-specific lipase", "PROTEIN", 373, 404], ["Spec fPL", "PROTEIN", 406, 414], ["feline", "SPECIES", 373, 379], ["vomiting", "PROBLEM", 82, 90], ["diarrhea", "PROBLEM", 98, 106], ["the study", "TEST", 137, 146], ["a baseline physical examination", "TEST", 220, 251], ["complete blood count", "TEST", 280, 300], ["serum chemistry panel", "TEST", 302, 323], ["total serum thyroxine concentration", "TEST", 325, 360], ["Total T4)", "TEST", 362, 371], ["feline pancreas", "TEST", 373, 388], ["specific lipase", "TEST", 389, 404], ["Spec fPL", "TEST", 406, 414], ["serum cobalamin", "TEST", 421, 436], ["folate testing", "TEST", 441, 455], ["pancreas", "ANATOMY", 380, 388]]], ["Viral screening consisted of feline coronavirus (FCoV) antibody by indirect fluorescent antibody and feline leukemia virus (FeLV) antigen and feline immunodeficiency virus (FIV) antibody by ELISA.", [["feline leukemia", "DISEASE", 101, 116], ["feline immunodeficiency virus", "DISEASE", 142, 171], ["feline coronavirus", "ORGANISM", 29, 47], ["FCoV", "ORGANISM", 49, 53], ["feline leukemia virus", "ORGANISM", 101, 122], ["FeLV", "ORGANISM", 124, 128], ["feline immunodeficiency virus", "ORGANISM", 142, 171], ["FIV", "ORGANISM", 173, 176], ["feline coronavirus (FCoV) antibody", "PROTEIN", 29, 63], ["indirect fluorescent antibody", "PROTEIN", 67, 96], ["feline leukemia virus (FeLV) antigen", "PROTEIN", 101, 137], ["feline immunodeficiency virus (FIV) antibody", "PROTEIN", 142, 186], ["feline coronavirus", "SPECIES", 29, 47], ["feline leukemia virus", "SPECIES", 101, 122], ["feline immunodeficiency virus", "SPECIES", 142, 171], ["feline coronavirus", "SPECIES", 29, 47], ["FCoV", "SPECIES", 49, 53], ["feline leukemia virus", "SPECIES", 101, 122], ["FeLV", "SPECIES", 124, 128], ["feline immunodeficiency virus", "SPECIES", 142, 171], ["FIV", "SPECIES", 173, 176], ["Viral screening", "TEST", 0, 15], ["feline coronavirus", "PROBLEM", 29, 47], ["FCoV) antibody", "TEST", 49, 63], ["indirect fluorescent antibody", "TEST", 67, 96], ["feline leukemia virus", "PROBLEM", 101, 122], ["FeLV) antigen", "TEST", 124, 137], ["feline immunodeficiency virus", "PROBLEM", 142, 171], ["ELISA", "TEST", 190, 195], ["feline leukemia virus", "OBSERVATION", 101, 122]]], ["Fecal examination included wet smear and zinc sulfate centrifugation flotation and a feline diarrhea PCR panel to detect Campylobacter coli, Campylobacter jejuni, Clostridium perfringens enterotoxin gene, Cryptosporidium spp., FCoV, feline panleukopenia virus, Giardia spp., Salmonella spp., Toxoplasma gondii, and Tritrichomonas fetus.", [["Fecal", "ANATOMY", 0, 5], ["fetus", "ANATOMY", 330, 335], ["zinc sulfate", "CHEMICAL", 41, 53], ["feline diarrhea", "DISEASE", 85, 100], ["Campylobacter coli", "DISEASE", 121, 139], ["Campylobacter jejuni", "DISEASE", 141, 161], ["Cryptosporidium spp.", "DISEASE", 205, 225], ["feline panleukopenia", "DISEASE", 233, 253], ["Giardia spp.", "DISEASE", 261, 273], ["Toxoplasma gondii", "DISEASE", 292, 309], ["zinc sulfate", "CHEMICAL", 41, 53], ["Fecal", "ORGANISM_SUBSTANCE", 0, 5], ["zinc sulfate", "SIMPLE_CHEMICAL", 41, 53], ["feline", "ORGANISM", 85, 91], ["Campylobacter coli", "ORGANISM", 121, 139], ["Campylobacter jejuni", "ORGANISM", 141, 161], ["Clostridium perfringens", "ORGANISM", 163, 186], ["enterotoxin", "GENE_OR_GENE_PRODUCT", 187, 198], ["Cryptosporidium spp.", "ORGANISM", 205, 225], ["FCoV", "GENE_OR_GENE_PRODUCT", 227, 231], ["feline panleukopenia virus", "ORGANISM", 233, 259], ["Giardia spp.", "ORGANISM", 261, 273], ["Salmonella spp.", "ORGANISM", 275, 290], ["Toxoplasma gondii", "ORGANISM", 292, 309], ["Tritrichomonas fetus", "ORGANISM", 315, 335], ["Campylobacter coli", "SPECIES", 121, 139], ["Campylobacter jejuni", "SPECIES", 141, 161], ["Clostridium perfringens enterotoxin", "SPECIES", 163, 198], ["Cryptosporidium spp.", "SPECIES", 205, 225], ["feline panleukopenia virus", "SPECIES", 233, 259], ["Giardia spp.", "SPECIES", 261, 273], ["Salmonella spp.", "SPECIES", 275, 290], ["Toxoplasma gondii", "SPECIES", 292, 309], ["Tritrichomonas fetus", "SPECIES", 315, 335], ["Campylobacter coli", "SPECIES", 121, 139], ["Campylobacter jejuni", "SPECIES", 141, 161], ["Clostridium perfringens", "SPECIES", 163, 186], ["Cryptosporidium spp.", "SPECIES", 205, 225], ["FCoV", "SPECIES", 227, 231], ["feline panleukopenia virus", "SPECIES", 233, 259], ["Giardia spp.", "SPECIES", 261, 273], ["Salmonella spp.", "SPECIES", 275, 290], ["Toxoplasma gondii", "SPECIES", 292, 309], ["Tritrichomonas fetus", "SPECIES", 315, 335], ["Fecal examination", "TEST", 0, 17], ["wet smear", "TEST", 27, 36], ["zinc sulfate centrifugation flotation", "TREATMENT", 41, 78], ["a feline diarrhea PCR panel", "TEST", 83, 110], ["Campylobacter coli", "PROBLEM", 121, 139], ["Campylobacter jejuni", "PROBLEM", 141, 161], ["Clostridium perfringens enterotoxin gene", "PROBLEM", 163, 203], ["Cryptosporidium spp.", "PROBLEM", 205, 225], ["FCoV", "PROBLEM", 227, 231], ["feline panleukopenia virus", "PROBLEM", 233, 259], ["Giardia spp.", "PROBLEM", 261, 273], ["Salmonella spp.", "PROBLEM", 275, 290], ["Toxoplasma gondii", "PROBLEM", 292, 309], ["Tritrichomonas fetus", "PROBLEM", 315, 335], ["Campylobacter coli", "OBSERVATION", 121, 139], ["Campylobacter jejuni", "ANATOMY", 141, 161], ["Toxoplasma gondii", "OBSERVATION", 292, 309], ["Tritrichomonas fetus", "OBSERVATION", 315, 335]]], ["Cats were excluded if diagnostic tests identified any systemic or infectious disease that could be associated with the clinical signs of vomiting or diarrhea, including, but not limited to FeLV, FIV, hepatic disease, renal disease, and hyperthyroidism.", [["hepatic", "ANATOMY", 200, 207], ["renal", "ANATOMY", 217, 222], ["vomiting", "DISEASE", 137, 145], ["diarrhea", "DISEASE", 149, 157], ["hepatic disease", "DISEASE", 200, 215], ["renal disease", "DISEASE", 217, 230], ["hyperthyroidism", "DISEASE", 236, 251], ["FeLV", "ORGANISM", 189, 193], ["FIV", "ORGANISM", 195, 198], ["hepatic", "ORGAN", 200, 207], ["renal", "ORGAN", 217, 222], ["FIV", "SPECIES", 195, 198], ["diagnostic tests", "TEST", 22, 38], ["any systemic or infectious disease", "PROBLEM", 50, 84], ["vomiting", "PROBLEM", 137, 145], ["diarrhea", "PROBLEM", 149, 157], ["FeLV", "PROBLEM", 189, 193], ["FIV", "PROBLEM", 195, 198], ["hepatic disease", "PROBLEM", 200, 215], ["renal disease", "PROBLEM", 217, 230], ["hyperthyroidism", "PROBLEM", 236, 251], ["infectious", "OBSERVATION", 66, 76], ["diarrhea", "OBSERVATION", 149, 157], ["FeLV", "OBSERVATION", 189, 193], ["hepatic", "ANATOMY", 200, 207], ["disease", "OBSERVATION", 208, 215], ["renal", "ANATOMY", 217, 222], ["disease", "OBSERVATION", 223, 230], ["hyperthyroidism", "OBSERVATION", 236, 251]]], ["Cats were also excluded if they were panhypoproteinemic, hypoalbuminemic, hypocobalaminemic, or had a Spec fPL \u22655.4 \u00b5g/L. Cats that tested positive for FCoV antibody, C. perfringens enterotoxin gene, C. coli, and FCoV via the PCR fecal panel were not excluded from the study.", [["hypoalbuminemic", "DISEASE", 57, 72], ["hypocobalaminemic", "DISEASE", 74, 91], ["Cats", "ORGANISM", 122, 126], ["FCoV antibody", "GENE_OR_GENE_PRODUCT", 152, 165], ["C. perfringens", "ORGANISM", 167, 181], ["enterotoxin", "GENE_OR_GENE_PRODUCT", 182, 193], ["C. coli", "ORGANISM", 200, 207], ["FCoV", "GENE_OR_GENE_PRODUCT", 213, 217], ["FCoV antibody", "PROTEIN", 152, 165], ["C. perfringens enterotoxin gene", "DNA", 167, 198], ["C. perfringens", "SPECIES", 167, 181], ["C. coli", "SPECIES", 200, 207], ["FCoV", "SPECIES", 152, 156], ["C. perfringens", "SPECIES", 167, 181], ["C. coli", "SPECIES", 200, 207], ["FCoV", "SPECIES", 213, 217], ["panhypoproteinemic", "PROBLEM", 37, 55], ["hypoalbuminemic", "PROBLEM", 57, 72], ["hypocobalaminemic", "PROBLEM", 74, 91], ["a Spec fPL", "TEST", 100, 110], ["\u00b5g/L. Cats", "TEST", 116, 126], ["FCoV antibody", "TEST", 152, 165], ["C. perfringens enterotoxin gene", "TEST", 167, 198], ["C. coli", "PROBLEM", 200, 207], ["FCoV", "PROBLEM", 213, 217], ["the PCR fecal panel", "TEST", 222, 241], ["the study", "TEST", 265, 274], ["C. coli", "OBSERVATION", 200, 207]]], ["All diagnostic analyses were conducted at a third party commercial laboratory.1Study Diets ::: Materials and MethodsCats were randomized to be fed one of two commercial veterinary therapeutic dry gastrointestinal formulas, Diet A2 or Diet B.3 No additional foods or treats were permitted.", [["gastrointestinal", "ANATOMY", 196, 212], ["gastrointestinal", "ORGANISM_SUBDIVISION", 196, 212], ["All diagnostic analyses", "TEST", 0, 23], ["MethodsCats", "TREATMENT", 109, 120], ["commercial veterinary therapeutic dry gastrointestinal formulas", "TREATMENT", 158, 221], ["gastrointestinal", "ANATOMY", 196, 212]]], ["All investigators and participants were masked to the identity of the diet.", [["participants", "SPECIES", 22, 34]]], ["Study diets were re-packaged into white bags, sealed, and delivered directly to participating veterinary clinics by plant employees not participating in the study.", [["white bags", "TREATMENT", 34, 44], ["the study", "TEST", 153, 162]]], ["Nutrient analysis (conducted internally at Iams Analytical Laboratory), caloric distribution, and ingredient composition is summarized in Table 1.", [["Nutrient analysis", "TEST", 0, 17], ["caloric distribution", "OBSERVATION", 72, 92]]], ["Cats were fed according to each product\u2019s feeding guidelines to maintain body weight.Study Design ::: Materials and MethodsOn day 0, cats that met all of the inclusion criteria were randomized to receive either Diet A or Diet B. The randomization was balanced by site, presence of diarrhea, and the owner reported weekly average number of vomiting and/or diarrhea episodes.", [["body", "ANATOMY", 73, 77], ["diarrhea", "DISEASE", 281, 289], ["vomiting", "DISEASE", 339, 347], ["diarrhea", "DISEASE", 355, 363], ["body", "ORGANISM_SUBDIVISION", 73, 77], ["cats", "ORGANISM", 133, 137], ["The randomization", "TREATMENT", 229, 246], ["diarrhea", "PROBLEM", 281, 289], ["vomiting", "PROBLEM", 339, 347], ["diarrhea episodes", "PROBLEM", 355, 372], ["diarrhea", "OBSERVATION", 281, 289]]], ["Randomization was conducted with an internally developed balance and assignment program through an electronic case record form.", [["Randomization", "TREATMENT", 0, 13]]], ["Withdrawal criteria included any identified condition that required immediate medical care.", [["Withdrawal criteria", "PROBLEM", 0, 19], ["any identified condition", "PROBLEM", 29, 53], ["immediate medical care", "TREATMENT", 68, 90]]], ["On days 1\u201328, owners received daily IVRS phone calls to record the number of vomiting episodes and presence of diarrhea over the 24-h period.", [["vomiting", "DISEASE", 77, 85], ["diarrhea", "DISEASE", 111, 119], ["vomiting episodes", "PROBLEM", 77, 94], ["diarrhea", "PROBLEM", 111, 119], ["diarrhea", "OBSERVATION", 111, 119]]], ["Owners were instructed to call the veterinary clinic if the cat did not consume the food, had a reduced appetite, reduction in body weight, or any other concerns.", [["body", "ANATOMY", 127, 131], ["cat", "ORGANISM", 60, 63], ["body", "ORGANISM_SUBDIVISION", 127, 131], ["a reduced appetite", "PROBLEM", 94, 112], ["reduction in body weight", "PROBLEM", 114, 138], ["any other concerns", "PROBLEM", 143, 161]]], ["On day 14, the owner was called by a veterinary technician to confirm that cat was eating well, had not lost weight, and did not have any concerns or significant decline in their clinical condition.", [["cat", "ORGANISM", 75, 78], ["cat", "SPECIES", 75, 78], ["significant decline in their clinical condition", "PROBLEM", 150, 197], ["significant", "OBSERVATION_MODIFIER", 150, 161], ["decline", "OBSERVATION", 162, 169]]], ["On day 28, the cats returned to the clinic for a final examination and diagnostic recheck (CBC, serum chemistry profile, and Spec fPL).Statistical Methods ::: Materials and MethodsThe weekly episodes of vomiting and diarrhea were analyzed with a mixed-effects negative binomial generalized linear model.", [["serum", "ANATOMY", 96, 101], ["vomiting", "DISEASE", 203, 211], ["diarrhea", "DISEASE", 216, 224], ["cats", "ORGANISM", 15, 19], ["serum", "ORGANISM_SUBSTANCE", 96, 101], ["Spec fPL", "GENE_OR_GENE_PRODUCT", 125, 133], ["cats", "SPECIES", 15, 19], ["a final examination", "TEST", 47, 66], ["diagnostic recheck", "TEST", 71, 89], ["CBC", "TEST", 91, 94], ["serum chemistry profile", "TEST", 96, 119], ["Spec fPL", "TEST", 125, 133], ["Materials", "TREATMENT", 159, 168], ["vomiting", "PROBLEM", 203, 211], ["diarrhea", "PROBLEM", 216, 224], ["binomial generalized linear model", "PROBLEM", 269, 302], ["linear model", "OBSERVATION_MODIFIER", 290, 302]]], ["Fixed effects in the model were week, diet, and the interaction between.", [["Fixed effects", "PROBLEM", 0, 13]]], ["For vomiting, the change from week 0 to weeks 1\u20134 for each diet and between diets was tested.", [["vomiting", "DISEASE", 4, 12], ["vomiting", "PROBLEM", 4, 12]]], ["For diarrhea, the change from week 1 to weeks 2\u20134 for each diet and between diets was tested.Statistical Methods ::: Materials and MethodsThe negative binomial models were also used to test for an effect of positive fecal testing for FCoV, C. perfringens enterotoxin gene, and FCoV antibody on vomiting and diarrhea occurrences by changing the fixed effects to week and positive/negative and retaining the same contrasts.", [["diarrhea", "DISEASE", 4, 12], ["vomiting", "DISEASE", 294, 302], ["diarrhea", "DISEASE", 307, 315], ["fecal", "ORGANISM_SUBSTANCE", 216, 221], ["FCoV", "GENE_OR_GENE_PRODUCT", 234, 238], ["C. perfringens enterotoxin", "GENE_OR_GENE_PRODUCT", 240, 266], ["FCoV antibody", "GENE_OR_GENE_PRODUCT", 277, 290], ["C. perfringens enterotoxin gene", "DNA", 240, 271], ["FCoV antibody", "PROTEIN", 277, 290], ["C. perfringens", "SPECIES", 240, 254], ["FCoV", "SPECIES", 234, 238], ["C. perfringens", "SPECIES", 240, 254], ["FCoV", "SPECIES", 277, 281], ["diarrhea", "PROBLEM", 4, 12], ["positive fecal testing", "PROBLEM", 207, 229], ["FCoV", "PROBLEM", 234, 238], ["C. perfringens enterotoxin gene", "PROBLEM", 240, 271], ["FCoV antibody", "PROBLEM", 277, 290], ["vomiting", "PROBLEM", 294, 302], ["diarrhea", "PROBLEM", 307, 315]]], ["This same model was altered to have a response of the total vomiting occurrences over the 4 weeks and fixed effects of diet and age.", [["vomiting", "DISEASE", 60, 68], ["the total vomiting occurrences", "PROBLEM", 50, 80]]], ["Vomiting was also modeled against the initial Spec fPL values using a negative binomial model, as before, however with the change in vomiting from baseline as the response and the fixed effect of Spec fPL results.", [["Vomiting", "DISEASE", 0, 8], ["vomiting", "DISEASE", 133, 141], ["Vomiting", "PROBLEM", 0, 8], ["the change in vomiting", "PROBLEM", 119, 141], ["Spec fPL", "TEST", 196, 204]]], ["The fecal scores were modeled using a linear mixed-effects model with fixed effects of day, diet, and the interaction between and a random effect of cat.Statistical Methods ::: Materials and MethodsThe binary data calculated from the vomiting occurrences was analyzed with a mixed-effects binomial model, using a logit link function.", [["fecal", "ANATOMY", 4, 9], ["vomiting", "DISEASE", 234, 242], ["fecal", "ORGANISM_SUBSTANCE", 4, 9], ["cat", "ORGANISM", 149, 152], ["The fecal scores", "TEST", 0, 16], ["a linear mixed-effects model", "TREATMENT", 36, 64], ["Methods", "TREATMENT", 191, 198], ["The binary data", "TEST", 198, 213], ["the vomiting occurrences", "PROBLEM", 230, 254], ["a mixed-effects binomial model", "TREATMENT", 273, 303], ["fecal", "ANATOMY", 4, 9]]], ["The same hypothesis tests were also performed comparing the change between weeks within and between diets.Statistical Methods ::: Materials and MethodsAll contrasts performed using the mixed-effects models were corrected for the multiple comparisons using stepwise correction, to achieve a family wise error rate of 5% within each measure.", [["The same hypothesis tests", "TEST", 0, 25], ["stepwise correction", "TREATMENT", 256, 275]]], ["The hypothesis tests of correlations were corrected using the false discovery rate method of Benjamini\u2013Hochberg, to the 5% level.", [["The hypothesis tests", "TEST", 0, 20]]], ["These analyses were performed in R v3.2.0 (10) statistical software with libraries lme4 (11) and multcomp (12).Study Population ::: ResultsFifty-six cats were screened to participate in the study.", [["cats", "ORGANISM", 149, 153], ["cats", "SPECIES", 149, 153], ["These analyses", "TEST", 0, 14], ["statistical software", "TEST", 47, 67], ["libraries lme4", "TEST", 73, 87], ["the study", "TEST", 186, 195]]], ["Of the 56 cats, 4 did not meet the initial pre-diagnostic inclusion criteria.", [["cats", "ORGANISM", 10, 14], ["cats", "SPECIES", 10, 14]]], ["On day 0, 52 cats were randomized to 1 of the 2 study diets, of which 17 were found to either violate the inclusion or meet the exclusion criteria based on the results of the diagnostic screening.", [["cats", "ORGANISM", 13, 17], ["cats", "SPECIES", 13, 17], ["the 2 study diets", "TREATMENT", 42, 59], ["the diagnostic screening", "TEST", 171, 195]]], ["Seven cats dropped out of the study prior to the day 28 visit.", [["cats", "ORGANISM", 6, 10], ["the study", "TEST", 26, 35]]], ["Reasons for dropping out included unwillingness to eat the diet in four cats (two cats fed Diet A and two cats fed Diet B), withdrawn by owner due to continued diarrhea in two cats (one fed Diet A for 1 day and one fed Diet B for 4 days), and one owner declined to participate following screening for one cat.", [["diarrhea", "DISEASE", 160, 168], ["cats", "ORGANISM", 72, 76], ["cats", "ORGANISM", 82, 86], ["cats", "ORGANISM", 106, 110], ["cats", "ORGANISM", 176, 180], ["cat", "ORGANISM", 305, 308], ["cats", "SPECIES", 72, 76], ["cats", "SPECIES", 82, 86], ["cats", "SPECIES", 106, 110], ["cats", "SPECIES", 176, 180], ["continued diarrhea", "PROBLEM", 150, 168], ["diarrhea", "OBSERVATION", 160, 168]]], ["The final study population of 28 cats included 13 cats fed Diet A and 15 cats fed Diet B. One of the cats in the Diet A group was inadvertently given the wrong diet after 2 weeks; therefore, data for this cat were included for only the first 2 weeks of the feeding period.Demographic and Baseline Characteristics ::: ResultsMean age was 8.0 years (SD = 3.9, range 2\u201315 years) and 6.5 years (SD = 3.6, 1.0\u201314 years) in cats fed Diets A and B, respectively.", [["cats", "ORGANISM", 33, 37], ["cats", "ORGANISM", 50, 54], ["cats", "ORGANISM", 73, 77], ["cats", "ORGANISM", 101, 105], ["cat", "ORGANISM", 205, 208], ["cats", "ORGANISM", 418, 422], ["B", "CELL", 439, 440], ["cats", "SPECIES", 33, 37], ["cats", "SPECIES", 50, 54], ["cats", "SPECIES", 73, 77], ["cats", "SPECIES", 101, 105], ["cats", "SPECIES", 418, 422], ["The final study population", "TEST", 0, 26], ["A and 15 cats fed Diet", "TREATMENT", 64, 86]]], ["Spayed females represented 62% (n = 6) and 40% (n = 6), while neutered males represented 38% (n = 5) and 60% (n = 9) of cats fed Diets A and B, respectively.", [["cats", "ORGANISM", 120, 124], ["B", "CELL", 141, 142], ["cats", "SPECIES", 120, 124]]], ["Mean body weight was 4.9 kg (SD = 1.3, range 3.0\u20137.3) and 4.6 kg (SD = 1.2, range 2.9\u20137.0); and mean BCS was 3.2 (SD = 0.6, range 2\u20134) and 3.1 (SD = 0.6, range 2\u20134) on a 5-point scale in cats fed Diets A and B, respectively.", [["body", "ANATOMY", 5, 9], ["body", "ORGANISM_SUBDIVISION", 5, 9], ["cats", "ORGANISM", 187, 191], ["B", "CELL", 208, 209], ["cats", "SPECIES", 187, 191], ["Mean body weight", "TEST", 0, 16], ["SD", "TEST", 29, 31], ["range", "TEST", 39, 44], ["SD", "TEST", 66, 68], ["range", "TEST", 76, 81], ["mean BCS", "TEST", 96, 104], ["SD", "TEST", 114, 116], ["range", "TEST", 124, 129], ["SD", "TEST", 144, 146], ["a 5-point scale in cats", "TREATMENT", 168, 191]]], ["Results of the PCR fecal panel showed that 16 of the 28 cats (Diet A n = 9; Diet B n = 7) tested positive for C. perfringens enterotoxin gene; 1 cat (Diet A n = 1; Diet B n = 0) tested positive for C. coli; and 17 cats (Diet A n = 9; Diet B n = 8) tested positive for FCoV.", [["FCoV", "CHEMICAL", 268, 272], ["cats", "ORGANISM", 56, 60], ["Diet B", "ORGANISM", 76, 82], ["C. perfringens enterotoxin", "ORGANISM", 110, 136], ["cat", "ORGANISM", 145, 148], ["Diet B", "ORGANISM", 164, 170], ["C. coli", "ORGANISM", 198, 205], ["cats", "ORGANISM", 214, 218], ["Diet B", "ORGANISM", 234, 240], ["FCoV", "GENE_OR_GENE_PRODUCT", 268, 272], ["C. perfringens enterotoxin gene", "DNA", 110, 141], ["FCoV", "PROTEIN", 268, 272], ["cats", "SPECIES", 56, 60], ["C. perfringens enterotoxin", "SPECIES", 110, 136], ["cat", "SPECIES", 145, 148], ["C. coli", "SPECIES", 198, 205], ["cats", "SPECIES", 214, 218], ["C. perfringens", "SPECIES", 110, 124], ["C. coli", "SPECIES", 198, 205], ["FCoV", "SPECIES", 268, 272], ["the PCR fecal panel", "TEST", 11, 30], ["Diet A n", "TREATMENT", 62, 70], ["Diet B n", "TEST", 76, 84], ["C. perfringens enterotoxin gene", "TREATMENT", 110, 141], ["Diet B n = 0)", "TEST", 164, 177], ["C. coli", "PROBLEM", 198, 205], ["Diet A n", "TREATMENT", 220, 228], ["Diet B n", "TREATMENT", 234, 242], ["FCoV", "PROBLEM", 268, 272], ["FCoV", "OBSERVATION", 268, 272]]], ["Eighteen of the 28 cats (Diet A n = 10; Diet B n = 8) tested positive for FCoV antibody.", [["cats", "ORGANISM", 19, 23], ["FCoV", "GENE_OR_GENE_PRODUCT", 74, 78], ["FCoV antibody", "PROTEIN", 74, 87], ["cats", "SPECIES", 19, 23], ["FCoV", "SPECIES", 74, 78], ["the 28 cats (Diet A n", "TREATMENT", 12, 33], ["Diet B n = 8)", "TEST", 40, 53], ["FCoV antibody", "TEST", 74, 87], ["FCoV antibody", "OBSERVATION", 74, 87]]], ["There were no statistically differences in the baseline characteristics of the cats between diet groups, and diagnostic screenings showed no clinically meaningful differences.Comparison of Dietary Interventions ::: ResultsCats fed both Diets A and B had a numerical reduction in the mean weekly number of vomiting episodes, with little to no change in weekly diarrhea episodes, over the 4-week period (Table 2).", [["vomiting", "DISEASE", 305, 313], ["diarrhea", "DISEASE", 359, 367], ["cats", "ORGANISM", 79, 83], ["cats", "SPECIES", 79, 83], ["diagnostic screenings", "TEST", 109, 130], ["a numerical reduction", "TREATMENT", 254, 275], ["vomiting episodes", "PROBLEM", 305, 322], ["change in weekly diarrhea episodes", "PROBLEM", 342, 376], ["no", "UNCERTAINTY", 11, 13], ["statistically", "OBSERVATION_MODIFIER", 14, 27], ["differences", "OBSERVATION_MODIFIER", 28, 39], ["no", "UNCERTAINTY", 138, 140]]], ["There were no differences between diet groups in the mean weekly number of vomiting or diarrhea episodes (p > 0.05).", [["vomiting", "DISEASE", 75, 83], ["diarrhea", "DISEASE", 87, 95], ["vomiting", "PROBLEM", 75, 83], ["diarrhea episodes", "PROBLEM", 87, 104], ["no", "UNCERTAINTY", 11, 13]]], ["Significant differences were seen in vomiting episodes over time within cats fed Diet A between week 0 and weeks 2\u20134.", [["vomiting", "DISEASE", 37, 45], ["Significant differences", "PROBLEM", 0, 23], ["vomiting episodes", "PROBLEM", 37, 54]]], ["These had fold changes in the number of vomiting occurrences of 3.24, 3.74, and 2.72 (indicating reduction of 69.1, 73.3, and 63.2%), respectively, with p values of 0.008, 0.003, and 0.029, respectively (Table 3).", [["vomiting", "DISEASE", 40, 48], ["fold changes", "PROBLEM", 10, 22], ["vomiting occurrences", "PROBLEM", 40, 60], ["reduction", "TEST", 97, 106], ["p values", "TEST", 153, 161], ["fold", "OBSERVATION_MODIFIER", 10, 14], ["changes", "OBSERVATION", 15, 22]]], ["Changes in vomiting episodes within cats fed Diet B did not reach significance over the 4-week study period (p > 0.05) (Table 3).", [["vomiting", "DISEASE", 11, 19], ["cats", "ORGANISM", 36, 40], ["cats", "SPECIES", 36, 40], ["Changes in vomiting episodes", "PROBLEM", 0, 28]]], ["There were no statistical differences in the change of diarrhea episodes over the 4-week study (p > 0.05).Comparison of Dietary Interventions ::: ResultsThe vomiting probability also numerically declined in both groups of cats over the 4-week study.", [["diarrhea", "DISEASE", 55, 63], ["vomiting", "DISEASE", 157, 165], ["cats", "ORGANISM", 222, 226], ["statistical differences", "PROBLEM", 14, 37], ["diarrhea episodes", "PROBLEM", 55, 72], ["The vomiting probability", "PROBLEM", 153, 177], ["no", "UNCERTAINTY", 11, 13], ["statistical", "OBSERVATION_MODIFIER", 14, 25], ["differences", "OBSERVATION_MODIFIER", 26, 37], ["diarrhea", "OBSERVATION", 55, 63]]], ["At weeks 0\u20134, cats fed Diet A had a probability of vomiting of 0.98 [95% confidence interval (CI) 0.42\u20131.00], 0.80 (95% CI 0.19\u20130.99), 0.3 (95% CI 0.03\u20130.87), 0.20 (95% CI 0.01\u20130.82), 0.20 (95% CI 0.01\u20130.82), respectively.", [["vomiting", "DISEASE", 51, 59], ["cats", "ORGANISM", 14, 18], ["vomiting", "PROBLEM", 51, 59], ["CI", "TEST", 94, 96], ["CI", "TEST", 120, 122], ["CI", "TEST", 144, 146], ["CI", "TEST", 169, 171], ["CI", "TEST", 194, 196]]], ["At weeks 0, 1, 2, 3, and 4 cats fed Diet B had a probability of vomiting of 0.96 (95% CI 0.45\u20131.00), 0.86 (95% CI 0.27\u20130.99), 0.92 (95% CI 0.35\u20131.0), 0.78 (95% CI 0.20\u20130.98), and 0.57 (0.10\u20130.94), respectively.", [["vomiting", "DISEASE", 64, 72], ["cats", "ORGANISM", 27, 31], ["vomiting", "PROBLEM", 64, 72], ["CI", "TEST", 86, 88], ["CI", "TEST", 111, 113], ["CI", "TEST", 136, 138], ["CI", "TEST", 160, 162]]], ["Statistical differences were seen between time points within cats fed Diet A between week 0 and weeks 2\u20134, with odds ratios of 0.008, 0.005, and 0.005 respectively (p values of 0.038, 0.023, and 0.023) (Table 4).", [["cats", "ORGANISM", 61, 65], ["Statistical differences", "PROBLEM", 0, 23], ["odds ratios", "TEST", 112, 123]]], ["The change in probability of vomiting within cats fed Diet B did not reach significance over the 4-week study period (p > 0.05) (Table 4).Comparison of Dietary Interventions ::: ResultsFecal Consistency Scale scores were available for only 4 (31%) cats fed Diet A and 10 (67%) cats fed Diet B. The model of FCS against day and diet over the 4 weeks showed no significant differences between the diets in the change in fecal score (p > 0.05).", [["fecal", "ANATOMY", 418, 423], ["vomiting", "DISEASE", 29, 37], ["cats", "ORGANISM", 45, 49], ["cats", "ORGANISM", 248, 252], ["cats", "ORGANISM", 277, 281], ["fecal", "ORGANISM_SUBDIVISION", 418, 423], ["cats", "SPECIES", 45, 49], ["cats", "SPECIES", 248, 252], ["cats", "SPECIES", 277, 281], ["vomiting", "PROBLEM", 29, 37], ["fecal score", "TEST", 418, 429], ["change", "OBSERVATION_MODIFIER", 4, 10], ["fecal", "ANATOMY", 418, 423]]], ["There was no correlation between the frequency of vomiting or diarrhea over the 4-week period and the presence of fecal enteropathogens detected via PCR or antibody testing (p > 0.05).", [["vomiting", "DISEASE", 50, 58], ["diarrhea", "DISEASE", 62, 70], ["vomiting", "PROBLEM", 50, 58], ["diarrhea", "PROBLEM", 62, 70], ["fecal enteropathogens", "PROBLEM", 114, 135], ["PCR", "TEST", 149, 152], ["antibody testing", "TEST", 156, 172], ["fecal", "ANATOMY", 114, 119], ["enteropathogens", "OBSERVATION", 120, 135]]], ["Similarly, neither Spec fPL results nor age of the cat correlated with the frequency of vomiting over the 4-week period (p > 0.05).DiscussionWhile therapeutic veterinary gastrointestinal diets are commonly utilized in veterinary practice for the management of gastroenteritis, this was the first study to evaluate the efficacy of these diets in vomiting cats with chronic gastroenteropathy.", [["gastrointestinal", "ANATOMY", 170, 186], ["vomiting", "DISEASE", 88, 96], ["gastroenteritis", "DISEASE", 260, 275], ["vomiting", "DISEASE", 345, 353], ["chronic gastroenteropathy", "DISEASE", 364, 389], ["Spec fPL", "GENE_OR_GENE_PRODUCT", 19, 27], ["cat", "ORGANISM", 51, 54], ["cats", "ORGANISM", 354, 358], ["cats", "SPECIES", 354, 358], ["Spec fPL", "TEST", 19, 27], ["vomiting", "PROBLEM", 88, 96], ["therapeutic veterinary gastrointestinal diets", "TREATMENT", 147, 192], ["the management", "TREATMENT", 242, 256], ["gastroenteritis", "PROBLEM", 260, 275], ["the first study", "TEST", 286, 301], ["vomiting cats", "PROBLEM", 345, 358], ["chronic gastroenteropathy", "PROBLEM", 364, 389], ["gastroenteritis", "OBSERVATION", 260, 275], ["chronic", "OBSERVATION_MODIFIER", 364, 371], ["gastroenteropathy", "OBSERVATION", 372, 389]]], ["The majority of cats in this study presented with chronic vomiting represented in 25 of the 28 cats (89%).", [["chronic vomiting", "DISEASE", 50, 66], ["cats", "ORGANISM", 16, 20], ["cats", "ORGANISM", 95, 99], ["cats", "SPECIES", 16, 20], ["this study", "TEST", 24, 34], ["chronic vomiting", "PROBLEM", 50, 66], ["cats", "OBSERVATION", 16, 20], ["chronic", "OBSERVATION_MODIFIER", 50, 57], ["vomiting", "OBSERVATION", 58, 66]]], ["There were no statistical differences between dietary treatments in the weekly mean vomiting frequency or change in weekly vomiting frequency over time.", [["vomiting", "DISEASE", 84, 92], ["vomiting", "DISEASE", 123, 131], ["statistical differences", "PROBLEM", 14, 37], ["dietary treatments", "TREATMENT", 46, 64], ["vomiting frequency", "PROBLEM", 84, 102], ["change in weekly vomiting frequency", "PROBLEM", 106, 141], ["no", "UNCERTAINTY", 11, 13]]], ["However, looking within dietary groups, cats fed Diet A showed a significant reduction in vomiting occurrences in weeks 2\u20134 compared to baseline, with a 63% reduction in the final week compared to baseline.", [["vomiting", "DISEASE", 90, 98], ["cats", "ORGANISM", 40, 44], ["cats", "SPECIES", 40, 44], ["a significant reduction in vomiting", "PROBLEM", 63, 98], ["a 63% reduction", "TREATMENT", 151, 166], ["significant", "OBSERVATION_MODIFIER", 65, 76], ["reduction", "OBSERVATION_MODIFIER", 77, 86]]], ["Cats fed Diet B, while not reaching statistical significance, also showed a numerical reduction from baseline over the study period.", [["a numerical reduction", "PROBLEM", 74, 95]]], ["Follow-up studies with additional cats are needed to better define the efficacy of Diet B and any potential differences between dietary treatments.DiscussionIn addition to the change of mean weekly vomiting episodes within treatment groups, it was also of interest to consider the number of cats that reached resolution, or no vomiting episodes, over the weekly period.", [["Diet B", "CHEMICAL", 83, 89], ["vomiting", "DISEASE", 198, 206], ["vomiting", "DISEASE", 327, 335], ["cats", "ORGANISM", 34, 38], ["Diet B", "CELL", 83, 89], ["cats", "ORGANISM", 291, 295], ["Follow-up studies", "TEST", 0, 17], ["additional cats", "TEST", 23, 38], ["Diet B", "TREATMENT", 83, 89], ["dietary treatments", "TREATMENT", 128, 146], ["mean weekly vomiting episodes", "PROBLEM", 186, 215], ["treatment groups", "TREATMENT", 223, 239], ["vomiting episodes", "PROBLEM", 327, 344], ["no", "UNCERTAINTY", 324, 326]]], ["The probability of vomiting declined during the course of the study, with a significant decline in cats fed Diet A in weeks 2\u20134, with a 0.2 probability in the final week.", [["vomiting", "DISEASE", 19, 27], ["cats", "ORGANISM", 99, 103], ["cats", "SPECIES", 99, 103], ["vomiting", "PROBLEM", 19, 27], ["the study", "TEST", 58, 67], ["a significant decline in cats", "PROBLEM", 74, 103], ["vomiting", "OBSERVATION", 19, 27], ["significant", "OBSERVATION_MODIFIER", 76, 87], ["decline", "OBSERVATION", 88, 95]]], ["Sixty seven percent (n = 8) of the cats fed Diet A and 47% (n = 7) of the cats fed Diet B had no vomiting episodes at the final week of the study.", [["vomiting", "DISEASE", 97, 105], ["cats", "ORGANISM", 35, 39], ["cats", "ORGANISM", 74, 78], ["cats", "SPECIES", 35, 39], ["cats", "SPECIES", 74, 78], ["vomiting episodes", "PROBLEM", 97, 114], ["the study", "TEST", 136, 145]]], ["Of these 15 cats, 3 showed an episodic pattern over the 4-week period, with 1 or more weeks without vomiting followed by a later week with vomiting.DiscussionChronic diarrhea was less common in this study population, with only two cats having concurrent vomiting and diarrhea and three cats with diarrhea alone.", [["vomiting", "DISEASE", 100, 108], ["vomiting", "DISEASE", 139, 147], ["diarrhea", "DISEASE", 166, 174], ["vomiting", "DISEASE", 254, 262], ["diarrhea", "DISEASE", 267, 275], ["diarrhea", "DISEASE", 296, 304], ["cats", "ORGANISM", 12, 16], ["cats", "ORGANISM", 231, 235], ["cats", "ORGANISM", 286, 290], ["cats", "SPECIES", 12, 16], ["cats", "SPECIES", 231, 235], ["cats", "SPECIES", 286, 290], ["an episodic pattern", "PROBLEM", 27, 46], ["vomiting", "PROBLEM", 100, 108], ["vomiting", "PROBLEM", 139, 147], ["Chronic diarrhea", "PROBLEM", 158, 174], ["concurrent vomiting", "PROBLEM", 243, 262], ["diarrhea", "PROBLEM", 267, 275], ["diarrhea", "PROBLEM", 296, 304], ["Chronic", "OBSERVATION_MODIFIER", 158, 165], ["diarrhea", "OBSERVATION", 166, 174], ["less common", "OBSERVATION_MODIFIER", 179, 190]]], ["It was considered that there may have been a lack of awareness or appreciation of diarrhea in the cats given the absorptive nature of litter that could have made diarrhea less recognizable to owner.", [["diarrhea", "DISEASE", 82, 90], ["diarrhea", "DISEASE", 162, 170], ["cats", "ORGANISM", 98, 102], ["cats", "SPECIES", 98, 102], ["diarrhea in the cats", "PROBLEM", 82, 102], ["diarrhea", "PROBLEM", 162, 170], ["diarrhea", "OBSERVATION", 82, 90]]], ["The FCS chart included images of stool within litter to help educate and increase awareness of the owners participating in this study; however, overall frequency of diarrhea remained low and did not significantly change over the 4-week period.DiscussionData from Banfield Pet Hospital\u00ae visits between 2008 and 2012 showed that older cats are more highly represented among cases of chronic gastrointestinal disease (8).", [["gastrointestinal", "ANATOMY", 389, 405], ["diarrhea", "DISEASE", 165, 173], ["chronic gastrointestinal disease", "DISEASE", 381, 413], ["stool", "ORGANISM_SUBSTANCE", 33, 38], ["cats", "ORGANISM", 333, 337], ["gastrointestinal", "ORGAN", 389, 405], ["cats", "SPECIES", 333, 337], ["The FCS chart", "TEST", 0, 13], ["images", "TEST", 23, 29], ["this study", "TEST", 123, 133], ["diarrhea", "PROBLEM", 165, 173], ["chronic gastrointestinal disease", "PROBLEM", 381, 413], ["chronic", "OBSERVATION_MODIFIER", 381, 388], ["gastrointestinal", "ANATOMY", 389, 405], ["disease", "OBSERVATION", 406, 413]]], ["Because of this, it was considered that age may have been associated with more severe clinical disease; however, no significant correlation was observed between age and vomiting occurrence within this study population.", [["vomiting", "DISEASE", 169, 177], ["more severe clinical disease", "PROBLEM", 74, 102], ["vomiting", "PROBLEM", 169, 177], ["this study population", "TEST", 196, 217], ["associated with", "UNCERTAINTY", 58, 73], ["severe", "OBSERVATION_MODIFIER", 79, 85], ["disease", "OBSERVATION", 95, 102]]], ["Previous studies evaluating diagnostic outcomes of cats with chronic gastroenteropathy have shown that older cats (mean ages ranging from 9.3 to 12.6 years) were more likely to have an underlying neoplastic etiology compared to younger populations (mean age 7.7\u20138.9 years) (13, 14).", [["neoplastic", "ANATOMY", 196, 206], ["chronic gastroenteropathy", "DISEASE", 61, 86], ["cats", "ORGANISM", 51, 55], ["cats", "ORGANISM", 109, 113], ["cats", "SPECIES", 51, 55], ["cats", "SPECIES", 109, 113], ["Previous studies", "TEST", 0, 16], ["chronic gastroenteropathy", "PROBLEM", 61, 86], ["an underlying neoplastic etiology", "PROBLEM", 182, 215], ["chronic", "OBSERVATION_MODIFIER", 61, 68], ["gastroenteropathy", "OBSERVATION", 69, 86], ["neoplastic", "OBSERVATION", 196, 206]]], ["The population in this present study was relatively younger (mean age of 7.2 years) and likely had less severe disease than those evaluated in previous studies at tertiary referral practices.", [["this present study", "TEST", 18, 36], ["less severe disease", "PROBLEM", 99, 118], ["previous studies", "TEST", 143, 159], ["population", "OBSERVATION_MODIFIER", 4, 14], ["less severe", "OBSERVATION_MODIFIER", 99, 110], ["disease", "OBSERVATION", 111, 118]]], ["Given the risk of underlying neoplastic disease in cats with chronic gastroenteropathy, dietary intervention in conjunction with additional diagnostics is warranted in older patients.DiscussionSimilar to previous reports, we found a relatively high prevalence of cats that were positive for FCoV antibody and C. perfringens enterotoxin gene (15).", [["neoplastic", "ANATOMY", 29, 39], ["neoplastic disease", "DISEASE", 29, 47], ["chronic gastroenteropathy", "DISEASE", 61, 86], ["cats", "ORGANISM", 51, 55], ["patients", "ORGANISM", 174, 182], ["cats", "ORGANISM", 263, 267], ["FCoV antibody", "GENE_OR_GENE_PRODUCT", 291, 304], ["C. perfringens enterotoxin", "GENE_OR_GENE_PRODUCT", 309, 335], ["FCoV antibody", "PROTEIN", 291, 304], ["C. perfringens enterotoxin gene", "DNA", 309, 340], ["cats", "SPECIES", 51, 55], ["patients", "SPECIES", 174, 182], ["cats", "SPECIES", 263, 267], ["C. perfringens enterotoxin", "SPECIES", 309, 335], ["FCoV", "SPECIES", 291, 295], ["C. perfringens", "SPECIES", 309, 323], ["underlying neoplastic disease in cats", "PROBLEM", 18, 55], ["chronic gastroenteropathy", "PROBLEM", 61, 86], ["dietary intervention", "TREATMENT", 88, 108], ["additional diagnostics", "TEST", 129, 151], ["FCoV antibody", "TEST", 291, 304], ["C. perfringens enterotoxin gene", "PROBLEM", 309, 340], ["neoplastic disease", "OBSERVATION", 29, 47], ["chronic", "OBSERVATION_MODIFIER", 61, 68], ["gastroenteropathy", "OBSERVATION", 69, 86]]], ["Cats with a positive status were included within this study population, receiving dietary intervention alone.", [["a positive status", "PROBLEM", 10, 27], ["this study", "TEST", 49, 59], ["dietary intervention", "TREATMENT", 82, 102]]], ["Similar to a previous report (15), a positive status did not correlate with the occurrence of vomiting or diarrhea over the study period.", [["vomiting", "DISEASE", 94, 102], ["diarrhea", "DISEASE", 106, 114], ["vomiting", "PROBLEM", 94, 102], ["diarrhea", "PROBLEM", 106, 114], ["the study", "TEST", 120, 129]]], ["It should be emphasized that the presence of FCoV antibody and C. perfringens toxin gene does not necessarily denote infection nor does it indicate the need to initiate medical therapy.", [["infection", "DISEASE", 117, 126], ["FCoV antibody", "GENE_OR_GENE_PRODUCT", 45, 58], ["C. perfringens toxin", "ORGANISM", 63, 83], ["FCoV antibody", "PROTEIN", 45, 58], ["C. perfringens toxin gene", "DNA", 63, 88], ["C. perfringens toxin", "SPECIES", 63, 83], ["C. perfringens", "SPECIES", 63, 77], ["FCoV antibody", "TEST", 45, 58], ["C. perfringens toxin gene", "PROBLEM", 63, 88], ["infection", "PROBLEM", 117, 126], ["medical therapy", "TREATMENT", 169, 184], ["FCoV antibody", "OBSERVATION", 45, 58], ["infection", "OBSERVATION", 117, 126]]], ["Similarly, antimicrobial therapy for Campylobacter spp. is not recommended in animals that are not immunocompromised or showing systemic signs of illness (fever, hemorrhagic diarrhea, abnormal leukogram findings) as it can prolong the carrier state and the diarrhea typically self-resolves with supportive care alone (16).DiscussionBoth Diet A and Diet B are categorized as therapeutic gastrointestinal diets designed to manage non-specific acute and chronic gastrointestinal disorders.", [["gastrointestinal", "ANATOMY", 386, 402], ["gastrointestinal", "ANATOMY", 459, 475], ["Campylobacter spp.", "DISEASE", 37, 55], ["illness", "DISEASE", 146, 153], ["fever", "DISEASE", 155, 160], ["hemorrhagic diarrhea", "DISEASE", 162, 182], ["abnormal leukogram", "DISEASE", 184, 202], ["diarrhea", "DISEASE", 257, 265], ["gastrointestinal disorders", "DISEASE", 459, 485], ["Campylobacter spp.", "ORGANISM", 37, 55], ["gastrointestinal", "ORGAN", 459, 475], ["Campylobacter spp.", "SPECIES", 37, 55], ["Campylobacter spp.", "SPECIES", 37, 55], ["antimicrobial therapy", "TREATMENT", 11, 32], ["Campylobacter spp.", "PROBLEM", 37, 55], ["immunocompromised", "PROBLEM", 99, 116], ["illness", "PROBLEM", 146, 153], ["fever", "PROBLEM", 155, 160], ["hemorrhagic diarrhea", "PROBLEM", 162, 182], ["abnormal leukogram findings", "PROBLEM", 184, 211], ["the diarrhea", "PROBLEM", 253, 265], ["supportive care", "TREATMENT", 295, 310], ["therapeutic gastrointestinal diets", "TREATMENT", 374, 408], ["non-specific acute and chronic gastrointestinal disorders", "PROBLEM", 428, 485], ["non-specific", "OBSERVATION_MODIFIER", 428, 440], ["acute", "OBSERVATION_MODIFIER", 441, 446], ["chronic", "OBSERVATION_MODIFIER", 451, 458], ["gastrointestinal", "ANATOMY", 459, 475], ["disorders", "OBSERVATION", 476, 485]]], ["The macronutrient distribution of protein, fat, and carbohydrate differed between the two formulas.", [["carbohydrate", "CHEMICAL", 52, 64], ["fat", "TISSUE", 43, 46], ["carbohydrate", "SIMPLE_CHEMICAL", 52, 64]]], ["The percent of calories from protein, fat, and carbohydrate were 31, 31, and 38% in Diet A and 35, 40, and 25% in Diet B, respectively (Table 1).", [["carbohydrate", "CHEMICAL", 47, 59], ["fat", "TISSUE", 38, 41], ["carbohydrate", "SIMPLE_CHEMICAL", 47, 59], ["carbohydrate", "TEST", 47, 59]]], ["While protein level was similar between the two formulas, the fat and carbohydrate contents varied more widely.", [["fat", "ANATOMY", 62, 65], ["carbohydrate", "CHEMICAL", 70, 82], ["fat", "TISSUE", 62, 65], ["carbohydrate", "SIMPLE_CHEMICAL", 70, 82], ["protein level", "TEST", 6, 19], ["fat", "ANATOMY", 62, 65], ["carbohydrate contents", "OBSERVATION", 70, 91]]], ["Reduced dietary fat has been recommended in patients with gastroenteropathy due to potentially impaired fat absorption (7, 8); however, dietary fat was shown to have no difference in clinical response in cats with chronic diarrhea (6).", [["fat", "ANATOMY", 104, 107], ["gastroenteropathy", "DISEASE", 58, 75], ["impaired fat absorption", "DISEASE", 95, 118], ["diarrhea", "DISEASE", 222, 230], ["fat", "TISSUE", 16, 19], ["patients", "ORGANISM", 44, 52], ["fat", "TISSUE", 104, 107], ["fat", "TISSUE", 144, 147], ["cats", "ORGANISM", 204, 208], ["patients", "SPECIES", 44, 52], ["cats", "SPECIES", 204, 208], ["Reduced dietary fat", "PROBLEM", 0, 19], ["gastroenteropathy", "TREATMENT", 58, 75], ["potentially impaired fat absorption", "PROBLEM", 83, 118], ["chronic diarrhea", "PROBLEM", 214, 230], ["dietary fat", "OBSERVATION", 8, 19], ["impaired", "OBSERVATION_MODIFIER", 95, 103], ["fat absorption", "OBSERVATION", 104, 118], ["chronic", "OBSERVATION_MODIFIER", 214, 221], ["diarrhea", "OBSERVATION", 222, 230]]], ["The presence of concurrent chronic pancreatitis has also been an indication for feeding reduced or moderate fat diets in cats with gastroenteropathies (17); however, cats with increased fPL levels were excluded from this study.", [["fat", "ANATOMY", 108, 111], ["pancreatitis", "DISEASE", 35, 47], ["gastroenteropathies", "DISEASE", 131, 150], ["fat", "TISSUE", 108, 111], ["cats", "ORGANISM", 121, 125], ["cats", "ORGANISM", 166, 170], ["fPL", "GENE_OR_GENE_PRODUCT", 186, 189], ["cats", "SPECIES", 121, 125], ["concurrent chronic pancreatitis", "PROBLEM", 16, 47], ["feeding reduced or moderate fat diets in cats", "PROBLEM", 80, 125], ["gastroenteropathies", "TEST", 131, 150], ["increased fPL levels", "PROBLEM", 176, 196], ["this study", "TEST", 216, 226], ["concurrent", "OBSERVATION_MODIFIER", 16, 26], ["chronic", "OBSERVATION_MODIFIER", 27, 34], ["pancreatitis", "OBSERVATION", 35, 47], ["moderate", "OBSERVATION_MODIFIER", 99, 107], ["fat diets", "OBSERVATION", 108, 117], ["increased", "OBSERVATION_MODIFIER", 176, 185], ["fPL levels", "OBSERVATION", 186, 196]]], ["Carbohydrate malabsorption was previously reported in cats with IBD, but dietary carbohydrates were not shown to negatively impact clinical signs (18).", [["Carbohydrate malabsorption", "DISEASE", 0, 26], ["IBD", "DISEASE", 64, 67], ["Carbohydrate", "CHEMICAL", 0, 12], ["carbohydrates", "CHEMICAL", 81, 94], ["cats", "ORGANISM", 54, 58], ["cats", "SPECIES", 54, 58], ["Carbohydrate malabsorption", "PROBLEM", 0, 26], ["IBD", "PROBLEM", 64, 67], ["dietary carbohydrates", "TREATMENT", 73, 94], ["malabsorption", "OBSERVATION", 13, 26]]], ["The higher dietary carbohydrate content of Diet A, relative to Diet B, did not appear to negatively impact diet performance and was well tolerated.DiscussionIn addition to total dietary fat, the fatty acid composition should also be considered.", [["fatty acid", "CHEMICAL", 195, 205], ["carbohydrate", "CHEMICAL", 19, 31], ["fatty acid", "CHEMICAL", 195, 205], ["carbohydrate", "SIMPLE_CHEMICAL", 19, 31], ["Diet A", "SIMPLE_CHEMICAL", 43, 49], ["fat", "TISSUE", 186, 189], ["fatty acid", "SIMPLE_CHEMICAL", 195, 205], ["total dietary fat", "TREATMENT", 172, 189], ["the fatty acid composition", "TREATMENT", 191, 217]]], ["Based on the guaranteed analysis for total omega-3 fatty acids and inclusion of fish oil (Table 1), Diet A was expected to provide greater concentrations of long-chain omega-3 fatty acid.", [["fish oil", "ANATOMY", 80, 88], ["omega-3 fatty acids", "CHEMICAL", 43, 62], ["omega-3 fatty acid", "CHEMICAL", 168, 186], ["omega-3 fatty acids", "CHEMICAL", 43, 62], ["omega-3 fatty acid", "CHEMICAL", 168, 186], ["omega-3 fatty acids", "SIMPLE_CHEMICAL", 43, 62], ["fish", "ORGANISM", 80, 84], ["oil", "ORGANISM_SUBSTANCE", 85, 88], ["long-chain omega-3 fatty acid", "SIMPLE_CHEMICAL", 157, 186], ["the guaranteed analysis", "TEST", 9, 32], ["total omega-3 fatty acids", "TREATMENT", 37, 62], ["fish oil", "TREATMENT", 80, 88], ["long-chain omega-3 fatty acid", "TREATMENT", 157, 186]]], ["Dietary long-chain omega-3 fatty acids have been shown to modulate inflammation within the body, providing benefit to a variety of inflammatory medical conditions (19).", [["body", "ANATOMY", 91, 95], ["omega-3 fatty acids", "CHEMICAL", 19, 38], ["inflammation", "DISEASE", 67, 79], ["omega-3 fatty acids", "CHEMICAL", 19, 38], ["long-chain omega-3 fatty acids", "SIMPLE_CHEMICAL", 8, 38], ["body", "ORGANISM_SUBDIVISION", 91, 95], ["Dietary long-chain omega-3 fatty acids", "TREATMENT", 0, 38], ["modulate inflammation", "PROBLEM", 58, 79], ["inflammatory medical conditions", "TREATMENT", 131, 162], ["chain omega", "OBSERVATION_MODIFIER", 13, 24], ["inflammation", "OBSERVATION", 67, 79], ["inflammatory", "OBSERVATION_MODIFIER", 131, 143]]], ["The underlying etiology was not defined in this study; however, IBD is commonly reported in feline gastroenteropathy, and the use of omega-3 fatty acids may have a beneficial effect in modulating the inflammatory response (19).", [["IBD", "DISEASE", 64, 67], ["feline gastroenteropathy", "DISEASE", 92, 116], ["omega-3 fatty acids", "CHEMICAL", 133, 152], ["omega-3 fatty acids", "CHEMICAL", 133, 152], ["feline", "ORGANISM", 92, 98], ["omega-3 fatty acids", "SIMPLE_CHEMICAL", 133, 152], ["feline", "SPECIES", 92, 98], ["this study", "TEST", 43, 53], ["IBD", "PROBLEM", 64, 67], ["omega-3 fatty acids", "TREATMENT", 133, 152], ["IBD", "OBSERVATION", 64, 67], ["inflammatory", "OBSERVATION_MODIFIER", 200, 212]]], ["While the duration of this study was relatively short, fatty acid incorporation into intestinal tissues can occur fairly rapidly, with one study showing significantly higher concentrations of eicosapentaenoic acid and docosahexaenoic acid in human colonic tissue following 7 days of supplementation compared to controls (20).", [["intestinal tissues", "ANATOMY", 85, 103], ["colonic tissue", "ANATOMY", 248, 262], ["fatty acid", "CHEMICAL", 55, 65], ["eicosapentaenoic acid", "CHEMICAL", 192, 213], ["docosahexaenoic acid", "CHEMICAL", 218, 238], ["fatty acid", "CHEMICAL", 55, 65], ["eicosapentaenoic acid", "CHEMICAL", 192, 213], ["docosahexaenoic acid", "CHEMICAL", 218, 238], ["fatty acid", "SIMPLE_CHEMICAL", 55, 65], ["intestinal tissues", "TISSUE", 85, 103], ["eicosapentaenoic acid", "SIMPLE_CHEMICAL", 192, 213], ["docosahexaenoic acid", "SIMPLE_CHEMICAL", 218, 238], ["human", "ORGANISM", 242, 247], ["colonic tissue", "TISSUE", 248, 262], ["human", "SPECIES", 242, 247], ["human", "SPECIES", 242, 247], ["this study", "TEST", 22, 32], ["fatty acid incorporation into intestinal tissues", "PROBLEM", 55, 103], ["one study", "TEST", 135, 144], ["eicosapentaenoic acid", "TREATMENT", 192, 213], ["docosahexaenoic acid in human colonic tissue", "PROBLEM", 218, 262], ["supplementation", "TREATMENT", 283, 298], ["intestinal tissues", "ANATOMY", 85, 103], ["eicosapentaenoic acid", "OBSERVATION", 192, 213], ["docosahexaenoic acid", "OBSERVATION", 218, 238], ["human", "ANATOMY_MODIFIER", 242, 247], ["colonic tissue", "ANATOMY", 248, 262]]], ["Additional studies evaluating diets with titrated levels of long-chain omega-3 fatty acids are required to better understand potential benefits in cats with chronic gastroenteropathy.DiscussionFinally, differences in dietary fiber and prebiotic ingredients may have influenced response.", [["omega-3 fatty acids", "CHEMICAL", 71, 90], ["chronic gastroenteropathy", "DISEASE", 157, 182], ["omega-3 fatty acids", "CHEMICAL", 71, 90], ["long-chain omega-3 fatty acids", "SIMPLE_CHEMICAL", 60, 90], ["cats", "ORGANISM", 147, 151], ["cats", "SPECIES", 147, 151], ["Additional studies", "TEST", 0, 18], ["long-chain omega-3 fatty acids", "TREATMENT", 60, 90], ["chronic gastroenteropathy", "PROBLEM", 157, 182], ["dietary fiber", "TREATMENT", 217, 230], ["prebiotic ingredients", "TREATMENT", 235, 256], ["chronic", "OBSERVATION_MODIFIER", 157, 164], ["gastroenteropathy", "OBSERVATION", 165, 182]]], ["Crude fiber analysis was 2.22% in Diet A and 3.16% in Diet B. Total dietary fiber and the soluble and insoluble fractions were not analyzed in this study.", [["Crude fiber analysis", "TEST", 0, 20], ["Total dietary fiber", "TREATMENT", 62, 81], ["the soluble and insoluble fractions", "TREATMENT", 86, 121], ["this study", "TEST", 143, 153]]], ["Diet A utilized dried beet pulp, fructooligosaccharides, and mannanoligosaccharides, while Diet B utilized powdered cellulose followed by dried beet pulp.", [["pulp", "ANATOMY", 27, 31], ["pulp", "ANATOMY", 149, 153], ["fructooligosaccharides", "CHEMICAL", 33, 55], ["mannanoligosaccharides", "CHEMICAL", 61, 83], ["Diet B", "CHEMICAL", 91, 97], ["mannanoligosaccharides", "CHEMICAL", 61, 83], ["pulp", "TISSUE", 27, 31], ["fructooligosaccharides", "SIMPLE_CHEMICAL", 33, 55], ["mannanoligosaccharides", "SIMPLE_CHEMICAL", 61, 83], ["Diet B", "SIMPLE_CHEMICAL", 91, 97], ["cellulose", "SIMPLE_CHEMICAL", 116, 125], ["pulp", "TISSUE", 149, 153], ["beet", "SPECIES", 22, 26], ["beet", "SPECIES", 144, 148], ["dried beet pulp", "TREATMENT", 16, 31], ["fructooligosaccharides", "TREATMENT", 33, 55], ["mannanoligosaccharides", "TREATMENT", 61, 83], ["powdered cellulose", "TREATMENT", 107, 125], ["pulp", "ANATOMY", 149, 153]]], ["Based on the ingredient composition, Diet A would be expected to provide more fermentable fibers and prebiotics that may have promoted an increased production of total intraluminal short-chain fatty acids and positively influenced microbial populations (21\u201330).", [["fibers", "ANATOMY", 90, 96], ["fatty acids", "CHEMICAL", 193, 204], ["short-chain fatty acids", "CHEMICAL", 181, 204], ["Diet A", "SIMPLE_CHEMICAL", 37, 43], ["intraluminal", "IMMATERIAL_ANATOMICAL_ENTITY", 168, 180], ["short-chain fatty acids", "SIMPLE_CHEMICAL", 181, 204], ["more fermentable fibers", "TREATMENT", 73, 96], ["prebiotics", "TREATMENT", 101, 111], ["an increased production of total intraluminal short-chain fatty acids", "PROBLEM", 135, 204], ["increased", "OBSERVATION_MODIFIER", 138, 147], ["production", "OBSERVATION_MODIFIER", 148, 158]]], ["While dietary fiber and prebiotics are generally considered to provide benefits primarily within the large intestine and aid in the management of diarrhea, recent studies have demonstrated immune modulating benefits that could have broader benefits, particularly in conditions with an inflammatory nature (31, 32).", [["intestine", "ANATOMY", 107, 116], ["diarrhea", "DISEASE", 146, 154], ["intestine", "ORGAN", 107, 116], ["dietary fiber", "TREATMENT", 6, 19], ["prebiotics", "TREATMENT", 24, 34], ["the management", "TREATMENT", 128, 142], ["diarrhea", "PROBLEM", 146, 154], ["recent studies", "TEST", 156, 170], ["immune modulating benefits", "TREATMENT", 189, 215], ["intestine", "ANATOMY", 107, 116], ["diarrhea", "OBSERVATION", 146, 154], ["inflammatory", "OBSERVATION_MODIFIER", 285, 297]]], ["The time required to see potential clinical benefits is unclear, and clinical improvement related to immunomodulation may require more than 1\u20132 weeks of dietary intervention.", [["immunomodulation", "TREATMENT", 101, 117], ["dietary intervention", "TREATMENT", 153, 173]]], ["Additional studies are needed to better understand the role of the microbiota in inflammatory gastrointestinal disease and the potential benefits of dietary fibers and prebiotics in animals with chronic gastroenteropathies.DiscussionThere were several limitations to this study, including the relatively small study population that was below the initial target of 25 cats per treatment group.", [["gastrointestinal", "ANATOMY", 94, 110], ["dietary fibers", "ANATOMY", 149, 163], ["gastrointestinal disease", "DISEASE", 94, 118], ["chronic gastroenteropathies", "DISEASE", 195, 222], ["gastrointestinal", "ORGAN", 94, 110], ["cats", "ORGANISM", 367, 371], ["Additional studies", "TEST", 0, 18], ["inflammatory gastrointestinal disease", "PROBLEM", 81, 118], ["dietary fibers", "TREATMENT", 149, 163], ["prebiotics", "TREATMENT", 168, 178], ["chronic gastroenteropathies", "PROBLEM", 195, 222], ["this study", "TEST", 267, 277], ["the relatively small study population", "PROBLEM", 289, 326], ["inflammatory", "OBSERVATION_MODIFIER", 81, 93], ["gastrointestinal", "ANATOMY", 94, 110], ["chronic", "OBSERVATION_MODIFIER", 195, 202], ["gastroenteropathies", "OBSERVATION", 203, 222], ["small", "OBSERVATION_MODIFIER", 304, 309]]], ["Additional numbers may have been required to demonstrate a significant difference in Diet B and between the two dietary interventions.", [["the two dietary interventions", "TREATMENT", 104, 133], ["significant", "OBSERVATION_MODIFIER", 59, 70], ["difference", "OBSERVATION", 71, 81]]], ["This study also relied on a comparison to baseline versus a comparison to a non-therapeutic control formula.", [["This study", "TEST", 0, 10], ["a non-therapeutic control formula", "TREATMENT", 74, 107]]], ["A non-therapeutic control would have been ideal for establishing effectiveness of the therapeutic diets; however, due to ethical considerations, all study participants were provided with a therapeutic dietary intervention.", [["participants", "SPECIES", 155, 167], ["A non-therapeutic control", "TREATMENT", 0, 25], ["the therapeutic diets", "TREATMENT", 82, 103], ["all study", "TEST", 145, 154], ["a therapeutic dietary intervention", "TREATMENT", 187, 221]]], ["Additionally, this study relied on the owner\u2019s recall to establish the baseline weekly vomiting frequency.", [["vomiting", "DISEASE", 87, 95], ["this study", "TEST", 14, 24], ["the baseline weekly vomiting frequency", "PROBLEM", 67, 105]]], ["A recorded baseline would have been preferred; however, it was decided that it was not in the cats\u2019 best interest to delay dietary intervention.", [["cats", "ORGANISM", 94, 98], ["dietary intervention", "TREATMENT", 123, 143]]], ["Finally, the lack of significance may have been influenced by the variability of clinical disease within individual cats.", [["cats", "ORGANISM", 116, 120], ["clinical disease within individual cats", "PROBLEM", 81, 120]]], ["It was appreciated in this study that while most cats had a progressive decline of vomiting occurrences, some cats had episodic occurrences of vomiting that varied from week to week (Figure 1).", [["vomiting", "DISEASE", 83, 91], ["vomiting", "DISEASE", 143, 151], ["cats", "ORGANISM", 49, 53], ["cats", "ORGANISM", 110, 114], ["cats", "SPECIES", 49, 53], ["this study", "TEST", 22, 32], ["a progressive decline of vomiting", "PROBLEM", 58, 91], ["vomiting", "PROBLEM", 143, 151], ["progressive", "OBSERVATION_MODIFIER", 60, 71], ["decline", "OBSERVATION_MODIFIER", 72, 79]]], ["The 4-week feeding period was chosen to approximate a reasonable duration for a dietary trial with a gastrointestinal therapeutic formula before additional diagnostic procedures and/or medical treatments would be employed to better characterize and manage the underlying disease.", [["gastrointestinal", "ANATOMY", 101, 117], ["gastrointestinal", "ORGANISM_SUBDIVISION", 101, 117], ["a gastrointestinal therapeutic formula", "TREATMENT", 99, 137], ["diagnostic procedures", "TREATMENT", 156, 177], ["medical treatments", "TREATMENT", 185, 203], ["the underlying disease", "PROBLEM", 256, 278], ["disease", "OBSERVATION", 271, 278]]], ["While this study did not follow the cats beyond the 4-week period, it would have been optimal to evaluate this cohort for 4\u20136 months to identify whether there were recrudescence of clinical signs and any differences between the two diet groups long term.ConclusionResults of this study suggest that gastrointestinal therapeutic diets alone can be effective in the management of cats with chronic vomiting associated with a chronic gastroenteropathy.", [["gastrointestinal", "ANATOMY", 299, 315], ["chronic vomiting", "DISEASE", 388, 404], ["gastroenteropathy", "DISEASE", 431, 448], ["cats", "ORGANISM", 36, 40], ["gastrointestinal", "ORGAN", 299, 315], ["cats", "ORGANISM", 378, 382], ["cats", "SPECIES", 378, 382], ["this study", "TEST", 6, 16], ["clinical signs", "PROBLEM", 181, 195], ["this study", "TEST", 275, 285], ["gastrointestinal therapeutic diets", "TREATMENT", 299, 333], ["chronic vomiting", "PROBLEM", 388, 404], ["a chronic gastroenteropathy", "PROBLEM", 421, 448], ["gastrointestinal", "ANATOMY", 299, 315], ["chronic", "OBSERVATION_MODIFIER", 388, 395], ["chronic", "OBSERVATION_MODIFIER", 423, 430], ["gastroenteropathy", "OBSERVATION", 431, 448]]], ["Cats that do not respond to dietary therapy require further diagnostics and/or medical therapy to adequately characterize and manage the underlying disease.", [["dietary therapy", "TREATMENT", 28, 43], ["further diagnostics", "TEST", 52, 71], ["medical therapy", "TREATMENT", 79, 94], ["the underlying disease", "PROBLEM", 133, 155], ["disease", "OBSERVATION", 148, 155]]], ["Additionally, cats that do not respond to gastrointestinal formulas may respond to diets formulated with limited novel ingredients or hydrolyzed protein sources.Ethics StatementThis study was carried out in accordance with the P&G Pet Care Animal Research Policy, and the protocol was approved by the P&G Pet Care Institutional Animal Care and Use Committee.", [["gastrointestinal", "ANATOMY", 42, 58], ["cats", "ORGANISM", 14, 18], ["cats", "SPECIES", 14, 18], ["gastrointestinal formulas", "TREATMENT", 42, 67], ["hydrolyzed protein sources", "PROBLEM", 134, 160], ["This study", "TEST", 177, 187]]], ["All cat owners provided written consent to participate in the study.Author ContributionsSP contributed to the design, to conducting of the study, to the analysis and interpretation of the results, and to the writing of the manuscript.", [["cat", "ORGANISM", 4, 7], ["the study", "TEST", 58, 67], ["the study", "TEST", 135, 144], ["the analysis", "TEST", 149, 161]]], ["SM contributed to the design, interpretation of the results, and writing of the manuscript.", [["SM", "PROTEIN", 0, 2]]], ["LD and PK contributed to the design, to the conducting of the study, to the interpretation of the results, and to the review of the manuscript.", [["the study", "TEST", 58, 67]]], ["RH contributed to the statistical analysis, interpretation of the results, and writing of the manuscript.Conflict of Interest StatementSP, LD, and PK were employed by Proctor and Gamble at the time of the study.", [["the statistical analysis", "TEST", 18, 42], ["the study", "TEST", 201, 210]]], ["SP and RH are current associates at Mars, Inc.", [["SP", "CHEMICAL", 0, 2], ["SP", "PROTEIN", 0, 2]]]], "4acc93d79bf6e7caf784e9eba57cce742b32a3f1": [["IntroductionThe family Adenoviridae comprises two genera Mastadenovirus and Aviadenovirus.", [["The family Adenoviridae", "TREATMENT", 12, 35], ["Aviadenovirus", "TREATMENT", 76, 89]]], ["The genus Mastadenovirus consists of 101 species that have been isolated from nine different host species [24] .", [["The genus Mastadenovirus", "TEST", 0, 24], ["101 species", "PROBLEM", 37, 48], ["genus Mastadenovirus", "OBSERVATION", 4, 24], ["nine different", "OBSERVATION_MODIFIER", 78, 92], ["host species", "OBSERVATION", 93, 105]]], ["The most extensively studied group is that of the human adenoviruses.", [["human", "ORGANISM", 50, 55], ["adenoviruses", "ORGANISM", 56, 68], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55], ["the human adenoviruses", "PROBLEM", 46, 68], ["adenoviruses", "OBSERVATION", 56, 68]]], ["So far, 49 human adenovirus (Ad) serotypes have been identi\u00aeed [27] and divided into six different subgenera, A to F, which differ from each other in various characteristics such as tropism.", [["human", "ORGANISM", 11, 16], ["adenovirus", "ORGANISM", 17, 27], ["Ad", "ORGANISM", 29, 31], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 11, 16], ["Ad", "SPECIES", 29, 31], ["human adenovirus (Ad) serotypes", "TREATMENT", 11, 42]]], ["Adenovirus type 7 (Ad7) is the serotype most frequently associated with severe diseases [17] .IntroductionAdenoviruses are non-enveloped icosahedral viruses.", [["Adenovirus type 7", "ORGANISM", 0, 17], ["Ad7", "GENE_OR_GENE_PRODUCT", 19, 22], ["Adenoviruses", "GENE_OR_GENE_PRODUCT", 106, 118], ["non-enveloped icosahedral viruses", "ORGANISM", 123, 156], ["Adenovirus type 7", "SPECIES", 0, 17], ["Adenovirus type 7", "PROBLEM", 0, 17], ["the serotype", "PROBLEM", 27, 39], ["severe diseases", "PROBLEM", 72, 87], ["IntroductionAdenoviruses", "TREATMENT", 94, 118], ["non-enveloped icosahedral viruses", "PROBLEM", 123, 156], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["diseases", "OBSERVATION", 79, 87], ["non-enveloped", "OBSERVATION_MODIFIER", 123, 136], ["icosahedral viruses", "OBSERVATION", 137, 156]]], ["The virion contains at least eleven different structural polypeptides.", [["The virion", "TREATMENT", 0, 10], ["virion", "OBSERVATION", 4, 10], ["at least", "OBSERVATION_MODIFIER", 20, 28], ["eleven different", "OBSERVATION_MODIFIER", 29, 45], ["structural polypeptides", "OBSERVATION", 46, 69]]], ["The hexon is the most abundantly produced protein.", [["hexon", "GENE_OR_GENE_PRODUCT", 4, 9], ["hexon", "PROTEIN", 4, 9], ["The hexon", "TREATMENT", 0, 9]]], ["Each virion contains 240 hexons which form the facets of the icosahedron.", [["icosahedron", "PROTEIN", 61, 72], ["Each virion", "PROBLEM", 0, 11], ["the icosahedron", "TREATMENT", 57, 72], ["240 hexons", "OBSERVATION_MODIFIER", 21, 31]]], ["The nine central hexon capsomers in each facet are cemented together by polypeptide IX to form a group-of-nine [7] .", [["IX", "GENE_OR_GENE_PRODUCT", 84, 86], ["central hexon capsomers", "PROTEIN", 9, 32], ["polypeptide IX", "PROTEIN", 72, 86], ["The nine central hexon capsomers in each facet", "TREATMENT", 0, 46], ["central", "OBSERVATION_MODIFIER", 9, 16], ["hexon capsomers", "OBSERVATION", 17, 32], ["facet", "ANATOMY", 41, 46], ["cemented", "OBSERVATION", 51, 59]]], ["The hexon is a homotrimer consisting of three identical polypeptide chains.", [["hexon", "PROTEIN", 4, 9], ["polypeptide chains", "PROTEIN", 56, 74], ["The hexon", "TREATMENT", 0, 9], ["a homotrimer", "TREATMENT", 13, 25], ["three identical polypeptide chains", "TREATMENT", 40, 74], ["polypeptide chains", "OBSERVATION", 56, 74]]], ["The monomer is an unusually large structural protein with a M r ranging from 102\u00b1109 k ( Table 2) .IntroductionAs several entire or partial hexon sequences of different serotypes have been published (references cited in Table 2 ), the hexons of several different serotypes have been compared at the nucleotide and predicted amino acid sequence levels [9, 14, 31, 36] .IntroductionThe biochemical and immunological properties and even the threedimensional structure of adenoviruses have been extensively studied.", [["amino acid", "CHEMICAL", 324, 334], ["nucleotide", "CHEMICAL", 299, 309], ["amino acid", "CHEMICAL", 324, 334], ["amino acid", "AMINO_ACID", 324, 334], ["adenoviruses", "ORGANISM", 468, 480], ["structural protein", "PROTEIN", 34, 52], ["hexon sequences", "DNA", 140, 155], ["an unusually large structural protein", "PROBLEM", 15, 52], ["IntroductionAs", "TREATMENT", 99, 113], ["partial hexon sequences", "TREATMENT", 132, 155], ["different serotypes", "PROBLEM", 159, 178], ["several different serotypes", "PROBLEM", 245, 272], ["amino acid sequence levels", "TEST", 324, 350], ["adenoviruses", "PROBLEM", 468, 480], ["unusually", "OBSERVATION_MODIFIER", 18, 27], ["large", "OBSERVATION_MODIFIER", 28, 33], ["structural protein", "OBSERVATION", 34, 52], ["adenoviruses", "OBSERVATION", 468, 480]]], ["The trimeric hexon molecule has a pseudo-hexagonal base with a large central cavity and a triangular top.", [["trimeric hexon molecule", "PROTEIN", 4, 27], ["The trimeric hexon molecule", "TEST", 0, 27], ["a large central cavity", "PROBLEM", 61, 83], ["trimeric", "ANATOMY_MODIFIER", 4, 12], ["hexon molecule", "OBSERVATION", 13, 27], ["hexagonal", "ANATOMY_MODIFIER", 41, 50], ["base", "ANATOMY_MODIFIER", 51, 55], ["large", "OBSERVATION_MODIFIER", 63, 68], ["central", "OBSERVATION_MODIFIER", 69, 76], ["cavity", "OBSERVATION", 77, 83], ["triangular", "OBSERVATION_MODIFIER", 90, 100], ["top", "OBSERVATION_MODIFIER", 101, 104]]], ["The base contains two pedestal domains, P1 and P2.", [["pedestal domains", "DNA", 22, 38], ["P1", "DNA", 40, 42], ["P2", "DNA", 47, 49], ["base", "ANATOMY_MODIFIER", 4, 8], ["two", "OBSERVATION_MODIFIER", 18, 21], ["pedestal domains", "OBSERVATION", 22, 38], ["P2", "OBSERVATION_MODIFIER", 47, 49]]], ["The top contains three long loops L1, L2 and L4 [3] .", [["L1", "DNA", 34, 36], ["L2", "DNA", 38, 40], ["top", "OBSERVATION_MODIFIER", 4, 7], ["three", "ANATOMY_MODIFIER", 17, 22], ["long", "ANATOMY_MODIFIER", 23, 27], ["loops", "ANATOMY_MODIFIER", 28, 33], ["L1", "ANATOMY_MODIFIER", 34, 36], ["L2", "ANATOMY_MODIFIER", 38, 40], ["L4", "ANATOMY_MODIFIER", 45, 47]]], ["However, the hydropathic character of the adenovirus hexons and the codon usage has not been analysed.", [["adenovirus", "ORGANISM", 42, 52], ["the adenovirus hexons", "TREATMENT", 38, 59], ["the codon usage", "TREATMENT", 64, 79], ["adenovirus", "OBSERVATION", 42, 52]]], ["The hydropathy of a protein is very important for predicting putative antigenic regions of the protein.", [["putative antigenic regions", "PROTEIN", 61, 87], ["The hydropathy of a protein", "PROBLEM", 0, 27], ["hydropathy", "OBSERVATION", 4, 14]]], ["The antigenic determinants can be deduced by searching the amino acid sequence for the areas of greatest local hydrophilicity.", [["amino acid", "CHEMICAL", 59, 69], ["amino acid", "CHEMICAL", 59, 69], ["amino acid", "AMINO_ACID", 59, 69], ["amino acid sequence", "PROTEIN", 59, 78], ["the amino acid sequence", "TEST", 55, 78], ["greatest local hydrophilicity", "PROBLEM", 96, 125], ["greatest", "OBSERVATION_MODIFIER", 96, 104], ["local hydrophilicity", "OBSERVATION", 105, 125]]], ["Generally, the highest peak of hydrophilicity correctly predicts an antigenic site [11] .IntroductionCodon usage bias for codons with thymidine (T) or cytidine (C) at second positions in mitochondrial DNA has been shown to be correlated with hydrophobicity [21] .", [["mitochondrial", "ANATOMY", 187, 200], ["thymidine", "CHEMICAL", 134, 143], ["T", "CHEMICAL", 145, 146], ["cytidine", "CHEMICAL", 151, 159], ["thymidine", "CHEMICAL", 134, 143], ["cytidine", "CHEMICAL", 151, 159], ["thymidine (T)", "GENE_OR_GENE_PRODUCT", 134, 147], ["cytidine (C", "SIMPLE_CHEMICAL", 151, 162], ["mitochondrial", "CELLULAR_COMPONENT", 187, 200], ["DNA", "CELLULAR_COMPONENT", 201, 204], ["mitochondrial DNA", "DNA", 187, 204], ["IntroductionCodon usage bias", "TREATMENT", 89, 117], ["thymidine (T)", "TREATMENT", 134, 147], ["cytidine (C) at second positions in mitochondrial DNA", "TREATMENT", 151, 204]]], ["Having analysed nine adenovirus hexon genes, we found the presence of purine and pyrimidine at the second codon position to be correlated to hydrophilicity and hydrophobicity, respectively [19] .", [["purine", "CHEMICAL", 70, 76], ["pyrimidine", "CHEMICAL", 81, 91], ["purine", "CHEMICAL", 70, 76], ["pyrimidine", "CHEMICAL", 81, 91], ["adenovirus", "ORGANISM", 21, 31], ["purine", "SIMPLE_CHEMICAL", 70, 76], ["pyrimidine", "SIMPLE_CHEMICAL", 81, 91], ["adenovirus hexon genes", "DNA", 21, 43], ["purine", "TREATMENT", 70, 76], ["pyrimidine", "TREATMENT", 81, 91], ["hydrophobicity", "PROBLEM", 160, 174]]], ["This \u00aending was recently con\u00aermed by analysis of further data obtained from GenBank.", [["further data", "TEST", 49, 61]]], ["Here, we report the hydropathy analysis of 14 adenovirus hexon sequences predicted from a newly determined Ad7 hexon DNA sequence and thirteen published hexon sequences of Ad2, Ad3, Ad4, Ad5, Ad12, Ad16, Ad40, Ad41, Ad48, Bav3, Mav1, Fav1 and Fav10.", [["adenovirus", "ORGANISM", 46, 56], ["DNA", "CELLULAR_COMPONENT", 117, 120], ["Ad2", "GENE_OR_GENE_PRODUCT", 172, 175], ["Ad3", "GENE_OR_GENE_PRODUCT", 177, 180], ["Ad4", "GENE_OR_GENE_PRODUCT", 182, 185], ["Ad5", "GENE_OR_GENE_PRODUCT", 187, 190], ["Ad12", "GENE_OR_GENE_PRODUCT", 192, 196], ["Ad16", "GENE_OR_GENE_PRODUCT", 198, 202], ["Ad40", "GENE_OR_GENE_PRODUCT", 204, 208], ["Ad41", "GENE_OR_GENE_PRODUCT", 210, 214], ["Ad48", "GENE_OR_GENE_PRODUCT", 216, 220], ["Bav3", "GENE_OR_GENE_PRODUCT", 222, 226], ["Mav1", "GENE_OR_GENE_PRODUCT", 228, 232], ["Fav1", "GENE_OR_GENE_PRODUCT", 234, 238], ["Fav10", "GENE_OR_GENE_PRODUCT", 243, 248], ["adenovirus hexon sequences", "DNA", 46, 72], ["Ad7 hexon DNA sequence", "DNA", 107, 129], ["hexon sequences", "DNA", 153, 168], ["Ad2, Ad3, Ad4, Ad5, Ad12, Ad16, Ad40, Ad41, Ad48, Bav3, Mav1, Fav1 and Fav10", "DNA", 172, 248], ["the hydropathy analysis", "TEST", 16, 39], ["14 adenovirus hexon sequences", "PROBLEM", 43, 72], ["Ad7 hexon DNA sequence", "TEST", 107, 129], ["thirteen published hexon sequences", "TEST", 134, 168], ["Ad5", "TEST", 187, 190], ["Ad12", "TEST", 192, 196], ["Ad48", "TEST", 216, 220], ["Bav3", "TEST", 222, 226], ["Mav1", "TEST", 228, 232], ["Fav1", "TEST", 234, 238], ["Fav10", "TEST", 243, 248]]], ["There is strong correlation between hydrophilicity and the codons with purine in the second position (CPUSs), and between hydrophobicity and the codons with pyrimidine in the second position (CPYSs) in adenovirus hexons.", [["purine", "CHEMICAL", 71, 77], ["pyrimidine", "CHEMICAL", 157, 167], ["purine", "CHEMICAL", 71, 77], ["pyrimidine", "CHEMICAL", 157, 167], ["purine", "SIMPLE_CHEMICAL", 71, 77], ["pyrimidine", "SIMPLE_CHEMICAL", 157, 167], ["adenovirus", "ORGANISM", 202, 212], ["CPUSs", "PROTEIN", 102, 107], ["CPYSs", "PROTEIN", 192, 197], ["purine", "TREATMENT", 71, 77], ["pyrimidine", "TREATMENT", 157, 167]]], ["Comparison of the surface charge on these 14 hexons suggests the strength of the surface charge accumulated in hydrophilic regions or hydrophobic regions to be correlated with the tissue tropism of the different adenovirus types.Virus and cellsThe Ad7 prototype strain Gomen, originally from the American Type Culture Collection (ATCC), was obtained from Dr. G. von Zeipel, Stockholm County Council Central Microbiological Laboratory, Stockholm, Sweden [34] .", [["surface", "ANATOMY", 18, 25], ["surface", "ANATOMY", 81, 88], ["tissue", "ANATOMY", 180, 186], ["cells", "ANATOMY", 239, 244], ["tissue", "TISSUE", 180, 186], ["adenovirus", "ORGANISM", 212, 222], ["Virus", "ORGANISM", 229, 234], ["cells", "CELL", 239, 244], ["hydrophilic regions", "PROTEIN", 111, 130], ["hydrophobic regions", "PROTEIN", 134, 153], ["the surface charge", "TEST", 14, 32], ["hydrophobic regions", "PROBLEM", 134, 153], ["the tissue tropism", "TEST", 176, 194], ["Virus", "PROBLEM", 229, 234], ["hydrophilic", "OBSERVATION_MODIFIER", 111, 122], ["hydrophobic regions", "OBSERVATION", 134, 153], ["different adenovirus types", "OBSERVATION", 202, 228], ["cells", "OBSERVATION", 239, 244]]], ["This strain was propagated in A549 cells.Cloning of hexon DNA fragmentsThe viral DNA of Ad7 strain Gomen was prepared as described [18] .", [["A549 cells", "ANATOMY", 30, 40], ["A549 cells", "CELL", 30, 40], ["DNA", "CELLULAR_COMPONENT", 58, 61], ["DNA", "CELLULAR_COMPONENT", 81, 84], ["Ad7 strain Gomen", "ORGANISM", 88, 104], ["A549 cells", "CELL_LINE", 30, 40], ["hexon DNA fragments", "DNA", 52, 71], ["viral DNA", "DNA", 75, 84], ["This strain", "PROBLEM", 0, 11], ["hexon DNA fragments", "TREATMENT", 52, 71], ["Ad7 strain", "PROBLEM", 88, 98], ["A549 cells", "OBSERVATION", 30, 40], ["hexon DNA", "OBSERVATION_MODIFIER", 52, 61], ["fragments", "OBSERVATION_MODIFIER", 62, 71], ["viral DNA", "OBSERVATION", 75, 84]]], ["The puri\u00aeed DNA was used as the template for PCR to amplify \u00aeve fragments which covered the entire hexon gene.", [["DNA", "CELLULAR_COMPONENT", 12, 15], ["puri\u00aeed DNA", "DNA", 4, 15], ["\u00aeve fragments", "DNA", 60, 73], ["hexon gene", "DNA", 99, 109], ["The puri\u00aeed DNA", "TREATMENT", 0, 15], ["the template", "TREATMENT", 28, 40], ["PCR", "PROBLEM", 45, 48], ["\u00aeve fragments", "PROBLEM", 60, 73], ["hexon gene", "OBSERVATION", 99, 109]]], ["The PCR products were cloned into pT7 Blue vector.", [["PCR products", "DNA", 4, 16], ["pT7 Blue vector", "DNA", 34, 49], ["The PCR products", "TREATMENT", 0, 16]]], ["Ligation, transformation and rapid screening were performed using the pT7 Blue T-vector Kit protocols (Novagen, Madison, WI, USA).", [["Ligation", "TREATMENT", 0, 8], ["rapid screening", "TEST", 29, 44]]], ["The recombinant pT7-Blue plasmid DNA was prepared for sequencing.Cloning of hexon DNA fragmentsAs the PCR method occasionally gave rise to error when the complementary DNA strand was synthesised using Taq polymerase, the sequence so obtained was con\u00aermed with the following procedure: The Ad7 hexon DNA Bam HI restriction fragments A and E, which contain the hexon gene, were cloned into plasmid vector pBR322 and multiplied in E. coli strain HB101 using conventional methods described previously [25] .", [["pT7", "GENE_OR_GENE_PRODUCT", 16, 19], ["DNA", "CELLULAR_COMPONENT", 33, 36], ["DNA", "CELLULAR_COMPONENT", 82, 85], ["DNA", "CELLULAR_COMPONENT", 168, 171], ["Taq polymerase", "GENE_OR_GENE_PRODUCT", 201, 215], ["DNA", "CELLULAR_COMPONENT", 299, 302], ["Bam HI restriction fragments A", "GENE_OR_GENE_PRODUCT", 303, 333], ["E", "GENE_OR_GENE_PRODUCT", 338, 339], ["pBR322", "GENE_OR_GENE_PRODUCT", 403, 409], ["E. coli", "ORGANISM", 428, 435], ["HB101", "CELL", 443, 448], ["recombinant pT7-Blue plasmid DNA", "DNA", 4, 36], ["hexon DNA fragments", "DNA", 76, 95], ["complementary DNA strand", "DNA", 154, 178], ["Taq polymerase", "PROTEIN", 201, 215], ["Ad7 hexon DNA Bam HI restriction fragments", "DNA", 289, 331], ["E", "DNA", 338, 339], ["hexon gene", "DNA", 359, 369], ["plasmid vector pBR322", "DNA", 388, 409], ["E. coli", "SPECIES", 428, 435], ["E. coli", "SPECIES", 428, 435], ["HB101", "SPECIES", 443, 448], ["The recombinant pT7", "TREATMENT", 0, 19], ["Blue plasmid DNA", "TREATMENT", 20, 36], ["hexon DNA fragments", "TREATMENT", 76, 95], ["the PCR method", "TEST", 98, 112], ["Taq polymerase", "TEST", 201, 215], ["the sequence", "TEST", 217, 229], ["The Ad7 hexon DNA Bam HI restriction fragments", "TREATMENT", 285, 331], ["the hexon gene", "TREATMENT", 355, 369], ["plasmid vector pBR322", "TREATMENT", 388, 409], ["E. coli strain HB101", "TREATMENT", 428, 448], ["conventional methods", "TREATMENT", 455, 475], ["hexon DNA", "OBSERVATION_MODIFIER", 76, 85], ["fragments", "OBSERVATION_MODIFIER", 86, 95], ["restriction", "OBSERVATION_MODIFIER", 310, 321], ["fragments", "OBSERVATION", 322, 331], ["E. coli", "OBSERVATION", 428, 435]]], ["These recombinant plasmid DNAs were used as the sequencing templates.SequencingThe nucleotide sequences were determined for both strands with the dideoxynucleotide chain determination method, following procedure C of the AutoRead Sequencing Kit (Pharmacia LKB Biotech, Sweden) and the manufacturer's instructions for the ALF DNA Sequencer (Pharmacia).Amino acid sequence analysisAll the sequence data were analysed with the LaserGene software (DNAStar Inc., Madison, WI) programs, Editseq, MegAlign and Protean.Amino acid sequence analysisEvery hexon DNA sequence was translated to protein sequence by using program EditSeq-Translation.", [["ALF", "DISEASE", 321, 324], ["Amino acid", "CHEMICAL", 351, 361], ["Amino acid", "CHEMICAL", 511, 521], ["nucleotide", "CHEMICAL", 83, 93], ["Amino acid", "CHEMICAL", 351, 361], ["Amino acid", "CHEMICAL", 511, 521], ["DNA", "CELLULAR_COMPONENT", 325, 328], ["Amino acid", "AMINO_ACID", 351, 361], ["Amino acid", "AMINO_ACID", 511, 521], ["DNA", "CELLULAR_COMPONENT", 551, 554], ["recombinant plasmid DNAs", "DNA", 6, 30], ["hexon DNA sequence", "DNA", 545, 563], ["These recombinant plasmid DNAs", "TREATMENT", 0, 30], ["the sequencing templates", "TREATMENT", 44, 68], ["The nucleotide sequences", "TEST", 79, 103], ["Amino acid sequence analysis", "TEST", 351, 379], ["All the sequence data", "TEST", 379, 400], ["Amino acid sequence analysis", "TEST", 511, 539], ["Every hexon DNA sequence", "TEST", 539, 563], ["plasmid DNAs", "OBSERVATION", 18, 30]]], ["The codon usage data could be obtained when a protein \u00aele was opened by EditSeq.", [["EditSeq", "PROTEIN", 72, 79], ["The codon usage data", "TEST", 0, 20], ["a protein \u00aele", "PROBLEM", 44, 57]]], ["The hydrophilicity plot (Kyte-Doolittle method) could be shown by program Protean.", [["The hydrophilicity plot", "TEST", 0, 23], ["Kyte-Doolittle method", "TREATMENT", 25, 46], ["hydrophilicity plot", "OBSERVATION", 4, 23]]], ["All the eight hydrophilicity plots could be moved together by the program Microsoft PowerPoint (Fig. 1 ).", [["hydrophilicity plots", "OBSERVATION", 14, 34]]], ["The isoelectric point and the net charge of a protein could be obtained by program Protean-Composition (Table 2) .Amino acid sequence analysisA tabular data of hydrophilicity and hydrophobicity for each amino acid could be obtained by program Protean-TabularData.", [["Amino acid", "CHEMICAL", 114, 124], ["amino acid", "CHEMICAL", 203, 213], ["Amino acid", "CHEMICAL", 114, 124], ["amino acid", "CHEMICAL", 203, 213], ["Amino acid", "AMINO_ACID", 114, 124], ["amino acid", "AMINO_ACID", 203, 213], ["The isoelectric point", "PROBLEM", 0, 21], ["Amino acid sequence analysisA", "TEST", 114, 143], ["tabular data", "TEST", 144, 156], ["hydrophilicity", "PROBLEM", 160, 174], ["hydrophobicity", "PROBLEM", 179, 193], ["each amino acid", "TEST", 198, 213], ["net charge", "OBSERVATION", 30, 40]]], ["The accumulated charge of all hydrophilic regions of a protein could be obtained by deleting manually all the hydrophobic regions according to the tabular data.", [["hydrophilic regions", "PROTEIN", 30, 49], ["hydrophobic regions", "PROTEIN", 110, 129], ["the tabular data", "TEST", 143, 159], ["accumulated", "OBSERVATION_MODIFIER", 4, 15], ["charge", "OBSERVATION_MODIFIER", 16, 22], ["all", "OBSERVATION_MODIFIER", 26, 29], ["hydrophilic", "OBSERVATION_MODIFIER", 30, 41], ["hydrophobic", "OBSERVATION_MODIFIER", 110, 121], ["tabular", "ANATOMY", 147, 154]]], ["An easier way was that, \u00aerst, to delete the hydrophobic regions within DNA sequence; second, to translate this DNA sequence to an amino acid sequence; then, to obtain the accumulated charge of hydrophilic regions by program Protean-Composition.", [["amino acid", "CHEMICAL", 130, 140], ["amino acid", "CHEMICAL", 130, 140], ["DNA", "CELLULAR_COMPONENT", 71, 74], ["DNA", "CELLULAR_COMPONENT", 111, 114], ["amino acid", "AMINO_ACID", 130, 140], ["hydrophobic regions", "PROTEIN", 44, 63], ["DNA sequence", "DNA", 71, 83], ["amino acid sequence", "PROTEIN", 130, 149], ["hydrophilic regions", "PROTEIN", 193, 212], ["DNA sequence", "TEST", 71, 83], ["this DNA sequence", "TEST", 106, 123], ["an amino acid sequence", "TEST", 127, 149], ["hydrophilic regions", "OBSERVATION", 193, 212]]], ["The accumulated charge of hydrophobic regions could be obtained in the same way ( Table 2) .Amino acid sequence analysisThe data of codon usage of accumulated hydrophilic and hydrophobic regions from 14 different serotypes were analysed by the computer program Microsoft Excel (Tables 1 and 5 ).Ad7 hexon DNA sequenceThe complete hexon gene DNA sequence of Ad7 prototype strain, Gomen, was determined.", [["Amino acid", "CHEMICAL", 92, 102], ["Amino acid", "CHEMICAL", 92, 102], ["Amino acid", "AMINO_ACID", 92, 102], ["DNA", "CELLULAR_COMPONENT", 305, 308], ["DNA", "CELLULAR_COMPONENT", 341, 344], ["hydrophobic regions", "PROTEIN", 26, 45], ["Ad7 hexon DNA sequence", "DNA", 295, 317], ["hexon gene DNA sequence", "DNA", 330, 353], ["The accumulated charge of hydrophobic regions", "PROBLEM", 0, 45], ["Amino acid sequence analysis", "TEST", 92, 120], ["accumulated hydrophilic and hydrophobic regions", "PROBLEM", 147, 194], ["14 different serotypes", "TREATMENT", 200, 222], ["hexon DNA sequence", "TEST", 299, 317], ["The complete hexon gene DNA sequence", "TEST", 317, 353], ["hydrophobic regions", "OBSERVATION", 26, 45], ["hydrophilic", "OBSERVATION_MODIFIER", 159, 170], ["hydrophobic", "OBSERVATION_MODIFIER", 175, 186]]], ["It consists of 2 814 nucleotides.", [["nucleotides", "CHEMICAL", 21, 32]]], ["This DNA sequence, together with Fig. 3 .", [["DNA", "CELLULAR_COMPONENT", 5, 8], ["DNA sequence", "DNA", 5, 17], ["This DNA sequence", "TEST", 0, 17]]], ["The \u00aegures around the boxes denote the amino acid numbers at the start and the end of each hypervariable region two short\u00afanking regions at each end, has been entered in the European Molecular Biology Laboratory (EMBL, accession number: Z48571).", [["amino acid", "CHEMICAL", 39, 49], ["amino acid", "CHEMICAL", 39, 49], ["amino acid", "AMINO_ACID", 39, 49], ["\u00aegures", "DNA", 4, 10], ["hypervariable region", "DNA", 91, 111], ["short\u00afanking regions", "DNA", 116, 136], ["the amino acid numbers", "TEST", 35, 57]]], ["The 5 H anking region has a splice acceptor site.", [["5 H anking region", "DNA", 4, 21], ["splice acceptor site", "DNA", 28, 48], ["The 5 H anking region", "TREATMENT", 0, 21], ["a splice acceptor site", "TREATMENT", 26, 48], ["splice", "OBSERVATION", 28, 34], ["acceptor site", "OBSERVATION", 35, 48]]], ["The 3 H\u00afa nking region ends just before the start codon of proteinase.", [["H\u00afa nking region", "DNA", 6, 22], ["proteinase", "PROTEIN", 59, 69], ["The 3 H\u00afa nking region", "TREATMENT", 0, 22]]], ["The sequence of the predicted protein, consisting of 937 amino acids, was obtained with the LaserGene software program EditSeq.", [["amino acids", "CHEMICAL", 57, 68], ["amino acids", "CHEMICAL", 57, 68], ["amino acids", "AMINO_ACID", 57, 68], ["amino acids", "TEST", 57, 68]]], ["The hydropathy data of hexon proteins from human adenovirus types 2, 3, 4, 5, 7, 12, 16, 40, 41, and 48, bovine adenovirus type 3, murine adenovirus type 1, and avian adenovirus types 1 and 10 were derived using the prediction method of Kyte-Doolittle in the LaserGene computer program Protean.", [["human adenovirus types 2", "ORGANISM", 43, 67], ["3", "GENE_OR_GENE_PRODUCT", 69, 70], ["4", "GENE_OR_GENE_PRODUCT", 72, 73], ["5", "GENE_OR_GENE_PRODUCT", 75, 76], ["7", "GENE_OR_GENE_PRODUCT", 78, 79], ["12", "GENE_OR_GENE_PRODUCT", 81, 83], ["16", "GENE_OR_GENE_PRODUCT", 85, 87], ["40", "GENE_OR_GENE_PRODUCT", 89, 91], ["41", "GENE_OR_GENE_PRODUCT", 93, 95], ["bovine adenovirus type 3", "ORGANISM", 105, 129], ["murine adenovirus type 1", "ORGANISM", 131, 155], ["avian adenovirus", "ORGANISM", 161, 177], ["hexon proteins", "PROTEIN", 23, 37], ["human", "SPECIES", 43, 48], ["bovine", "SPECIES", 105, 111], ["murine", "SPECIES", 131, 137], ["avian adenovirus", "SPECIES", 161, 177], ["human adenovirus", "SPECIES", 43, 59], ["bovine adenovirus type 3", "SPECIES", 105, 129], ["murine adenovirus type 1", "SPECIES", 131, 155], ["The hydropathy data", "TEST", 0, 19], ["hexon proteins", "TEST", 23, 37], ["human adenovirus types", "TEST", 43, 65], ["bovine adenovirus type", "TEST", 105, 127], ["murine adenovirus type", "TEST", 131, 153], ["avian adenovirus types", "TEST", 161, 183], ["hydropathy", "OBSERVATION", 4, 14]]], ["Analysis of the codon usage for the codons corresponding to hydrophilic and hydrophobic regions showed the presence of CPUSs and CPYSs to be strongly correlated with hydrophilicity and hydrophobicity, respectively.", [["CPUSs", "SIMPLE_CHEMICAL", 119, 124], ["CPYSs", "SIMPLE_CHEMICAL", 129, 134], ["hydrophilic and hydrophobic regions", "PROTEIN", 60, 95], ["CPUSs", "PROTEIN", 119, 124], ["CPYSs", "PROTEIN", 129, 134], ["the codon usage", "TREATMENT", 12, 27], ["the codons", "PROBLEM", 32, 42], ["hydrophilic and hydrophobic regions", "PROBLEM", 60, 95], ["CPUSs", "PROBLEM", 119, 124], ["CPYSs", "PROBLEM", 129, 134], ["hydrophobicity", "PROBLEM", 185, 199], ["CPUSs", "OBSERVATION", 119, 124], ["hydrophobicity", "OBSERVATION_MODIFIER", 185, 199]]], ["Statistical analysis using the chi square test showed a highly signi\u00aecant difference (1 2 192X79Y P`0X001) for the total numbers of CPUSs and CPYSs in hydrophilic and hydrophobic regions ( Table 1) .Alignment of the 14 complete sequences of adenovirus hexonsThe multiple sequence alignments of the 14 complete nucleotide sequences and the amino acid sequences of adenovirus hexons were determined by the program MegAlign (data not shown).", [["CPUSs", "DISEASE", 132, 137], ["CPYSs", "CHEMICAL", 142, 147], ["nucleotide", "CHEMICAL", 310, 320], ["amino acid", "CHEMICAL", 339, 349], ["nucleotide", "CHEMICAL", 310, 320], ["amino acid", "CHEMICAL", 339, 349], ["adenovirus", "ORGANISM", 241, 251], ["amino acid", "AMINO_ACID", 339, 349], ["adenovirus", "ORGANISM", 363, 373], ["CPYSs", "PROTEIN", 142, 147], ["hydrophilic and hydrophobic regions", "PROTEIN", 151, 186], ["adenovirus hexons", "DNA", 241, 258], ["14 complete nucleotide sequences", "DNA", 298, 330], ["Statistical analysis", "TEST", 0, 20], ["the chi square test", "TEST", 27, 46], ["CPUSs", "TREATMENT", 132, 137], ["CPYSs in hydrophilic and hydrophobic regions", "TREATMENT", 142, 186], ["adenovirus hexons", "TREATMENT", 241, 258], ["the 14 complete nucleotide sequences", "TEST", 294, 330], ["the amino acid sequences", "TEST", 335, 359], ["adenovirus hexons", "TREATMENT", 363, 380], ["hydrophilic", "OBSERVATION_MODIFIER", 151, 162], ["hydrophobic", "OBSERVATION_MODIFIER", 167, 178]]], ["The nucleotide and amino acid sequence pair distances and the phylogenetic tree of 14 hexon proteins showed serotypes of subgenera B, D and E to be closely related (Table 3 and Fig. 2) .", [["nucleotide", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 19, 29], ["nucleotide", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 19, 29], ["amino acid", "AMINO_ACID", 19, 29], ["B", "GENE_OR_GENE_PRODUCT", 131, 132], ["D", "GENE_OR_GENE_PRODUCT", 134, 135], ["14 hexon proteins", "PROTEIN", 83, 100], ["The nucleotide and amino acid sequence pair distances", "TEST", 0, 53], ["the phylogenetic tree", "TEST", 58, 79], ["hexon proteins", "TEST", 86, 100], ["subgenera B, D and E", "PROBLEM", 121, 141], ["tree", "ANATOMY_MODIFIER", 75, 79]]], ["They manifest 82.0\u00b193.9% amino acid sequence homology.", [["amino acid", "CHEMICAL", 25, 35], ["amino acid", "CHEMICAL", 25, 35], ["amino acid", "AMINO_ACID", 25, 35]]], ["Ad4 (subgenus E) is very similar to Ad16 (subgenus B), the amino acid sequence homology between these two serotypes reaching 93.4%.", [["amino acid", "CHEMICAL", 59, 69], ["amino acid", "CHEMICAL", 59, 69], ["Ad4", "GENE_OR_GENE_PRODUCT", 0, 3], ["subgenus E", "GENE_OR_GENE_PRODUCT", 5, 15], ["Ad16", "GENE_OR_GENE_PRODUCT", 36, 40], ["subgenus B", "ORGANISM", 42, 52], ["amino acid", "AMINO_ACID", 59, 69], ["Ad4", "DNA", 0, 3], ["Ad16", "DNA", 36, 40], ["the amino acid sequence homology", "TEST", 55, 87], ["these two serotypes", "TEST", 96, 115]]], ["This is in agreement with the cross neutralisation seen between antihexon sera speci\u00aec for Ad4 and Ad16 [22] .", [["sera", "ANATOMY", 74, 78], ["sera", "ORGANISM_SUBSTANCE", 74, 78], ["Ad4", "GENE_OR_GENE_PRODUCT", 91, 94], ["Ad4", "PROTEIN", 91, 94]]], ["The alignment data also showed Ad12 (subgenus A) to be closely related to Ad40 and Ad41 (subgenus F), the level of sequence homology being 81.5\u00b187.1%.", [["Ad12", "ORGANISM", 31, 35], ["Ad40", "GENE_OR_GENE_PRODUCT", 74, 78], ["Ad41", "GENE_OR_GENE_PRODUCT", 83, 87], ["Ad40", "DNA", 74, 78], ["Ad41", "DNA", 83, 87], ["The alignment data", "TEST", 0, 18], ["Ad12 (subgenus A)", "PROBLEM", 31, 48], ["Ad40", "TEST", 74, 78], ["sequence homology", "TEST", 115, 132]]], ["In contrast, the sequence similarity of E3a proteins between Ad12 and Ad41 was very low, only 30% in E3 RL1 and 34% in E3 RL2 [37] .", [["E3a", "GENE_OR_GENE_PRODUCT", 40, 43], ["Ad12", "ORGANISM", 61, 65], ["Ad41", "GENE_OR_GENE_PRODUCT", 70, 74], ["E3", "GENE_OR_GENE_PRODUCT", 101, 103], ["E3a proteins", "PROTEIN", 40, 52], ["Ad41", "PROTEIN", 70, 74], ["E3", "PROTEIN", 101, 103], ["RL1", "PROTEIN", 104, 107], ["E3", "PROTEIN", 119, 121], ["E3a proteins", "TEST", 40, 52], ["Ad12", "TEST", 61, 65], ["Ad41", "TEST", 70, 74], ["low", "OBSERVATION_MODIFIER", 84, 87]]], ["The alignment of the 14 complete sequences of adenovirus hexons showed nucleotide sequence homology to be 77\u00b194% within a subgenus of human adenoviruses, 65\u00b177% between members of different subgenera with the exception between Ad4 and Ad16 (86.2%); 64\u00b194% between adenoviruses from the same host species and 35\u00b159% between adenoviruses from different host species; and 35\u00b143% between the two adenovirus genera Mastadenovirus and Aviadenovirus.Comparison of hydropathy plots demonstrates the existence of seven hypervariable regionsThe alignment of the 14 complete amino acid sequences of adenovirus hexons revealed the existence of seven hypervariable regions (Fig. 3) .", [["nucleotide", "CHEMICAL", 71, 81], ["amino acid", "CHEMICAL", 564, 574], ["amino acid", "CHEMICAL", 564, 574], ["adenovirus", "ORGANISM", 46, 56], ["human", "ORGANISM", 134, 139], ["adenoviruses", "ORGANISM", 140, 152], ["Ad4", "GENE_OR_GENE_PRODUCT", 227, 230], ["adenoviruses", "ORGANISM", 264, 276], ["adenoviruses", "ORGANISM", 323, 335], ["adenovirus", "ORGANISM", 392, 402], ["amino acid", "AMINO_ACID", 564, 574], ["adenovirus", "ORGANISM", 588, 598], ["adenovirus hexons", "DNA", 46, 63], ["Ad4", "DNA", 227, 230], ["hypervariable regions", "DNA", 510, 531], ["hypervariable regions", "PROTEIN", 638, 659], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 134, 139], ["nucleotide sequence homology", "TEST", 71, 99], ["Ad16", "TEST", 235, 239], ["adenoviruses", "PROBLEM", 264, 276], ["adenoviruses", "PROBLEM", 323, 335], ["different host species", "PROBLEM", 341, 363], ["Aviadenovirus", "TREATMENT", 429, 442], ["hydropathy plots", "TEST", 457, 473], ["seven hypervariable regions", "PROBLEM", 504, 531], ["the 14 complete amino acid sequences of adenovirus hexons", "TEST", 548, 605], ["host species", "OBSERVATION", 351, 363], ["hydropathy plots", "OBSERVATION", 457, 473], ["seven", "OBSERVATION_MODIFIER", 504, 509], ["hypervariable", "OBSERVATION_MODIFIER", 510, 523], ["regions", "OBSERVATION_MODIFIER", 524, 531], ["seven", "OBSERVATION_MODIFIER", 632, 637], ["hypervariable", "OBSERVATION_MODIFIER", 638, 651]]], ["Hydrophilicity plots derived from the hexon sequences of eight serotypes representing eight subgenera of Mastadenovirus were compared (Fig. 1) .", [["Mastadenovirus", "GENE_OR_GENE_PRODUCT", 105, 119], ["hexon sequences", "DNA", 38, 53], ["Hydrophilicity plots", "PROBLEM", 0, 20], ["the hexon sequences", "TEST", 34, 53], ["eight serotypes", "PROBLEM", 57, 72], ["eight subgenera of Mastadenovirus", "PROBLEM", 86, 119], ["eight", "OBSERVATION_MODIFIER", 57, 62], ["serotypes", "OBSERVATION_MODIFIER", 63, 72], ["eight", "OBSERVATION_MODIFIER", 86, 91], ["subgenera", "OBSERVATION_MODIFIER", 92, 101]]], ["Seven hypervariable regions were demonstrated (in boxes, corresponding to the boxes in Fig. 3) .", [["hypervariable regions", "DNA", 6, 27], ["Seven hypervariable regions", "PROBLEM", 0, 27], ["hypervariable", "OBSERVATION_MODIFIER", 6, 19], ["Fig", "OBSERVATION_MODIFIER", 87, 90]]], ["The \u00aerst four hypervariable regions, A1 to A4, covered most of the external loop 1 (L1) of the hexon.", [["hexon", "CELLULAR_COMPONENT", 95, 100], ["\u00aerst four hypervariable regions", "DNA", 4, 35], ["A1", "DNA", 37, 39], ["A4", "DNA", 43, 45], ["external loop 1", "DNA", 67, 82], ["L1", "DNA", 84, 86], ["hexon", "DNA", 95, 100], ["hypervariable", "OBSERVATION_MODIFIER", 14, 27], ["regions", "ANATOMY_MODIFIER", 28, 35], ["external loop", "ANATOMY", 67, 80], ["L1)", "ANATOMY_MODIFIER", 84, 87], ["hexon", "ANATOMY_MODIFIER", 95, 100]]], ["They were separated by three short relatively conserved sequences which may stabilise the outer shell structure of the hexon.", [["hexon", "CELLULAR_COMPONENT", 119, 124], ["hexon", "PROTEIN", 119, 124], ["outer shell", "OBSERVATION_MODIFIER", 90, 101]]], ["The L2 contains two hypervariable regions, B1 and B2.", [["L2", "DNA", 4, 6], ["hypervariable regions", "DNA", 20, 41], ["B1", "DNA", 43, 45], ["B2", "DNA", 50, 52], ["two hypervariable regions", "PROBLEM", 16, 41], ["L2", "ANATOMY_MODIFIER", 4, 6], ["two", "OBSERVATION_MODIFIER", 16, 19], ["hypervariable", "OBSERVATION", 20, 33], ["B2", "OBSERVATION_MODIFIER", 50, 52]]], ["All of the hypervariable regions in L1 and L2 contained longer or shorter deletions/insertions.", [["hypervariable regions", "DNA", 11, 32], ["L1", "DNA", 36, 38], ["L2", "DNA", 43, 45], ["the hypervariable regions in L1 and L2", "PROBLEM", 7, 45], ["shorter deletions/insertions", "PROBLEM", 66, 94], ["hypervariable", "OBSERVATION_MODIFIER", 11, 24], ["regions", "ANATOMY_MODIFIER", 25, 32], ["L1", "ANATOMY", 36, 38], ["L2", "ANATOMY_MODIFIER", 43, 45], ["longer", "OBSERVATION_MODIFIER", 56, 62], ["shorter deletions", "OBSERVATION", 66, 83], ["insertions", "OBSERVATION_MODIFIER", 84, 94]]], ["The amino acid sequences of these regions were serotype speci\u00aec) The hypervariable region D of Mastadenovirus consisting of 13\u00b114 amino acids was located in L4.", [["amino acid", "CHEMICAL", 4, 14], ["amino acids", "CHEMICAL", 130, 141], ["amino acid", "CHEMICAL", 4, 14], ["amino acids", "CHEMICAL", 130, 141], ["amino acid", "AMINO_ACID", 4, 14], ["amino acids", "AMINO_ACID", 130, 141], ["hypervariable region D", "DNA", 69, 91], ["Mastadenovirus", "DNA", 95, 109], ["L4", "PROTEIN", 157, 159], ["The amino acid sequences", "TEST", 0, 24], ["The hypervariable region D of Mastadenovirus", "PROBLEM", 65, 109], ["amino acids", "TEST", 130, 141], ["hypervariable", "OBSERVATION_MODIFIER", 69, 82], ["region", "OBSERVATION_MODIFIER", 83, 89], ["L4", "ANATOMY", 157, 159]]], ["Amino acid sequence homology showed the region D to be subgenus speci\u00aec.", [["Amino acid", "CHEMICAL", 0, 10], ["Amino acid", "CHEMICAL", 0, 10], ["Amino acid", "AMINO_ACID", 0, 10], ["Amino acid sequence homology", "TEST", 0, 28], ["subgenus speci\u00aec", "PROBLEM", 55, 71], ["subgenus speci\u00aec", "OBSERVATION", 55, 71]]], ["Sequence homology was 93\u00b1100% for pairs of serotypes within a subgenus, and less than 79% between serotypes belonging to different subgenera.Comparison of hydropathy plots demonstrates the existence of seven hypervariable regionsInterestingly, the major portion of the hypervariable regions manifest hydrophilicity.", [["hypervariable regions", "DNA", 208, 229], ["hypervariable regions", "DNA", 269, 290], ["Sequence homology", "TEST", 0, 17], ["serotypes", "PROBLEM", 43, 52], ["a subgenus", "TEST", 60, 70], ["hydropathy plots", "TEST", 155, 171], ["seven hypervariable regions", "PROBLEM", 202, 229], ["the hypervariable regions manifest hydrophilicity", "PROBLEM", 265, 314], ["hydropathy plots", "OBSERVATION", 155, 171], ["seven", "OBSERVATION_MODIFIER", 202, 207], ["hypervariable", "OBSERVATION_MODIFIER", 208, 221], ["regions", "OBSERVATION_MODIFIER", 222, 229], ["major", "OBSERVATION_MODIFIER", 248, 253], ["hypervariable", "OBSERVATION_MODIFIER", 269, 282], ["hydrophilicity", "OBSERVATION_MODIFIER", 300, 314]]], ["According to the ribbon representation of the Ad2 hexon subunit [3] , the major portion of the hydrophilic regions in hypervariable areas was located at the surface of the hexon molecule.Comparison of hydropathy plots demonstrates the existence of seven hypervariable regionsCodons with cytidine in the third position are highly preferred Analysis of codon usage for the 14 serotypes showed that among the synonymous codons those with cytidine in the third position (NNC) were highly preferred (Table 1) .", [["surface", "ANATOMY", 157, 164], ["cytidine", "CHEMICAL", 287, 295], ["cytidine", "CHEMICAL", 435, 443], ["cytidine", "CHEMICAL", 287, 295], ["cytidine", "CHEMICAL", 435, 443], ["surface", "CELLULAR_COMPONENT", 157, 164], ["cytidine", "SIMPLE_CHEMICAL", 287, 295], ["cytidine", "SIMPLE_CHEMICAL", 435, 443], ["Ad2 hexon subunit", "PROTEIN", 46, 63], ["hydrophilic regions", "PROTEIN", 95, 114], ["hexon molecule", "PROTEIN", 172, 186], ["hypervariable regions", "DNA", 254, 275], ["the Ad2 hexon subunit", "TREATMENT", 42, 63], ["hypervariable areas", "PROBLEM", 118, 137], ["hydropathy plots", "TEST", 201, 217], ["seven hypervariable regions", "PROBLEM", 248, 275], ["Codons with cytidine", "TREATMENT", 275, 295], ["codon usage", "TREATMENT", 351, 362], ["the 14 serotypes", "PROBLEM", 367, 383], ["the synonymous codons", "TREATMENT", 402, 423], ["cytidine", "TREATMENT", 435, 443], ["major", "OBSERVATION_MODIFIER", 74, 79], ["portion", "OBSERVATION_MODIFIER", 80, 87], ["hydrophilic", "OBSERVATION_MODIFIER", 95, 106], ["hypervariable", "OBSERVATION_MODIFIER", 118, 131], ["areas", "OBSERVATION_MODIFIER", 132, 137], ["surface", "ANATOMY_MODIFIER", 157, 164], ["hexon molecule", "OBSERVATION", 172, 186], ["hydropathy plots", "OBSERVATION", 201, 217], ["seven", "OBSERVATION_MODIFIER", 248, 253], ["hypervariable", "OBSERVATION_MODIFIER", 254, 267], ["regions", "OBSERVATION_MODIFIER", 268, 275], ["synonymous codons", "OBSERVATION", 406, 423]]], ["Among CPUSs the bias for NNC codons was strong.", [["CPUSs", "CANCER", 6, 11], ["NNC", "GENE_OR_GENE_PRODUCT", 25, 28], ["NNC codons", "DNA", 25, 35]]], ["However, although the codon preference for NNC among CPYSs was generally manifest, this was not the case for the NNC codons for the hydrophobic amino acids Ile, Leu and Val.Hexon surface chargeThe isoelectric point and the surface charge for hexons of the 14 serotypes were deduced with the program LaserGene-Protean-Composition (Table 2) .", [["surface", "ANATOMY", 179, 186], ["surface", "ANATOMY", 223, 230], ["amino acids Ile", "CHEMICAL", 144, 159], ["Leu", "CHEMICAL", 161, 164], ["amino acids", "CHEMICAL", 144, 155], ["Ile", "CHEMICAL", 156, 159], ["Leu", "CHEMICAL", 161, 164], ["Val", "CHEMICAL", 169, 172], ["NNC", "GENE_OR_GENE_PRODUCT", 43, 46], ["CPYSs", "GENE_OR_GENE_PRODUCT", 53, 58], ["NNC", "GENE_OR_GENE_PRODUCT", 113, 116], ["amino acids", "AMINO_ACID", 144, 155], ["Ile", "AMINO_ACID", 156, 159], ["Leu", "AMINO_ACID", 161, 164], ["Val", "AMINO_ACID", 169, 172], ["NNC", "PROTEIN", 43, 46], ["CPYSs", "DNA", 53, 58], ["NNC codons", "DNA", 113, 123], ["the NNC codons", "TREATMENT", 109, 123], ["the hydrophobic amino acids Ile", "TREATMENT", 128, 159], ["Hexon surface charge", "TREATMENT", 173, 193], ["The isoelectric point", "PROBLEM", 193, 214], ["the surface charge", "TREATMENT", 219, 237], ["hexons of the 14 serotypes", "TREATMENT", 242, 268], ["surface", "OBSERVATION_MODIFIER", 223, 230]]], ["At pH 7, the charges of the hexon proteins from different subgenera varied widely.", [["hexon proteins", "PROTEIN", 28, 42], ["pH", "TEST", 3, 5], ["the hexon proteins", "TEST", 24, 42], ["subgenera varied", "OBSERVATION", 58, 74]]], ["The hexons of Ad2 and Ad5 belonging to subgenus C carried the highest negative charge, \u00c026X73 and \u00c022X57, respectively.", [["hexons", "GENE_OR_GENE_PRODUCT", 4, 10], ["Ad2", "GENE_OR_GENE_PRODUCT", 14, 17], ["Ad5", "GENE_OR_GENE_PRODUCT", 22, 25], ["The hexons of Ad2", "TREATMENT", 0, 17]]], ["These charges were about 2.5 times greater than those of hexons of subgenus F, Bav3, Mav1 and Fav10.", [["subgenus F", "GENE_OR_GENE_PRODUCT", 67, 77], ["Bav3", "GENE_OR_GENE_PRODUCT", 79, 83], ["Mav1", "GENE_OR_GENE_PRODUCT", 85, 89], ["Fav10", "GENE_OR_GENE_PRODUCT", 94, 99], ["hexons", "PROTEIN", 57, 63], ["Bav3", "PROTEIN", 79, 83], ["Mav1", "PROTEIN", 85, 89], ["Fav10", "PROTEIN", 94, 99], ["subgenus F", "TEST", 67, 77], ["Fav10", "TEST", 94, 99]]], ["More interestingly, the strength of the accumulated charge of hydrophilic or hydrophobic regions correlated with tissue tropism.", [["tissue", "ANATOMY", 113, 119], ["tissue", "TISSUE", 113, 119], ["hydrophilic or hydrophobic regions", "PROTEIN", 62, 96], ["hydrophilic or hydrophobic regions", "PROBLEM", 62, 96], ["tissue tropism", "PROBLEM", 113, 127], ["hydrophilic", "OBSERVATION_MODIFIER", 62, 73], ["hydrophobic regions", "OBSERVATION", 77, 96], ["tissue tropism", "OBSERVATION", 113, 127]]], ["The prototypes of Ad3, Ad7, Ad2 and Ad5 were isolated from respiratory tract specimens.", [["respiratory tract specimens", "ANATOMY", 59, 86], ["Ad3", "GENE_OR_GENE_PRODUCT", 18, 21], ["Ad7", "GENE_OR_GENE_PRODUCT", 23, 26], ["Ad2", "GENE_OR_GENE_PRODUCT", 28, 31], ["Ad5", "GENE_OR_GENE_PRODUCT", 36, 39], ["respiratory tract specimens", "CANCER", 59, 86], ["Ad3", "PROTEIN", 18, 21], ["Ad7", "PROTEIN", 23, 26], ["Ad5", "SPECIES", 36, 39], ["Ad5", "TREATMENT", 36, 39], ["respiratory tract specimens", "TEST", 59, 86], ["respiratory tract", "ANATOMY", 59, 76]]], ["The prototype of Ad3 was isolated from nasal washing, Ad7 from throat washing, and both Ad2 and Ad5 from adenoid tissue cultures [6] .", [["nasal", "ANATOMY", 39, 44], ["throat", "ANATOMY", 63, 69], ["adenoid tissue cultures", "ANATOMY", 105, 128], ["Ad3", "CHEMICAL", 17, 20], ["Ad3", "GENE_OR_GENE_PRODUCT", 17, 20], ["nasal", "ORGANISM_SUBDIVISION", 39, 44], ["throat", "ORGANISM_SUBDIVISION", 63, 69], ["Ad2", "GENE_OR_GENE_PRODUCT", 88, 91], ["Ad5", "ORGANISM", 96, 99], ["adenoid tissue", "CELL", 105, 119], ["Ad3", "PROTEIN", 17, 20], ["Ad5", "SPECIES", 96, 99], ["nasal washing", "TREATMENT", 39, 52], ["throat washing", "TREATMENT", 63, 77], ["adenoid tissue cultures", "TEST", 105, 128]]], ["These adenoviruses were frequently isolated from patients with respiratory diseases [26] .", [["respiratory", "ANATOMY", 63, 74], ["respiratory diseases", "DISEASE", 63, 83], ["adenoviruses", "ORGANISM", 6, 18], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["These adenoviruses", "PROBLEM", 0, 18], ["respiratory diseases", "PROBLEM", 63, 83]]], ["The hexons of these four serotypes were characterised by strong accumulated charges of \u00c012X3 to \u00c020X97 in hydrophilic regions, but manifestly weaker charges of only \u00c03X62 to \u00c05X85 in hydrophobic regions.", [["\u00c05X85", "CHEMICAL", 174, 179], ["\u00c012X3", "CHEMICAL", 87, 92], ["\u00c020X97", "CHEMICAL", 96, 102], ["\u00c03X62", "CHEMICAL", 165, 170], ["\u00c05X85", "CHEMICAL", 174, 179], ["\u00c012X3", "SIMPLE_CHEMICAL", 87, 92], ["\u00c020X97", "PROTEIN", 96, 102], ["\u00c03X62", "PROTEIN", 165, 170], ["\u00c05X85", "PROTEIN", 174, 179], ["hydrophobic regions", "PROTEIN", 183, 202], ["strong", "OBSERVATION_MODIFIER", 57, 63], ["accumulated", "OBSERVATION_MODIFIER", 64, 75], ["charges", "OBSERVATION_MODIFIER", 76, 83], ["hydrophilic", "ANATOMY_MODIFIER", 106, 117], ["regions", "ANATOMY_MODIFIER", 118, 125], ["weaker", "OBSERVATION_MODIFIER", 142, 148], ["charges", "OBSERVATION_MODIFIER", 149, 156]]], ["The prototypes of Ad16 and Bav3 were isolated from conjunctival scrapings and conjunctiva, respectively [6] , the hydrophobic regions of their hexons manifest charges of \u00c011X62 and \u00c010X51.", [["conjunctival scrapings", "ANATOMY", 51, 73], ["conjunctiva", "ANATOMY", 78, 89], ["\u00c011X62", "CHEMICAL", 170, 176], ["\u00c010X51", "CHEMICAL", 181, 187], ["Ad16", "GENE_OR_GENE_PRODUCT", 18, 22], ["Bav3", "GENE_OR_GENE_PRODUCT", 27, 31], ["conjunctival scrapings", "MULTI-TISSUE_STRUCTURE", 51, 73], ["conjunctiva", "ORGAN", 78, 89], ["Ad16", "PROTEIN", 18, 22], ["Bav3", "PROTEIN", 27, 31], ["\u00c011X62", "PROTEIN", 170, 176], ["\u00c010X51", "PROTEIN", 181, 187], ["Ad16", "TEST", 18, 22], ["Bav3", "TEST", 27, 31], ["conjunctival scrapings", "TEST", 51, 73], ["conjunctival scrapings", "OBSERVATION", 51, 73], ["conjunctiva", "ANATOMY", 78, 89]]], ["Ad4 can be isolated both from the eye and the respiratory tract [16] .", [["eye", "ANATOMY", 34, 37], ["respiratory tract", "ANATOMY", 46, 63], ["Ad4", "GENE_OR_GENE_PRODUCT", 0, 3], ["eye", "ORGAN", 34, 37], ["Ad4", "PROTEIN", 0, 3], ["eye", "ANATOMY", 34, 37], ["respiratory tract", "ANATOMY", 46, 63]]], ["The negative charges of the hydrophilic and the hydrophobic regions of the Ad4 hexon were similar, \u00c08X16 and \u00c09X48, respectively.", [["Ad4 hexon", "GENE_OR_GENE_PRODUCT", 75, 84], ["hydrophobic regions", "PROTEIN", 48, 67], ["Ad4 hexon", "PROTEIN", 75, 84], ["\u00c08X16", "PROTEIN", 99, 104], ["\u00c09X48", "PROTEIN", 109, 114], ["the Ad4 hexon", "TEST", 71, 84], ["negative", "OBSERVATION_MODIFIER", 4, 12], ["charges", "OBSERVATION_MODIFIER", 13, 20], ["hydrophilic", "OBSERVATION_MODIFIER", 28, 39], ["hydrophobic", "ANATOMY_MODIFIER", 48, 59]]], ["The prototypes of Ad12, Ad40, Ad41 and Fav10 were isolated from faeces or rectal swabs [6, 8, 32] .", [["faeces", "ANATOMY", 64, 70], ["rectal swabs", "ANATOMY", 74, 86], ["Ad12", "GENE_OR_GENE_PRODUCT", 18, 22], ["Ad40", "GENE_OR_GENE_PRODUCT", 24, 28], ["Ad41", "GENE_OR_GENE_PRODUCT", 30, 34], ["Fav10", "GENE_OR_GENE_PRODUCT", 39, 44], ["faeces", "ORGANISM_SUBSTANCE", 64, 70], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 74, 86], ["Ad12", "DNA", 18, 22], ["Ad40", "PROTEIN", 24, 28], ["Ad41", "PROTEIN", 30, 34], ["Fav10", "PROTEIN", 39, 44], ["Ad12", "SPECIES", 18, 22], ["Ad12", "TEST", 18, 22], ["Ad40", "TEST", 24, 28], ["Ad41", "TEST", 30, 34], ["Fav10", "TEST", 39, 44], ["rectal swabs", "TEST", 74, 86], ["rectal", "ANATOMY", 74, 80]]], ["All four of these enteric adenoviruses were characterised by lower negative charges of \u00c03X81 to \u00c07X78 in both hydrophilic and hydrophobic regions of their hexons.", [["\u00c07X78", "CHEMICAL", 96, 101], ["adenoviruses", "ORGANISM", 26, 38], ["\u00c03X81", "GENE_OR_GENE_PRODUCT", 87, 92], ["\u00c03X81", "PROTEIN", 87, 92], ["\u00c07X78", "PROTEIN", 96, 101], ["hydrophilic and hydrophobic regions", "PROTEIN", 110, 145], ["hexons", "PROTEIN", 155, 161], ["these enteric adenoviruses", "PROBLEM", 12, 38], ["four", "OBSERVATION_MODIFIER", 4, 8], ["enteric", "ANATOMY", 18, 25], ["adenoviruses", "OBSERVATION", 26, 38], ["lower", "OBSERVATION_MODIFIER", 61, 66], ["negative", "OBSERVATION", 67, 75], ["hydrophilic", "OBSERVATION_MODIFIER", 110, 121], ["hydrophobic", "OBSERVATION_MODIFIER", 126, 137]]], ["Mav1 isolated from spleen and Fav1 isolated from allantois [6] manifested individually unique patterns of surface charge.DiscussionThe hydropathic type and value of an amino acid is dependent on its codon usage and its position in a protein structure.DiscussionScales for evaluating the hydropathic characteristics of amino acids have been developed by many different research groups.", [["spleen", "ANATOMY", 19, 25], ["surface", "ANATOMY", 106, 113], ["Mav1", "CHEMICAL", 0, 4], ["amino acid", "CHEMICAL", 168, 178], ["amino acids", "CHEMICAL", 318, 329], ["amino acid", "CHEMICAL", 168, 178], ["amino acids", "CHEMICAL", 318, 329], ["Mav1", "GENE_OR_GENE_PRODUCT", 0, 4], ["spleen", "ORGAN", 19, 25], ["Fav1", "GENE_OR_GENE_PRODUCT", 30, 34], ["amino acid", "AMINO_ACID", 168, 178], ["amino acids", "AMINO_ACID", 318, 329], ["Mav1", "PROTEIN", 0, 4], ["protein structure", "PROTEIN", 233, 250], ["Mav1", "TEST", 0, 4], ["an amino acid", "TEST", 165, 178], ["amino acids", "PROBLEM", 318, 329], ["spleen", "ANATOMY", 19, 25], ["surface charge", "OBSERVATION", 106, 120]]], ["However, the hydrophilicity and hydrophobicity values obtained differ substantially [10, 11, 15] .", [["the hydrophilicity and hydrophobicity values", "TEST", 9, 53], ["hydrophilicity", "OBSERVATION_MODIFIER", 13, 27], ["hydrophobicity", "OBSERVATION_MODIFIER", 32, 46]]], ["The most frequently used scales, introduced by Kyte and Doolittle were used in the present study.", [["the present study", "TEST", 79, 96]]], ["As ranked on hydropathy scales [15] , the 20 common amino acids can be divided into three different classes.", [["amino acids", "CHEMICAL", 52, 63], ["amino acids", "CHEMICAL", 52, 63], ["amino acids", "AMINO_ACID", 52, 63], ["hydropathy scales", "TEST", 13, 30], ["the 20 common amino acids", "TREATMENT", 38, 63]]], ["The \u00aerst is the hydrophobic class including Ile, Val, Leu, Phe and Cys.", [["Ile, Val, Leu, Phe", "CHEMICAL", 44, 62], ["Ile", "CHEMICAL", 44, 47], ["Val", "CHEMICAL", 49, 52], ["Leu", "CHEMICAL", 54, 57], ["Phe", "CHEMICAL", 59, 62], ["Cys", "CHEMICAL", 67, 70], ["Ile", "AMINO_ACID", 44, 47], ["Leu", "AMINO_ACID", 54, 57], ["Phe", "AMINO_ACID", 59, 62], ["Cys", "AMINO_ACID", 67, 70], ["Leu", "ANATOMY_MODIFIER", 54, 57]]], ["Of these \u00aeve amino acids, only Cys is encoded by CPUSs, the other four being encoded by CPYSs.", [["amino acids", "CHEMICAL", 13, 24], ["Cys", "CHEMICAL", 31, 34], ["amino acids", "CHEMICAL", 13, 24], ["Cys", "CHEMICAL", 31, 34], ["\u00aeve", "SIMPLE_CHEMICAL", 9, 12], ["amino acids", "AMINO_ACID", 13, 24], ["Cys", "AMINO_ACID", 31, 34], ["CPUSs", "GENE_OR_GENE_PRODUCT", 49, 54], ["CPYSs", "GENE_OR_GENE_PRODUCT", 88, 93], ["CPUSs", "PROTEIN", 49, 54], ["CPYSs", "PROTEIN", 88, 93], ["these \u00aeve amino acids", "TREATMENT", 3, 24]]], ["The second is the hydrophilic class consisting of His, Glu, Gln, Asp, Asn, Lys and Arg, all of In general, a A G-rich region (A, adenosine; G, guanine) in a nucleotide sequence contains more CPUS codons, and C T-rich region contains more CPYS codons.", [["Glu", "CHEMICAL", 55, 58], ["Gln, Asp, Asn, Lys", "CHEMICAL", 60, 78], ["adenosine", "CHEMICAL", 129, 138], ["guanine", "CHEMICAL", 143, 150], ["nucleotide", "CHEMICAL", 157, 167], ["His", "CHEMICAL", 50, 53], ["Glu", "CHEMICAL", 55, 58], ["Gln", "CHEMICAL", 60, 63], ["Asp", "CHEMICAL", 65, 68], ["Asn", "CHEMICAL", 70, 73], ["Lys", "CHEMICAL", 75, 78], ["Arg", "CHEMICAL", 83, 86], ["adenosine", "CHEMICAL", 129, 138], ["guanine", "CHEMICAL", 143, 150], ["nucleotide", "CHEMICAL", 157, 167], ["His", "GENE_OR_GENE_PRODUCT", 50, 53], ["Glu", "AMINO_ACID", 55, 58], ["Gln", "AMINO_ACID", 60, 63], ["Asp", "AMINO_ACID", 65, 68], ["Asn", "AMINO_ACID", 70, 73], ["Lys", "AMINO_ACID", 75, 78], ["Arg", "AMINO_ACID", 83, 86], ["adenosine; G, guanine", "SIMPLE_CHEMICAL", 129, 150], ["CPUS", "GENE_OR_GENE_PRODUCT", 191, 195], ["CPYS", "GENE_OR_GENE_PRODUCT", 238, 242], ["CPUS codons", "DNA", 191, 202], ["C T-rich region", "PROTEIN", 208, 223], ["CPYS codons", "DNA", 238, 249], ["Glu", "TEST", 55, 58], ["Gln", "TEST", 60, 63], ["Asp", "TEST", 65, 68], ["Asn", "TEST", 70, 73], ["Lys", "TEST", 75, 78], ["Arg", "TEST", 83, 86], ["adenosine", "TREATMENT", 129, 138], ["a nucleotide sequence", "TEST", 155, 176], ["more CPUS codons", "PROBLEM", 186, 202], ["C T-rich region", "PROBLEM", 208, 223], ["hydrophilic class", "OBSERVATION_MODIFIER", 18, 35], ["CPUS codons", "OBSERVATION", 191, 202], ["CPYS codons", "OBSERVATION", 238, 249]]], ["Therefore, the part of a protein, which is encoded by A G-rich region usually manifests hydrophilicity and a C T-rich region encoded peptide usually shows hydrophobic characteristics.DiscussionThe hydropathy value of an amino acid in a protein chain is dependent on the protein conformation.", [["amino acid", "CHEMICAL", 220, 230], ["amino acid", "CHEMICAL", 220, 230], ["amino acid", "AMINO_ACID", 220, 230], ["A G-rich region", "PROTEIN", 54, 69], ["C T-rich region", "PROTEIN", 109, 124], ["protein chain", "PROTEIN", 236, 249], ["a protein", "TEST", 23, 32], ["hydrophilicity", "PROBLEM", 88, 102], ["a C T-rich region", "PROBLEM", 107, 124], ["The hydropathy value", "TEST", 193, 213], ["an amino acid", "TEST", 217, 230], ["a protein chain", "TREATMENT", 234, 249], ["hydrophobic characteristics", "OBSERVATION", 155, 182]]], ["The residue side-chains can protrude at the interior or exterior portion of a protein chain.", [["protein chain", "PROTEIN", 78, 91], ["interior", "ANATOMY_MODIFIER", 44, 52], ["exterior", "ANATOMY_MODIFIER", 56, 64], ["portion", "ANATOMY_MODIFIER", 65, 72], ["protein chain", "OBSERVATION", 78, 91]]], ["The hydropathy value of an amino acid was determined by averaging over a window which contains several consecutive residues surrounding the amino acid in question [15] .", [["amino acid", "CHEMICAL", 27, 37], ["amino acid", "CHEMICAL", 140, 150], ["amino acid", "CHEMICAL", 27, 37], ["amino acid", "CHEMICAL", 140, 150], ["amino acid", "AMINO_ACID", 27, 37], ["amino acid", "AMINO_ACID", 140, 150], ["The hydropathy value", "TEST", 0, 20], ["an amino acid", "TEST", 24, 37], ["several consecutive residues", "TREATMENT", 95, 123], ["the amino acid", "TREATMENT", 136, 150], ["hydropathy", "OBSERVATION", 4, 14]]], ["Therefore, the strength and even the type of the hydropathy of an individual amino acid may vary according to its location within a peptide chain.", [["amino acid", "CHEMICAL", 77, 87], ["amino acid", "CHEMICAL", 77, 87], ["amino acid", "AMINO_ACID", 77, 87], ["the hydropathy", "PROBLEM", 45, 59], ["an individual amino acid", "TREATMENT", 63, 87], ["hydropathy", "OBSERVATION", 49, 59]]], ["In particular, the hydropathy of the amino acids in the intermediate class was found to vary more frequently and in a more pronounced way ( Table 1) .DiscussionThe major portion of hydrophobic sequences in a protein will be found in the interior of the native structure, and the major portion of hydrophilic sequences will be found on the exterior [15] .", [["amino acids", "CHEMICAL", 37, 48], ["amino acids", "CHEMICAL", 37, 48], ["amino acids", "AMINO_ACID", 37, 48], ["hydrophobic sequences", "PROTEIN", 181, 202], ["the amino acids", "TEST", 33, 48], ["hydrophobic sequences", "TEST", 181, 202], ["a protein", "TEST", 206, 215], ["hydropathy", "OBSERVATION", 19, 29], ["interior", "ANATOMY_MODIFIER", 237, 245], ["native structure", "OBSERVATION", 253, 269]]], ["Branden and Tooze [5] found that the hydropathy plots (Kyte-Doolittle method) agree with the crystal structure data in a polypeptide of R. Sphaeroides.", [["R. Sphaeroides", "ORGANISM", 136, 150], ["R. Sphaeroides", "SPECIES", 136, 150], ["R. Sphaeroides", "SPECIES", 136, 150], ["the hydropathy plots", "PROBLEM", 33, 53], ["Kyte-Doolittle method", "TREATMENT", 55, 76], ["a polypeptide of R. Sphaeroides", "TREATMENT", 119, 150]]], ["In this study, we found the major portion of the hypervariable areas to manifest hydrophilicity.", [["this study", "TEST", 3, 13], ["hydrophilicity", "PROBLEM", 81, 95], ["hypervariable", "OBSERVATION_MODIFIER", 49, 62], ["hydrophilicity", "OBSERVATION_MODIFIER", 81, 95]]], ["The major portion of the hydrophilic regions in hypervariable areas is located at the surface of the crystal structure of the hexon.DiscussionThe NNC codons in adenovirus hexons manifested high usage.", [["surface", "CELLULAR_COMPONENT", 86, 93], ["hexon", "CELLULAR_COMPONENT", 126, 131], ["NNC", "GENE_OR_GENE_PRODUCT", 146, 149], ["adenovirus", "ORGANISM", 160, 170], ["hydrophilic regions", "PROTEIN", 25, 44], ["hexon", "PROTEIN", 126, 131], ["NNC codons", "DNA", 146, 156], ["The NNC codons", "TREATMENT", 142, 156], ["adenovirus hexons", "TREATMENT", 160, 177], ["major", "OBSERVATION_MODIFIER", 4, 9], ["portion", "OBSERVATION_MODIFIER", 10, 17], ["hydrophilic", "OBSERVATION_MODIFIER", 25, 36], ["hypervariable", "OBSERVATION_MODIFIER", 48, 61], ["areas", "OBSERVATION_MODIFIER", 62, 67], ["surface", "OBSERVATION_MODIFIER", 86, 93], ["crystal structure", "OBSERVATION", 101, 118], ["hexon", "ANATOMY", 126, 131]]], ["The result is compatible with that derived from analysis of 28 different genes of Ad2 (except the Phe) [33] .", [["Phe", "CHEMICAL", 98, 101], ["Ad2", "GENE_OR_GENE_PRODUCT", 82, 85], ["Ad2", "DNA", 82, 85], ["analysis", "TEST", 48, 56], ["compatible with", "UNCERTAINTY", 14, 29]]], ["Preference for the synonymous codon for Phe, UUC was greater than UUU in 14 hexon genes (Table 1) .", [["Phe", "CHEMICAL", 40, 43], ["Phe", "CHEMICAL", 40, 43], ["Phe", "AMINO_ACID", 40, 43], ["UUU", "PROTEIN", 66, 69], ["hexon genes", "DNA", 76, 87], ["the synonymous codon", "TREATMENT", 15, 35]]], ["However, the reverse result was true of 28 different Ad2 genes, UUC accounting for 1.44% and UUU was 2.07%.", [["Ad2", "GENE_OR_GENE_PRODUCT", 53, 56], ["Ad2 genes", "DNA", 53, 62], ["UUC", "DNA", 64, 67], ["UUU", "TEST", 93, 96]]], ["Phe with its aromatic side chain is highly hydrophobic, nonpolar and chemically stable.", [["Phe", "CHEMICAL", 0, 3], ["Phe", "CHEMICAL", 0, 3], ["Phe", "AMINO_ACID", 0, 3], ["aromatic", "OBSERVATION_MODIFIER", 13, 21], ["highly", "OBSERVATION_MODIFIER", 36, 42], ["hydrophobic", "OBSERVATION_MODIFIER", 43, 54], ["chemically", "OBSERVATION_MODIFIER", 69, 79], ["stable", "OBSERVATION_MODIFIER", 80, 86]]], ["The variability of the Phe residue is one of the lowest during divergence of homologous proteins [10] .", [["Phe", "CHEMICAL", 23, 26], ["Phe", "CHEMICAL", 23, 26], ["Phe", "AMINO_ACID", 23, 26], ["homologous proteins", "PROTEIN", 77, 96], ["the Phe residue", "PROBLEM", 19, 34], ["homologous proteins", "TREATMENT", 77, 96], ["variability", "OBSERVATION_MODIFIER", 4, 15], ["Phe residue", "OBSERVATION", 23, 34]]], ["The patterns of codon usage for Phe in hexon genes were shown to be subgenus speci\u00aec ( Table 4 ).", [["Phe", "CHEMICAL", 32, 35], ["Phe", "CHEMICAL", 32, 35], ["Phe", "AMINO_ACID", 32, 35], ["hexon genes", "DNA", 39, 50], ["codon usage", "TREATMENT", 16, 27], ["Phe in hexon genes", "PROBLEM", 32, 50], ["codon usage", "OBSERVATION", 16, 27]]], ["The codon usage for Phe in the hexon genes of the species of each subgenus is highly similar within subgenera B, C and F. The codon preferably used for Phe in hexon genes of members of subgenera A, C and F is UUU, whereas, UUC is preferably used in hexon genes of the species of subgenera B, D and E. These \u00aendings corroborate the relatedness of the VA RNA 1 genes [13] , and also the relatedness of the hexon genes of human adenoviruses [4] .DiscussionWe found the NNC codons in adenovirus hexon genes to be highly preferred.", [["Phe", "CHEMICAL", 20, 23], ["Phe", "CHEMICAL", 152, 155], ["Phe", "CHEMICAL", 20, 23], ["Phe", "CHEMICAL", 152, 155], ["Phe", "AMINO_ACID", 20, 23], ["B", "GENE_OR_GENE_PRODUCT", 110, 111], ["Phe", "AMINO_ACID", 152, 155], ["B", "GENE_OR_GENE_PRODUCT", 289, 290], ["D", "GENE_OR_GENE_PRODUCT", 292, 293], ["VA RNA 1", "GENE_OR_GENE_PRODUCT", 350, 358], ["human", "ORGANISM", 419, 424], ["adenoviruses", "ORGANISM", 425, 437], ["adenovirus", "ORGANISM", 480, 490], ["hexon genes", "DNA", 31, 42], ["hexon genes", "DNA", 159, 170], ["UUC", "DNA", 223, 226], ["hexon genes", "DNA", 249, 260], ["VA RNA 1 genes", "DNA", 350, 364], ["hexon genes", "DNA", 404, 415], ["NNC codons", "DNA", 466, 476], ["adenovirus hexon genes", "DNA", 480, 502], ["human", "SPECIES", 419, 424], ["human", "SPECIES", 419, 424], ["The codon usage", "TREATMENT", 0, 15], ["Phe", "PROBLEM", 20, 23], ["The codon", "TREATMENT", 122, 131], ["human adenoviruses", "PROBLEM", 419, 437], ["the NNC codons", "TREATMENT", 462, 476], ["adenovirus hexon genes", "TREATMENT", 480, 502], ["NNC codons", "OBSERVATION", 466, 476]]], ["Analysis of the data obtained from GenBank [33] The C G content of different organisms is used as one of the criteria in taxonomy.", [["C G", "SIMPLE_CHEMICAL", 52, 55], ["the data", "TEST", 12, 20], ["The C G content", "TREATMENT", 48, 63], ["different organisms", "PROBLEM", 67, 86]]], ["Among various eubacteria the C G content of the genome DNA ranges from 25% to 75% [20] .", [["C G", "GENE_OR_GENE_PRODUCT", 29, 32], ["DNA", "CELLULAR_COMPONENT", 55, 58], ["genome DNA", "DNA", 48, 58], ["the genome DNA", "TEST", 44, 58], ["eubacteria", "OBSERVATION_MODIFIER", 14, 24], ["C G content", "OBSERVATION_MODIFIER", 29, 40]]], ["In Adenoviridae the DNA C G content varies from 48\u00b161% for mastadenoviruses and 54\u00b155% for aviadenoviruses [24] .", [["mastadenoviruses", "DISEASE", 59, 75], ["DNA", "CELLULAR_COMPONENT", 20, 23], ["C G", "GENE_OR_GENE_PRODUCT", 24, 27], ["mastadenoviruses", "CANCER", 59, 75], ["the DNA C G content", "TEST", 16, 35], ["mastadenoviruses", "TEST", 59, 75], ["aviadenoviruses", "TEST", 91, 106]]], ["In the six different subgenera of human adenoviruses the C G content of genome DNA ranges from 48% to 58% [35] .", [["human", "ORGANISM", 34, 39], ["adenoviruses", "ORGANISM", 40, 52], ["C G", "GENE_OR_GENE_PRODUCT", 57, 60], ["DNA", "CELLULAR_COMPONENT", 79, 82], ["genome DNA", "DNA", 72, 82], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 34, 39], ["human adenoviruses", "TREATMENT", 34, 52], ["genome DNA", "TEST", 72, 82], ["human adenoviruses", "OBSERVATION", 34, 52]]], ["The C G content of all 14 serotypes reveals the existence of two groups: higher C G content (54.59\u00b158.23%) group including Ad48, Ad4, Bav3, Fav1 and Fav10, and lower C G content (47.48\u00b150.78%) group including the remaining nine serotypes ( Table 2 ).", [["C G", "SIMPLE_CHEMICAL", 4, 7], ["C G", "SIMPLE_CHEMICAL", 80, 83], ["Ad48", "GENE_OR_GENE_PRODUCT", 123, 127], ["Ad4", "GENE_OR_GENE_PRODUCT", 129, 132], ["Bav3", "GENE_OR_GENE_PRODUCT", 134, 138], ["Fav1", "GENE_OR_GENE_PRODUCT", 140, 144], ["Fav10", "GENE_OR_GENE_PRODUCT", 149, 154], ["C G", "GENE_OR_GENE_PRODUCT", 166, 169], ["Ad48", "PROTEIN", 123, 127], ["Ad4", "PROTEIN", 129, 132], ["Bav3", "PROTEIN", 134, 138], ["Fav1", "PROTEIN", 140, 144], ["Fav10", "PROTEIN", 149, 154], ["C G", "PROTEIN", 166, 169], ["The C G content", "TEST", 0, 15], ["higher C G content", "PROBLEM", 73, 91], ["Ad48", "TEST", 123, 127], ["Ad4", "TEST", 129, 132], ["Bav3", "TEST", 134, 138], ["Fav1", "TEST", 140, 144], ["Fav10", "TEST", 149, 154], ["lower C G content", "PROBLEM", 160, 177], ["lower", "OBSERVATION_MODIFIER", 160, 165]]], ["The C G content of human adenovirus hexons was consistent with the level of C G content of whole adenovirus genome DNA with the exception of subgenus C, Ad2 and Ad5, which has higher C G content (58%) in genome DNA.DiscussionThere are 15 amino acids encoded by synonymous codons which contain NNC (Table 5 ).", [["amino acids", "CHEMICAL", 238, 249], ["amino acids", "CHEMICAL", 238, 249], ["C G", "GENE_OR_GENE_PRODUCT", 4, 7], ["human", "ORGANISM", 19, 24], ["adenovirus hexons", "ORGANISM", 25, 42], ["C G", "GENE_OR_GENE_PRODUCT", 76, 79], ["adenovirus", "ORGANISM", 97, 107], ["DNA", "CELLULAR_COMPONENT", 115, 118], ["C", "GENE_OR_GENE_PRODUCT", 150, 151], ["Ad2", "GENE_OR_GENE_PRODUCT", 153, 156], ["Ad5", "GENE_OR_GENE_PRODUCT", 161, 164], ["C G", "GENE_OR_GENE_PRODUCT", 183, 186], ["DNA", "CELLULAR_COMPONENT", 211, 214], ["amino acids", "AMINO_ACID", 238, 249], ["adenovirus genome DNA", "DNA", 97, 118], ["genome DNA", "DNA", 204, 214], ["NNC", "PROTEIN", 293, 296], ["human", "SPECIES", 19, 24], ["human adenovirus", "SPECIES", 19, 35], ["Ad5", "SPECIES", 161, 164], ["The C G content of human adenovirus hexons", "TREATMENT", 0, 42], ["C G content", "TREATMENT", 76, 87], ["whole adenovirus genome DNA", "PROBLEM", 91, 118], ["subgenus C, Ad2 and Ad5", "PROBLEM", 141, 164], ["higher C G content", "PROBLEM", 176, 194], ["genome DNA", "PROBLEM", 204, 214], ["15 amino acids", "TREATMENT", 235, 249], ["synonymous codons", "TREATMENT", 261, 278], ["C G content", "OBSERVATION_MODIFIER", 4, 15], ["G content", "OBSERVATION_MODIFIER", 185, 194], ["genome DNA", "OBSERVATION", 204, 214], ["synonymous codons", "OBSERVATION", 261, 278]]], ["Of these 15 amino acids, nine manifested NNC high usage, and three (Asp, Ile and Pro) showed at same level of NNC usage, whereas only three (Cys, Leu and Val) showed low NNC usage.", [["amino acids", "CHEMICAL", 12, 23], ["NNC", "CHEMICAL", 170, 173], ["amino acids", "CHEMICAL", 12, 23], ["Asp", "CHEMICAL", 68, 71], ["Ile", "CHEMICAL", 73, 76], ["Pro", "CHEMICAL", 81, 84], ["Cys", "CHEMICAL", 141, 144], ["Leu", "CHEMICAL", 146, 149], ["Val", "CHEMICAL", 154, 157], ["amino acids", "AMINO_ACID", 12, 23], ["NNC", "SIMPLE_CHEMICAL", 110, 113], ["NNC", "SIMPLE_CHEMICAL", 170, 173], ["NNC", "PROTEIN", 110, 113], ["NNC", "PROTEIN", 170, 173], ["these 15 amino acids", "TREATMENT", 3, 23], ["Asp, Ile and Pro", "TREATMENT", 68, 84], ["Leu", "TEST", 146, 149], ["low NNC usage", "PROBLEM", 166, 179], ["low NNC", "OBSERVATION", 166, 173]]], ["Cys is a rare amino UUC 12 30 28 30 20 19 38 36 21 17 18 5 31 40 UUU 37 17 20 19 25 28 13 11 29 30 29 46 15 9 acid and only four cysteines in Ad7 hexon.", [["Cys", "CHEMICAL", 0, 3], ["amino UUC", "CHEMICAL", 14, 23], ["29 46 15 9 acid", "CHEMICAL", 99, 114], ["Cys", "CHEMICAL", 0, 3], ["amino UUC", "CHEMICAL", 14, 23], ["cysteines", "CHEMICAL", 129, 138], ["Cys", "AMINO_ACID", 0, 3], ["Ad7 hexon", "GENE_OR_GENE_PRODUCT", 142, 151], ["Ad7 hexon", "PROTEIN", 142, 151], ["a rare amino UUC", "TEST", 7, 23], ["UUU", "TEST", 65, 68], ["acid", "TEST", 110, 114], ["hexon", "TEST", 146, 151]]], ["Among the synonymous codons for Val, seven GUCs appeared in the hydrophobic region.", [["Val", "CHEMICAL", 32, 35], ["GUCs", "PROTEIN", 43, 47], ["hydrophobic region", "PROTEIN", 64, 82], ["the synonymous codons", "TREATMENT", 6, 27], ["synonymous codons", "OBSERVATION", 10, 27], ["hydrophobic", "ANATOMY_MODIFIER", 64, 75]]], ["Therefore, the conclusion is that the NNC codons in Ad7 hexon were frequently used although Ad7 is one of the serotypes which contain lower level of C G content in hexon DNAs.", [["NNC", "GENE_OR_GENE_PRODUCT", 38, 41], ["Ad7 hexon", "GENE_OR_GENE_PRODUCT", 52, 61], ["Ad7", "GENE_OR_GENE_PRODUCT", 92, 95], ["C G", "GENE_OR_GENE_PRODUCT", 149, 152], ["NNC codons", "DNA", 38, 48], ["Ad7 hexon", "DNA", 52, 61], ["Ad7", "DNA", 92, 95], ["hexon DNAs", "DNA", 164, 174], ["the NNC codons", "TREATMENT", 34, 48], ["Ad7 hexon", "TREATMENT", 52, 61], ["the serotypes", "PROBLEM", 106, 119], ["C G content in hexon DNAs", "TREATMENT", 149, 174], ["lower", "OBSERVATION_MODIFIER", 134, 139], ["hexon DNAs", "OBSERVATION", 164, 174]]]]}